Glioblastoma: Modern Research, Ayurvedic Treatment & Evidence

Ayurvedic treatment for glioblastoma is increasingly explored by patients who want evidence-based supportive care alongside surgery, radiation, temozolomide, rehabilitation, and regular MRI monitoring. This guide examines the modern research, classical Ayurvedic rationale, ingredient-specific mechanisms, safety concerns, treatment interactions, and realistic clinical limits of integrating Ayurveda into glioma and glioblastoma care.

When you or someone in your family is diagnosed with glioma or glioblastoma, you may hear very different claims about treatment. Some people may tell you that only modern oncology should be considered. Others may tell you that one herb, one supplement, or one Ayurvedic formula can remove the tumour completely.

Neither approach helps you make a properly informed decision.

You need clear answers. You need to know why a particular Ayurvedic ingredient has been selected, what classical Ayurvedic books say about it, what modern research has found, whether the research was performed in patients or only in laboratory cells, and whether the studied dose is relevant to the medicine you will actually take.

This evidence review has therefore not been designed to ask you to accept Ayurveda only because it is ancient. It has been designed to show you the complete reasoning behind an individualized Ayurvedic plan for glioma and glioblastoma.

You should be able to see what is scientifically established, what is supported by early research, what is based on classical Ayurvedic knowledge, and what still requires stronger clinical evidence.

Why You Should Ask for Evidence Before Accepting Any Treatment

A reference alone is not enough to prove that a treatment works.

A laboratory study may show that a purified natural compound damages glioblastoma cells in a petri dish. However, this does not automatically mean that the same effect will occur when you take the whole herb by mouth.

The compound may not be absorbed properly. It may be rapidly broken down in the liver. It may not reach the brain. It may not enter the tumour in a useful amount. The laboratory concentration may also be much higher than the concentration that can be safely reached in your body.

In the same way, a study showing that an ingredient reduces cerebral edema does not prove that it has destroyed the tumour. A medicine may reduce swelling around the tumour and help you feel better without directly reducing the number of glioblastoma cells.

This does not make the supportive effect unimportant. Reduced swelling may improve headache, weakness, speech, movement, alertness, or steroid requirements. However, you should be clearly told what outcome was studied.

You should not be shown evidence for improved appetite and then be told that the same study proves tumour regression. You should not be shown an animal study and be told that the treatment is already clinically proven in human beings.

A trustworthy evidence review tells you exactly what each study found and what it did not find.

How the Research Is Selected

The research for this article is reviewed through a structured process rather than by selecting only favourable papers.

The PRISMA 2020 guidance is used to make the literature-search and study-selection process more transparent [1]. This means that the review should explain where the research was searched, which terms were used, what type of studies were included, and why some studies were excluded.

This is important because one favourable paper can create a misleading impression when several other studies show weaker, different, or contradictory results.

For every major Ayurvedic ingredient, the search examines the Sanskrit name, botanical name, common name, plant part, extract, and important active compounds. These are searched with terms such as glioma, glioblastoma, astrocytoma, glioma stem cells, temozolomide resistance, radiation resistance, cerebral edema, apoptosis, angiogenesis, tumour invasion, recurrence, blood–brain barrier, pharmacokinetics, safety, and medicine interaction.

Research in glioblastoma patients is given greater clinical importance than research in another cancer. Research using patient-derived glioblastoma cells is considered more directly relevant than research using an unrelated cancer cell line.

However, even a strong laboratory model cannot replace a properly designed human clinical study.

Why the Exact Ingredient Identity Matters

You cannot evaluate an Ayurvedic ingredient correctly by its common name alone.

Ashwagandha root, Ashwagandha leaf, an alcohol-based Ashwagandha extract, a water extract, and purified withaferin A are not the same intervention. They may contain different compounds in very different concentrations.

The same problem applies to Haridra and curcumin. Turmeric powder may contain only a limited amount of curcumin, while a laboratory experiment may use highly purified curcumin at a much higher concentration.

Shallaki resin is not automatically equivalent to purified acetyl-11-keto-β-boswellic acid. Pippali powder is not the same as isolated piperine. Brahmi powder is not the same as purified bacoside-A.

This is why the CONSORT extension for herbal interventions requires clinical studies to report the botanical identity, plant part, preparation method, extraction process, standardization, dosage, and quality testing of the herbal intervention [2].

Without this information, you cannot know whether the substance studied in a research paper is genuinely comparable with the ingredient present in an Ayurvedic Avaleha.

How Every Ingredient Is Examined

Every major ingredient used in the Ayurvedic strategy should be examined through several connected questions.

First, you need to know the exact botanical or mineral identity. For a herb, the plant part must be stated. For a bhasma, the raw material and processing method must be identified.

Second, you need to understand why the ingredient is used according to Ayurveda. This requires the original classical reference, chapter, verse, traditional properties, and therapeutic role.

Third, you need to know which modern compounds have been studied. These may include withanolides, boswellic acids, curcuminoids, piperine, bacosides, asiatic acid, glycyrrhetinic acid, or other constituents.

Fourth, the research model must be explained. You should be told whether the study involved patients, human tumour tissue, patient-derived glioblastoma cells, ordinary laboratory cell lines, animals with tumours inside the brain, animals with tumours under the skin, another type of cancer, or only computer-based molecular prediction.

Fifth, the dose must be compared with the dose that you may receive from the actual formulation. If a laboratory study used a purified compound at a concentration that cannot be safely reached in your body, this limitation must be stated.

Sixth, absorption and brain exposure must be examined. An ingredient should not be described as crossing the blood–brain barrier unless the research actually measured the compound or its active metabolites in the brain, cerebrospinal fluid, or tumour tissue.

Seventh, safety and medicine interactions must be reviewed. This includes possible interactions with temozolomide, corticosteroids, antiseizure medicines, anticoagulants, antiemetics, antibiotics, diabetes medicines, and medicines metabolized through the liver.

This process helps you understand not only whether an ingredient appears promising, but also how directly the research applies to your treatment.

Why the Complete Avaleha Must Be Described Clearly

Research on individual ingredients does not automatically prove the clinical effect of the complete Majja-Arbuda Rasayana Avaleha.

A multi-ingredient Avaleha may behave differently from every ingredient used alone. Ingredients may influence absorption, digestion, metabolism, stability, or tolerability. Some combinations may strengthen a desired effect. Other combinations may reduce absorption or increase interaction risks.

The complete intervention must therefore be reported in enough detail for another qualified doctor or researcher to understand what was actually administered.

The TIDieR reporting framework supports complete descriptions of healthcare interventions, including the materials used, procedures followed, dose, frequency, duration, route of administration, and methods of personalization [3].

For you, this means that the evidence should not simply say that you received “Ayurvedic medicine.”

It should explain the ingredient composition, plant parts, ingredient quantities, preparation method, final formulation weight, daily dose, timing, Anupana, duration, batch details, and any changes made according to your condition.

If the formula is modified because of your age, tumour subtype, seizures, steroid use, liver function, kidney function, digestion, constipation, sleep, or Prakriti, those changes should also be documented.

How Classical Ayurvedic Evidence Is Used

Classical Ayurvedic evidence and modern experimental evidence answer different questions.

Classical texts may help explain why a physician selects Rasayana support, Majja-related ingredients, Agni-supporting ingredients, or medicines intended to address abnormal tissue growth, obstruction, weakness, inflammation, and loss of strength.

Modern research may examine apoptosis, cell proliferation, glioma stem-like cells, inflammation, cerebral edema, tumour invasion, angiogenesis, treatment resistance, cognition, or drug absorption.

These two systems should be connected carefully, but they should not be falsely presented as identical.

Kapha should not be described as a scientific synonym for tumour-cell proliferation. Pitta should not be called a synonym for inflammatory cytokines. Vata should not be presented as a synonym for tumour invasion. Ama should not be treated as though it is one laboratory marker.

Ayurvedic concepts provide a clinical framework for understanding the whole patient. Modern research examines measurable biological processes. When both are used honestly, they can help you understand why a treatment has been designed in a particular way.

Why Animal Research Must Be Examined Carefully

Animal studies can provide useful information about dose, toxicity, tumour growth, survival, tissue distribution, and possible biological mechanisms. However, the design of the animal study matters.

A compound tested against a tumour grown under the skin does not answer the same question as a compound tested against a tumour growing inside the brain. A subcutaneous tumour model may show antitumour activity without proving that the compound can cross the blood–brain barrier.

The ARRIVE 2.0 guidelines are used to assess whether animal studies properly report the model, number of animals, controls, randomization, blinding, dosage, route of administration, outcomes, and adverse effects [8].

You should therefore be told whether the animal tumour was intracranial or outside the brain. This is especially important when a study is being used to support a claim about brain delivery.

How Patient Cases Should Be Reported

Individual patient cases can provide meaningful evidence when they are documented carefully.

A case report can show that a treatment was feasible, tolerated, associated with better appetite, linked with reduced steroid use, followed by improved neurological function, or accompanied by a radiological change.

However, one case cannot prove that the same result will occur in every patient.

The CARE guidelines provide a standard structure for reporting clinical cases [4,5]. A properly documented glioma case should include the confirmed diagnosis, molecular markers, surgery details, radiotherapy, chemotherapy, MRI dates, neurological condition, steroid dose, antiseizure medicines, exact Ayurvedic formulation, laboratory monitoring, adverse effects, and follow-up duration.

The treatment timeline is especially important. You need to know whether an MRI change occurred after surgery, radiation, temozolomide, steroid adjustment, Ayurveda, or several treatments used together.

Without this timeline, it may be impossible to identify which treatment contributed to the result.

Why Real-World Patient Data Must Include All Outcomes

A clinic should not publish only its strongest success stories.

If real-world evidence is collected, it should also include patients who remained stable, patients who progressed, patients who stopped treatment, patients who developed adverse effects, and patients who were lost to follow-up.

The STROBE reporting standards help improve the reporting of observational studies [6]. The RECORD guidance is particularly useful when evidence comes from routine hospital files, prescriptions, laboratory results, MRI reports, and follow-up records [7].

For you, this means that percentages should not be published without explaining the total number of patients evaluated.

A statement such as “80% of patients improved” has little meaning unless you are told what improvement meant, how many patients were included, how long they were followed, whether MRI was used, whether standard oncology treatment was also given, and how many patients were unavailable for follow-up.

Transparent reporting does not weaken Ayurveda. It helps separate genuine clinical observations from promotional claims.

What This Evidence Process Means for You

You should not have to choose between blind faith in Ayurveda and complete rejection of it.

You should be able to examine why each ingredient has been selected, what its strongest evidence is, what remains uncertain, what safety monitoring is required, and how the treatment will be evaluated in your own case.

This evidence process also protects you from assuming that every positive laboratory study applies directly to you.

Your glioma subtype, grade, molecular profile, treatment stage, residual disease, neurological condition, steroid requirement, seizures, organ function, and current medicines all influence how relevant an ingredient may be.

The purpose of this article is therefore not to present Ayurveda as a collection of general anticancer herbs. It is to examine whether each component has a rational, documented, and measurable role within an individualized glioma or glioblastoma treatment strategy.

In the next section, you will see why glioma cannot be treated as one disease and why the biological differences between glioblastoma, IDH-mutant astrocytoma, oligodendroglioma, low-grade glioma, recurrent disease, and postoperative residual disease directly affect the Ayurvedic plan.

Why Glioma Is Not One Disease—and Why Your Ayurvedic Plan Must Be Individualized

When you receive a diagnosis of glioma, the word may sound like the name of one disease. In reality, glioma is a large family of brain tumours. Different gliomas can arise from different biological pathways, carry different genetic changes, grow at different speeds, respond differently to treatment, and have very different long-term outcomes.

This is why you should never be offered one fixed treatment only because your report contains the word “glioma.”

Your treatment plan should begin with the exact tumour diagnosis. Your doctor should review the tumour type, grade, molecular markers, location, surgery details, remaining tumour, neurological condition, current medicines, and treatment stage before designing any Ayurvedic formulation.

Modern glioma research strongly supports this individualized approach. The current World Health Organization classification does not identify gliomas only by how the cells look under a microscope. It combines microscopic findings with molecular and genetic information [9,10].

This means that two tumours that appear similar on MRI may still be biologically different diseases.

The Word Glioma Covers Several Different Tumours

Glioma is a broad term used for tumours connected with glial or glial-like cells in the brain and central nervous system. However, the final diagnosis may be astrocytoma, oligodendroglioma, glioblastoma, diffuse midline glioma, or another molecularly defined tumour.

The major adult diffuse gliomas include astrocytoma, IDH-mutant; oligodendroglioma, IDH-mutant and 1p/19q-codeleted; and glioblastoma, IDH-wildtype [9,10].

These are not simply different names for the same condition.

They differ in their molecular origin, expected behaviour, treatment sensitivity, recurrence pattern, and prognosis. They may also affect people of different ages and arise in different parts of the brain.

When you are considering Ayurveda, these differences are equally important. An ingredient selected for a slowly growing IDH-mutant tumour should not automatically be used in the same way for a rapidly progressing IDH-wildtype glioblastoma.

Your Ayurvedic plan must be built around the disease you actually have, not around the general word written at the top of the MRI report.

Glioblastoma Is a Specific Diagnosis

Glioblastoma is often used casually to describe any aggressive brain tumour. Under the present WHO system, glioblastoma is mainly defined as an adult-type diffuse astrocytic tumour that is IDH-wildtype and has specific microscopic or molecular features [9,10].

This is different from astrocytoma, IDH-mutant, CNS WHO grade 4.

Both may be called grade 4 tumours, but they do not have the same underlying biology. They may differ in age distribution, treatment response, survival pattern, recurrence behaviour, and eligibility for targeted treatment.

This distinction is important because older reports may use the term “secondary glioblastoma” for some tumours that would now be classified as IDH-mutant astrocytoma. Changes in classification can also make older survival statistics difficult to apply directly to you [16,17].

You should therefore not rely only on an old pathology label.

Your diagnosis should be reviewed together with the molecular findings whenever possible.

Why Tumour Grade Alone Is Not Enough

Tumour grade remains important because it gives information about how abnormal and aggressive the tumour appears. However, grade alone cannot explain the complete behaviour of a modern glioma.

A grade 2 IDH-mutant astrocytoma is not the same disease as a grade 2 oligodendroglioma. A grade 4 IDH-mutant astrocytoma is not the same disease as an IDH-wildtype glioblastoma.

The molecular profile helps your doctors understand the tumour more accurately.

IDH1 and IDH2 status help distinguish major glioma groups. A combined IDH mutation and 1p/19q codeletion supports the diagnosis of oligodendroglioma. ATRX loss and TP53 alterations may support an astrocytic lineage. MGMT promoter methylation may influence how likely a glioblastoma is to benefit from temozolomide. CDKN2A/B deletion may indicate more aggressive behaviour in an IDH-mutant astrocytoma. TERT promoter mutation, EGFR amplification, and characteristic chromosome changes may support an aggressive IDH-wildtype diagnosis [9–17].

Other alterations such as BRAF, NTRK, FGFR, or H3 changes may also matter in selected patients [15].

You do not need to become a molecular pathologist. However, you should understand that these markers are not optional scientific decoration. They can change the meaning of your diagnosis and may change your treatment options.

Why Two Patients With Similar MRI Scans May Need Different Treatment

An MRI can show the location, size, contrast enhancement, swelling, necrosis, and pressure caused by a tumour. However, MRI alone usually cannot confirm the exact molecular diagnosis.

Two patients may both have a large enhancing tumour in the frontal lobe. One may have glioblastoma, IDH-wildtype. The other may have astrocytoma, IDH-mutant, grade 4.

The scans may appear similar, but the tumours may behave differently.

This is why an Ayurvedic plan should not be designed only from an MRI image or from tumour size.

Your pathology, molecular markers, treatment history, and neurological condition must also be considered.

If a clinic offers you the same medicine after seeing only one scan, without asking for the pathology report or treatment details, the plan is unlikely to be sufficiently individualized.

Glioblastoma Can Contain Different Cell Populations

Glioblastoma is not always made of one uniform group of tumour cells.

Single-cell research has shown that different tumour-cell populations can exist within the same glioblastoma [18]. These populations may have different genetic activity, different metabolic behaviour, and different levels of treatment sensitivity.

Glioblastoma cells may also move between different cellular states. Treatment can create pressure that allows some resistant populations to survive and become more dominant [19].

This helps explain why one part of a tumour may respond while another part continues to grow.

It also explains why a treatment that targets only one pathway may not control every tumour-cell population.

For Ayurveda, this does not prove that a multi-herb formulation will automatically overcome tumour heterogeneity. However, it gives a scientific reason to avoid simplistic claims that one herb, one isolated compound, or one fixed formulation will work equally for every patient.

A multi-component Ayurvedic strategy may be designed to address several biological and clinical problems at the same time. However, each proposed action still needs evidence, realistic dosing, safety review, and proper monitoring.

Why Surgery Cannot Always Remove Every Tumour Cell

Surgery can reduce tumour burden, relieve pressure, improve symptoms, and provide tissue for an accurate diagnosis. When safely possible, maximal safe resection remains an important part of treatment.

However, diffuse glioma cells may move into the surrounding brain beyond the visible tumour margin [20].

The neurosurgeon must balance tumour removal with the protection of speech, movement, memory, vision, personality, and other essential brain functions.

This means that even when the surgeon removes all visible enhancing tumour, microscopic tumour cells may remain outside the surgical cavity.

You should therefore understand the difference between complete removal of visible tumour and complete biological elimination of the disease.

This is one reason why radiation, chemotherapy, targeted treatment, surveillance, and carefully coordinated supportive care may still be required after surgery.

It is also why postoperative Ayurveda should not be planned as though the operation has either completely cured the disease or completely failed.

The correct question is what remains, what treatment is planned next, what risks are present, and how Ayurveda may safely support your recovery and longer-term strategy.

Why Glioma Stem-Like Cells Matter

Some glioblastoma cells show stem-like properties. These cells may be able to renew themselves, produce different tumour-cell populations, survive treatment, and contribute to recurrence [21].

Experimental research has also shown that glioma stem-like cells may activate DNA-repair systems that help them survive radiation [22].

This makes them an important research target.

When an Ayurvedic ingredient is claimed to act against glioma stem cells, you should ask what type of evidence exists.

Was the ingredient studied in an ordinary glioma cell line, a patient-derived stem-like cell model, an animal with an intracranial tumour, or a human clinical trial?

A positive result in a stem-cell laboratory model may be scientifically interesting. However, it does not prove that the ingredient will reach the same cells inside your brain after oral use.

The dose, absorption, metabolism, brain exposure, and safety must still be examined.

Why the Blood–Brain Barrier Changes the Meaning of Research

The brain has protective barriers that control which substances can enter brain tissue. A tumour may partly disturb these barriers, but drug delivery remains uneven and difficult.

Some parts of a glioblastoma may allow greater drug entry, while infiltrating cells outside the main tumour may remain protected by a more intact blood–brain barrier [23].

This creates a major problem when interpreting research on Ayurvedic ingredients.

A compound may kill glioblastoma cells in a laboratory dish because the cells are directly exposed to it. Your body is much more complex.

After you swallow an ingredient, it must survive digestion, be absorbed through the intestine, enter the blood, avoid rapid breakdown, reach the brain, enter the tumour, and remain at a useful concentration for enough time.

This complete process cannot be assumed.

The statement that an ingredient is “small,” “fat soluble,” “nano-sized,” or “bioactive” is not sufficient proof that it reaches your tumour.

Human blood, cerebrospinal fluid, brain-tissue, or tumour-tissue measurements provide much stronger evidence than computer predictions or laboratory assumptions.

Cerebral Edema Is Not the Same as Tumour Growth

Gliomas can produce swelling around the tumour. This is called peritumoral or cerebral edema.

Edema may cause headache, vomiting, weakness, speech difficulty, reduced alertness, imbalance, or worsening neurological function. Steroids such as dexamethasone are often used to reduce this swelling.

However, the amount of edema does not always directly represent the number of tumour cells [24].

A treatment may reduce edema and help you feel significantly better without shrinking the tumour itself.

This distinction is essential when evaluating Ayurvedic ingredients such as Shallaki or other anti-inflammatory substances.

If your weakness improves after the swelling reduces, the clinical benefit may be real and important. But the improvement should not automatically be described as proof that the tumour has disappeared.

Your MRI findings, steroid dose, neurological examination, and treatment timing must be reviewed together.

How Molecular Differences Change the Modern Treatment Plan

Modern glioma treatment is selected according to the exact diagnosis rather than one universal protocol [11–15].

A patient with newly diagnosed glioblastoma may require surgery followed by radiation and temozolomide. A patient with IDH-mutant grade 2 glioma may have a different pathway depending on age, residual tumour, symptoms, and risk factors. A patient with oligodendroglioma may receive another chemotherapy strategy. A patient with an actionable molecular alteration may become eligible for targeted treatment or a clinical trial.

The same principle should apply when Ayurveda is added.

You should not receive a formula selected only because an ingredient has been described as “anticancer.”

Your formula should reflect your tumour biology and your current clinical needs.

How Your Ayurvedic Plan Should Change According to Your Diagnosis

If you have a newly diagnosed glioblastoma after surgery, your immediate priorities may include recovery, edema control, seizure monitoring, nutrition, blood-count support, liver safety, and preparation for radiation and temozolomide.

If you have an IDH-mutant lower-grade glioma under surveillance, your priorities may be different. Your plan may focus more on neurological function, seizure control, cognition, metabolic health, long-term safety, and careful MRI monitoring.

If you have recurrent glioblastoma, your plan must consider previous radiation, previous chemotherapy, current blood counts, steroid dependence, neurological decline, treatment resistance, and the options still available through oncology.

If your tumour is inoperable, the formula should not simply copy a postoperative prescription. Your swallowing, consciousness, edema, seizures, mobility, pressure symptoms, and ability to tolerate oral medicine may become more important.

If you are elderly or medically weak, a strong or complex formulation may not be appropriate in the same dose used for a younger, stable patient.

If your liver enzymes are elevated, ingredients with possible liver risk may need to be avoided, reduced, or monitored closely.

If your platelet count is low, ingredients that may influence bleeding or medicine metabolism require special caution.

If you take antiseizure medicines, steroids, anticoagulants, diabetes medicines, or several other drugs, the interaction review becomes part of the treatment itself.

Why Prakriti Alone Is Not Enough

Your Prakriti is important in Ayurveda, but it cannot replace your tumour diagnosis.

Two patients may both be Vata-Pitta dominant, yet one may have a small IDH-mutant astrocytoma and the other may have a recurrent IDH-wildtype glioblastoma with severe edema.

They should not receive the same formula merely because their constitutional pattern appears similar.

Your Ayurvedic doctor should consider both your constitutional profile and your present disease condition.

This includes Prakriti, Vikriti, Agni, bowel function, appetite, sleep, strength, weight, neurological symptoms, treatment tolerance, and other diseases.

However, these findings should be assessed together with pathology, molecular markers, MRI, laboratory tests, and oncology treatment.

Personalization becomes stronger when both systems are used carefully.

Why Molecular Markers Should Not Be Directly Converted Into Doshas

It may be tempting to say that one molecular pathway represents Vata, another represents Pitta, and another represents Kapha.

This may sound simple, but it is not scientifically established.

IDH mutation is not a direct equivalent of one Dosha. MGMT methylation is not an Ayurvedic constitutional type. EGFR amplification cannot be translated into Kapha without evidence. Cerebral edema cannot always be reduced to one Dosha.

Modern molecular markers and Ayurvedic diagnosis describe the patient through different systems.

They can inform one treatment plan, but they should not be forced into false one-to-one relationships.

A responsible Ayurvedic physician may use molecular information to understand tumour behaviour while using Dosha, Dhatu, Srotas, Agni, and Ojas to understand the whole patient.

This creates integration without distorting either system.

Why One Fixed Avaleha Is Not Scientifically Credible

One fixed Avaleha cannot be assumed suitable for every glioma patient.

The formula may need to change according to your exact diagnosis, tumour grade, IDH status, MGMT status, residual disease, edema, seizure history, steroid dose, chemotherapy schedule, radiation phase, blood counts, liver function, kidney function, age, weight, appetite, sleep, bowel function, and neurological symptoms.

The core treatment philosophy may remain consistent, but the ingredient proportions, supportive groups, dose, Anupana, timing, and monitoring requirements may need to change.

One patient may need greater attention to edema and steroid support. Another may need more careful cognitive and neurological support. Another may require a gentler formula because of liver dysfunction. Another may need treatment-resistance-focused ingredients during recurrence research.

This does not mean that every ingredient can be changed without discipline.

The formula should still have a documented structure, clear therapeutic groups, quality controls, and a defined clinical reason for every modification.

What You Should Expect Before Accepting an Ayurvedic Plan

Before you accept a treatment plan, the doctor should understand your complete diagnosis.

Your pathology report, molecular findings, preoperative MRI, postoperative MRI, surgery notes, radiation history, chemotherapy history, steroid dose, seizure medicines, blood counts, liver function, kidney function, appetite, weight, sleep, bowel function, and neurological symptoms should be reviewed.

The doctor should also explain what each Ayurvedic ingredient is expected to do.

You should be told whether the intended role is tumour-directed research, treatment-resistance support, edema control, neurological recovery, digestion, nutrition, sleep, or treatment tolerance.

You should also be told what evidence supports that role.

A herb with laboratory glioblastoma evidence should be described differently from a herb supported mainly for cognition or appetite. An ingredient studied for cerebral edema should not be presented as though it has proven survival benefit.

What This Means for You

The main lesson is simple.

You should not treat glioma as one disease, and you should not accept one universal Ayurvedic formula for every glioma patient.

Your exact tumour biology matters. Your surgery matters. Your molecular markers matter. Your treatment stage matters. Your neurological condition matters. Your liver, kidneys, blood counts, digestion, strength, and current medicines also matter.

Modern glioma science shows that these tumours are heterogeneous, infiltrative, adaptable, and difficult to reach with medicines [18–23].

Ayurveda adds a personalized way of understanding your constitution, strength, digestion, symptoms, recovery, and treatment tolerance. However, this personalization becomes medically meaningful only when it is connected with your confirmed diagnosis and monitored outcomes.

The next section will explain the main biological and clinical problems that an integrative glioma strategy may need to address, including microscopic infiltration, glioma stem-like cells, treatment resistance, angiogenesis, cerebral edema, neurological injury, blood–brain barrier limitations, and loss of strength.

What an Integrative Glioma Strategy Must Try to Address

When you are treated for glioma or glioblastoma, the visible tumour is only one part of the problem.

Your treatment strategy may also need to consider microscopic tumour cells, biological differences within the tumour, treatment-resistant cell populations, swelling around the brain, seizures, neurological damage, loss of appetite, weight loss, weakness, and the effects of surgery, radiation, chemotherapy, and steroids.

This is why a meaningful integrative plan cannot be based only on the idea of “boosting immunity.”

Your plan must first identify the actual problems present in your case. It must then explain which problems are being addressed by surgery, radiation, chemotherapy, targeted treatment, rehabilitation, nutrition, and Ayurveda.

Ayurveda should not be presented as one medicine that performs every function. Different ingredients may be selected for different purposes. Some may have direct laboratory evidence against glioma-related pathways. Others may be used mainly for cerebral edema, cognition, appetite, sleep, digestion, strength, or treatment tolerance.

You should be clearly told which role applies to each ingredient.

The Visible Tumour Is Not the Whole Disease

An MRI may show a central tumour mass, contrast enhancement, necrosis, and swelling. Surgery may remove much of the visible tumour.

However, diffuse glioma cells can move into the surrounding brain tissue beyond the visible border [20].

These infiltrating cells may be present in tissue that appears nearly normal on the scan. Removing all surrounding brain tissue would not be safe because important areas may control your speech, movement, memory, vision, personality, or consciousness.

This means that a successful operation can remove the visible tumour without removing every microscopic tumour cell.

You should not interpret this as meaning that surgery is useless. Surgery can reduce tumour burden, relieve pressure, improve symptoms, provide tissue for diagnosis, and help guide further treatment.

However, you should understand why additional treatment is often recommended after surgery.

Radiation and chemotherapy are used partly because microscopic disease may remain outside the surgical cavity. Long-term monitoring is also required because these remaining cells may later contribute to progression or recurrence.

An Ayurvedic plan after surgery should therefore not focus only on wound recovery. It may also consider treatment tolerance, neurological rehabilitation, edema, nutrition, residual disease, and the risk of microscopic tumour persistence.

Glioblastoma Contains More Than One Type of Tumour Cell

A glioblastoma is not always a uniform mass containing identical cells.

Research using single-cell analysis has shown that one tumour may contain several cell populations with different patterns of gene activity [18]. Some cells may divide rapidly. Some may be more invasive. Some may survive in low-oxygen areas. Others may be better able to repair treatment-related damage.

Glioblastoma cells may also change their biological state when they are exposed to treatment pressure [19].

This means that a treatment may affect one cell population more strongly than another. The more sensitive cells may die, while resistant cells survive and later become more dominant.

This is one reason why a treatment that appears helpful at first may become less effective later.

It is also why you should be cautious when someone claims that one isolated pathway explains your entire tumour.

A compound may reduce one signalling pathway in a laboratory study. This may be scientifically useful, but the tumour may activate another pathway or contain cells that are not dependent on the same mechanism.

A multi-ingredient Ayurvedic formulation may be designed to influence several biological and supportive targets. However, the presence of many ingredients does not automatically prove that all tumour-cell populations will be controlled.

Each proposed role must still be supported by research, dose relevance, quality control, and clinical monitoring.

Glioma Stem-Like Cells May Contribute to Recurrence

Some glioblastoma cells show stem-like properties. These cells may be able to renew themselves and produce different types of tumour cells [21].

They are being studied because they may contribute to tumour regrowth, treatment resistance, and recurrence.

Experimental research has shown that glioma stem-like cells may activate DNA-damage responses more effectively than some other tumour cells. This may help them survive radiation [22].

You may see an Ayurvedic ingredient described as acting against glioblastoma stem cells. This can be important evidence, but you should look closely at the study.

The study may have used an ordinary established cell line. It may have used patient-derived stem-like cells. It may have tested the compound in an animal. It may have used a purified chemical rather than the whole herb.

These differences matter.

Research using patient-derived glioblastoma stem-like cells may be more relevant than research using an unrelated cancer line. However, it is still not the same as showing that the ingredient controls glioblastoma stem-like cells inside a patient.

The ingredient must be absorbed, reach the tumour, remain active, and achieve a useful concentration without causing unacceptable toxicity.

Ingredients such as curcumin, boswellic acids, bacoside-A, piperine, and some other natural compounds have been studied in glioma or glioblastoma stem-like models [59,77,88,98,112]. These studies provide a biological reason for further research.

They do not yet establish that the same effect occurs in you after taking the ingredient orally.

Tumour Cells May Resist Normal Cell Death

Healthy cells usually have internal systems that can stop abnormal growth or trigger programmed cell death when severe damage occurs.

Cancer cells may interfere with these systems. They may continue surviving even when they carry major genetic abnormalities.

Many laboratory studies on Ayurvedic plants and natural compounds examine apoptosis. Apoptosis is a regulated form of cell death.

For example, experimental glioblastoma studies have reported apoptosis-related effects from boswellic acids, withaferin A, curcumin, asiatic acid, bacoside-A, and glycyrrhetinic acid [60,67,77,99,106,113].

These findings can help explain why such ingredients may be considered for tumour-directed research.

However, the word “apoptosis” should not be used as though it proves clinical tumour removal.

A compound may trigger apoptosis in cells that are directly exposed to a high concentration in a laboratory. The same concentration may not be achievable in your tumour after oral treatment.

The laboratory finding is evidence of a possible mechanism. It is not proof that the ingredient will produce the same result in your body.

Temozolomide Resistance Must Be Considered

Temozolomide is commonly used with radiation and as adjuvant treatment for glioblastoma [25].

It damages tumour-cell DNA. However, not every tumour responds equally.

The MGMT protein can repair some of the DNA damage caused by temozolomide. When the MGMT promoter is methylated, the tumour may produce less MGMT protein and may be more sensitive to temozolomide. When the MGMT promoter is unmethylated, the tumour may be more capable of repairing the damage [26].

This does not mean that MGMT status can perfectly predict what will happen to you. It is an important marker, but other biological factors also affect treatment response.

Resistance may involve DNA repair, tumour-cell survival pathways, glioma stem-like cells, drug transport, hypoxia, and changes that develop during treatment.

Some natural compounds have been studied for possible effects on temozolomide resistance.

Piperine has been investigated in temozolomide-resistant human glioma cell lines [87]. It has also been studied in relation to survivin, a protein associated with cell survival, in glioblastoma stem-like cells [88].

Curcumin has been studied with temozolomide through pathways involving oxidative stress and AKT/mTOR signalling [78].

Bacoside-A has also been studied with temozolomide in a recent U87MG laboratory model [101].

These findings may help identify ingredients for a treatment-resistance research group within an Ayurvedic formulation.

However, these studies do not prove that adding the herb to temozolomide will improve survival in patients.

The combination must also be assessed for safety. A compound that changes medicine absorption or liver metabolism may increase or reduce the effect of another medicine.

Piperine, for example, can influence P-glycoprotein and CYP3A4 activity [90]. This may be useful for bioavailability research, but it also creates a reason to check interactions with antiseizure medicines, steroids, anticoagulants, and other drugs.

You should not be told that a bioenhancer is automatically safe simply because it is natural.

Radiation Resistance Is Not Caused by One Factor

Radiation damages tumour-cell DNA, but glioblastoma cells may survive through several mechanisms.

Glioma stem-like cells may activate stronger DNA-repair responses [22]. Low-oxygen areas within the tumour may reduce radiation sensitivity. Some tumour cells may temporarily stop dividing or activate survival pathways.

The tumour may also contain cell populations that are naturally more resistant.

Several natural compounds have been studied in combination with radiation.

Curcumin has shown experimental anti-glioma activity when combined with radiation in preclinical models [79]. AKBA, a boswellic-acid compound, has also been examined with radiation in glioblastoma cells [61].

These studies may support further investigation of selected combinations.

However, radiation can also damage normal tissues. Any ingredient used during radiotherapy must be assessed not only for possible tumour effects but also for its influence on normal cells, liver function, blood counts, bleeding, inflammation, and treatment tolerance.

You should not begin several concentrated extracts during radiation without knowing the dose, formulation, and interaction risks.

Tumour Invasion Is Different From Tumour Size

Glioma cells can migrate through the brain along white-matter pathways, blood vessels, and other tissue structures [20].

A treatment may reduce the size of the main tumour but have less effect on the cells that have moved away from it.

Laboratory researchers therefore study not only tumour-cell death but also migration and invasion.

Boswellic-acid research has examined the movement and invasion of glioblastoma cells [60]. Other natural compounds have also been studied for effects on enzymes, signalling pathways, and cellular structures involved in tumour movement.

This evidence may be relevant when selecting tumour-directed ingredients.

However, reduced cell movement in a laboratory dish does not prove that microscopic invasion has stopped in your brain.

Clinical monitoring still depends on your neurological condition, MRI findings, treatment history, and time.

Angiogenesis Helps the Tumour Maintain Its Blood Supply

A growing tumour requires oxygen and nutrients. Glioblastoma can stimulate the development of abnormal blood vessels through processes known as angiogenesis.

These tumour vessels are often disorganized and leaky. They may contribute to contrast enhancement and cerebral edema.

Many natural compounds are described as anti-angiogenic because they affect VEGF or related pathways in laboratory models.

This can be an important research finding, but you should ask what was actually measured.

Did the study measure a molecular marker in cells? Did it examine blood-vessel formation in an animal? Did it show reduced tumour growth? Did it involve human patients?

The strength of the claim should match the study.

An ingredient that affects an angiogenesis-related protein in a laboratory should not automatically be presented as clinically proven to stop the tumour’s blood supply.

Hypoxia Can Make the Tumour More Difficult to Treat

Hypoxia means that parts of the tumour have low oxygen levels.

Rapid tumour growth and abnormal blood vessels can create areas where oxygen delivery is poor. Tumour cells that survive in these areas may become more invasive and resistant to treatment.

Hypoxia may influence metabolism, stem-like behaviour, angiogenesis, and radiation response.

Asiatic acid has been studied in glioblastoma cells under hypoxic conditions [107]. This gives direct preclinical relevance to one aspect of aggressive tumour biology.

However, it remains laboratory evidence. It does not show that oral Mandukaparni or isolated asiatic acid will reverse hypoxia inside your tumour.

The amount present in the actual formulation and the ability of the compound to reach the tumour must still be examined.

Cerebral Edema May Be an Immediate Clinical Priority

Sometimes the most urgent problem is not only the tumour itself. It is the swelling around it.

Cerebral edema can increase pressure inside the skull and worsen headache, vomiting, weakness, speech difficulty, confusion, drowsiness, and seizures [24].

Steroids such as dexamethasone are often used because they can reduce swelling quickly.

However, long-term or high-dose steroid use may cause high blood sugar, muscle weakness, sleep problems, mood changes, infection risk, stomach irritation, bone loss, and other complications.

An integrative strategy may therefore include ingredients intended to support edema and inflammation. However, they must not be used as an unsafe replacement for steroids when urgent swelling is present.

Shallaki is one of the more important examples.

In a small randomized trial involving patients receiving radiation for primary or secondary brain tumours, Boswellia serrata was associated with a greater reduction in cerebral edema than placebo [57].

This is direct human brain-tumour evidence for an edema-related outcome.

It does not prove that Boswellia eliminated glioblastoma cells or improved survival.

This distinction should be explained to you clearly.

An edema-support ingredient may still be valuable because reducing swelling can improve your comfort and neurological function. However, your steroid dose, MRI findings, blood sugar, symptoms, and clinical examination must be considered together.

You should never reduce dexamethasone suddenly without medical supervision.

Neuroinflammation May Affect Symptoms and Recovery

The tumour, surgery, radiation, and surrounding tissue injury can create inflammatory changes in the brain.

Inflammation may contribute to edema, fatigue, cognitive problems, and neurological symptoms.

Many Ayurvedic herbs have anti-inflammatory effects in experimental research. However, inflammation is not always harmful in the same way.

Some immune responses may damage normal tissue, while other immune responses may help the body recognize tumour cells.

This means that broadly suppressing every inflammatory pathway is not automatically beneficial.

The licorice-related HMGB1 evidence demonstrates this complexity. Glycyrrhizin has been studied for suppressing HMGB1 in the glioblastoma microenvironment [114]. However, other research has shown that HMGB1 may help activate an antitumour immune response in certain experimental conditions [115].

You should therefore be cautious when a treatment is described simply as “anti-inflammatory” or “immune boosting.”

The immune system is highly complex. The correct effect may depend on the tumour, treatment stage, steroid use, infection risk, and exact biological pathway.

The Blood–Brain Barrier Limits Many Promising Compounds

An ingredient can show strong laboratory activity and still fail as a treatment because it does not reach the tumour.

The blood–brain barrier protects the brain from many chemicals circulating in the blood. Glioblastoma may disturb this barrier in some areas, but the barrier can remain more intact around infiltrating tumour cells [23].

This creates uneven drug delivery.

To make a serious brain-penetration claim, researchers should measure the compound or its metabolites in blood, cerebrospinal fluid, brain tissue, or tumour tissue.

Computer modelling, molecular size, fat solubility, or nano-sized appearance may generate a hypothesis. They are not proof.

Boswellic acids have been measured in the brain and plasma in experimental pharmacokinetic research [64]. This is more relevant than simply claiming that the compound is fat soluble.

However, animal brain detection does not automatically prove that a human oral dose will produce a therapeutic concentration in glioblastoma tissue.

The same caution must be applied to curcumin, withanolides, piperine, bacosides, asiatic acid, and bhasmas.

Nano-Sized Material Does Not Automatically Reach Your Tumour

Some bhasmas have been found to contain nanoscale structures in specific laboratory analyses.

For example, one tested Swarna Bhasma sample contained nanoscale gold structures [121].

This finding may help researchers understand the physical nature of the prepared material.

However, it does not prove that the particles are absorbed intact from your intestine. It does not prove that they enter your blood, cross the blood–brain barrier, accumulate inside glioblastoma tissue, or produce a clinically useful effect.

Each bhasma batch may also differ according to the raw material, purification, incineration, number of heating cycles, temperature, grinding, and storage.

A serious nano-medicine claim requires detailed characterization and pharmacokinetic evidence [54].

You should be shown batch quality, preparation standards, elemental composition, contaminant testing, and safety monitoring. You should not be asked to accept brain-penetration claims only because the word “nano” is used.

Neurological Recovery Requires a Separate Treatment Goal

Even when tumour control is the main objective, you may also need help with speech, movement, memory, balance, swallowing, vision, seizures, fatigue, or personality changes.

These problems may result from the tumour, surgery, edema, seizures, medicines, radiation, or treatment-related injury.

Tumour-directed treatment and neurological recovery are not the same goal.

A medicine that affects glioma cells may not restore movement or speech. In the same way, an intervention that improves sleep, cognition, or rehabilitation does not prove that the tumour has reduced.

Your plan should therefore separate neurological support from tumour-directed research.

Brahmi and Mandukaparni have human evidence concerning selected cognitive outcomes [102,103,108]. This may support their use in neurological and cognitive care.

However, human cognitive studies in healthy adults or non-cancer populations do not establish glioblastoma control.

Physiotherapy, occupational therapy, speech therapy, swallowing therapy, and cognitive rehabilitation may also be required [37,38].

Ayurveda may support your recovery, but it should not replace rehabilitation when you have a clear neurological deficit.

Seizure Control Must Remain a Major Priority

Seizures are common in several glioma types. They may occur before diagnosis, after surgery, during treatment, or at recurrence.

A seizure can cause injury, loss of consciousness, aspiration, or a medical emergency.

Your Ayurvedic plan must therefore be reviewed together with your antiseizure treatment [34].

Some herbs may cause sedation. Some may affect liver enzymes that metabolize antiseizure medicines. Some may change drug absorption. Others may influence electrolytes or blood sugar and indirectly affect seizure risk.

You should not stop or reduce antiseizure medicine because an Ayurvedic formulation has been started.

The goal should be safe coordination, symptom recording, and interaction monitoring.

Appetite, Weight, and Muscle Affect Your Ability to Continue Treatment

Glioma treatment can affect your appetite, digestion, taste, bowel habits, energy, and body weight.

Surgery, radiation, temozolomide, nausea, steroids, anxiety, reduced movement, swallowing difficulty, and infection can all influence nutrition.

Loss of body weight and muscle can reduce your strength and make rehabilitation more difficult. It may also affect your ability to complete treatment.

This is why appetite and nutrition support are medically meaningful goals. They should not be dismissed as minor supportive outcomes.

However, better appetite should not be described as proof of tumour regression.

An Ayurvedic formulation may include ingredients selected for Agni, digestion, bowel function, nourishment, strength, or recovery. These roles should be explained separately from ingredients selected for tumour-directed research.

Your calorie intake, protein intake, body weight, muscle loss, swallowing, blood sugar, and bowel movements should be monitored [130,131].

Steroid Effects Must Be Managed Carefully

Dexamethasone can be essential when brain swelling is causing serious symptoms.

However, prolonged steroid treatment may cause muscle wasting, high blood sugar, increased appetite, weight gain, facial swelling, infection risk, poor sleep, mood changes, stomach irritation, and weakness.

Your integrative plan should therefore consider the total steroid burden.

This does not mean that Ayurveda can always replace dexamethasone.

The safer goal may be to support edema control, blood-sugar management, digestion, muscle preservation, sleep, and recovery while your oncology team decides whether the steroid dose can be reduced.

Any steroid taper must be supervised. Sudden withdrawal can be dangerous.

Treatment Tolerance Can Influence the Final Outcome

A treatment can only help you if you are able to receive it safely.

Temozolomide may reduce blood counts and can affect the liver [144]. Radiation may cause fatigue, appetite changes, skin reactions, and neurological symptoms.

Antiseizure medicines, steroids, antibiotics, and other drugs may create additional effects.

An integrative strategy may therefore aim to help you maintain appetite, weight, bowel function, sleep, energy, and organ safety.

These supportive goals may help you remain fit enough for treatment.

However, the evidence must remain clear.

If an Ayurvedic ingredient improves appetite, it should be described as appetite support. If it helps constipation, it should be described as bowel support. If it has laboratory activity against glioblastoma cells, that should be described as preclinical tumour-directed evidence.

Different outcomes should not be combined into one general claim of “cure.”

Why a Multi-Target Strategy May Be Rational

Glioblastoma involves several connected problems. These can include microscopic invasion, biological heterogeneity, treatment resistance, stem-like cell populations, hypoxia, abnormal blood vessels, edema, seizures, neurological injury, and declining strength.

This gives a logical reason to investigate a multi-target strategy.

A carefully designed Ayurvedic formulation may contain different functional groups. One group may be selected because of direct glioma research. Another may focus on edema and inflammation. Another may support cognition and neurological recovery. Another may help digestion, absorption, bowel function, or treatment tolerance. Another may support nutrition and strength.

This structure is more rational than calling every ingredient “anticancer.”

However, multi-target does not mean universally effective.

A formulation with many ingredients can also create more complexity. It can become difficult to identify which component is helping, which is causing an adverse effect, or how the combination affects modern medicines.

This is why formulation design, ingredient quantity, batch quality, laboratory monitoring, and proper clinical documentation are necessary.

What This Means for Your Treatment Plan

Your integrative plan should begin by identifying the main biological and clinical problems in your case.

If your immediate problem is severe cerebral edema, that may require urgent steroid treatment and neurological monitoring.

If your main challenge is postoperative weakness, you may need rehabilitation, nutrition, and recovery support.

If you are receiving temozolomide, your blood counts, liver function, nausea, appetite, and interaction risks become important.

If your disease has recurred, previous treatment, current performance status, steroid dependence, molecular findings, and available oncology options must be reviewed.

If your tumour is stable and you are under surveillance, the focus may include seizure control, cognition, functional recovery, long-term safety, and careful MRI monitoring.

The same Avaleha should not be used blindly in all these situations.

You should be able to understand which part of the treatment is intended for tumour-directed research, which part is intended for symptom support, which part is intended for recovery, and which part is based mainly on classical Ayurvedic reasoning.

The next section will explain the classical Ayurvedic foundation of this strategy, including Arbuda, Granthi, Majja, Dosha, Dhatu, Srotas, Agni, Ojas, and Rasayana, without falsely claiming that Ayurvedic concepts are identical to modern molecular biology.

The Ayurvedic Understanding of Glioma and Glioblastoma

Ayurvedic treatment for glioma and glioblastoma should not begin by forcing your modern diagnosis into one Sanskrit disease name.

Glioma and glioblastoma are modern medical diagnoses defined through MRI, surgery, histopathology, immunohistochemistry, and molecular testing. Classical Ayurvedic texts were written long before brain imaging, microscopic tumour grading, IDH testing, MGMT promoter methylation, or genetic sequencing became available.

This does not make Ayurveda irrelevant to your condition. It means that Ayurveda and modern neuro-oncology answer different but connected questions.

Modern diagnosis tells you what type of tumour you have, where it is located, how aggressive it may be, and which molecular changes may affect treatment.

Ayurveda examines how the tumour, surgery, radiation, chemotherapy, steroids, seizures, reduced movement, poor appetite, disturbed sleep, constipation, anxiety, and loss of strength are affecting you as a complete person.

The classical Ayurvedic framework may involve Arbuda, Granthi, Majja, Dosha, Dhatu, Srotas, Agni, Ama, Bala, Ojas, and Rasayana [41–47]. These concepts can guide an individualized treatment strategy, but they should not replace your pathology report, MRI findings, or molecular diagnosis.

Does Ayurveda Describe Glioblastoma by Name?

Classical Ayurvedic texts do not use the modern term glioblastoma.

Glioblastoma is defined today by its microscopic and molecular characteristics. Under the current World Health Organization system, glioblastoma is primarily an IDH-wildtype adult diffuse glioma with specific histological or molecular features [9,10].

The classical texts do discuss abnormal tissue growths under terms such as Granthi and Arbuda. Suśruta Saṃhitā provides one of the most important classical discussions of these conditions [42].

Arbuda is generally described as a substantial, deep-rooted, relatively fixed abnormal growth involving disturbed Doshas and affected tissues. Granthi is usually discussed as a more localized, nodular, or gland-like swelling.

These descriptions give Ayurveda a classical framework for examining abnormal tissue formation.

However, Arbuda should not be translated simply as “glioblastoma.”

A glioblastoma is highly infiltrative. Its cells may move into surrounding brain tissue beyond the visible tumour margin. It may also contain several tumour-cell populations with different genetic activity and treatment sensitivity [18–20].

A classical Arbuda description cannot provide information about IDH status, MGMT methylation, EGFR amplification, TERT promoter mutation, CDKN2A/B deletion, or chromosome changes.

The responsible conclusion is that Arbuda provides a broad Ayurvedic framework for abnormal growth, while glioblastoma remains a specific modern molecular and pathological diagnosis.

Why Glioma Cannot Be Reduced to One Ayurvedic Term

Your glioma may be an IDH-mutant astrocytoma, an oligodendroglioma, an IDH-wildtype glioblastoma, a paediatric-type diffuse glioma, or another molecularly defined tumour.

These diseases do not all behave in the same way.

Some gliomas may grow slowly for years. Others may progress rapidly. Some respond more favourably to temozolomide. Some are more strongly influenced by specific molecular alterations. Some cause severe cerebral edema, while others mainly produce seizures or gradual cognitive changes.

Ayurvedic assessment must therefore go beyond assigning one disease label.

Your doctor needs to examine the nature of the abnormal growth, the tissues and functions affected, your neurological symptoms, your strength, digestion, appetite, bowel function, sleep, mental condition, treatment exposure, and current complications.

The diagnosis may be interpreted through several connected Ayurvedic principles rather than through one fixed term.

This is one reason why the phrase Majja-Arbuda may be used as a clinical framework in this project. It connects abnormal tissue growth with the involvement of brain and neurological functions.

However, Majja-Arbuda should be presented as a modern Ayurvedic interpretive term. It is not a substitute for the WHO diagnosis, and it should not be falsely described as the exact classical Sanskrit name for glioblastoma.

What Does Majja Mean in an Ayurvedic Brain-Tumour Strategy?

Majja is one of the seven principal Dhatus described in Ayurveda.

Classical Ayurveda associates Majja with filling internal bony spaces, supporting strength, and contributing to deeper tissue nourishment. In later Ayurvedic clinical reasoning, Majja-related assessment is also used when considering some disorders involving the nervous system, cognition, sensation, movement, and deeper neurological functions.

You should not be told that Majja is scientifically identical to brain tissue, glial cells, neurons, myelin, bone marrow, or cerebrospinal fluid.

These are different systems of description.

Glial cells are defined through modern anatomy, histology, and molecular biology. Majja is a broader Ayurvedic tissue concept with its own classical meaning.

In a glioma patient, Majja-related reasoning may help your Ayurvedic doctor assess neurological weakness, disturbed coordination, cognitive decline, speech difficulty, tremors, sensory changes, loss of strength, sleep disturbance, and recovery after brain surgery.

It does not tell the doctor whether your tumour is IDH-mutant or IDH-wildtype.

Your modern diagnosis identifies the tumour. Majja-related assessment helps the Ayurvedic physician understand how the disease and its treatment are affecting your deeper neurological and functional condition.

How Vata May Be Involved in Your Neurological Symptoms

Vata governs movement, communication, sensation, coordination, and many functional activities in the Ayurvedic system.

When a brain tumour, surgery, swelling, seizure, or treatment disrupts neurological function, you may experience weakness, paralysis, tremors, speech difficulty, altered sensation, loss of balance, constipation, insomnia, anxiety, or irregular movement.

These symptoms may be interpreted partly through disturbed Vata.

Prana Vata is traditionally connected with higher functions involving the head, awareness, sensory activity, breathing, and mental function. Udana Vata is associated with speech, effort, expression, and upward movement. Vyana Vata supports wider movement and coordination throughout the body. Apana Vata affects bowel and urinary functions.

A glioma patient may therefore show several different Vata disturbances.

For example, your tumour may affect speech while steroids disturb your sleep and reduced movement causes constipation. These problems should not all be treated as one symptom.

Ayurvedic treatment may need to support neurological stability, bowel regularity, sleep, mobility, and mental calm through different measures.

However, Vata should not be called a scientific synonym for tumour invasion, nerve impulses, neurotransmitters, or one specific molecular pathway.

Vata is an Ayurvedic functional principle. It may help guide treatment of your complete symptom pattern, but it does not replace neurological examination or molecular science.

How Pitta May Be Considered Without Calling It Cancer Inflammation

Pitta is traditionally associated with transformation, heat, digestion, metabolism, discrimination, and several biochemical functions.

In a glioma patient, Pitta-related disturbance may be considered when you have excessive heat, acidity, irritability, inflammatory symptoms, burning sensations, disturbed sleep, bleeding tendency, digestive intolerance, or treatment-related liver stress.

Radiation, steroids, antibiotics, chemotherapy, poor diet, and multiple medicines may also disturb digestion and metabolism.

Your Ayurvedic doctor may therefore consider Pitta while selecting the intensity, heating quality, cooling support, digestive ingredients, and Anupana of the formulation.

This does not mean that Pitta is identical to inflammation, cytokines, oxidative stress, fever, or tumour metabolism.

Modern inflammation involves many immune cells, signalling proteins, blood vessels, and tissue responses. Pitta is a wider Ayurvedic principle and should not be forced into a one-to-one scientific definition.

The useful question is not whether Pitta “caused” your glioblastoma. The useful question is whether your present Pitta-related symptoms and treatment tolerance require modification of the Ayurvedic plan.

How Kapha May Relate to Abnormal Growth and Obstruction

Kapha is traditionally associated with structure, stability, cohesion, lubrication, nourishment, and tissue maintenance.

When Kapha becomes disturbed, Ayurveda may describe excessive heaviness, stagnation, abnormal accumulation, reduced movement, obstruction, swelling, or slow metabolic activity.

This may appear relevant when discussing an abnormal tissue mass. However, Kapha should not be presented as the direct cause of every tumour.

Kapha is not a synonym for cancer-cell proliferation, tumour volume, cerebral edema, or mucus.

A patient with glioblastoma may have an abnormal growth but also show severe Vata disturbance, tissue depletion, weakness, insomnia, poor appetite, and neurological instability.

Using only strong Kapha-reducing treatment in such a patient may worsen dryness, weakness, weight loss, constipation, or neurological symptoms.

This is why your doctor must assess the whole disease pattern.

The presence of a mass does not automatically justify one aggressive “Kapha-reducing” formula for every patient.

Why Dosha Assessment Must Be Based on Your Present Condition

Your Prakriti describes your underlying constitutional tendencies. Your Vikriti describes the disturbances currently present.

Both matter, but neither should replace your tumour diagnosis.

Two people may have a similar Prakriti while having completely different gliomas.

You may have an IDH-mutant lower-grade astrocytoma with seizures but good physical strength. Another person with the same Prakriti may have recurrent glioblastoma with severe edema, steroid dependence, poor appetite, muscle loss, and impaired consciousness.

The same Ayurvedic formulation would not be appropriate merely because both patients have a similar constitutional type.

Your present condition must be assessed through your symptoms, strength, digestion, bowel function, sleep, neurological status, laboratory tests, MRI findings, treatment phase, and current medicines.

Your formula may then be adjusted without abandoning its central treatment purpose.

This is genuine Ayurvedic personalization. It is not simply changing two herbs according to whether you are labelled Vata, Pitta, or Kapha.

What Agni Means During Glioma and Glioblastoma Treatment

Agni is commonly understood as the Ayurvedic principle governing digestion, transformation, assimilation, and metabolism.

In practical terms, your Agni influences whether you can digest food, tolerate medicine, maintain appetite, preserve strength, and eliminate waste regularly.

Glioma treatment can disturb these functions.

After surgery, you may have nausea, reduced appetite, constipation, swallowing difficulty, sedation, or altered taste. Temozolomide may cause nausea and poor appetite. Steroids may increase appetite while worsening blood sugar and muscle loss. Antibiotics and antiseizure medicines may also affect digestion and bowel function.

If your Agni is weak, giving you a very heavy, oily, highly concentrated, or excessively complex formulation may lead to bloating, nausea, loose stools, constipation, heaviness, or poor adherence.

If your digestion is excessively sharp or irritated, heating ingredients may worsen acidity, burning, disturbed sleep, or treatment intolerance.

Your Ayurvedic doctor may therefore adjust the preparation, dose, timing, Anupana, and digestive support according to your Agni.

This is not merely a comfort issue.

If you cannot tolerate the medicine, you will not receive the intended dose consistently. Poor digestion and reduced food intake may also worsen weight loss, muscle decline, and weakness.

Agni support should therefore be treated as part of the clinical strategy, not as a claim that improving digestion alone will eliminate glioblastoma.

What Ama Means—and What It Does Not Mean

Ama is commonly described as a harmful product of incomplete digestion, metabolism, or tissue processing in Ayurvedic theory.

The concept may be used when you have heaviness, coating of the tongue, reduced appetite, sluggish digestion, bowel disturbance, fatigue, or a sense that food and medicine are not being processed properly.

However, Ama should not be described as one scientifically measured toxin.

It is not automatically equivalent to tumour waste, lactic acid, inflammatory cytokines, free radicals, dead cancer cells, or one blood-test abnormality.

Statements such as “Ama is the root cause of every cancer” are too broad and are not supported by modern glioma evidence.

In your treatment, Ama-related reasoning may help the physician decide whether you first need better digestion, bowel regulation, a lighter dose, or fewer heavy ingredients.

Strong cleansing should not be used automatically.

A patient recovering from brain surgery, losing weight, taking steroids, or receiving chemoradiation may be too weak for aggressive procedures.

Your actual strength and treatment stage must guide the decision.

How Srotas and Srotorodha Are Understood

Srotas are the functional pathways through which substances, nourishment, waste, and physiological activities are understood to move in Ayurveda.

Srotorodha means obstruction or impaired flow within these pathways.

In a glioma patient, this idea may be used to understand disturbed tissue nourishment, swelling, impaired movement, constipation, reduced circulation, altered neurological function, or poor distribution of strength.

However, Srotorodha is not automatically the same as a blocked blood vessel, cerebral edema, hydrocephalus, or obstruction visible on MRI.

Those conditions have specific modern definitions and may require urgent medical treatment.

For example, severe cerebral edema may require dexamethasone and urgent neurological assessment. Obstructive hydrocephalus may require a neurosurgical procedure. Ayurveda should not delay those interventions by calling the problem Srotorodha alone.

The Ayurvedic concept may help guide supportive treatment, but modern imaging and emergency care determine whether a dangerous physical obstruction is present.

What Ojas Means for a Glioma Patient

Ojas is traditionally associated with vitality, stability, resistance, strength, and the ability to sustain life and recovery.

A person undergoing surgery, radiation, chemotherapy, repeated seizures, steroid treatment, disturbed sleep, poor appetite, and emotional stress may gradually lose strength and resilience.

Ayurveda may interpret this decline partly through reduced Ojas and Bala.

You may notice that you are eating less, losing weight, becoming more dependent, sleeping poorly, developing repeated infections, or struggling to complete treatment.

These are clinically important changes.

However, Ojas should not be described as a direct synonym for immunity, white blood cells, antibodies, albumin, or one laboratory value.

A patient may have a normal white blood cell count but still be weak and functionally depleted. Another may feel relatively strong while having treatment-related lymphopenia.

Your clinical strength and laboratory safety must therefore both be assessed.

Ojas-oriented treatment may focus on nourishment, sleep, mental stability, digestion, muscle preservation, and recovery. It should not be used as a vague claim that the medicine “boosts immunity and cures the tumour.”

What Rasayana Means in Glioma and Glioblastoma Care

Rasayana is one of the most important Ayurvedic principles for long-term restoration, tissue nourishment, strength, functional preservation, and healthy ageing [41,46,47].

It should not be reduced to the word “tonic.”

A serious Rasayana plan requires attention to digestion, diet, behaviour, sleep, medicine quality, dose, timing, and the patient’s ability to assimilate the treatment.

In glioma and glioblastoma care, Rasayana may have several possible roles.

It may support recovery after surgery, help maintain appetite and weight, support neurological rehabilitation, improve sleep, reduce treatment-related weakness, and help you remain strong enough to continue necessary treatment.

Selected Rasayana ingredients may also have modern laboratory evidence involving glioma cells, treatment resistance, inflammation, cognition, or oxidative pathways.

These different types of evidence must remain separate.

Classical Rasayana evidence can support the traditional rationale for restoration and long-term care. Laboratory research can support investigation of specific biological mechanisms. Human clinical evidence is still required to prove whether the complete formulation affects tumour progression or survival.

The word Rasayana should therefore communicate a disciplined restorative strategy, not an automatic promise of tumour elimination.

Why Rasayana Is Not the Same for Every Patient

Rasayana treatment must match your ability to digest and tolerate it.

A nourishing formulation may help a weak postoperative patient with poor appetite and weight loss. The same heavy formulation may worsen nausea or sluggish digestion in another person.

A strongly heating preparation may be poorly tolerated when you have acidity, liver stress, mouth ulcers, severe Pitta symptoms, or treatment-related inflammation.

A very drying or reducing plan may worsen constipation, insomnia, weight loss, and Vata-related neurological symptoms.

Your doctor may therefore change the base, proportion, dose, Anupana, or supporting ingredients.

This does not make the treatment unscientific. It reflects the classical Ayurvedic principle that the medicine must be suitable for the patient, disease stage, strength, digestion, season, and accompanying conditions.

The reason for every important modification should still be documented.

How Rasa, Guna, Virya, Vipaka, and Karma Guide Ingredient Selection

Ayurvedic ingredients are not selected only because a laboratory study describes them as anticancer.

The classical assessment may include Rasa, Guna, Virya, Vipaka, Prabhava, and Karma. These properties help the physician estimate how an ingredient may affect digestion, heat, dryness, heaviness, movement, elimination, strength, and Dosha balance [43–45].

Rasa describes the primary taste-related action. Guna describes qualities such as lightness, heaviness, dryness, oiliness, sharpness, or softness. Virya describes the dominant heating or cooling potency. Vipaka refers to the post-digestive effect. Prabhava may describe a distinctive action not fully explained through the other properties. Karma describes the traditional therapeutic action.

These principles are particularly important in a multi-ingredient formula.

An ingredient may show promising laboratory activity but be too heating, irritating, drying, or difficult to digest for your present condition at a high dose.

Another ingredient may be included to improve tolerability, balance excessive qualities, support digestion, or protect strength.

This is one reason why the complete formulation cannot be understood simply by listing the strongest experimental compounds.

The balance among ingredients is part of the Ayurvedic design.

Why Classical Drug Identity Must Be Verified

A Sanskrit drug name may refer to different botanical species in different regions or texts.

The plant part also matters.

The root, leaf, stem, bark, fruit, seed, resin, and purified extract may contain different chemical profiles. Modern research performed on one part cannot automatically support the use of another part.

For example, research on purified withaferin A is not identical to research on Ashwagandha root powder. Research on isolated curcumin is not identical to the use of whole Haridra. Research on purified bacoside-A is not identical to ordinary Brahmi powder.

This is why classical Nighantus, official pharmacopoeial monographs, and botanical authentication are necessary [43–45].

The final article should identify the Sanskrit name, accepted botanical name, plant part, preparation, and amount present in the Avaleha.

This gives you a way to compare the actual medicine with the material studied in research.

Why Classical Verses Must Be Used Responsibly

A Sanskrit verse can improve the authenticity of an Ayurvedic article only when it is accurate and relevant.

The book name, Sthāna, chapter, verse number, original Sanskrit, transliteration, and translation should be verified through an authoritative edition [41–44].

A verse should not be shortened in a way that changes its meaning. It should not be copied from an unverified commercial page and presented as though it directly describes glioblastoma.

Classical passages on Arbuda, Granthi, Rasayana, Majja, Agni, Ojas, and individualized treatment may support the Ayurvedic reasoning.

They cannot prove a modern clinical outcome such as longer overall survival, reduced MRI tumour volume, MGMT modification, or blood–brain barrier penetration.

Using classical evidence within its proper scope makes the article stronger and more credible.

What Majja-Arbuda Rasayana Avaleha Actually Means

Majja-Arbuda Rasayana Avaleha is a descriptive name for an individualized Ayurvedic formulation strategy.

Majja indicates the deeper neurological and tissue-related framework being considered. Arbuda indicates the classical framework of abnormal tissue growth. Rasayana indicates recovery, strength, nourishment, and long-term restorative care. Avaleha describes the semisolid dosage form.

You should not be told that this exact complete formulation appears as one fixed recipe in a single ancient book unless that claim can be verified.

Glioma and glioblastoma are complex modern diseases. The final formulation may draw on several classical principles, individual drug monographs, modern glioma research, pharmacological evidence, patient-specific assessment, and present-day quality testing.

Its credibility should not depend on pretending that the entire formula was copied from one verse.

Its credibility should come from showing why every ingredient is present, how much is used, what classical action supports it, what modern research has found, how it fits your condition, and how safety is monitored.

Why One Classical Formula Cannot Suit Every Glioma Patient

Classical Ayurveda repeatedly emphasizes individualized assessment [41–44].

Modern glioblastoma research also shows major differences among tumours and among cell populations within the same tumour [18,19].

These two systems therefore reach a compatible practical conclusion through different forms of knowledge: one fixed formula is unlikely to be appropriate for every patient.

Your formula may need to change according to your tumour subtype, grade, molecular markers, surgery, residual disease, recurrence status, cerebral edema, seizures, radiation, chemotherapy, steroids, age, weight, strength, digestion, liver function, kidney function, sleep, bowel function, and neurological deficits.

The formula should still retain a clear structure.

Personalization should not mean adding random ingredients without a documented reason. It should mean modifying a defined therapeutic plan according to your real clinical needs.

How Modern Neuro-Oncology and Ayurveda Can Work Together

Modern neuro-oncology and Ayurveda should not compete to provide the same information.

Your pathology and molecular reports determine what tumour you have.

Your MRI shows its location, size, enhancement, swelling, and changes over time.

Your neurosurgeon determines whether surgery or biopsy is possible.

Your oncology team evaluates radiation, chemotherapy, targeted treatment, Tumour Treating Fields, clinical trials, and recurrence options.

Your Ayurvedic assessment examines how the disease and its treatment are affecting your digestion, strength, sleep, bowel function, mobility, cognition, emotional state, recovery, and long-term resilience.

Ayurvedic ingredients may also be evaluated through modern research for direct glioma-related mechanisms, cerebral edema, treatment resistance, neurological support, or treatment tolerance.

This creates a disciplined integrative model.

The tumour should not be treated without understanding the patient. The patient should not be treated while ignoring the tumour biology.

What Classical Ayurveda Can Legitimately Support

Classical Ayurvedic evidence can support the rationale for individualized treatment, Rasayana care, Agni assessment, Dosha-based modification, tissue nourishment, symptom management, and long-term restoration.

It can explain why two people with the same modern diagnosis may receive different supporting ingredients or doses.

It can also explain why an Avaleha contains ingredients with different functions rather than several substances all described as direct tumour killers.

Classical evidence cannot by itself prove that a formulation crosses the blood–brain barrier, suppresses MGMT, eliminates glioma stem-like cells, reduces MRI tumour volume, prevents recurrence, or extends survival.

Those claims require modern experimental and clinical evidence.

Being clear about this distinction does not weaken Ayurveda. It protects Ayurveda from claims that the classical texts were never intended to prove.

What This Ayurvedic Framework Means for You

Your Ayurvedic plan should not be based only on the word glioma, one Dosha label, or one general anticancer formula.

Your doctor should understand your exact modern diagnosis and your complete Ayurvedic condition.

The classical framework may help identify abnormal growth, neurological disturbance, impaired digestion, obstruction, tissue depletion, reduced strength, disturbed sleep, bowel dysfunction, and loss of resilience.

Modern research can then be used to examine whether specific ingredients have relevant activity against glioma cells, treatment resistance, cerebral edema, inflammation, neurological symptoms, or treatment-related weakness.

Your final formulation should connect these two levels without confusing them.

The next section will explain why a multi-ingredient Majja-Arbuda Rasayana Avaleha may be rational, how its ingredients should be divided into distinct functional groups, and why every ingredient should have a clearly defined purpose rather than being described only as “anticancer.”

Why a Multi-Ingredient Majja-Arbuda Rasayana Avaleha May Be Rational

Ayurvedic treatment for glioma and glioblastoma should not mean mixing many herbs together and calling the result an anticancer medicine.

A multi-ingredient formulation becomes meaningful only when every ingredient has a clear purpose. You should be able to understand why it was selected, which part of the plant is used, how much is present, what Ayurveda says about it, what modern research has found, and whether the evidence relates to tumour biology, cerebral edema, neurological recovery, digestion, strength, or treatment tolerance.

Glioblastoma is not driven by one biological problem. It can involve microscopic invasion, different tumour-cell populations, glioma stem-like cells, treatment resistance, abnormal blood vessels, hypoxia, cerebral edema, seizures, neurological damage, and progressive loss of strength [18–24].

This gives a reasonable basis for investigating a carefully designed multi-target strategy.

However, using many ingredients does not automatically make a formulation more effective. It may also make the treatment more difficult to standardize, study, and monitor.

The value of Majja-Arbuda Rasayana Avaleha must therefore come from disciplined formulation design, not merely from the number or price of its ingredients.

A Multi-Ingredient Formula Should Be Structured, Not Random

Every ingredient in Majja-Arbuda Rasayana Avaleha should have a primary role.

Some ingredients may be selected because they have direct laboratory evidence in glioma or glioblastoma models. Some may be used mainly for swelling around the brain. Others may support cognition, speech, movement, sleep, appetite, digestion, bowel function, or physical strength.

One ingredient may have more than one possible action, but its strongest evidence should remain clear.

For example, Shallaki may be relevant to cerebral edema because a small randomized human study examined Boswellia serrata in patients receiving radiotherapy for brain tumours [57]. Boswellic acids have also been studied in experimental glioblastoma models [58–61].

These are two different levels of evidence.

The human study supports an edema-related role. The laboratory studies support further investigation of tumour-related mechanisms. Neither type of evidence should be stretched beyond the outcome that was actually studied. (PubMed)

The same discipline must be followed for every other ingredient.

The Classical Principle of Individualized Formulation

The following verse directly supports patient-specific treatment rather than one fixed medicine for everyone.

Book: Charaka Samhita
Section: Sutra Sthana
Chapter: Dīrghañjīvitīya Adhyāya, Chapter 1
Text number: 1/123

योगमासां तु यो विद्याद्देशकालोपपादितम्।
पुरुषं पुरुषं वीक्ष्य स ज्ञेयो भिषगुत्तमः॥१२३॥

Transliteration

Yogam āsāṁ tu yo vidyād deśa-kālopapāditam |
Puruṣaṁ puruṣaṁ vīkṣya sa jñeyo bhiṣag-uttamaḥ ||123||

English translation

The best physician is one who understands how medicines should be used according to place and time, after examining each person individually.

Urdu translation

جو طبیب ادویاتی ترکیبوں کو مقام اور وقت کے مطابق سمجھتا ہے اور ہر مریض کی انفرادی حالت کو دیکھ کر علاج کرتا ہے، وہی بہترین طبیب سمجھا جاتا ہے۔

Arabic translation

يُعَدّ الطبيب الأفضل من يعرف كيفية تركيب الأدوية واستعمالها وفق المكان والزمان، ويعالج كل مريض بعد تقييم حالته الفردية.

This verse is directly relevant to your glioma treatment because the same formulation should not be used without considering your tumour type, age, treatment stage, strength, digestion, location, climate, current medicines, and complications.

It does not mean that classical Ayurveda described IDH, MGMT, or glioblastoma molecular subtypes. It means that Ayurveda already requires the physician to examine each person separately before deciding the medicine.

Your pathology and molecular reports provide modern tumour-specific information. Your Ayurvedic assessment provides patient-specific information. Both should influence the final plan. (Charak Samhita)

The Urdu and Arabic translations in this section are plain-language explanatory translations prepared for international readers. The Sanskrit text and stated classical reference remain the primary source.

The Classical Principle of Correct Preparation and Safe Use

The next verse is especially important when discussing concentrated extracts, strong herbs, bhasmas, bioenhancers, and complex combinations.

Book: Charaka Samhita
Section: Sutra Sthana
Chapter: Dīrghañjīvitīya Adhyāya, Chapter 1
Text number: 1/126

योगादपि विषं तीक्ष्णमुत्तमं भेषजं भवेत्।
भेषजं चापि दुर्युक्तं तीक्ष्णं सम्पद्यते विषम्॥१२६॥

Transliteration

Yogād api viṣaṁ tīkṣṇam uttamaṁ bheṣajaṁ bhavet |
Bheṣajaṁ cāpi duryuktaṁ tīkṣṇaṁ sampadyate viṣam ||126||

English translation

Even a potent poison may become a useful medicine when it is correctly prepared and properly used. In contrast, even a medicine may become harmful like poison when it is wrongly prepared or improperly administered.

Urdu translation

درست تیاری اور صحیح استعمال سے ایک شدید زہر بھی مفید دوا بن سکتا ہے، جبکہ غلط تیاری یا غلط استعمال سے اچھی دوا بھی زہر جیسا نقصان پہنچا سکتی ہے۔

Arabic translation

قد تتحول مادة شديدة السمية إلى دواء نافع إذا حُضّرت واستُعملت بالطريقة الصحيحة، وقد يصبح الدواء نفسه مؤذياً كالسُّم إذا أسيء تحضيره أو استعماله.

This verse should never be used as permission to give toxic substances without evidence or monitoring.

Its real message is that the result depends on identity, purification, processing, combination, dose, timing, route, patient selection, and medical supervision.

A medicine that may be suitable for one patient can become unsafe for another.

For example, an ingredient that affects drug-metabolizing enzymes may create an interaction with your antiseizure medicine. A heavy or sweet Avaleha may be unsuitable when your blood sugar is poorly controlled. A concentrated ingredient may become unsafe when your liver or kidneys are already under stress.

The correct formulation is therefore not simply the strongest formulation. It is the formulation that is appropriate for your condition and can be used without creating a new avoidable problem. (siva.sh)

The Classical Qualities of an Appropriate Medicine

Vagbhata also provides a short but valuable description of an ideal medicine.

Book: Ashtanga Hridaya
Section: Sutra Sthana
Chapter: Āyuṣkāmīya Adhyāya, Chapter 1
Text number: 1/28

बहुकल्पं बहुगुणं सम्पन्नं योग्यमौषधम्॥२८॥

Transliteration

Bahukalpaṁ bahuguṇaṁ sampannaṁ yogyam auṣadham ||28||

English translation

An ideal medicine should be adaptable into suitable preparations, possess several useful qualities, be properly endowed with its expected quality, and be appropriate for the disease and patient.

Urdu translation

اچھی دوا وہ ہے جسے مختلف مناسب صورتوں میں تیار کیا جا سکے، جو کئی مفید خصوصیات رکھتی ہو، معیاری ہو اور مریض و مرض کے لیے موزوں ہو۔

Arabic translation

الدواء الجيد هو ما يمكن تحضيره بصور مناسبة، ويجمع خصائص نافعة متعددة، ويكون مستوفياً للجودة وملائماً للمريض والمرض.

The final word, yogya, is especially important.

A medicine may have several useful actions and still be unsuitable for you. Suitability depends on your diagnosis, treatment stage, digestive tolerance, laboratory results, concurrent medicines, and clinical risks.

This verse also helps explain why one herb may be prepared as a decoction, powder, extract, medicated ghee, or Avaleha depending on the treatment purpose.

It does not mean that every dosage form produces the same concentration or clinical effect. (eSamhita)

Why an Avaleha May Be Chosen as the Dosage Form

Avaleha is a semisolid Ayurvedic dosage form. Its general pharmaceutical principles are described in the Sharangadhara Samhita, Madhyama Khanda, Chapter 8, known as Avaleha Kalpana.

Traditional Avaleha preparation commonly combines a medicinal decoction or juice with a sweetening base and later-added powdered ingredients. Honey, ghee, or other components may be added according to the formulation and preparation method.

This dosage form can allow several ingredients to be administered together in measured quantities. It may also improve palatability for a patient who cannot tolerate several separate powders or decoctions.

However, the Avaleha form should not be described as automatically superior for every glioma patient.

Traditional Avaleha may contain sugar, jaggery, sugar candy, or honey. This becomes important when you have diabetes, steroid-induced high blood sugar, severe obesity, poor glucose control, oral infection, or difficulty swallowing.

Your base may need to be modified, reduced, divided differently, or replaced with another dosage form.

The classical Avaleha form also does not prove blood–brain barrier penetration. The presence of ghee, honey, piperine, or a semisolid base may influence palatability or absorption, but a brain-delivery claim requires direct pharmacokinetic evidence.

Majja-Arbuda Rasayana Avaleha should therefore be understood as a contemporary, individualized formulation built through Ayurvedic pharmaceutical principles. It should not be presented as one fixed glioblastoma recipe copied from a single classical verse.

The Tumour-Directed Research Group

The first functional group may contain ingredients selected because their extracts or active compounds have been investigated in glioma or glioblastoma models.

Potential examples include Shallaki-derived boswellic acids, Ashwagandha-derived withanolides, Haridra-derived curcuminoids, Guduchi extracts, bacosides from Brahmi, asiatic acid from Mandukaparni, and selected compounds from Jatamansi or Amalaki [58–61,67–68,77–81,92,98–101,105–107,110,117].

These ingredients should not all be described as clinically proven glioblastoma treatments.

The evidence may come from very different models.

Ashwagandha research has included a standardized extract containing concentrated withaferin A, conventional glioma cells, patient-derived glioblastoma cultures, and a small intracranial mouse model [67]. This is more directly relevant than a study in an unrelated cancer, but it remains preclinical evidence rather than a human glioblastoma trial.

Curcumin has been studied in patient-derived glioblastoma stem-like cells, where researchers examined cell viability, proliferation, sphere formation, and oxidative mechanisms [77]. This is relevant to tumour biology, but the experimental concentration cannot be assumed to occur in your tumour after consuming ordinary turmeric or an Avaleha.

Guduchi extract has shown differentiation-related effects in experimental glioma cells [92]. The research used a defined aqueous-ethanolic extract, which is not automatically equivalent to every Guduchi powder, decoction, or Avaleha preparation.

Bacoside-A has shown experimental effects in human glioblastoma cell lines, including unusual cell-death mechanisms and possible enhancement of temozolomide-related cytotoxicity [98,99,101]. These findings support further research, but not a claim of proven clinical tumour control.

The purpose of this group is therefore to include ingredients with the most relevant tumour-directed research while clearly disclosing the evidence level.

The Treatment-Resistance Research Group

Glioblastoma may develop resistance to temozolomide and radiation through several mechanisms. These can involve MGMT, DNA repair, cellular survival pathways, drug transport, hypoxia, and glioma stem-like cells.

A treatment-resistance group may include ingredients studied with temozolomide or against resistant cell populations.

Piperine has been studied in temozolomide-resistant human glioma cell lines [87]. It has also been investigated in relation to survivin in glioblastoma stem-like cells [88].

Curcumin has been studied with temozolomide through oxidative and AKT/mTOR-related mechanisms [78]. Bacoside-A has also been studied experimentally with temozolomide [101].

These findings may explain why selected ingredients are considered during radiation or chemotherapy.

They do not prove that the combination is safe and effective in patients.

Piperine is a good example of why possible benefit and possible interaction must be considered together. Piperine may alter P-glycoprotein and CYP3A4 activity [90]. This means it may influence the handling of other medicines.

You may be taking temozolomide, dexamethasone, an antiseizure medicine, an anticoagulant, an antiemetic, an antibiotic, or a diabetes medicine at the same time.

An ingredient intended as a bioenhancer may also change the exposure to one of these medicines.

Therefore, bioavailability enhancement should never be discussed without interaction screening. (PubMed Central (PMC))

The Cerebral Edema and Inflammation Group

This group should be separated from the tumour-directed group because improvement in swelling is not the same as tumour-cell destruction.

Cerebral edema can worsen headache, weakness, speech, movement, alertness, and seizures. It may also increase your need for dexamethasone.

Shallaki is particularly relevant because Boswellia serrata has limited direct human evidence involving edema during brain-tumour radiotherapy [57].

In the randomized pilot study, 44 patients with primary or secondary malignant brain tumours received either Boswellia serrata at 4,200 mg daily or placebo during radiotherapy. The main outcome was edema volume on MRI.

This research supports further consideration of Boswellia for an edema-related role. It does not prove that the herb controls glioblastoma progression or improves survival. (PubMed)

The formulation may also contain other ingredients selected for inflammatory or fluid-related support according to your Ayurvedic condition.

However, no herbal ingredient should be used as an automatic replacement for dexamethasone when severe brain swelling is causing dangerous symptoms.

Your neurological examination, MRI findings, blood sugar, steroid dose, infection risk, and clinical stability must guide treatment.

A steroid taper should remain medically supervised.

The Majja and Neurological Recovery Group

Your neurological needs may continue even when the tumour-directed treatment has been decided.

You may need support for memory, concentration, sleep, speech, movement, coordination, anxiety, fatigue, or rehabilitation after surgery.

Brahmi, Mandukaparni, Jatamansi, and Shankhapushpi may be considered mainly within this neurological-support group.

Brahmi and Mandukaparni have some human research concerning selected cognitive outcomes [102–104,108]. Their direct glioblastoma evidence is mainly preclinical and generally relates to purified compounds or experimental extracts [98–107].

This distinction matters.

A cognitive study in a person without a brain tumour may support a neurological or supportive rationale. It cannot be used as proof that the herb reduces glioblastoma.

Similarly, a glioblastoma-cell study may support a possible tumour-directed mechanism. It does not prove that ordinary oral use improves memory, movement, or survival in a patient.

The formula should therefore identify the primary role assigned to the ingredient.

Neurological herbs should also be used alongside physiotherapy, speech therapy, occupational therapy, swallowing support, or cognitive rehabilitation when these are needed.

The Agni, Absorption, and Tolerability Group

An effective formulation has little practical value when you cannot digest or tolerate it.

A patient recovering from brain surgery may have nausea, constipation, low appetite, swallowing difficulty, sedation, or abdominal heaviness. Temozolomide, steroids, antiseizure medicines, antibiotics, and reduced movement may add further digestive problems.

The formulation may therefore include ingredients intended to support Agni, bowel function, medicine tolerance, or absorption.

Pippali or piperine may be considered for this purpose. However, its research on bioavailability also creates interaction concerns [89,90].

A digestive ingredient should not be included simply because every classical Avaleha traditionally uses it.

Your acidity, liver function, bowel pattern, medicine list, appetite, and Pitta-Vata condition should be considered.

A strongly heating ingredient may be poorly tolerated when you have mouth ulcers, severe acidity, liver irritation, disturbed sleep, or treatment-related burning. A heavy nourishing base may be poorly tolerated when your digestion is weak.

The goal is not to make the formula as strong as possible. The goal is to help you receive the intended medicine consistently and safely.

The Rasayana, Nutrition, and Strength Group

Glioma and glioblastoma treatment may gradually reduce your strength.

You may lose appetite, body weight, muscle, sleep, mobility, or confidence. Steroids can increase blood sugar and appetite while still contributing to muscle weakness. Radiation and chemotherapy may cause fatigue, nausea, and reduced food intake.

The Rasayana group may therefore include ingredients intended to support nourishment, recovery, sleep, functional strength, and longer-term treatment tolerance.

Amalaki, selected Guduchi preparations, suitable Ghrita, and other Rasayana ingredients may be considered according to your individual condition.

These ingredients should not all be described as direct tumour killers.

Their main value may lie in helping you eat, recover, preserve strength, tolerate treatment, or maintain bowel and metabolic function.

These are clinically meaningful outcomes. They should still be reported honestly as supportive outcomes rather than tumour regression.

The Avaleha base also matters. A highly sweetened formula may provide calories, but it may be unsuitable when you have uncontrolled glucose or steroid-induced diabetes.

Rasayana care must support your body without creating a new metabolic burden.

The Patient-Specific Corrective Group

The final layer allows the physician to adjust the formula according to your present condition.

You may require greater attention to edema, seizures, constipation, insomnia, poor appetite, liver stress, kidney function, high blood sugar, weight loss, weakness, or cognitive changes.

Another patient with the same tumour name may have a completely different combination of problems.

The patient-specific group should not become an excuse to add random ingredients.

Every addition or removal should have a stated reason.

If an ingredient is reduced because your liver enzymes are elevated, that change should be recorded. If the base is changed because of high blood sugar, the reason should be documented. If a sedating ingredient is avoided because you are already taking several neurological medicines, that should also be explained.

Personalization should remain structured and reproducible.

Why the Same Ingredient May Have More Than One Role

A natural ingredient may affect several biological pathways and also have a classical supportive role.

For example, Brahmi may be selected mainly for neurological support while bacoside-A research creates a secondary tumour-directed hypothesis.

Shallaki may be selected mainly for edema support while boswellic-acid research provides a secondary tumour-related hypothesis.

Pippali may be selected for digestion or absorption while piperine research creates a secondary treatment-resistance hypothesis.

This does not mean that every possible mechanism should be listed as though it occurs clinically in your body.

The article should identify the strongest established role first, followed by secondary or experimental roles.

This prevents one ingredient from being advertised as a cure for every part of the disease.

Why More Ingredients Are Not Automatically Better

Adding more herbs can increase the number of possible actions. It can also increase the number of possible interactions and make the result harder to interpret.

A very large formula may create problems with digestion, taste, adherence, liver metabolism, blood sugar, sedation, bleeding risk, or medicine interactions.

It may also reduce the amount of each important ingredient delivered in your daily dose.

A formula containing 40 ingredients may sound more powerful than one containing 15. However, the quantity of each ingredient may become so small that it no longer resembles the material or dose used in the research being cited.

The number of ingredients should therefore be determined by therapeutic necessity, not by marketing value.

The Actual Daily Dose Must Be Compared With the Research Dose

This is one of the most important parts of evidence-based Ayurvedic formulation.

Suppose a 900-gram batch contains 10 grams of one ingredient. If your total prescribed Avaleha intake is 30 grams daily, you would receive approximately 333 milligrams of that ingredient per day, before considering processing losses, extraction strength, or batch variation.

It would be misleading to cite a human study that used 4,200 milligrams of Boswellia serrata daily and imply that 333 milligrams of an unstandardized ingredient is the same intervention [57].

The same problem applies to purified curcumin, withaferin A, piperine, bacoside-A, and asiatic acid.

A laboratory study may use a purified compound. Your Avaleha may contain the whole herb, of which the active compound is only one small part.

A mouse study may use a dose calculated per kilogram of body weight. That dose cannot be directly transferred to a human without appropriate conversion and safety assessment.

For each important ingredient, the article should disclose the amount present in the batch, your estimated daily exposure, the material used in the research, and whether a meaningful comparison is possible.

Whole Herbs and Purified Compounds Must Not Be Treated as Identical

Withaferin A is one component of Ashwagandha. It is not the same as ordinary Ashwagandha root powder.

Curcumin is one group of compounds derived from Haridra. It is not the same as whole turmeric.

AKBA is one boswellic acid. It is not the same as every Shallaki resin or Boswellia extract.

Bacoside-A is not the same as every Brahmi preparation.

Piperine is not the same as whole Pippali or black pepper.

The whole herb may contain several compounds that alter absorption, effect, or tolerance. The concentration may also vary according to plant species, growing conditions, plant part, harvesting, processing, and storage.

Therefore, an ingredient monograph must state whether the evidence relates to the whole herb, a water extract, an alcohol extract, a standardized extract, a fraction, or one purified compound.

Bhasmas Require a Separate Level of Evidence

Swarna Bhasma, Abhraka Bhasma, Heeraka Bhasma, or another processed mineral ingredient should not be added only because it is considered powerful or expensive.

If a bhasma is included, the exact product and batch need characterization.

The preparation method, Shodhana, Marana, number and type of heating cycles, elemental composition, chemical form, particle-size distribution, microbial quality, and contaminant results must be documented [54,55,121–129].

Research showing nanoscale structures in one tested Swarna Bhasma sample does not prove that every Swarna Bhasma is identical [121].

It also does not prove that the material is absorbed intact, crosses the human blood–brain barrier, accumulates in glioblastoma tissue, or improves clinical outcomes.

The bhasma should therefore have a defined classical role, a clear reason for use in your case, batch-specific testing, an appropriate dose, and laboratory safety monitoring.

The word nano should never replace pharmacokinetic and clinical evidence.

The Finished Avaleha Needs Its Own Quality Evidence

Even when every ingredient has supporting research, the complete Avaleha remains a new combined intervention.

The final formulation should have its own identity and quality documentation.

Botanical authentication helps confirm that the correct species and plant part were used. HPTLC or HPLC fingerprinting can help compare batches. Selected marker compounds can help determine whether important constituents are present consistently.

The finished formulation should also be tested for microbial contamination, pesticides, aflatoxins, inappropriate elemental impurities, and stability [49–56].

When bhasmas are present, the herbal and mineral parts of the formulation require separate and combined quality assessment.

The batch record should state when each ingredient was added, the temperature at which heat-sensitive components were mixed, the final yield, and the storage conditions.

Without this information, two batches carrying the same formulation name may not be chemically equivalent.

Individual Ingredient Evidence Does Not Prove the Complete Formula

This limitation must be stated clearly:

Evidence for the individual ingredients does not automatically prove the safety or effectiveness of the complete Majja-Arbuda Rasayana Avaleha.

Ingredients may act differently when combined.

One may improve the absorption of another. One may reduce another ingredient’s stability. Two ingredients may strengthen the same effect. They may also compete, cause digestive intolerance, or increase medicine interactions.

The complete formulation should eventually be tested as a complete formulation.

This may begin with chemical fingerprinting, stability testing, and safety evaluation. It may then progress to studies using patient-derived glioblastoma cells, combination testing with temozolomide or radiation, appropriate animal research, prospective patient safety monitoring, and registered clinical studies.

Computer-based network pharmacology may help generate research questions. It cannot prove that the complete Avaleha works in patients.

How the Formula Should Be Adjusted During Treatment

Your formula may need to change as your clinical situation changes.

The postoperative phase may require emphasis on digestion, wound recovery, bowel function, neurological rehabilitation, and edema.

During radiation and temozolomide, the priorities may shift toward blood-count monitoring, liver safety, nausea, appetite, fatigue, infection risk, and medicine interactions.

During surveillance, the emphasis may shift toward neurological function, seizures, cognition, sleep, metabolic health, strength, and long-term safety.

At recurrence, previous treatments, current performance status, steroid dependence, molecular findings, and available oncology options must be reviewed again.

Personalization should therefore be a continuing process, not a one-time constitutional label.

How You Should Know Whether the Avaleha Is Helping

The treatment should have measurable goals.

Your doctors may monitor neurological function, seizure frequency, steroid dose, appetite, weight, bowel function, sleep, mobility, speech, cognition, treatment completion, blood counts, liver function, and kidney function.

MRI findings should be interpreted in relation to surgery, radiation, chemotherapy, steroid exposure, clinical symptoms, and the possibility of pseudoprogression [32,33].

Better appetite is meaningful, but it is not tumour regression.

Reduced edema may be clinically important, but it is not identical to tumour elimination.

Improved movement may result from rehabilitation, reduced swelling, recovery after surgery, or several treatments working together.

A scan change should not be attributed entirely to Ayurveda when surgery, radiation, temozolomide, steroids, or another therapy was used during the same period.

Transparent interpretation is essential if Panaceayur intends to build credible real-world evidence.

What This Formulation Strategy Means for You

Majja-Arbuda Rasayana Avaleha should not be presented to you as a secret mixture or a universal cancer medicine.

You should be shown the structure behind it.

You should understand which ingredients are being investigated for glioma-related mechanisms, which are mainly intended for cerebral edema, which support neurological recovery, which improve digestion or tolerability, and which are used for Rasayana and strength.

You should also know the evidence level for each role.

A convincing Ayurvedic formulation is not one that claims every herb kills glioblastoma.

It is one that connects classical reasoning, modern research, realistic dosing, product quality, medicine-interaction review, patient-specific selection, and measurable clinical monitoring.

The next section will examine the important Ayurvedic ingredients individually. It will explain how each ingredient may work, which glioma or glioblastoma models were studied, whether human evidence exists, whether brain exposure has been measured, how the research dose compares with the Avaleha dose, and what safety limitations you should understand.

Shallaki for Glioma and Glioblastoma: Ayurvedic Use, Brain-Edema Evidence, and Modern Tumour Research

Shallaki is one of the most important Ayurvedic ingredients to examine when you are considering supportive treatment for glioma or glioblastoma.

It deserves attention for a specific reason. Unlike many herbs that are promoted for brain tumours only through general anticancer research, Shallaki has evidence across several relevant levels.

It has a documented place in Ayurvedic literature. Boswellia serrata has been studied directly in patients receiving radiotherapy for brain tumours. Boswellic acids have also been tested in glioma cells, patient-derived glioma stem-like cultures, radiation-combination experiments, and animal tumour models [57–64].

This does not mean that Shallaki has been proven to cure glioblastoma.

It means that Shallaki has a more direct scientific connection with brain-tumour care than many ingredients supported only by research in unrelated cancers.

For you, its most credible present role is related to cerebral edema and inflammation. Its possible direct effects on glioblastoma cells remain promising but preclinical.

What Is Shallaki?

Shallaki is generally identified as Boswellia serrata Roxb. ex Colebr., a tree belonging to the Burseraceae family.

The medicinal material most relevant to the research discussed here is the gum oleoresin collected from the tree. This fragrant resin is also known as Indian frankincense or Salai guggul.

The exact material must be stated because Shallaki gum resin, ordinary bark powder, Boswellia essential oil, a standardized Boswellia extract, purified boswellic acids, and isolated AKBA are not the same intervention.

They can contain very different amounts of active compounds.

The evidence for a purified boswellic acid cannot automatically be transferred to an unstandardized Shallaki powder. In the same way, evidence for one branded extract cannot automatically prove that every Boswellia product will act in the same way.

For Majja-Arbuda Rasayana Avaleha, the botanical identity, resin quality, extraction method, amount used, and marker-compound content should therefore be recorded.

What Ayurveda Says About Shallaki

Bhavaprakasha Nighantu describes the names and classical properties of Shallaki in the Vatadi Varga.

The verse numbering varies among editions. These verses are numbered 22–23 in several commonly used editions and online Sanskrit versions, while some printed editions number them 19–20. This variation should be mentioned so that readers can trace the passage correctly [43,44].

Book: Bhavaprakasha Nighantu
Section: Vatadi Varga
Text numbers: 22–23 in commonly used numbering; 19–20 in some editions

शल्लकी गजभक्ष्या च सुवहा सुरभी रसा ।
महेरुणा कुन्दुरुकी वल्लकी च बहुस्रवा ॥२२॥

शल्लकी तुवरा शीता पित्तश्लेष्मातिसारजित् ।
रक्तपित्तव्रणहरी पुष्टिकृत्समुदीरिता ॥२३॥

Transliteration

Śallakī gajabhakṣyā ca suvahā surabhī rasā |
Maheruṇā kundurukī vallakī ca bahusravā ||22||

Śallakī tuvarā śītā pitta-śleṣmātisārajit |
Raktapitta-vraṇaharī puṣṭikṛt samudīritā ||23||

English translation

Shallaki is also known by names such as Gajabhakshya, Suvaha, Surabhi, Rasa, Maheruna, Kunduruki, Vallaki, and Bahusrava.

It is described as astringent and cooling. It is traditionally used in conditions involving aggravated Pitta and Kapha, diarrhoea, bleeding disorders, and wounds, and it is described as supporting nourishment.

Urdu translation

شَلّکی کو گج بھکشیا، سووہا، سُربھی، رَسا، مہیرُنا، کُندُرُکی، وَلّکی اور بہُسراوا جیسے ناموں سے بھی بیان کیا گیا ہے۔

شَلّکی کو قابض ذائقے اور ٹھنڈی تاثیر والی دوا کہا گیا ہے۔ روایتی طور پر اسے پِتّ اور کَف کی زیادتی، اسہال، خون بہنے کی بعض کیفیتوں اور زخموں میں مفید اور جسمانی پرورش میں معاون بتایا گیا ہے۔

Arabic translation

تُذكر الشلّكي أيضاً بأسماء مثل غاجابهاكشيا، وسوفاها، وسورابهي، وراسا، وماهيرونا، وكُندوروكي، وفالّكي، وباهوسرافا.

تُوصَف الشلّكي بأنها قابضة وباردة التأثير. وقد استُخدمت تقليدياً في الحالات المرتبطة باضطراب بيتّا وكافا، وبعض حالات الإسهال والنزف والجروح، كما وُصفت بأنها داعمة للتغذية والقوة.

The Sanskrit passage supports the classical understanding of Shallaki as a cooling, astringent, wound-supporting, and nourishing substance.

It does not directly describe glioma, glioblastoma, cerebral edema, radiation injury, or tumour-cell death.

Its use in glioma care must therefore be built by combining the classical properties with modern brain-tumour research rather than by claiming that this verse itself describes glioblastoma. The classical text and common edition-numbering variations are independently traceable in Sanskrit sources.

Why Shallaki Is Relevant to Brain-Tumour Care

Shallaki may have two different roles in a glioma or glioblastoma strategy.

The first is a supportive role related to cerebral edema and inflammation. This is the area in which Boswellia has its most clinically relevant human brain-tumour evidence.

The second is an investigational tumour-directed role based on studies of boswellic acids in glioma cells, glioma stem-like cells, animal models, and combinations with radiation or temozolomide.

These two roles must not be confused.

Reducing cerebral edema may improve your headache, weakness, speech, balance, alertness, or steroid requirement. However, this does not necessarily mean that the number of tumour cells has decreased.

Laboratory activity against glioblastoma cells is also meaningful, but it does not prove that an oral Shallaki preparation will reach the tumour at the same concentration.

The Strongest Human Evidence Is for Cerebral Edema

The most important clinical study of Boswellia in brain-tumour care was a prospective, randomized, double-blind, placebo-controlled pilot trial involving 44 patients receiving radiotherapy for primary or secondary malignant brain tumours [57].

The patients received either Boswellia serrata at 4,200 milligrams daily or a placebo during radiotherapy.

The main outcome was the change in cerebral edema measured through T2-weighted MRI.

A reduction in cerebral edema of more than 75% was reported in 60% of the patients receiving Boswellia, compared with 26% of the patients receiving placebo. The difference was statistically significant.

No severe adverse effects were reported. Six patients in the Boswellia group experienced minor gastrointestinal discomfort.

The study did not show a significant improvement in cognitive function or quality of life. It also did not demonstrate a statistically significant reduction in dexamethasone use between the two groups.

Boswellic acids were detected in the patients’ blood, confirming that at least some constituents were absorbed.

This trial is important because it studied an outcome directly relevant to brain-tumour patients rather than relying only on general anti-inflammatory research.

What the Boswellia Brain-Edema Trial Proves

The trial provides limited but direct human evidence that a defined oral Boswellia serrata intervention may help reduce radiotherapy-associated cerebral edema in some patients with brain tumours [57].

It supports further research into Boswellia as an adjunct for swelling around the brain.

It also gives a clinically meaningful reason for considering Shallaki in a patient who has cerebral edema, steroid-related complications, or radiation-associated swelling.

The trial does not prove that Boswellia shrinks glioblastoma.

It does not prove that it prevents recurrence.

It does not prove that it extends overall survival.

It does not prove that it can safely replace dexamethasone in an emergency.

The study population also included different primary and secondary malignant brain tumours. It was not a large glioblastoma-only trial.

A later evidence review concluded that the available findings are promising but remain limited by small studies, different products, different doses, and the absence of large confirmatory trials [63].

Why Reducing Cerebral Edema Can Still Be Clinically Important

Brain swelling can cause serious neurological problems.

You may experience headache, vomiting, weakness, difficulty speaking, poor balance, confusion, increasing sleepiness, or seizures.

If Shallaki helps reduce edema, your symptoms may improve even when the underlying tumour has not changed.

This benefit should not be dismissed merely because it is supportive.

A reduction in edema may improve your ability to walk, eat, speak, participate in rehabilitation, or tolerate further treatment. It may also reduce some complications associated with prolonged high-dose steroid use if your treating doctor is able to taper the steroid safely.

However, your steroid dose should never be reduced only because you have started Shallaki.

Dexamethasone withdrawal must be supervised. A sudden or poorly planned reduction can lead to worsening brain swelling and adrenal complications.

Your neurological symptoms, MRI findings, blood sugar, infection risk, and steroid history must all be considered.

Cerebral Edema Reduction Is Not the Same as Tumour Regression

When swelling falls, an MRI may look better and your symptoms may improve.

This can create the impression that the tumour itself has reduced.

However, cerebral edema and tumour burden are different measurements.

T2 or FLAIR changes may reflect water content, inflammation, treatment effects, infiltrating tumour, or several of these factors together.

Contrast enhancement can also be influenced by steroid treatment and blood–brain barrier changes.

A true tumour-response assessment should consider comparable MRI sequences, treatment timing, steroid dose, neurological findings, and accepted response criteria [32].

The most accurate statement is therefore:

Shallaki has limited human evidence for reducing cerebral edema during brain-tumour radiotherapy. This outcome is clinically valuable, but it is not proof of glioblastoma elimination.

What Are Boswellic Acids?

Boswellia gum resin contains several pentacyclic triterpenes known as boswellic acids.

The most commonly discussed compounds include beta-boswellic acid, acetyl-beta-boswellic acid, 11-keto-beta-boswellic acid, often shortened to KBA, and acetyl-11-keto-beta-boswellic acid, commonly shortened to AKBA.

These compounds do not all behave in the same way.

They may differ in concentration, absorption, metabolism, brain distribution, and biological activity.

AKBA receives considerable attention because it has shown anti-inflammatory and tumour-related activity in experimental studies.

However, a Shallaki preparation containing gum resin is not the same as purified AKBA.

If a research paper used 99% pure AKBA, the result cannot be directly attributed to an ordinary Shallaki powder or Avaleha unless the amount of AKBA in the final formulation has been measured.

Boswellic Acids and Glioma Stem-Like Cells

One important study examined boswellic-acid derivatives in nine long-term human glioma cell lines and five patient-derived glioma-initiating or stem-like cultures [59].

The researchers found concentration-dependent reductions in cell viability and colony-forming ability.

Boswellic acids also inhibited sphere formation in selected patient-derived glioma stem-like cultures.

This is relevant because sphere formation is used as one experimental way to examine the self-renewing behaviour of stem-like tumour cells.

The study found that AKBA showed strong activity in several of the tested models. Cell death showed features consistent with apoptosis.

Sensitivity to the boswellic acids did not appear to depend clearly on p53 or MGMT status in these laboratory models.

When boswellic acids were combined with temozolomide or radiation, the effects were mainly additive. Some combinations showed experimental synergy, but this did not occur in every cell model.

The researchers also gave an important warning. The concentrations needed for strong tumour-cell effects might not be maintained inside a living organism after ordinary oral administration.

This limitation is critical. It prevents a positive cell-culture result from being presented as proof of clinical glioblastoma control.

What the Glioma Stem-Cell Study Means for You

The study makes the tumour-directed use of boswellic acids scientifically reasonable to investigate.

It is stronger than research performed only in an unrelated cancer because it included several glioma cell lines and patient-derived stem-like cultures.

However, the study did not involve patients taking Shallaki.

It did not measure MRI response.

It did not measure progression-free survival or overall survival.

It did not show that an Ayurvedic dose of Shallaki produces the same concentration in a human glioblastoma.

The correct conclusion is that boswellic acids have direct preclinical activity in glioma and glioma stem-like models, but clinical tumour-control evidence is still required.

Boswellic Acids and Glioma Growth

Earlier experimental research also reported that boswellic acids inhibited glioma growth [58].

These studies helped create the scientific basis for later research on apoptosis, cell-cycle regulation, migration, invasion, radiation response, and glioma stem-like cells.

However, older glioma models must be interpreted carefully.

Cell lines used for many years may no longer represent the full biological complexity of a modern molecularly classified human glioblastoma.

They remain useful for studying mechanisms, but they cannot reproduce the patient’s immune system, blood–brain barrier, tumour heterogeneity, surgery, radiation exposure, steroid use, or metabolism.

AKBA and Glioblastoma Cell-Cycle Control

A later study examined AKBA in glioblastoma models and reported effects on cell proliferation, migration, invasion, cell-cycle regulation, and apoptosis [60].

The research linked these effects with pathways involving p21, FOXM1, and cyclin B1.

In simple terms, these proteins help regulate whether cells continue dividing.

FOXM1 is associated with cell proliferation and progression through the cell cycle. Cyclin B1 helps cells enter an important stage of cell division. p21 can help slow or stop cell-cycle progression.

The study suggested that AKBA may interfere with the ability of glioblastoma cells to continue dividing normally.

It also reported reduced tumour growth in an animal xenograft model.

However, the tumour was grown under the skin rather than inside the brain.

This matters because a subcutaneous tumour model does not test the blood–brain barrier in the same way as an intracranial glioblastoma model.

The study supports a tumour-directed mechanism. It does not prove that oral AKBA reaches a human brain tumour at the concentration required for the same effect.

AKBA Combined With Radiation

Another study examined AKBA together with ionizing radiation in four glioma or glioblastoma-related cell lines [61].

AKBA reduced cell survival in a concentration-dependent manner. Some combinations with radiation showed greater inhibition than radiation alone.

The researchers also reported signs of apoptosis and changes in proteins associated with proliferation, angiogenesis, cell survival, and NF-kappa B signalling.

In the animal part of the study, the combined treatment reduced tumour growth more than either intervention alone.

However, the animal tumours were again grown under the skin rather than inside the brain.

The AKBA used in the laboratory was highly purified. It was dissolved and applied directly to tumour cells.

This is very different from taking whole Shallaki resin through an Avaleha.

The study supports further research into AKBA as a possible radiation-modifying compound. It does not yet establish that adding Shallaki to radiotherapy improves survival in glioblastoma patients.

What NF-Kappa B Means in Simple Language

NF-kappa B is a family of signalling proteins involved in inflammation, cell survival, immune activity, and the response to stress.

Abnormal NF-kappa B activity may help some glioblastoma cells survive radiation or other treatment.

AKBA has been studied partly because it may influence this pathway [61].

However, NF-kappa B is not simply a harmful cancer switch.

It also has normal roles in immunity and tissue responses. Its effects can differ among cells and treatment situations.

You should therefore be cautious when a website claims that one herb “blocks NF-kappa B and cures cancer.”

A laboratory pathway finding helps explain a possible mechanism. It does not prove the complete clinical result.

Can Shallaki Make Radiation More Effective?

Current evidence allows only an investigational answer.

Laboratory studies suggest that selected boswellic acids may increase the effect of radiation in certain glioblastoma models [59,61].

The human radiotherapy trial showed a meaningful reduction in cerebral edema in some patients [57].

However, that trial was not designed to prove that Boswellia made radiation kill more tumour cells. It did not demonstrate a survival advantage.

Therefore, Shallaki may have two possible roles during radiation.

Its better-supported clinical role is edema support. Its proposed radiosensitizing role remains preclinical.

You should not assume that a higher dose will produce a stronger antitumour effect. Higher exposure may instead cause digestive intolerance or increase interaction uncertainty.

Important Contradictory Evidence in Paediatric High-Grade Glioma

Not every Boswellia study has produced a favourable result.

A 2024 study examining boswellic-acid formulations in paediatric high-grade glioma models reported tumour-promoting potential under the tested conditions [62].

This finding is extremely important.

It shows why adult glioblastoma evidence cannot automatically be transferred to children.

It also shows why one boswellic-acid formulation cannot be assumed equivalent to another.

The tumour subtype, patient age, product composition, concentration, and biological model may change the result.

For a child with a brain tumour, Shallaki should therefore not be prescribed merely because adult studies appear promising. Paediatric neuro-oncology review and formulation-specific evidence are essential.

Why Negative Evidence Makes the Shallaki Section Stronger

Including contradictory evidence does not weaken the article.

It protects you from the false belief that every natural compound behaves favourably in every tumour.

Glioblastoma in an older adult, an IDH-mutant astrocytoma, and a paediatric high-grade glioma may have very different biology.

A substance that reduces growth in one model may have a neutral or unwanted effect in another.

This evidence supports the central principle of the entire glioma project:

You should not treat glioma as one disease, and you should not use one fixed Ayurvedic formula for every patient.

Do Boswellic Acids Reach the Brain?

Animal pharmacokinetic research has detected several boswellic acids in blood and brain tissue after oral administration [64].

This provides stronger evidence than simply predicting brain penetration from molecular size or fat solubility.

However, the finding must be interpreted correctly.

The research was performed in animals, not in human glioblastoma patients.

The concentration measured in brain tissue was relatively low. In some analyses, the brain concentrations were lower than the concentrations required for strong tumour-cell killing in laboratory studies.

The glioma stem-like cell study itself noted that achievable in-vivo concentrations may be below the levels needed for pronounced cytotoxic effects [59].

The human cerebral-edema trial detected boswellic acids in serum, but it did not measure them inside resected glioblastoma tissue [57].

The evidence therefore supports the statement that some orally administered boswellic-acid constituents can reach animal brain tissue.

It does not yet prove that an Ayurvedic oral dose reaches a human glioblastoma at a tumour-killing concentration.

Why You Should Be Careful With the Phrase “Crosses the Blood–Brain Barrier”

The phrase is often used too loosely.

A compound may be detected in animal brain tissue but still be present at a concentration too low to control a tumour.

It may reach normal brain tissue but not distribute evenly through glioblastoma.

It may enter the central enhancing part of the tumour but fail to reach infiltrating cells protected by a more intact blood–brain barrier.

It may also be rapidly metabolized.

The more accurate statement for Shallaki is:

Animal research has detected selected boswellic acids in brain tissue after oral administration. Human serum absorption has also been demonstrated. Direct measurement of therapeutically relevant concentrations inside human glioblastoma tissue remains limited.

Whole Shallaki Resin Is Not the Same as Purified AKBA

This distinction is essential when you read research claims.

Whole Shallaki gum resin contains several boswellic acids, volatile substances, sugars, and other resin components.

A standardized extract may contain a declared percentage of total boswellic acids.

An AKBA-enriched extract may contain a higher amount of one selected compound.

Purified AKBA may be almost entirely one isolated substance.

These interventions may have different absorption, metabolism, safety, and biological effects.

If an experiment used purified AKBA, an Avaleha containing ordinary gum resin should not claim the same dose or effect without chemical testing.

The final formulation should ideally report total boswellic acids and important markers such as KBA and AKBA.

Frankincense Oil Is Not the Same as Shallaki Resin Extract

Frankincense essential oil and Boswellia gum-resin extract should not be treated as identical.

Essential oil mainly contains volatile aromatic compounds.

The major boswellic acids discussed in glioma research are non-volatile resin compounds.

Therefore, evidence involving boswellic acids should not be used to claim that inhaling or applying frankincense essential oil will produce the same brain-tumour effect.

The form of the medicine matters as much as the plant name.

How the Shallaki Dose in the Avaleha Should Be Calculated

The daily amount of Shallaki received from Majja-Arbuda Rasayana Avaleha must be calculated before comparing it with research.

The calculation is straightforward.

The amount of Shallaki in the complete batch should be divided by the final weight of the Avaleha. The result should then be multiplied by the patient’s total daily Avaleha dose.

For example, imagine that a 900-gram batch contains 90 grams of Shallaki resin and that you take 30 grams of Avaleha daily.

In that hypothetical example, Shallaki forms 10% of the final batch. Your calculated daily exposure would therefore be approximately 3 grams.

This is only a mathematical estimate. It does not reveal how much AKBA or KBA is present.

Processing, heating, raw-material variation, moisture, extraction, and storage may affect the final chemical content.

The human brain-edema trial used 4,200 milligrams of a particular Boswellia preparation each day [57].

A much smaller amount of unstandardized Shallaki inside a complex Avaleha cannot be described as equivalent to that trial.

The research dose, formulation type, and marker content must all be compared.

Why Adding More Shallaki Is Not Automatically Better

A higher dose may increase exposure to boswellic acids, but it may also increase nausea, abdominal discomfort, diarrhoea, constipation, reflux, or difficulty tolerating the complete Avaleha.

The correct dose should be based on the treatment goal.

A dose intended for digestive or general anti-inflammatory support may be different from the product used in the cerebral-edema trial.

A standardized high-boswellic-acid extract may deliver a different amount of active compounds than the same weight of raw resin.

Your age, digestion, body weight, liver function, current medicines, radiation schedule, steroid dose, and ability to swallow should also be considered.

Can Shallaki Replace Dexamethasone?

You should not use Shallaki as an automatic replacement for dexamethasone.

Dexamethasone can reduce dangerous brain swelling rapidly. It may be essential when edema is causing weakness, vomiting, reduced consciousness, severe headache, or mass effect.

Boswellia may be considered as a supervised adjunct in selected patients, particularly when steroid exposure is becoming difficult.

However, the clinical trial did not show a statistically significant reduction in dexamethasone dose [57].

Any attempt to reduce steroids should be based on your symptoms, neurological examination, MRI findings, blood pressure, blood sugar, infection risk, and previous steroid duration.

Possible Digestive Side Effects

The most commonly reported unwanted effects of Boswellia are gastrointestinal.

You may experience nausea, abdominal discomfort, heartburn, diarrhoea, or constipation.

In the brain-tumour radiotherapy trial, six patients receiving Boswellia reported minor gastrointestinal discomfort [57].

This matters because glioma patients may already have nausea or constipation from temozolomide, antiemetics, steroids, antiseizure medicines, reduced movement, or poor appetite.

If Shallaki worsens your digestion, it may reduce your ability to take the complete Avaleha consistently.

The dose, timing, formulation base, and Anupana may need adjustment.

What Is Known About Liver Safety?

Boswellia has not been convincingly linked to clinically apparent liver injury in the available LiverTox assessment [66].

Controlled studies have generally described it as well tolerated, with adverse effects mainly involving mild digestive symptoms.

However, this does not mean that laboratory monitoring is unnecessary in a glioblastoma patient.

You may be taking temozolomide, antiseizure medicines, antibiotics, steroids, or several other products. A multi-ingredient Avaleha may also contain ingredients with different liver-safety profiles.

When several substances are used together, a safe record for Shallaki alone cannot prove the safety of the complete formula.

Your liver function should therefore be reviewed according to your oncology treatment and the complete Ayurvedic prescription.

Possible Medicine Interactions

Laboratory research has found that extracts from different Boswellia species can affect certain cytochrome P450 drug-metabolizing enzymes [65].

An in-vitro enzyme effect does not automatically mean that a clinically important interaction will occur at the dose you receive.

However, it creates a reason for caution.

Your complete medicine list should be reviewed, especially if you take antiseizure medicines, anticoagulants, corticosteroids, diabetes medicines, immunosuppressive medicines, or several liver-metabolized drugs.

Product composition matters because different Boswellia species and extracts may not produce the same interaction pattern.

When Shallaki Requires Extra Caution

Shallaki should not delay emergency treatment when you have worsening consciousness, repeated vomiting, new weakness, uncontrolled seizures, severe headache, or signs of increasing intracranial pressure.

It should also be reviewed carefully when you cannot swallow safely, have severe gastrointestinal symptoms, are preparing for surgery, use anticoagulants, have unexplained bleeding, or are taking several interacting medicines.

A paediatric brain-tumour patient requires particular caution because adult evidence cannot be transferred directly and contradictory paediatric laboratory findings exist [62].

Where Shallaki Fits in Majja-Arbuda Rasayana Avaleha

Within Majja-Arbuda Rasayana Avaleha, Shallaki may reasonably be placed in two functional groups.

Its primary evidence-based role is within the cerebral-edema and inflammatory-support group.

Its secondary role is within the tumour-directed research group because boswellic acids have shown direct activity in glioma cells, glioma stem-like cells, combination-radiation experiments, and animal tumour models [58–61].

These roles should remain clearly separated.

The formulation should not describe Shallaki as a proven glioblastoma cure.

A more accurate explanation is:

Shallaki is included because it has direct human brain-tumour evidence for cerebral-edema reduction and preclinical evidence involving glioma-cell survival, stem-like behaviour, cell division, invasion, apoptosis, and radiation response.

This statement is strong because it explains both the value and the evidence limit.

What Must Be Documented Before Shallaki Is Used

The final formulation record should identify the accepted botanical species, the resin part used, raw or extracted form, extraction ratio where relevant, total amount in the batch, estimated daily exposure, and available chemical markers.

If a standardized extract is used, the percentage of total boswellic acids and the amounts of KBA and AKBA should be reported wherever possible.

The final batch should also be checked for identity, microbial contamination, pesticides, aflatoxins, and inappropriate elemental contamination [49–52].

This allows you to know whether the medicine being given is reasonably comparable with the research being quoted.

What Outcomes Should Be Monitored

If Shallaki is being used mainly for cerebral edema, the relevant outcomes include your neurological symptoms, dexamethasone dose, blood sugar, MRI edema volume, strength, speech, balance, and alertness.

If it is being used as part of a tumour-directed investigational strategy, the outcome cannot be judged from symptoms alone.

Comparable MRI scans, treatment dates, steroid changes, radiation timing, temozolomide exposure, and neurological status must be reviewed together.

A better appetite or reduced headache may be valuable, but these outcomes should not be called tumour regression.

Current Evidence Verdict for Shallaki

Classical Ayurvedic support is present for Shallaki as an astringent, cooling, wound-supporting, and nourishing resin [43,44].

Direct human brain-tumour evidence is present but limited. It mainly supports possible reduction of radiotherapy-associated cerebral edema [57,63].

Direct preclinical glioma evidence is present. Boswellic acids have been studied in conventional glioma cell lines, patient-derived glioma stem-like cultures, radiation and temozolomide combinations, and animal tumour models [58–61].

Human evidence proving glioblastoma shrinkage, prevention of recurrence, or longer survival is not established.

Brain-distribution evidence exists mainly from animal research, while human tumour-tissue concentrations remain uncertain [57,59,64].

Safety appears generally favourable for Boswellia alone, but digestive effects, product variation, treatment interactions, and the safety of the complete multi-ingredient formulation must still be considered [65,66].

What Shallaki Evidence Means for You

Shallaki is not included merely because Ayurveda has used it for centuries.

It has a traceable classical identity, clinically relevant brain-edema research, and direct experimental evidence in glioma biology.

That makes it one of the stronger ingredients to examine for an individualized glioma or glioblastoma plan.

However, the form and dose matter.

You should know whether you are receiving raw resin, a decoction, a standardized extract, an AKBA-enriched preparation, or Shallaki as one smaller component of an Avaleha.

You should also know which outcome the doctor is trying to achieve.

If the goal is edema support, your symptoms, steroid dose, and MRI swelling should be monitored.

If the goal includes tumour-directed research, the doctor should clearly explain that the current evidence is mainly preclinical and should not be presented as established human tumour control.

Shallaki has limited direct human evidence for helping reduce brain-tumour-associated edema and meaningful preclinical evidence against several glioblastoma-related processes. It is a rational ingredient for further clinical investigation, but its ability to control glioblastoma progression or improve survival has not yet been proven in a large human trial.

Ashwagandha for Glioma and Glioblastoma: Ayurvedic Rationale, Withaferin A Research, and Safety

Ashwagandha is one of the most widely known Rasayana herbs in Ayurveda. It is commonly associated with strength, recovery, sleep, stress regulation, and restoration after illness.

Its role in glioma and glioblastoma deserves more careful attention because a standardized Ashwagandha root extract and its important compound withaferin A have been tested directly in conventional glioblastoma cells, patient-derived glioblastoma cultures, and mice carrying tumours inside the brain [67].

This makes Ashwagandha more relevant than a herb supported only by research in breast, lung, colon, or another unrelated cancer.

However, the evidence must be explained correctly.

The glioblastoma studies did not use ordinary Ashwagandha powder. They used purified withaferin A and a specially standardized Ashwagandha root extract containing a high amount of withaferin A.

The research was also preclinical. It was performed in tumour cells and mice, not in people with glioblastoma.

Therefore, Ashwagandha should not be described as a clinically proven cure for glioblastoma. Its strongest current position is as a classically supported Rasayana ingredient with direct preclinical glioblastoma evidence and possible supportive value for strength, sleep, stress, and recovery.

What Is Ashwagandha?

Ashwagandha is generally identified as Withania somnifera (L.) Dunal. It belongs to the Solanaceae family.

It is also known as Indian winter cherry. The name Indian ginseng is commonly used in commercial language, but Ashwagandha is not botanically related to true ginseng.

The part of the plant matters.

Ashwagandha root powder, root extract, leaf extract, root-and-leaf extract, purified withanolides, and isolated withaferin A are different interventions. They may contain very different amounts of active compounds.

For the classical Ayurvedic formulation discussed in this article, Ashwagandha should mean the authenticated dried mature root unless another plant part is specifically stated.

This is important because the Ayurvedic Pharmacopoeia identifies the dried mature root as the medicinal Ashwagandha material. The Ministry of AYUSH has also directed that Ashwagandha roots should be used in AYUSH products and has raised concerns about the use of leaves, particularly because leaves may contain higher concentrations of reactive withanolides such as withaferin A [75].

What Ayurveda Says About Ashwagandha

Bhavaprakasha Nighantu describes Ashwagandha in the Guduchyadi Varga.

The following verses identify its classical names and major properties.

Book: Bhavaprakasha Nighantu
Section: Guduchyadi Varga
Text numbers: 189–190

गन्धान्ता वाजिनामादिरश्वगन्धा हयाह्वया ।
वाराहकर्णी वरदा बलदा कुष्ठगन्धिनी ॥१८९॥

अश्वगन्धाऽनिलश्लेष्मश्वित्रशोथक्षयापहा ।
बल्या रसायनी तिक्ता कषायोष्णाऽतिशुक्रला ॥१९०॥

Transliteration

Gandhāntā vājināmādir aśvagandhā hayāhvayā |
Vārāhakarṇī varadā baladā kuṣṭhagandhinī ||189||

Aśvagandhā’nila-śleṣma-śvitra-śotha-kṣayāpahā |
Balyā rasāyanī tiktā kaṣāyoṣṇātiśukralā ||190||

English translation

Ashwagandha is known by names including Hayahvaya, Varahakarni, Varada, Balada, and Kushthagandhini.

It is traditionally described as reducing disturbed Vata and Kapha and as being useful in conditions involving swelling, depletion, and loss of strength. It is strengthening, Rasayana, bitter and astringent in taste, heating in potency, and strongly supportive of reproductive tissue.

Urdu translation

اشوگندھا کو ہَی اہوَیا، وراہ کرنی، وَردا، بَلدا اور کُشتھ گندھنی جیسے ناموں سے بھی بیان کیا گیا ہے۔

روایتی طور پر اسے وات اور کف کی بے ترتیبی، سوجن، جسمانی کمزوری اور بافتوں کی کمی میں مفید سمجھا گیا ہے۔ اسے طاقت بخش، رسایَن، کڑوی اور کسیلی، گرم تاثیر والی اور تولیدی دھات کو تقویت دینے والی دوا کہا گیا ہے۔

Arabic translation

تُذكر الأشواغاندا أيضاً بأسماء مثل هاياهفايا، وفاراهكارني، وفارادا، وبالادا، وكوشثاغانديني.

تُوصَف تقليدياً بأنها تساعد في اضطرابات فاتا وكافا، وفي حالات التورم والوهن ونقص قوة الأنسجة. كما توصف بأنها مقوية، ودواء راسايانا، وذات طعم مر وقابض، وتأثير دافئ، وداعمة للأنسجة التناسلية.

The wording and verse numbering are traceable to Bhavaprakasha Nighantu, Guduchyadi Varga [43,44].

These verses do not describe glioma, glioblastoma, withaferin A, brain penetration, or tumour-cell death.

Their importance is different.

They explain why Ashwagandha may be considered when you have Vata-related neurological disturbance, reduced strength, tissue depletion, swelling, poor recovery, disturbed sleep, or progressive weakness.

The tumour-directed argument must come from modern glioblastoma research, not from stretching the classical verse beyond its actual meaning.

Why Ashwagandha May Be Relevant After Glioma Surgery

Brain surgery, cerebral edema, seizures, steroids, radiation, chemotherapy, poor sleep, reduced movement, and emotional stress can gradually reduce your strength.

You may feel physically weak even when your blood tests appear acceptable. You may lose muscle, sleep poorly, become constipated, struggle with appetite, or find rehabilitation more difficult.

This is where Ashwagandha’s classical Balya and Rasayana roles may become relevant.

Balya means that the ingredient is traditionally used to support strength. Rasayana refers to a broader restorative approach involving nourishment, functional recovery, resilience, and long-term tissue support.

This does not prove that Ashwagandha removes the tumour.

It provides a classical reason for including it in the recovery and strength group of an individualized Avaleha.

Its tumour-directed role requires separate analysis of withaferin A and standardized Ashwagandha extracts.

Ashwagandha Root Is Not the Same as Withaferin A

Withaferin A is one of the withanolides found in Withania somnifera.

Withanolides are naturally occurring steroidal lactones. Different roots, leaves, extracts, and products can contain different withanolide patterns and concentrations.

Purified withaferin A is a concentrated single compound.

Ashwagandha root powder contains withaferin A along with many other natural constituents, usually at a much lower concentration than the material used in experimental cancer studies.

A standardized root extract may concentrate selected withanolides.

This means that research on isolated withaferin A cannot automatically prove that ordinary Ashwagandha root powder will produce the same effect.

The whole root may have broader supportive actions and may be tolerated differently. However, it may not deliver enough withaferin A to reproduce the concentration used in a tumour-cell experiment.

The exact preparation must therefore be identified before the research can be applied to your formulation.

What Was AshwaMAX in the Glioblastoma Study?

The most important direct Ashwagandha–glioblastoma study used a specialized extract called AshwaMAX [67].

AshwaMAX was a standardized Ashwagandha root extract containing approximately 4.3% withaferin A. Later descriptions of the same extract also report approximately 8.4% total withanolides.

This is a highly concentrated research material.

It should not be confused with ordinary Ashwagandha root powder, a general commercial capsule, or the amount of Ashwagandha contained within a large multi-ingredient Avaleha.

The study also tested isolated withaferin A separately. This allowed the researchers to compare the standardized whole-root extract with one of its main active compounds.

What Type of Glioblastoma Cells Were Studied?

The researchers used U87-MG cells and two patient-derived glioblastoma cultures called GBM2 and GBM39 [67].

U87-MG is an established laboratory glioblastoma cell line. It is widely used, but it does not represent the full biological complexity of every human glioblastoma.

GBM2 and GBM39 were derived from human glioblastoma tumours. Patient-derived cultures can preserve more clinically relevant characteristics than a conventional cell line, although they still do not reproduce the complete condition inside a patient.

The cells were grown as neurospheres.

A neurosphere is a rounded group of cells maintained under conditions that allow researchers to examine self-renewal and stem-like behaviour.

The ability to reduce neurosphere formation is relevant because glioma stem-like cells are being studied for their possible roles in treatment resistance, tumour regrowth, and recurrence.

However, a neurosphere experiment remains a laboratory model. It does not prove that the same stem-like cells will be eliminated from your tumour after oral Ashwagandha.

What Did AshwaMAX and Withaferin A Do to the Glioblastoma Cultures?

Both AshwaMAX and purified withaferin A reduced the growth and viability of the three glioblastoma cultures [67].

The researchers calculated the concentration required to reduce the measured cellular response by approximately 50%. This is commonly called the IC50.

For AshwaMAX, the reported IC50 values were approximately 1.4 micromolar equivalent in U87-MG cells, 0.19 micromolar equivalent in GBM2 cells, and 0.22 micromolar equivalent in GBM39 cells.

For purified withaferin A, the corresponding values were approximately 0.31, 0.28, and 0.25 micromolar.

These results suggest that the patient-derived GBM2 and GBM39 cultures were particularly sensitive to the standardized extract under the tested conditions.

The neurospheres also lost their organized structure and collapsed during treatment.

This is meaningful direct preclinical glioblastoma evidence.

It is stronger than a general statement that Ashwagandha is “anticancer.”

It still does not establish the oral dose required in a patient or prove that the same concentration can be reached inside a human glioblastoma.

Why Laboratory Concentrations Cannot Be Converted Directly Into an Oral Dose

A micromolar concentration describes how much compound was present in the liquid surrounding the tumour cells.

In that experiment, the tumour cells were directly exposed to AshwaMAX or withaferin A.

When you swallow Ashwagandha, several additional steps occur.

The medicine must be released from the formulation, survive digestion, be absorbed through the intestine, enter the blood, avoid rapid breakdown, reach the brain, move into tumour tissue, and remain there at a useful concentration.

The amount that you swallow is not the same as the amount that reaches your tumour.

For this reason, the laboratory IC50 cannot be converted directly into grams of Ashwagandha root powder.

You would need pharmacokinetic information showing the blood concentration, active metabolites, brain distribution, tumour concentration, and duration of exposure.

Why the Mouse Study Was More Relevant Than a Subcutaneous Tumour Study

The same research group also tested AshwaMAX in mice carrying human glioblastoma cells inside the brain [67].

This is called an orthotopic intracranial model.

Orthotopic means that the tumour was placed in the organ where the disease naturally occurs. In this case, the glioblastoma cells were implanted in the frontal region of the mouse brain.

This is more relevant to brain-tumour research than growing the tumour under the skin.

An intracranial model includes at least some of the biological challenges created by brain tissue, brain blood vessels, and systemic oral administration.

The researchers gave AshwaMAX orally at approximately 40 milligrams per kilogram every other day. Tumour activity was followed through bioluminescent imaging.

AshwaMAX reduced the bioluminescent signal during the early treatment period.

This suggests that the orally administered extract, or compounds and metabolites produced from it, had a measurable effect on tumour activity inside the mouse brain.

What the Intracranial Mouse Study Does Not Prove

The mouse study does not prove that AshwaMAX cures glioblastoma in people.

Only a very small number of mice were used. The animals were immune-deficient so that human tumour cells could grow in them. Their immune response was therefore different from the immune response of a patient.

Bioluminescent signal was used to monitor tumour activity. This is a valuable research method, but it is not the same as proving long-term clinical tumour control in a human being.

The study also did not measure withaferin A directly inside the human-type tumour tissue at repeated time points.

It therefore suggests biological activity after oral administration in an intracranial mouse model, but it does not establish the effective or safe dose for you.

Why the Rise in Tumour Signal After 30 Days Is Important

One of the most valuable findings from the AshwaMAX study was not only the early reduction in tumour signal.

After approximately 30 days, the bioluminescent signal began increasing again. The researchers interpreted this as possible development or selection of resistance [67].

This finding must not be hidden.

It shows that even when a standardized Ashwagandha extract initially affects glioblastoma in a mouse model, some tumour cells may survive and later resume growth.

This is consistent with what is already known about glioblastoma. It contains different cell populations and can adapt under treatment pressure.

The result supports several important conclusions.

Ashwagandha should not be treated as a complete stand-alone solution.

One active compound is unlikely to control every glioblastoma pathway indefinitely.

Repeated monitoring remains essential.

A multi-target formulation may be rational to investigate, but simply adding more herbs does not prove that resistance will be prevented.

The rise in signal also supports the need to study Ashwagandha in properly designed combinations rather than presenting it as a universal monotherapy.

Does Ashwagandha Target Glioma Stem-Like Cells?

The AshwaMAX study provides direct preclinical evidence involving glioblastoma neurospheres, including cultures derived from patient tumours [67].

The extract and purified withaferin A reduced neurosphere viability and caused structural collapse.

This suggests possible activity against cells maintained under stem-like growth conditions.

However, it would be inaccurate to say that Ashwagandha has been clinically proven to eliminate glioma stem cells in patients.

A neurosphere is an experimental model. It cannot reproduce the complete tumour environment, including blood vessels, immune cells, surrounding brain tissue, steroid exposure, oxygen differences, and treatment history.

The most accurate statement is:

A standardized Ashwagandha root extract and purified withaferin A have shown direct preclinical activity against conventional and patient-derived glioblastoma neurosphere cultures. Whether an oral Ayurvedic formulation can achieve the same effect inside a human tumour remains unproven.

Ashwagandha and Tumour Treating Fields

Withaferin A has also been studied with Tumour Treating Fields, commonly called TTFields [68].

TTFields use alternating electric fields delivered through arrays placed on the scalp. They are used in selected patients with glioblastoma.

In the laboratory study, low concentrations of withaferin A were combined with TTFields. The combination inhibited glioma-cell growth more strongly than either intervention alone.

The researchers described the interaction as synergistic.

Synergy means that the combined effect was greater than would be expected from simply adding the two separate effects.

This is an interesting combination-treatment finding because it examined withaferin A with an established glioblastoma treatment method rather than testing the compound only by itself.

However, the study was performed in cells.

It did not test patients receiving TTFields and Ashwagandha.

It did not establish the correct oral dose.

It did not evaluate liver safety, neurological side effects, quality of life, progression-free survival, or overall survival.

You should therefore not add a high-withaferin-A extract to TTFields treatment only because laboratory synergy was reported. The combination remains investigational.

Why Withaferin A May Work Differently From Whole Ashwagandha

Withaferin A is a chemically reactive compound. It can interact with several cellular proteins and may influence cell division, cellular structure, stress responses, and cell survival.

Whole Ashwagandha root contains many compounds in addition to withaferin A.

These other compounds may change absorption, metabolism, tolerability, and overall biological action.

This creates two important possibilities.

The whole-root extract may produce a broader but weaker effect than purified withaferin A.

Alternatively, some components of the whole root may improve, reduce, or change the activity of withaferin A.

You cannot assume that the isolated compound and the whole herb are clinically interchangeable.

This is why the AshwaMAX study is useful. It tested both a standardized root extract and purified withaferin A.

However, AshwaMAX itself was still a specialized extract. It was not the same as ordinary Ashwagandha powder used in a traditional formulation.

Does Ashwagandha Cross the Blood–Brain Barrier?

The oral intracranial mouse study suggests that AshwaMAX or its biologically active metabolites produced an effect on tumour cells growing inside the brain [67].

This provides indirect evidence of relevant systemic and intracranial exposure.

However, the study did not directly prove how much intact withaferin A entered normal brain tissue or glioblastoma tissue.

It also did not establish the concentration reached in human brain tumours.

Therefore, you should not be told that ordinary Ashwagandha root powder is clinically proven to cross the human blood–brain barrier and kill glioblastoma cells.

The scientifically accurate statement is:

Oral AshwaMAX affected intracranial glioblastoma growth in a small mouse model, suggesting that absorbed compounds or metabolites reached a biologically relevant site. Direct evidence of a therapeutic concentration inside human glioblastoma tissue is not established.

Why Root, Leaf, and Extract Evidence Must Remain Separate

Ashwagandha leaves may contain a different withanolide profile and often higher concentrations of withaferin A than the root.

This can make leaf extracts attractive for laboratory experiments. It may also increase the possibility of toxicity or create a preparation that no longer matches classical Ayurvedic root use.

For an Ayurvedic medicine, using a leaf extract and calling it equivalent to classical Ashwagandha root is not appropriate.

The ingredient label should clearly state whether the formulation contains root powder, root decoction, standardized root extract, leaf extract, or a mixed root-and-leaf preparation.

For Majja-Arbuda Rasayana Avaleha, root-only use provides the clearest connection with classical literature, pharmacopoeial identity, and current AYUSH product direction [75].

How the Ashwagandha Dose in the Avaleha Should Be Calculated

The total Ashwagandha content of the batch should be known.

You then need to calculate how much Ashwagandha you receive in your daily Avaleha dose.

Imagine that a 900-gram finished batch contains 90 grams of Ashwagandha root.

Ashwagandha would represent 10% of the final formulation.

If you take 30 grams of Avaleha daily, your estimated Ashwagandha exposure would be approximately 3 grams of root material per day.

This does not mean that you receive 3 grams of AshwaMAX.

It also does not mean that you receive 129 milligrams of withaferin A merely because AshwaMAX contained approximately 4.3% withaferin A.

Ordinary root powder may contain a very different amount.

Heating, decoction, extraction, filtration, processing, moisture, and storage can also alter the final chemical content.

The finished formulation should therefore be tested for relevant withanolide markers whenever a tumour-directed withaferin A claim is being made.

Why Withanolide Percentage Matters

A label stating “500 milligrams of Ashwagandha” does not tell you the amount of withaferin A.

One product may contain ordinary root powder. Another may contain a concentrated root extract standardized to 5% total withanolides. Another may contain leaf extract with a much higher withaferin A concentration.

These products should not be compared only by total milligram weight.

For research comparison, the formulation record should state the plant part, extract ratio, total withanolide percentage, withaferin A content where measured, extraction solvent, and daily amount delivered.

Without this information, the laboratory research cannot be connected honestly with the Avaleha.

Can Ashwagandha Be Used During Temozolomide?

The glioblastoma references reviewed here do not establish that Ashwagandha improves the effect of temozolomide in patients.

The direct studies focused mainly on AshwaMAX or withaferin A alone and with TTFields [67,68].

Therefore, you should not be told that Ashwagandha has been clinically proven to reverse MGMT-mediated temozolomide resistance.

Ashwagandha may still be considered during temozolomide for selected supportive or investigational reasons, but it requires supervision.

Temozolomide can reduce blood counts and may affect liver function. Ashwagandha has also been linked with rare but clinically important liver injury [72,73,76].

When both are used, it may become difficult to identify the cause of rising liver enzymes unless baseline and follow-up testing are properly documented.

Your liver function, blood counts, nausea, appetite, bowel function, sedation, and complete medicine list should therefore be reviewed.

Can Ashwagandha Be Used During Radiation?

There is no human glioblastoma trial proving that Ashwagandha makes radiation more effective.

The orthotopic mouse study supports general tumour-directed research, and laboratory findings with TTFields support combination investigation [67,68]. They do not establish clinical radiosensitization.

Ashwagandha may be considered during radiation for recovery, sleep, stress, appetite, or strength when appropriate.

However, the formulation should not delay radiation or be presented as a replacement for it.

Any concentrated withaferin-A extract used during radiation should be treated as an investigational combination. The effect on normal tissues, liver function, blood counts, and treatment tolerance must be considered.

How Ashwagandha May Support Sleep and Stress

A glioma diagnosis can seriously disturb sleep.

Steroids may cause insomnia, restlessness, or mood changes. Seizure medicines may cause daytime drowsiness. Anxiety about recurrence can keep you awake even when you are physically exhausted.

Ashwagandha has human research related to stress and sleep, although different studies have used different preparations and relatively small groups.

This can support its use as a possible supportive ingredient.

However, improved sleep does not mean that the tumour has reduced.

Sleep, stress, strength, and tumour response should be measured separately.

Ashwagandha’s possible calming effect can also become a disadvantage when you already take sedating antiseizure medicines, opioids, sleeping medicines, or anti-anxiety medicines.

You should be monitored for excessive sleepiness, slowed responses, reduced balance, falls, or difficulty participating in rehabilitation [74].

Can Ashwagandha Support Strength and Rehabilitation?

The classical description of Ashwagandha as Balya and Rasayana supports its use when you have weakness, reduced body weight, muscle loss, or prolonged recovery.

This may be particularly relevant after surgery or during steroid treatment.

However, Ashwagandha should not replace adequate protein, calories, physiotherapy, speech therapy, occupational therapy, or progressive movement.

If your weakness is caused by increasing cerebral edema, tumour progression, electrolyte disturbance, infection, a seizure, or steroid myopathy, the underlying cause must be identified.

A Rasayana ingredient can be part of recovery. It cannot replace investigation of a new neurological decline.

What Human Safety Studies Show

Several short human studies have found defined Ashwagandha root extracts to be generally well tolerated.

In one randomized placebo-controlled study, healthy adults received an Ashwagandha root extract for eight weeks. The investigators reported no clinically important safety problem in the studied group [70].

A later study evaluated a standardized root extract over a longer period and also reported good tolerability in the participants studied [71].

These studies are useful for understanding general root-extract safety.

They do not prove safety in a glioblastoma patient receiving temozolomide, dexamethasone, antiseizure medicines, antibiotics, anticoagulants, or several other herbs.

Healthy volunteers usually have better liver, kidney, neurological, and nutritional status than patients undergoing brain-tumour treatment.

Ashwagandha and Liver-Injury Reports

Ashwagandha is generally tolerated by many people, but rare clinically important liver injuries have been reported.

A case series from Iceland and the United States described a pattern that was often cholestatic or mixed, with jaundice and severe itching [72].

An Indian case series also reported Ashwagandha-associated liver injury, including serious outcomes in some patients who already had chronic liver disease [73].

The LiverTox assessment considers Ashwagandha a likely cause of clinically apparent liver injury in rare cases. The typical onset has been reported within approximately two to twelve weeks after starting a product. Most patients recovered after stopping it, but severe and occasionally fatal cases have occurred, particularly in people with pre-existing liver disease [76].

This evidence should not be used to claim that Ashwagandha is generally poisonous.

It means that “natural” does not equal “risk-free,” especially when the liver is already processing several medicines.

Signs That May Suggest Ashwagandha-Related Liver Injury

You should report new yellowing of the eyes or skin, dark urine, pale stools, severe itching, unusual nausea, loss of appetite, right-sided upper abdominal discomfort, or unexplained worsening fatigue.

These symptoms do not prove that Ashwagandha caused liver injury. Temozolomide, antibiotics, antiseizure medicines, infection, tumour-related illness, or another ingredient may also be responsible.

The suspected medicine should be reviewed promptly, and liver-function testing may be required.

Rechallenge with the same product should be avoided after a probable Ashwagandha-related liver injury [76].

Who Requires Greater Liver Caution?

Ashwagandha requires greater caution when you already have cirrhosis, chronic hepatitis, significant fatty-liver disease, previous herb-induced liver injury, persistent jaundice, or unexplained abnormal liver enzymes.

It also requires greater caution when your Ayurvedic formulation contains several ingredients associated with possible liver reactions.

A clean safety record for one standardized Ashwagandha extract does not prove that every commercial product or multi-herb Avaleha is safe.

Botanical identity, plant part, contaminants, extraction, dose, and the complete combination all matter.

Ashwagandha and Thyroid Function

Some research and case reports suggest that Ashwagandha may influence thyroid hormone levels.

This may be relevant if you have hyperthyroidism, thyroiditis, suppressed TSH, or are taking levothyroxine or another thyroid medicine.

Your thyroid history should be reviewed before treatment.

New palpitations, tremor, unusual sweating, unexplained weight loss, heat intolerance, or severe restlessness should not automatically be blamed on anxiety.

They may require thyroid testing.

Ashwagandha should not be described as universally balancing for every thyroid condition [74].

Ashwagandha and Antiseizure Medicines

Many glioma patients take antiseizure medicines.

Ashwagandha may cause drowsiness in some people and may interact with anticonvulsant or sedative medicines [74].

The exact interaction can depend on the medicine and Ashwagandha preparation.

The practical concern is that combined sedation may worsen sleepiness, balance, reaction time, swallowing safety, or falls.

You should not stop an antiseizure medicine because Ashwagandha has been added.

Your seizure control, alertness, balance, sleep pattern, and medicine timing should be observed.

Any new seizure, confusion, severe drowsiness, or loss of consciousness requires medical assessment.

Ashwagandha and Blood Sugar or Blood Pressure

Ashwagandha may influence blood sugar or blood pressure in some people.

This becomes relevant when dexamethasone has raised your blood sugar or when you are already taking diabetes or blood-pressure medicines.

The effect may be helpful, neutral, or excessive depending on your treatment and dose.

Your Ayurvedic physician should know all the medicines you take.

Dizziness, sweating, shakiness, faintness, or confusion may represent low blood sugar or low blood pressure and should not be assumed to be part of healing.

Ashwagandha and Immune-Modifying Treatment

Ashwagandha is often promoted as an immune-boosting herb.

This phrase is too simple for glioblastoma.

The immune system contains many cell types and signalling pathways. Stimulating one part of the immune response may not improve antitumour immunity. It may also be undesirable when you have an autoimmune disease, take immunosuppressive treatment, or are enrolled in an immunotherapy or vaccine trial.

If you are receiving an investigational glioblastoma vaccine, checkpoint inhibitor, CAR-T therapy, or another immune-based treatment, Ashwagandha should not be added without informing the trial or oncology team.

The possibility of an immune effect is a reason for coordination, not a reason for assuming universal benefit.

When Ashwagandha May Need to Be Paused

Ashwagandha should be reviewed or paused when you develop jaundice, marked liver-enzyme elevation, severe vomiting, persistent diarrhoea, an allergic reaction, excessive sedation, new thyroid overactivity, or another suspected adverse reaction.

It should also be reviewed before surgery because of possible effects on sedation, thyroid function, blood pressure, blood sugar, and interactions with perioperative medicines [74].

When you cannot swallow safely, any oral Avaleha may create an aspiration risk.

A medicine that was appropriate during stable recovery may become unsuitable during an acute infection, emergency surgery, severe neurological decline, or liver injury.

Where Ashwagandha Fits in Majja-Arbuda Rasayana Avaleha

Ashwagandha may have two clearly separated roles within Majja-Arbuda Rasayana Avaleha.

Its primary classical role is within the Rasayana, strength, recovery, and Vata-support group.

This role is supported by its traditional description as Balya and Rasayana and by its use in conditions involving depletion and loss of strength [43,44,69].

Its secondary role is within the tumour-directed research group.

This role is supported by direct preclinical evidence involving a standardized root extract and purified withaferin A in conventional glioblastoma cells, patient-derived glioblastoma neurospheres, and an oral intracranial mouse model [67].

A third investigational role relates to combination treatment, because withaferin A showed laboratory synergy with Tumour Treating Fields [68].

These roles should not be blended into one vague claim.

How Ashwagandha Should Be Described to a Patient

An inaccurate statement would be:

Ashwagandha is proven to kill glioblastoma and prevent recurrence.

A more scientifically responsible statement is:

A standardized Ashwagandha root extract and its compound withaferin A have shown direct activity in conventional and patient-derived glioblastoma models. Oral treatment also affected intracranial tumour activity in a small mouse study. These results support further investigation, but human glioblastoma tumour control, recurrence prevention, and survival benefit have not yet been established.

This language is still strong.

It tells you exactly why the ingredient was selected without presenting preclinical research as a completed human cure trial.

What Must Be Documented in the Finished Formulation

The formulation record should identify Withania somnifera root as the plant material.

It should state whether the root is used as powder, decoction material, concentrated extract, or standardized extract.

The quantity placed in the batch and your estimated daily exposure should be calculated.

Where tumour-directed withaferin A research is being used to support the ingredient, the finished product should ideally be tested for total withanolides and withaferin A.

Microbial limits, pesticide residues, aflatoxins, and inappropriate elemental contamination should also be checked.

Without these details, the formulation cannot be meaningfully compared with AshwaMAX or another research preparation.

How Your Response Should Be Monitored

If Ashwagandha is used mainly for Rasayana and recovery, the relevant outcomes include strength, sleep, appetite, body weight, rehabilitation participation, fatigue, bowel function, and daily activity.

If it is included partly for tumour-directed research, symptoms alone are not enough.

Comparable MRI scans, neurological examination, steroid dose, treatment dates, and oncology treatment must be reviewed.

Better sleep is a supportive benefit. It is not tumour regression.

Increased appetite is useful. It does not prove that glioblastoma cells have reduced.

A lower tumour signal in a mouse experiment cannot be used to declare that your MRI will show the same result.

Your blood counts, liver function, kidney function, thyroid status when indicated, seizure control, and adverse symptoms should also be followed.

Current Evidence Verdict for Ashwagandha

Classical Ayurvedic support is strong for Ashwagandha as a Balya and Rasayana ingredient used in Vata-Kapha disturbance, swelling, depletion, and loss of strength [43,44,69].

Direct preclinical glioblastoma evidence is present. A standardized root extract and purified withaferin A inhibited conventional and patient-derived glioblastoma neurospheres. Oral AshwaMAX also reduced tumour-associated bioluminescent activity in a small intracranial mouse model [67].

The preclinical evidence also revealed an important limitation. Tumour signal began rising again after approximately 30 days, suggesting possible resistance or regrowth [67].

Combination evidence with Tumour Treating Fields is present but remains laboratory-based [68].

Direct human evidence showing glioblastoma shrinkage, delayed recurrence, longer progression-free survival, or longer overall survival is not established.

General human root-extract safety data are reassuring for short-term use in selected healthy adults [70,71]. Rare but clinically important liver injury has nevertheless been reported [72,73,76].

Possible drowsiness, thyroid effects, and interactions with anticonvulsants, sedatives, diabetes medicines, blood-pressure medicines, immunosuppressants, and thyroid medicines require attention [74].

What Ashwagandha Evidence Means for You

Ashwagandha is a rational ingredient to investigate in an individualized glioma or glioblastoma plan.

Its classical role supports strength, recovery, and Rasayana care.

Its standardized root extract and withaferin A have direct preclinical relevance to glioblastoma cells and intracranial tumour models.

However, you need to know what form you are receiving.

Ordinary root powder is not equivalent to purified withaferin A. A small quantity inside an Avaleha is not automatically equivalent to a concentrated 4.3% withaferin A research extract.

The dose, plant part, extraction, withanolide content, treatment stage, liver function, thyroid status, seizure medicines, and complete formulation all matter.

Ashwagandha has a credible classical role in restoring strength and supporting recovery, together with meaningful preclinical research involving glioblastoma cells, patient-derived cultures, and an intracranial mouse model. It remains an investigational tumour-directed ingredient rather than a clinically proven glioblastoma cure, and it must be used with clear root identity, realistic dose comparison, interaction review, and liver-safety monitoring.

Haridra and Curcumin for Glioma and Glioblastoma: Ayurvedic Rationale, Stem-Cell Research, and Clinical Limits

Haridra is one of the most frequently discussed Ayurvedic ingredients in cancer research. Its principal researched compounds, known as curcuminoids, have been studied in inflammation, oxidative stress, tumour-cell survival, treatment resistance, invasion, angiogenesis, and glioblastoma stem-like cells.

This makes Haridra relevant to an evidence-based discussion of Ayurveda for glioma and glioblastoma.

However, you need to understand an important distinction from the beginning. Whole turmeric, a concentrated turmeric extract, purified curcumin, a high-bioavailability curcumin product, and curcumin applied directly to glioblastoma cells in a laboratory are not the same intervention.

Most of the tumour-directed evidence discussed in this section comes from laboratory or animal research using purified curcumin. It does not prove that ordinary turmeric powder or the quantity of Haridra present in an Avaleha will produce the same concentration inside your brain tumour.

Haridra may still have a rational place in an individualized formulation. Its role should be explained through classical Ayurveda, modern glioblastoma research, actual dose, absorption, safety, and your present Pitta, liver, digestive, and treatment condition.

What Is Haridra?

Haridra is generally identified as Curcuma longa L., a plant belonging to the Zingiberaceae family.

The rhizome is the medicinal part most commonly used in Ayurveda. A rhizome is an underground plant stem that is dried and processed into turmeric powder or used for preparing other medicinal forms.

Haridra contains several natural constituents. The most widely researched group is known as curcuminoids. Curcumin is the best-known curcuminoid, but turmeric also contains demethoxycurcumin, bisdemethoxycurcumin, volatile oils, proteins, carbohydrates, minerals, and other compounds.

The natural yellow colour of turmeric mainly comes from curcuminoids.

You should not assume that one gram of turmeric contains one gram of curcumin. The actual curcumin content can vary according to plant variety, cultivation, harvesting, processing, storage, and laboratory method [84].

This distinction becomes especially important when purified curcumin research is used to support Haridra in Majja-Arbuda Rasayana Avaleha.

What Ayurveda Says About Haridra

Bhavaprakasha Nighantu describes Haridra in the Haritakyadi Varga. Verse numbering varies between editions, but the following verses are commonly placed around text numbers 196–197.

Book: Bhavaprakasha Nighantu
Section: Haritakyadi Varga
Text numbers: Commonly numbered 196–197; numbering may differ by edition

हरिद्रा काञ्चनी पीता निशाख्या वरवर्णिनी ।
कृमिघ्नी हलदी योषित्प्रिया हेमरागिणी ॥

हरिद्रा कटुका तिक्ता रूक्षोष्णा कफपित्तनुत् ।
वर्ण्या त्वग्दोषमेहास्रशोथपाण्डुव्रणापहा ॥

Transliteration

Haridrā kāñcanī pītā niśākhyā varavarṇinī |
Kṛmighnī haladī yoṣitpriyā hemarāgiṇī ||

Haridrā kaṭukā tiktā rūkṣoṣṇā kapha-pittanut |
Varṇyā tvagdoṣa-mehāsra-śotha-pāṇḍu-vraṇāpahā ||

English translation

Haridra is also known by names such as Kanchani, Pita, Nisha, Varavarnini, Krimighni, Haladi, and Hemaragini.

It is described as pungent and bitter, dry and heating in quality. Traditionally, it is used in conditions involving disturbed Kapha and Pitta, skin disorders, metabolic and urinary disturbances, abnormal bleeding, swelling, pallor, and wounds.

Urdu translation

ہلدی کو کانچنی، پیتا، نِشا، وَر وَرنِنی، کرمِگھنی، ہلدی اور ہیم راگنی جیسے ناموں سے بھی بیان کیا گیا ہے۔

اسے تیز اور کڑوے ذائقے، خشک مزاج اور گرم تاثیر والی دوا کہا گیا ہے۔ روایتی طور پر اسے کف اور پِتّ کی بعض بے ترتیبیوں، جلدی امراض، سوجن، زخم، خون کی بعض خرابیوں، رنگت کی کمی اور استحالہ سے متعلق مسائل میں استعمال کیا گیا ہے۔

Arabic translation

تُعرف الهاريدرا أيضاً بأسماء مثل كانشاني، وبيتا، ونيشا، وفارافارنيني، وكريميغني، وهالادي، وهيماراغيني.

تُوصَف بأنها لاذعة ومُرّة، جافة وذات تأثير دافئ. وقد استُخدمت تقليدياً في بعض اضطرابات كافا وبيتّا، وفي أمراض الجلد، والتورم، والجروح، وبعض اضطرابات الدم والاستقلاب.

These verses support the traditional use of Haridra in swelling, wounds, disturbed tissue conditions, and selected metabolic and inflammatory patterns [43,44].

They do not describe glioma, glioblastoma, glioma stem cells, MGMT, temozolomide resistance, radiation sensitivity, or blood–brain barrier penetration.

The modern tumour-directed reasoning must therefore come from experimental glioblastoma research rather than from presenting the classical verse as direct proof of brain-tumour treatment.

Why Haridra May Be Considered in Glioma Care

Haridra may be considered for more than one possible role in a glioma or glioblastoma plan.

Its classical role may relate to swelling, disturbed metabolism, tissue injury, wound recovery, and selected Kapha-Pitta conditions.

Its modern investigational role comes mainly from curcumin research involving glioblastoma stem-like cells, oxidative stress, cell survival, apoptosis, AKT/mTOR, STAT3, invasion, angiogenesis, temozolomide response, and radiation response [77–81].

These roles should not be combined into one exaggerated statement.

A classical indication related to swelling does not prove that Haridra reduces cerebral edema in glioblastoma patients.

A laboratory study showing curcumin-induced death of tumour cells does not prove that culinary turmeric will remove your tumour.

The value of the ingredient depends on whether the actual formulation, daily dose, absorption, and patient condition make the published research clinically relevant.

Haridra Is Not the Same as Purified Curcumin

This is one of the most important distinctions in the entire evidence article.

Haridra is the whole turmeric rhizome. Curcumin is one purified constituent of turmeric.

A laboratory study may expose glioblastoma cells directly to purified curcumin at a known micromolar concentration. When you take Haridra orally, only part of the turmeric consists of curcuminoids, and only part of those curcuminoids is curcumin.

The curcumin must then be released from the formulation, absorbed through your intestine, transported in the blood, survive metabolism, reach the brain, enter the tumour, and remain present for enough time.

Therefore, a result produced by 25 micromolar purified curcumin in a laboratory cannot be described as the expected effect of a small quantity of turmeric powder inside an Avaleha.

The whole herb and the purified compound may both be useful, but they need separate evidence explanations.

What Glioblastoma Stem-Like Cell Research Found

One of the most relevant curcumin studies used patient-derived glioblastoma stem-like cell cultures [77].

Patient-derived cultures are prepared from human tumour samples. They may preserve more of the biological characteristics of real glioblastoma than a laboratory cell line that has been maintained for many years.

The researchers found that curcumin reduced the viability of glioblastoma stem-like cells in a dose-dependent manner.

The approximate concentration required to reduce cell viability by half was around 25 micromolar in the tested models.

Lower curcumin concentrations that did not immediately kill most cells still reduced several malignant characteristics. These included cell proliferation, the ability to form colonies, and the ability to form tumour spheres.

Sphere formation is one laboratory method used to examine stem-like behaviour and self-renewal.

These findings are relevant because glioma stem-like cells are being studied for their possible roles in treatment resistance, tumour maintenance, and recurrence [21,22].

However, the study did not involve patients taking turmeric or curcumin.

It did not measure curcumin inside human brain-tumour tissue.

It did not show improved progression-free survival or overall survival.

The correct conclusion is that curcumin has direct preclinical activity against patient-derived glioblastoma stem-like cells. Human clinical effectiveness remains unproven.

What a Concentration of 25 Micromolar Means

The concentration used in a laboratory is not the same as an oral dose.

In the cell study, curcumin was placed directly into the liquid surrounding the tumour cells. The cells were continuously exposed to a controlled concentration.

Your digestive system and bloodstream do not work like a laboratory dish.

After you swallow curcumin, much of it may remain unabsorbed. The absorbed portion may be rapidly converted into metabolites in the intestine and liver. These metabolites may have different biological actions from the original compound.

Even when curcumin appears in the blood, the concentration may be far lower than the concentration used to kill glioblastoma cells in the laboratory [82].

This is known as a translational gap.

The laboratory result provides a reason to investigate curcumin further. It does not show that ordinary oral turmeric delivers 25 micromolar curcumin to a human glioblastoma.

How Curcumin Affected Glioblastoma Stem-Like Behaviour

The glioblastoma stem-like cell study found that curcumin affected more than short-term cell viability [77].

It reduced proliferation, which means that the cells divided less actively.

It reduced colony formation, which means that fewer individual tumour cells were able to continue growing into larger groups.

It also reduced sphere formation, which may suggest an effect on stem-like self-renewing behaviour under the tested conditions.

These findings are meaningful because a substance that affects only rapidly dividing cells may leave some resistant stem-like populations untouched.

Curcumin appeared to influence several cellular processes at the same time.

However, the study does not prove permanent elimination of all stem-like cells. Surviving cells may recover, adapt, or use other pathways.

Long-term tumour behaviour inside a living human brain is much more complex than sphere formation in a culture dish.

Curcumin, Oxidative Stress, and Reactive Oxygen Species

Reactive oxygen species are chemically reactive molecules produced during normal metabolism and cellular stress.

At controlled levels, they participate in signalling. At high levels, they can damage proteins, membranes, and DNA.

The patient-derived glioblastoma study reported that curcumin increased reactive oxygen species inside the tumour cells [77].

The increase in cellular stress was associated with changes in signalling pathways and reduced tumour-cell survival.

This may sound surprising because curcumin is often promoted only as an antioxidant.

A substance can act differently according to dose, cell type, surrounding chemistry, and biological condition. Curcumin may show antioxidant effects in some settings and pro-oxidant effects in others.

In the experimental glioblastoma cells, increased oxidative stress appeared to contribute to the antitumour effect.

This does not mean that taking more turmeric will always produce greater tumour-cell oxidative stress.

A higher oral dose may instead cause digestive intolerance, interact with other medicines, or still fail to reach the tumour at the required concentration.

Curcumin and MAPK Signalling

The study also reported activation of stress-related MAPK pathways [77].

MAPK refers to groups of proteins that transmit signals inside cells. These signals can influence growth, stress response, inflammation, differentiation, and cell death.

Curcumin-related oxidative stress was associated with changes in pathways including p38 and JNK.

In simple terms, the tumour cells appeared to receive stronger internal stress signals, which contributed to reduced survival and loss of malignant behaviour.

This provides a possible molecular explanation for the laboratory findings.

It should not be described as proof that Haridra clinically controls every MAPK pathway in a patient.

MAPK signalling is complex, and different gliomas may use these pathways differently.

Curcumin and STAT3

STAT3 is a signalling protein involved in cell survival, inflammation, immune regulation, stem-like behaviour, and tumour growth.

Abnormal STAT3 activity is found in several cancers, including glioblastoma.

The patient-derived glioblastoma research reported reduced STAT3 activity after curcumin exposure [77].

This is relevant because STAT3 may help glioblastoma stem-like cells survive and maintain their malignant characteristics.

However, reduced STAT3 activity in cultured cells does not prove that orally administered Haridra will suppress STAT3 inside your tumour.

The finding supports a plausible mechanism. It does not establish the clinical dose or outcome.

Curcumin and Proteins That Protect Tumour Cells From Death

Glioblastoma cells may produce proteins that help them resist apoptosis.

The curcumin research reported changes in inhibitor-of-apoptosis proteins [77]. These proteins normally help cells avoid programmed cell death.

By reducing some of these survival signals, curcumin may make tumour cells more vulnerable to internal stress.

This is one reason curcumin is being studied in combination with chemotherapy and radiation.

The possibility is scientifically interesting, but the complete combination must be tested in humans before you can assume that it improves treatment effectiveness.

Curcumin and Temozolomide Resistance

Temozolomide is commonly used in glioblastoma treatment [25].

Some glioblastoma cells survive temozolomide because they repair DNA damage or activate survival pathways.

Curcumin has been studied experimentally as a possible temozolomide-sensitizing compound [78].

The research reported that curcumin increased reactive oxygen species and reduced activity in the AKT/mTOR survival pathway. This appeared to make glioblastoma cells more sensitive to temozolomide under the tested conditions.

AKT and mTOR are important cellular signalling proteins. They influence growth, metabolism, protein production, survival, and treatment resistance.

When these pathways remain highly active, tumour cells may be better able to survive stress.

The experimental finding suggests that curcumin may weaken some of these survival mechanisms.

However, this does not prove that curcumin reverses temozolomide resistance in patients.

The evidence remains preclinical. The safe human combination dose, brain-tumour concentration, effect on blood counts, and influence on survival have not been established.

Curcumin Is Not Proven to Change MGMT Status

MGMT promoter methylation is an important marker in glioblastoma because it may influence sensitivity to temozolomide [26].

Curcumin is sometimes promoted online as a natural way to overcome MGMT-related resistance.

The evidence reviewed here does not justify a clinical claim that oral curcumin changes your MGMT promoter methylation status or reliably overcomes an unmethylated MGMT tumour.

Experimental effects on AKT/mTOR, oxidative stress, apoptosis, or other survival pathways may still be relevant [78].

They should not be presented as proof that curcumin has reversed the molecular reason for temozolomide resistance.

Your MGMT result remains a tumour biomarker. It should not be replaced by assumptions based on herbal mechanisms.

Curcumin and Radiation

Curcumin has also been studied with radiation in preclinical glioma models [79].

The combination produced stronger anti-glioma effects than either intervention alone in some experimental settings.

The proposed mechanisms included increased cellular stress, reduced survival signalling, and greater treatment-related damage to tumour cells.

This creates a reasonable research question: could curcumin make selected glioblastoma cells more sensitive to radiation?

The current answer is that this remains possible but unproven in patients.

A preclinical combination result does not establish that you should take a concentrated curcumin product during radiation without supervision.

The effect on normal brain tissue, skin, liver function, gastrointestinal tolerance, blood counts, and other medicines must also be considered.

Why Combination Research Needs Greater Caution

When one natural compound is combined with chemotherapy or radiation, the result may be beneficial, neutral, or harmful.

A compound may make tumour cells more sensitive to treatment. It may also affect normal cells or change medicine exposure.

Curcumin can influence several signalling and metabolic pathways. The effect may depend on the dose, formulation, timing, and tumour biology.

Therefore, the statement “curcumin increases the effect of radiation” is too broad.

A more accurate statement is:

Curcumin has produced radiosensitizing effects in selected preclinical glioma models. Human evidence proving improved tumour control or survival during glioblastoma radiotherapy remains insufficient.

Curcumin and Apoptosis

Several laboratory studies report that curcumin can promote apoptosis in glioma or glioblastoma cells [77–81].

Apoptosis is a controlled process through which a damaged or abnormal cell dismantles itself.

Cancer cells often resist this process.

Curcumin may influence mitochondrial function, oxidative stress, caspases, survival proteins, and signalling pathways that regulate apoptosis.

This makes apoptosis one of the most frequently discussed curcumin mechanisms.

However, apoptosis in a laboratory dish is not the same as measurable tumour regression in a patient.

You should always ask whether the research involved cultured cells, animals, or human beings.

Curcumin and Tumour Invasion

Glioblastoma cells can move into surrounding brain tissue beyond the visible tumour border [20].

Some preclinical studies and reviews suggest that curcumin may affect proteins involved in tumour-cell migration, invasion, adhesion, and breakdown of surrounding tissue [80,81].

This may include effects on matrix metalloproteinases and other signalling pathways.

These mechanisms are relevant because controlling only the central tumour mass may not address infiltrating cells.

However, there is no human evidence showing that oral curcumin stops microscopic glioblastoma invasion in the brain.

The evidence remains mechanistic and preclinical.

Curcumin and Angiogenesis

Glioblastoma can stimulate abnormal blood-vessel formation to support its growth.

Curcumin has shown anti-angiogenic activity in laboratory and animal research [80,81].

It has been studied in relation to VEGF and other signals involved in blood-vessel formation.

This may partly explain reduced tumour growth in selected experimental models.

However, reduced VEGF activity in a laboratory does not prove that Haridra will clinically stop the blood supply of a human glioblastoma.

Angiogenesis is influenced by many pathways, and tumours can adapt when one pathway is reduced.

Curcumin and the Tumour Microenvironment

A glioblastoma is not made only of tumour cells.

It also contains immune cells, blood vessels, connective structures, inflammatory signals, and surrounding brain tissue.

Curcumin may influence some inflammatory and immune pathways within this tumour microenvironment [80,81].

This creates additional research interest.

However, immune effects can be complex. Reducing one inflammatory pathway may help in one situation and interfere with a beneficial immune response in another.

You should not be told that curcumin simply “boosts immunity.”

The immune system should not be described as one switch that only needs to be turned on.

Does Curcumin Cross the Blood–Brain Barrier?

Curcumin is fat soluble, and preclinical research suggests that curcumin or its metabolites can reach brain tissue under some experimental conditions.

This does not prove that ordinary oral turmeric delivers a tumour-killing concentration to a human glioblastoma.

Blood–brain barrier penetration is not a yes-or-no question.

The clinically important questions are how much compound reaches the blood, how much reaches normal brain tissue, how much reaches the tumour, how long it remains there, and whether the concentration is sufficient to affect tumour cells.

Oral curcumin has poor systemic bioavailability because of limited absorption, rapid metabolism, and rapid elimination [82].

Therefore, it is misleading to say only that curcumin crosses the blood–brain barrier without discussing concentration.

Why Curcumin Bioavailability Is a Major Limitation

Bioavailability means the amount of a substance that reaches the circulation in an active form.

Ordinary curcumin has low oral bioavailability [82].

It dissolves poorly in water. Much of the ingested amount may not be absorbed. The absorbed portion may be rapidly converted into glucuronide, sulfate, and other metabolites.

This is one of the greatest barriers between promising glioblastoma cell research and actual treatment in a patient.

A substance can appear powerful when placed directly on tumour cells and still have little clinical effect because it does not reach the tumour in adequate concentration.

This limitation should be explained whenever curcumin laboratory research is cited.

High-Bioavailability Curcumin Products Are Different Interventions

Several modern formulations have been developed to increase curcumin absorption.

These may use phospholipids, nanoparticles, micelles, liposomes, essential oils, piperine, or other delivery technologies.

A high-bioavailability curcumin product may produce much greater blood exposure than ordinary turmeric powder.

This can make the product more relevant to pharmacological research.

It can also increase the possibility of interactions and adverse effects.

You should not assume that a high-absorption product is automatically safer or more Ayurvedic because it contains curcumin.

The exact product, carrier, curcuminoid concentration, dose, and safety data must be reviewed.

Why Curcumin Research Can Be Overinterpreted

Curcumin has been studied in thousands of laboratory experiments. However, not every reported molecular effect is equally reliable.

Curcumin can be chemically unstable under some laboratory conditions. It may bind non-specifically to proteins, interfere with assay methods, or produce false-positive signals in selected experiments [83].

This does not mean that all curcumin research is invalid.

It means that one isolated laboratory result should not be accepted without examining the study design, controls, concentration, and whether the effect was reproduced through different methods.

A strong evidence article should include this limitation rather than listing dozens of pathways as though each has been clinically proven.

Whole Haridra May Behave Differently From Purified Curcumin

Whole turmeric contains curcuminoids and many additional compounds.

These other constituents may influence digestion, absorption, inflammation, metabolism, or tolerability.

A whole-herb preparation may produce a broader but less concentrated effect than purified curcumin.

It may also reflect classical Ayurvedic use more closely.

However, whole Haridra cannot claim the same tumour-cell effect as purified curcumin unless the delivered curcumin dose and exposure are comparable.

The safest evidence language is to describe whole Haridra and purified curcumin separately.

How Much Curcumin Is Present in Turmeric?

The amount of curcumin in turmeric powder is variable [84].

Culinary turmeric and medicinal turmeric may differ. One batch may contain more curcuminoids than another.

The percentage may also change with plant variety, cultivation, storage, and laboratory method.

Therefore, a formulation containing ten grams of Haridra does not automatically contain ten grams of curcumin.

Without chemical testing, the exact curcumin exposure remains an estimate.

If the formulation makes a tumour-directed curcumin claim, the finished batch should ideally be tested for total curcuminoids and curcumin.

How the Haridra Dose in the Avaleha Should Be Calculated

The total quantity of Haridra placed into the batch should be documented.

The daily amount can then be calculated from the final batch weight and your prescribed Avaleha dose.

For example, imagine that a 900-gram Avaleha contains 45 grams of Haridra.

Haridra would represent 5% of the finished formulation.

If you take 30 grams of Avaleha daily, your estimated Haridra intake would be approximately 1.5 grams per day.

This would not mean that you receive 1.5 grams of curcumin.

The actual curcumin exposure would depend on the curcuminoid content of the Haridra and the effect of processing.

It would also not be equivalent to a study using purified curcumin directly on tumour cells.

Why Processing Temperature Matters

Curcumin can be affected by heat, light, pH, oxygen, and storage.

The Avaleha preparation process may involve prolonged heating. The stage at which Haridra or a curcumin-rich extract is added can influence the final chemical content.

If Haridra is included in the decoction, some compounds may be extracted poorly because curcumin is not highly water soluble.

If it is added later as a fine powder, the final amount may be easier to preserve, but absorption may still remain limited.

The manufacturing record should therefore explain when Haridra was added, in what form, at what temperature, and how the final formulation was stored.

Why Haridra Should Not Be Included Automatically in Every Glioma Formula

Haridra is widely used in Ayurveda, but this does not mean that every glioma patient should receive it in the same dose.

Its heating and drying qualities may be unsuitable when you have severe acidity, mouth ulcers, burning, dehydration, low body weight, marked Vata aggravation, or poor digestive tolerance.

Your liver function, gallbladder condition, bleeding risk, medicines, radiation phase, and total formulation also matter.

A patient with strong digestion and Kapha-related heaviness may tolerate Haridra differently from a weak postoperative patient with dryness, constipation, poor appetite, and Pitta irritation.

Personalization should determine whether Haridra is included, reduced, balanced, or avoided.

Haridra During Temozolomide Treatment

Preclinical evidence suggests that curcumin may increase temozolomide sensitivity through oxidative stress and inhibition of survival pathways [78].

This does not prove that combining curcumin with temozolomide improves outcomes in patients.

Temozolomide can reduce white blood cells and platelets and may affect liver function [144].

Concentrated curcumin products may also cause digestive symptoms or, rarely, liver injury [86].

When both are used, baseline and follow-up liver tests become important. The complete formulation should also be reviewed for other ingredients that may affect the liver or drug metabolism.

You should not begin a high-bioavailability curcumin product during temozolomide without informing your treating doctors.

Haridra During Radiation

Preclinical research provides a reason to investigate curcumin as a radiation-sensitizing compound [79].

However, the clinical effect in glioblastoma patients is not established.

Radiation can cause fatigue, nausea, skin changes, neurological symptoms, and temporary worsening on MRI.

If Haridra or curcumin is used during radiation, its role should be clearly stated.

It may be included for classical anti-swelling or metabolic reasoning, general supportive care, or an investigational radiosensitizing hypothesis.

These are not the same level of evidence.

Can Haridra Replace Steroids for Cerebral Edema?

The references reviewed here do not provide direct human brain-tumour evidence showing that Haridra can replace dexamethasone.

Haridra has classical and general anti-inflammatory relevance, but that should not be confused with proven control of severe cerebral edema.

If brain swelling is causing weakness, vomiting, reduced consciousness, severe headache, or seizures, urgent neurological treatment may be required.

Dexamethasone should not be stopped or rapidly reduced because turmeric has been added.

Possible Digestive Side Effects

Turmeric in ordinary food amounts is generally well tolerated by many people.

Concentrated turmeric or curcumin products may cause nausea, abdominal discomfort, reflux, loose stools, or diarrhoea.

This becomes important when temozolomide, antibiotics, antiemetics, or other Ayurvedic ingredients are already affecting your digestion.

If you develop persistent vomiting or diarrhoea, you may become dehydrated and unable to take your other medicines correctly.

The dose and formulation should be reviewed rather than assuming that discomfort is part of a detoxification process.

Curcumin and Liver Injury

Turmeric and curcumin have generally been considered well tolerated, but clinically important liver injury has been reported, particularly with some concentrated or enhanced-bioavailability products [86].

The risk appears uncommon, but it must not be ignored.

Symptoms may include jaundice, dark urine, severe itching, nausea, reduced appetite, abdominal discomfort, or unexplained fatigue.

These symptoms require medical assessment.

In a glioblastoma patient, several other medicines can also affect the liver. Temozolomide, antiseizure medicines, antibiotics, and other herbal ingredients may all be possible causes.

This is why baseline and follow-up liver tests are more useful than assuming which product is responsible.

Why Piperine-Enhanced Curcumin Needs Greater Caution

Piperine can increase curcumin exposure, but it can also affect drug-metabolizing enzymes and transport proteins [89,90].

A curcumin-piperine combination may therefore produce a different effect from Haridra alone.

This can be useful when improved absorption is the intended research goal.

It can also increase interaction concerns with antiseizure medicines, corticosteroids, anticoagulants, diabetes medicines, and other drugs.

The Pippali section will examine this issue separately.

Possible Bleeding and Surgery Considerations

Concentrated turmeric or curcumin products may require caution when you are taking anticoagulants, antiplatelet medicines, or preparing for surgery.

The available evidence does not justify treating ordinary food-level turmeric and high-dose curcumin extracts as the same exposure.

Before brain surgery or another invasive procedure, your surgical team should be told about every herb, extract, and supplement you take.

The decision to continue or pause the product should be based on the exact formulation and your bleeding risk.

When Haridra or Curcumin May Need to Be Paused

Haridra or concentrated curcumin should be reviewed when you develop jaundice, significant liver-enzyme elevation, severe digestive symptoms, allergic reaction, unexpected bleeding, or another suspected adverse effect.

It should also be reassessed when you cannot swallow safely, are preparing for surgery, have severe dehydration, or begin a new medicine with possible interaction concerns.

The complete Avaleha may need to be paused even when Haridra alone is not confirmed as the cause.

Where Haridra Fits in Majja-Arbuda Rasayana Avaleha

Haridra may fit into more than one functional group.

Its primary classical role may be within the swelling, tissue-response, metabolic, and Kapha-Pitta-balancing group.

Its secondary role may be within the tumour-directed research group because purified curcumin has shown direct preclinical effects on patient-derived glioblastoma stem-like cells, cell proliferation, sphere formation, apoptosis-related pathways, and treatment sensitivity [77–81].

A third investigational role may relate to temozolomide and radiation combinations [78,79].

These roles should be separated in the patient explanation.

Haridra should not be described only as an anticancer ingredient.

What Must Be Documented in the Finished Formulation

The formulation record should identify Curcuma longa rhizome as the plant material.

It should explain whether Haridra is used as raw powder, decoction material, concentrated extract, or standardized curcuminoid preparation.

The quantity added to the batch and your estimated daily Haridra exposure should be calculated.

Where direct curcumin research is being used to support a tumour-directed claim, total curcuminoids and curcumin should ideally be measured in the finished product.

The manufacturing record should also state when Haridra was added, the processing temperature, final moisture, storage conditions, and batch-testing results.

How Your Response Should Be Monitored

If Haridra is used mainly for digestion, swelling, or general supportive care, the relevant outcomes may include appetite, digestive tolerance, inflammatory symptoms, bowel function, and overall treatment tolerance.

If it is included for tumour-directed research, symptoms alone cannot prove that it is working against the tumour.

MRI findings, neurological condition, steroid dose, radiation dates, temozolomide exposure, and other treatments must be assessed together.

A reduction in inflammation or better digestion may be valuable. It should not be called tumour regression.

Your liver function should be monitored according to the dose, product type, treatment phase, and complete medicine list.

Current Evidence Verdict for Haridra and Curcumin

Classical Ayurvedic support is present for Haridra in swelling, wounds, disturbed tissue conditions, and selected Kapha-Pitta patterns [43,44].

Direct preclinical glioblastoma evidence is present for purified curcumin. It has reduced viability, proliferation, colony formation, and sphere formation in patient-derived glioblastoma stem-like cells [77].

Preclinical evidence also suggests effects on reactive oxygen species, STAT3, MAPK signalling, apoptosis-related proteins, AKT/mTOR, temozolomide sensitivity, and radiation response [77–81].

Direct human evidence showing glioblastoma shrinkage, delayed recurrence, improved progression-free survival, or longer overall survival is not established.

Poor oral bioavailability remains a major barrier [82]. Curcumin’s chemical behaviour and possible assay interference also require careful interpretation of laboratory studies [83].

Whole turmeric is not equivalent to purified curcumin, and different turmeric products contain different amounts of curcuminoids [84].

Safety is generally acceptable for many people, but concentrated and enhanced-bioavailability products may cause digestive problems, interactions, or rare clinically important liver injury [85,86].

What Haridra Evidence Means for You

Haridra has a valid classical role and meaningful modern research relevance.

Purified curcumin has shown direct activity in patient-derived glioblastoma stem-like cells and has been studied with temozolomide and radiation.

These findings justify further investigation.

They do not prove that ordinary turmeric powder or a small Haridra dose inside an Avaleha reaches your brain tumour at the same concentration used in laboratory studies.

The form, dose, curcuminoid content, processing method, bioavailability, liver condition, digestive tolerance, tumour treatment, and medicine interactions all matter.

Haridra has a credible Ayurvedic role in selected swelling, tissue, metabolic, and recovery patterns, while purified curcumin has meaningful preclinical activity in glioblastoma stem-like cells and treatment-resistance pathways. Its clinical ability to control glioblastoma or improve survival remains unproven, and its use should be based on realistic dose comparison, formulation testing, liver-safety monitoring, and coordinated oncology care.

Pippali and Piperine for Glioma and Glioblastoma: Temozolomide Resistance, Bioavailability, and Safety

Pippali has an important but complex role in an Ayurvedic strategy for glioma and glioblastoma. It may be selected to support Agni, digestion, medicine tolerance, and the absorption of other ingredients. Its major researched alkaloid, piperine, has also shown direct activity in temozolomide-resistant glioma cells and glioblastoma stem-like cell models [87,88].

These findings make Pippali relevant to the treatment-resistance group of Majja-Arbuda Rasayana Avaleha. However, you need to understand that whole Pippali fruit, Pippali extract, black pepper, purified piperine, and piperlongumine are different substances.

Most direct glioblastoma research discussed in this section was performed with purified piperine. It was not performed with ordinary Pippali powder or with the complete Ayurvedic Avaleha.

Piperine is also widely described as a bioavailability enhancer. This may be useful when the objective is to improve the absorption of another ingredient. At the same time, it creates a serious need for medicine-interaction review because improving absorption may also increase your exposure to prescription medicines.

For this reason, Pippali should not be added automatically to every glioma formula. Its amount, purpose, preparation, digestive effect, Pitta tolerance, and interaction with your oncology and neurological medicines must be assessed carefully.

What Is Pippali?

Pippali is generally identified as Piper longum L., a climbing plant belonging to the Piperaceae family. The dried immature fruit is the part commonly called Pippali or long pepper.

The root is known as Pippalimula and should be treated as a separate medicinal material. Research performed on the fruit cannot automatically support the use of the root, and research on the root cannot automatically support the fruit.

Pippali is also different from Maricha, which is generally identified as Piper nigrum, or black pepper. Both plants belong to the same botanical family and may contain piperine, but their chemical composition, classical use, and piperine concentration can differ.

You should therefore not be told that black pepper, long pepper, and purified piperine are medically identical.

Pippali contains several natural compounds, including alkaloids and amides. Piperine is one of its best-known constituents, but it is not the only active compound present in the plant.

The amount of piperine in Pippali can vary according to botanical source, maturity, cultivation, storage, processing, and analytical method. A statement that an Avaleha contains a certain number of grams of Pippali does not reveal the amount of piperine unless the finished formulation is chemically tested.

What Ayurveda Says About Pippali

Bhavaprakasha Nighantu describes Pippali in the Haritakyadi Varga. The following verse is commonly numbered as text 54, although small differences may appear between printed editions.

Book: Bhavaprakasha Nighantu
Section: Haritakyadi Varga
Text number: 54

पिप्पली दीपना वृष्या स्वादुपाका रसायनी ।
अनुष्णा कटुका स्निग्धा वातश्लेष्महरी लघुः ॥५४॥

Transliteration

Pippalī dīpanā vṛṣyā svādupākā rasāyanī |
Anuṣṇā kaṭukā snigdhā vāta-śleṣmaharī laghuḥ ||54||

English translation

Pippali is described as supporting digestive fire, promoting strength and vitality, having a sweet post-digestive effect, and acting as a Rasayana. It is pungent, mildly warming rather than excessively hot, unctuous and light, and traditionally used to reduce disturbed Vata and Kapha.

Urdu translation

پِپّلی کو ہاضمہ اور اگنی کو بہتر بنانے والی، طاقت و توانائی کی معاون، میٹھے بعد از ہضم اثر والی اور رسایَن دوا کہا گیا ہے۔ اسے تیز ذائقے، معتدل گرم تاثیر، چکناہٹ اور ہلکی خاصیت والی دوا مانا گیا ہے جو روایتی طور پر وات اور کف کی بے ترتیبی میں استعمال ہوتی ہے۔

Arabic translation

تُوصَف البيبّالي بأنها داعمة لقوة الهضم، ومقوية للحيوية، وذات تأثير حلو بعد الهضم، ومن أدوية الراسايانا. وهي لاذعة، دافئة باعتدال وليست شديدة الحرارة، ذات خاصية دهنية وخفيفة، وتُستخدم تقليدياً للمساعدة في اضطرابات فاتا وكافا.

This verse is relevant to the use of Pippali within the Agni, tolerability, absorption, and Rasayana groups of an Ayurvedic formulation. It does not describe glioblastoma, temozolomide resistance, glioma stem cells, piperine pharmacokinetics, or the blood–brain barrier [43,44].

The tumour-directed argument must therefore come from modern piperine research. The classical verse explains why Pippali may be selected to support digestion, assimilation, strength, and the handling of other medicines.

Why Pippali May Be Relevant in Glioma Treatment

Pippali may be considered for three distinct purposes in a glioma or glioblastoma plan.

Its first role is classical. It may be used to support Agni when your appetite, digestion, bowel function, or tolerance of a complex formulation has declined.

Its second role relates to absorption. Piperine has been shown to alter the bioavailability of selected compounds and the activity of certain drug-transport and metabolism systems [89,90].

Its third role is experimental and tumour-directed. Purified piperine has shown activity in temozolomide-resistant glioma cell lines and in a glioblastoma stem-like cell model [87,88].

These three roles should not be merged into the broad statement that Pippali cures glioblastoma.

An ingredient may improve digestion without directly affecting the tumour. It may alter the absorption of another ingredient without having a useful brain-tumour concentration itself. It may also affect glioblastoma cells in a laboratory while remaining unproven in human patients.

You should be told which role is the main reason for including Pippali in your formulation.

Pippali Is Not the Same as Purified Piperine

The direct glioma studies used piperine as an isolated chemical compound.

Whole Pippali fruit contains piperine together with many other substances. The quantity of piperine delivered through whole Pippali may be far lower than the quantity applied directly to tumour cells in a laboratory.

The whole fruit may also behave differently because its other compounds can change digestion, absorption, metabolism, or tolerance.

This difference does not make whole Pippali inferior. It means that whole-herb evidence and isolated-compound evidence must be described separately.

A laboratory effect from purified piperine cannot be attributed directly to three or four grams of Pippali powder unless the piperine content and expected exposure are known.

Piperine Is Also Found in Black Pepper

Piperine is associated with both Pippali and Maricha. It is one of the compounds responsible for their pungent taste.

Many commercial piperine extracts are obtained from black pepper rather than long pepper. Therefore, a research paper using purified piperine may not tell you which plant source was used, or the source may not influence the final purified molecule.

The purified piperine molecule may be chemically similar regardless of whether it originated from Piper longum or Piper nigrum. The whole plants are still not interchangeable.

If Majja-Arbuda Rasayana Avaleha contains Pippali, the correct botanical name and fruit part should be recorded. If it contains a standardized piperine extract, that should be stated separately.

Piperine and Temozolomide-Resistant Glioma Cells

One of the most directly relevant studies examined piperine together with temozolomide in temozolomide-resistant human glioma cell lines [87].

The researchers used U251-MG and T98G cells. These laboratory models are commonly used to investigate aggressive glioma biology and reduced temozolomide sensitivity.

Piperine and temozolomide were tested separately and in combination. The lower-dose combination reduced cell viability more strongly than either substance used alone under the tested conditions.

The researchers also found increased evidence of apoptosis and activation of stress-related JNK and p38 MAPK pathways in the combination-treated cells [87].

This is direct preclinical glioma evidence. It is more relevant than research performed only in an unrelated cancer.

However, the study was conducted in cultured cells. It did not involve people with glioblastoma, an animal carrying an intracranial tumour, or a complete Pippali-based formulation.

What Temozolomide Resistance Means

Temozolomide damages tumour-cell DNA. Some glioblastoma cells can survive this damage because they have effective DNA-repair systems or activate pathways that protect them from treatment-related stress.

MGMT is one important factor, but it is not the only cause of temozolomide resistance. Resistance may also involve altered apoptosis, survival pathways, drug transport, stem-like cells, hypoxia, and biological changes that develop during treatment.

The piperine study suggests that piperine may make certain resistant cells more vulnerable to temozolomide by increasing cellular stress and promoting programmed cell death [87].

It does not prove that piperine changes your MGMT promoter methylation status.

It also does not prove that piperine will overcome every unmethylated MGMT glioblastoma.

You should therefore not be told that Pippali reverses MGMT resistance unless a properly designed human study demonstrates that effect.

What Synergy Means in the Piperine Study

Synergy means that two treatments used together produce a stronger effect than would be expected from simply adding their separate effects.

The glioma-cell study reported a synergistic relationship between low concentrations of piperine and temozolomide under the tested laboratory conditions [87].

This is important because reducing the amount of a toxic treatment while maintaining or increasing its tumour-cell effect is a major goal in combination research.

However, laboratory synergy does not automatically become clinical synergy.

A combination may appear effective when both substances are placed directly around tumour cells. After oral use, piperine must be absorbed and reach the brain tumour at a useful concentration.

The combination must also be tested for effects on normal cells, blood counts, liver function, neurological symptoms, and other medicines.

The term synergy should therefore be followed by the words “in the tested cell model” unless human evidence is available.

Piperine, JNK, and p38 MAPK

The temozolomide-resistance study reported greater activation of JNK and p38 MAPK in the combination-treated glioma cells [87].

JNK and p38 are stress-responsive signalling pathways. When tumour cells experience sufficient stress, these pathways can contribute to cell-cycle disruption or apoptosis.

In simple language, the combination appeared to increase internal stress signals that made the glioma cells less able to survive.

This provides one possible explanation for the observed laboratory effect.

It does not mean that JNK and p38 are always beneficial pathways. Their roles can change according to cell type, treatment, duration, and tumour condition.

A website should not reduce the result to the statement that piperine switches on two proteins and therefore cures glioblastoma.

Piperine and Apoptosis

The combination of piperine and temozolomide increased markers associated with apoptosis in the resistant glioma cells [87].

Apoptosis is a regulated form of cell death. Cancer cells often survive because they block or weaken the internal signals that would normally cause a severely damaged cell to die.

Piperine may have reduced some of this resistance under laboratory conditions.

The finding supports piperine as a possible chemosensitizing compound. It does not establish the oral dose needed to produce the same effect in your tumour.

The concentration around a cultured cell is controlled directly by the researcher. Your blood and brain tumour may never reach the same concentration after taking whole Pippali.

Why the U251-MG and T98G Models Have Limits

U251-MG and T98G are established laboratory cell lines.

They are useful for comparing mechanisms, treatment responses, and molecular pathways. They also provide repeatable experimental systems that can be used by different research groups.

However, they do not reproduce the full complexity of your tumour.

Your glioblastoma may contain several cell populations, blood vessels, immune cells, hypoxic areas, treatment-related scar tissue, and infiltrating cells protected by a partly intact blood–brain barrier.

A cell line also does not reproduce your digestion, liver metabolism, kidney elimination, concurrent medicines, or immune response.

The laboratory study supports a research hypothesis. It does not provide a clinical treatment protocol.

Piperine and Glioblastoma Stem-Like Cells

A second study examined piperine in a glioblastoma stem-like cell model and focused on a protein called survivin [88].

The researchers produced stem-like cells from the U87 glioblastoma cell line. They then examined survivin expression and the effects of piperine on stemness, tumour-related behaviour, and temozolomide response.

The reported piperine IC50 was approximately 120 micromolar in the tested cells. This means that around this concentration was required to reduce the measured cell response by approximately half [88].

This concentration is important because it reminds you that the experiment used purified piperine applied directly to cells.

The study does not show that an oral Pippali dose produces 120 micromolar piperine inside a human brain tumour.

What Is Survivin?

Survivin is a protein also known as BIRC5. It participates in cell division and helps some cells resist apoptosis.

Survivin is frequently expressed at high levels in cancers while being much less active in many mature normal tissues.

In glioblastoma research, survivin is of interest because it may help tumour cells continue dividing, resist cell death, and survive treatment.

The stem-like cell study reported that survivin was connected with stemness and treatment resistance in the experimental model [88].

When piperine reduced survivin-related activity, the glioblastoma stem-like cells became more responsive to temozolomide.

This makes survivin a plausible target for combination research. It does not prove that piperine will suppress survivin safely and sufficiently in a human glioblastoma.

How Piperine Affected Stem-Like Characteristics

The study examined markers associated with stemness, migration, and tumour behaviour [88].

Piperine treatment was associated with reduced survivin activity and changes in genes or proteins connected with the stem-like condition.

The researchers also examined migration-related markers and the response to temozolomide.

The combination of lower concentrations of piperine and temozolomide produced a stronger effect than either intervention alone in the U87-derived model [88].

This supports further investigation of piperine as a compound that may weaken selected stem-like and survival characteristics.

The model was derived from one established cell line. It was not a collection of patient-derived glioblastoma stem cells from people with different molecular tumours.

This limits how broadly the findings can be applied.

Why the Piperine Concentration Matters

An IC50 of approximately 120 micromolar is a relatively high direct laboratory exposure.

You should not compare this concentration with milligrams of Pippali without pharmacokinetic data.

A micromolar concentration describes the amount of purified piperine in the liquid around the cells. A milligram dose describes the amount swallowed.

Between these two measurements, the compound must pass through digestion, absorption, metabolism, circulation, brain delivery, and tumour entry.

Without measuring piperine in human blood and tumour tissue, you cannot assume that a Pippali-containing Avaleha reaches the concentration used in the stem-like cell experiment.

This is one of the main limitations of the tumour-directed piperine evidence.

Does Piperine Eliminate Glioma Stem Cells?

The available evidence does not justify that claim.

Piperine affected U87-derived stem-like cells, survivin, and temozolomide responsiveness under laboratory conditions [88].

This is meaningful preclinical evidence.

It does not show that oral Pippali eliminates all glioma stem cells inside a patient.

Glioblastoma stem-like cells are not one uniform population. Their behaviour can vary according to tumour genetics, oxygen levels, treatment history, and surrounding brain tissue.

Even a compound that affects one stem-like model may be less effective in another.

The accurate conclusion is that piperine has shown direct experimental activity in a glioblastoma stem-like cell model and deserves further study.

Piperine Should Not Be Confused With Piperlongumine

Piperlongumine is another natural compound found in some Piper species, including Piper longum.

Piperlongumine has also been studied in glioblastoma and treatment-resistance research.

It is chemically different from piperine.

A study of piperlongumine cannot be cited as though it were a study of piperine or whole Pippali. The dose, targets, absorption, and safety may differ.

This distinction is necessary because the similar names can easily mislead readers.

If the formulation contains whole Pippali, it may contain several related compounds, but the amount of each must be measured before assigning the effect of a purified compound to the finished Avaleha.

Piperine as a Bioavailability Enhancer

Piperine is widely known for increasing the systemic exposure of selected compounds.

One well-known human study examined curcumin alone and curcumin combined with piperine [89].

When healthy volunteers received two grams of curcumin alone, blood concentrations were very low or undetectable. When 20 milligrams of piperine was given with the same curcumin dose, the measured relative bioavailability of curcumin increased substantially during the early period after administration.

The study reported an approximately 2,000% increase in relative bioavailability under the tested conditions [89].

This finding is often used to justify combining Pippali or piperine with Haridra.

However, the study was small, involved healthy volunteers, and measured curcumin in blood over a short period. It did not involve glioblastoma patients, tumour tissue, MRI response, or survival.

An increase in blood curcumin does not prove that a tumour-killing concentration reached the brain.

What a 2,000% Increase Really Means

A percentage can sound more impressive than the underlying result.

A 2,000% relative increase may occur when the original blood concentration is extremely low. The final concentration may still be far below the level required to reproduce a laboratory tumour-cell effect.

The study shows that piperine can meaningfully alter curcumin pharmacokinetics [89].

It does not show that the resulting curcumin concentration is sufficient to control glioblastoma.

The time period also matters. The increased levels were most evident during the early hours after administration.

Therefore, you should not be told that adding Pippali automatically solves the entire curcumin bioavailability problem.

Why Bioavailability Enhancement Is a Double-Edged Effect

Improving absorption is not always beneficial.

Piperine cannot decide whether the absorbed substance is a useful herb, a prescription drug, or an unwanted chemical.

If it reduces the metabolism or transport of a medicine, the blood concentration of that medicine may rise. This could increase both its desired effect and its side effects.

The same principle applies to a multi-ingredient Avaleha. Piperine may change the exposure to several constituents at the same time.

This can make the complete formulation behave differently from each herb used alone.

For this reason, piperine should not be called a harmless bioenhancer.

It is a pharmacologically active compound that may affect absorption, metabolism, cellular signalling, and medicine response.

Piperine and P-Glycoprotein

P-glycoprotein is a transport protein found in the intestine, liver, kidneys, blood–brain barrier, and other tissues.

It can move certain substances out of cells. In the intestine, this may reduce the absorption of selected medicines. At the blood–brain barrier, it may limit the entry of some drugs into the brain.

Laboratory research has shown that piperine can inhibit human P-glycoprotein activity [90].

This may partly explain its bioenhancing effect.

However, P-glycoprotein is also a protective system. Blocking it may increase exposure to substances that the body would normally transport away.

The effect can differ according to dose, medicine, tissue, and patient.

An in-vitro inhibition result does not prove that a small Pippali dose will clinically block the blood–brain barrier transporter.

Piperine and CYP3A4

CYP3A4 is an important drug-metabolizing enzyme found mainly in the intestine and liver.

A large number of prescription medicines are partly processed through this enzyme.

Laboratory research has shown that piperine can inhibit CYP3A4 activity [90].

This creates a possible interaction risk when piperine is combined with a medicine that depends heavily on CYP3A4 for metabolism.

The actual clinical effect will depend on the piperine dose, formulation, treatment duration, medicine, and individual patient.

The in-vitro study does not prove that every culinary or Ayurvedic Pippali dose produces a major interaction.

It does provide a clear reason to review your complete medicine list.

Piperine Does Not Automatically Increase Temozolomide Blood Levels

The piperine–temozolomide laboratory synergy should not be confused with a proven pharmacokinetic interaction in patients.

Temozolomide does not depend mainly on CYP3A4 for its activation. It undergoes spontaneous chemical conversion under physiological conditions.

Therefore, CYP3A4 inhibition does not automatically mean that piperine will increase temozolomide blood concentration.

The laboratory combination effect may have resulted from changes in tumour-cell stress, apoptosis, JNK, p38 MAPK, survivin, or other cellular processes [87,88].

No human glioblastoma study has established that oral piperine safely raises temozolomide concentration inside the tumour.

Possible Interactions With Antiseizure Medicines

Many glioma patients take antiseizure medicines.

Some antiseizure medicines are metabolized through liver enzymes or transported through systems that piperine may influence. Others, such as levetiracetam, have different metabolic pathways.

You should not assume that all antiseizure medicines interact with Pippali in the same way.

The concern is greatest when you use concentrated piperine or a high-Pippali formula together with medicines that have a narrow safe concentration range.

An increase in medicine exposure could contribute to excessive sleepiness, dizziness, poor balance, blurred vision, confusion, nausea, or other adverse effects.

A reduction in effective medicine exposure could increase seizure risk.

Your antiseizure medicine should never be stopped or reduced only because Pippali has been added.

Possible Interactions With Steroids and Other Medicines

Glioma patients may also take dexamethasone, antiemetics, antibiotics, anticoagulants, diabetes medicines, blood-pressure medicines, pain medicines, sedatives, or experimental treatments.

Piperine’s effects on transporters and enzymes create a reason to review these medicines individually [90,91].

This does not mean that a serious interaction will occur in every patient.

It means that a concentrated bioenhancing ingredient should not be prescribed without knowing the complete medicine list.

The risk may change when several bioactive ingredients are combined. For example, an Avaleha containing Pippali, Haridra, Ashwagandha, Shallaki, and mineral ingredients cannot be evaluated only from Pippali safety data.

Can Piperine Improve Brain Delivery?

Piperine’s effects on drug transporters have created interest in whether it could improve the delivery of selected compounds to the brain.

This remains a complex and product-specific question.

Inhibition of P-glycoprotein in an intestinal or laboratory system does not prove that oral Pippali delivers another medicine into a human glioblastoma.

The blood–brain barrier contains several transporters and protective systems. Glioblastoma also has an uneven blood–tumour barrier. Some regions may be leaky, while infiltrating cells may remain behind a more intact barrier.

The clinically important evidence would require measurement of the compound in plasma, cerebrospinal fluid, normal brain tissue, or tumour tissue.

The current references do not establish that Pippali or piperine delivers a therapeutically effective concentration of temozolomide, curcumin, or another Ayurvedic compound into human glioblastoma tissue.

Why the Word Bioenhancer Must Be Used Carefully

A bioenhancer is usually described as a substance that increases the bioavailability or effect of another compound.

This definition may create the impression that the enhancer itself is inactive.

Piperine is not inactive. It has its own cellular, digestive, metabolic, and pharmacological actions.

It may influence membrane transport, glucuronidation, CYP enzymes, inflammatory pathways, and cellular stress responses [89–91].

Therefore, Pippali should not be added as though it is only a neutral carrier.

Its dose contributes to the biological and safety profile of the complete formulation.

The Ayurvedic Meaning of Deepana Is Broader Than Drug Absorption

Bhavaprakasha describes Pippali as Deepana [43,44].

Deepana means supporting Agni and improving the capacity to digest or process food and medicine.

This is not scientifically identical to CYP inhibition, P-glycoprotein inhibition, or increased plasma concentration.

The classical concept and modern pharmacokinetic findings may point toward a common practical theme involving digestion and assimilation, but they should not be presented as exact synonyms.

Ayurvedic Deepana assessment depends on your appetite, tongue, bowel pattern, abdominal comfort, heaviness, nausea, and tolerance.

Modern bioavailability is measured through blood concentrations and pharmacokinetic parameters.

Both can inform the formulation, but they answer different questions.

How Pippali May Help a Patient With Weak Agni

After brain surgery or during chemoradiation, you may develop poor appetite, nausea, abdominal heaviness, constipation, reduced food intake, or difficulty tolerating medicines.

A small and properly selected Pippali dose may be used to support digestion and medicine tolerance.

This can be clinically useful because poor intake and repeated nausea can reduce your strength and interfere with treatment.

However, digestive improvement should not be described as direct tumour regression.

Your nausea may also result from intracranial pressure, temozolomide, constipation, infection, electrolyte disturbance, or another medicine.

Pippali should not be used to hide a symptom that requires medical evaluation.

Pippali Is Not Suitable for Every Digestive Problem

Pippali is pungent and can be stimulating.

It may be poorly tolerated when you have severe acidity, reflux, mouth ulcers, burning, active gastritis, dehydration, or marked Pitta irritation.

Classical descriptions also distinguish fresh and dried Pippali. The dried form is described as potentially aggravating Pitta in some conditions [43,44].

This is important because the medicinal Pippali used in formulations is commonly dried.

A patient with poor appetite and Kapha-related heaviness may tolerate Pippali differently from a patient with severe burning, dryness, constipation, weight loss, and treatment-related mucosal irritation.

Your dose should reflect your actual condition rather than the general belief that more Deepana always improves absorption.

Pippali and Vata-Kapha Balance

The classical verse describes Pippali as reducing disturbed Vata and Kapha while remaining unctuous and light [43,44].

This combination may be useful when you have heaviness, sluggish digestion, mucus, poor appetite, abdominal gas, or certain Vata-Kapha patterns.

However, a glioma patient may also have severe Vata depletion, dryness, insomnia, constipation, and weight loss.

A high dose of pungent medicine may worsen some of these problems if it is not balanced with nourishing or unctuous ingredients.

This is one reason Pippali may be included in a complete Avaleha rather than given alone.

The base and accompanying ingredients may help balance its intensity, but that balance should not be assumed without observing your response.

Whole Pippali May Not Produce the Piperine Dose Used in Research

The amount of Pippali in the Avaleha and the amount of piperine within that Pippali should both be known.

Suppose a 900-gram batch contains 18 grams of Pippali and you take 30 grams of Avaleha daily.

Pippali would represent 2% of the finished batch. Your calculated daily Pippali intake would be approximately 600 milligrams.

This does not mean that you receive 600 milligrams of piperine.

If the Pippali contained only a small percentage of piperine, the purified piperine exposure would be much lower.

It would also not be equivalent to applying piperine directly to tumour cells at a micromolar concentration.

The example is only mathematical. The actual formulation must use its own batch quantities and chemical testing.

How the Research Dose Should Be Compared

The comparison should state the research material, concentration, route, and actual formulation exposure.

The glioma studies used purified piperine applied directly to cells [87,88].

The curcumin pharmacokinetic study used 20 milligrams of piperine with two grams of curcumin in healthy human volunteers [89].

Majja-Arbuda Rasayana Avaleha may contain whole Pippali fruit, not purified piperine.

These are three different interventions.

A valid evidence section should not cite the 20-milligram piperine study unless it also calculates whether the Avaleha delivers anything close to that piperine amount.

Even a similar milligram amount would not prove glioblastoma efficacy because the human study measured curcumin bioavailability, not brain-tumour response.

Why Finished-Product Testing Adds Major Value

If Pippali is being included partly because of piperine research, the finished formulation should ideally be tested for piperine content.

The test should not examine only the raw Pippali before preparation. Heating, moisture, extraction, mixing, and storage may influence the final measurable amount.

Chemical fingerprinting can also help compare one batch with another.

This allows Panaceayur to report the approximate daily piperine exposure instead of relying only on the weight of the whole herb.

It would make the comparison with studies [87–90] much more meaningful.

Pippali During Temozolomide Treatment

Pippali or piperine should not replace temozolomide when temozolomide is clinically indicated.

The current evidence supports an experimental combination hypothesis, not an established human treatment protocol.

If Pippali is used during temozolomide, the purpose should be stated clearly. It may be included for digestion, Avaleha tolerance, curcumin absorption, or preclinical treatment-resistance reasoning.

Your blood counts, liver function, nausea, vomiting, appetite, bowel pattern, seizures, and complete medicine list should continue to be monitored.

An unexpected adverse effect should not be dismissed as a cleansing reaction.

Can Pippali Reduce the Required Temozolomide Dose?

No human evidence currently supports making that change solely because Pippali or piperine has been added.

The cell study found synergy at lower concentrations under laboratory conditions [87].

That result is useful for future research design. It is not sufficient to reduce a prescribed chemotherapy dose in a patient.

Any temozolomide dose modification should be based on your oncology protocol, blood counts, liver function, tolerance, age, performance status, and tumour response.

Pippali During Radiation

The references used in this section do not establish that Pippali improves radiation response in glioblastoma patients.

Its possible role during radiation may relate more to digestion, appetite, medicine tolerance, or absorption of selected formulation ingredients.

Because radiation may already cause fatigue, nausea, mucosal irritation, and appetite changes, a pungent ingredient should be adjusted according to your tolerance.

If you develop mouth ulcers, severe acidity, vomiting, or burning, continuing the same Pippali dose may not be appropriate.

Possible Gastrointestinal Effects

Pippali and concentrated piperine may cause burning, reflux, abdominal irritation, loose stools, or discomfort in some people, particularly at higher doses.

A mild stimulating effect on digestion may be useful in one patient and irritating in another.

Your digestive response should therefore be monitored after the formula begins.

Persistent burning, vomiting, diarrhoea, abdominal pain, or inability to eat should not be considered a normal sign that the medicine is working.

Dehydration and reduced food intake can be dangerous during brain-tumour treatment.

Possible Effects on Sedation and Neurological Safety

Piperine may change exposure to selected medicines through transporter or enzyme effects [90].

If you already take sedating medicines, even a moderate change in exposure may affect alertness, balance, or swallowing.

This is particularly important after brain surgery or when you already have weakness, visual-field loss, or impaired coordination.

Your family should observe for new excessive sleepiness, confusion, poor balance, repeated falls, or unusual behavioural change.

These symptoms may also indicate tumour progression, edema, seizure activity, infection, or electrolyte disturbance. They require clinical review rather than automatic attribution to one herb.

When Pippali May Need to Be Reduced or Paused

Pippali should be reassessed when you develop severe acidity, mouth ulcers, persistent vomiting, significant diarrhoea, dehydration, unexplained bleeding, marked liver abnormalities, or a suspected interaction.

It may also need to be paused when you cannot swallow safely, are preparing for surgery, develop an acute infection, or have a major change in neurological status.

A formula suitable during stable recovery may not remain suitable during an acute medical event.

Where Pippali Fits in Majja-Arbuda Rasayana Avaleha

Pippali fits most clearly within the Agni, absorption, and tolerability group.

Its classical Deepana and Rasayana properties support this role [43,44].

Piperine also provides a secondary research role within the treatment-resistance group because it has shown synergy with temozolomide in resistant glioma cells and has affected survivin-related behaviour in a glioblastoma stem-like model [87,88].

A third role may involve improving the bioavailability of selected compounds, particularly curcumin [89].

These roles should be described separately.

Pippali should not be presented as a direct human glioblastoma treatment simply because purified piperine affected cultured cells.

What Must Be Documented in the Finished Avaleha

The formulation record should identify Piper longum fruit as the medicinal material.

It should distinguish the fruit from Pippalimula and from Piper nigrum.

The record should state whether Pippali is used as powder, decoction material, extract, or standardized piperine preparation.

Its total quantity in the batch and estimated daily whole-Pippali exposure should be calculated.

If piperine research is used to support a tumour-directed or bioenhancing claim, the finished batch should ideally be tested for piperine.

The complete prescription should also record antiseizure medicines, steroids, anticoagulants, diabetes medicines, and other treatments that may be affected by altered absorption or metabolism.

How Your Response Should Be Monitored

If Pippali is used mainly for Agni and tolerability, relevant outcomes include appetite, nausea, abdominal heaviness, bowel function, reflux, food intake, and your ability to take the complete Avaleha.

If it is used partly as a bioenhancer, the doctor should observe both benefit and possible increased adverse effects from the substances being combined with it.

If it is included for the experimental temozolomide-resistance rationale, symptoms alone cannot establish a tumour-directed effect.

MRI findings, neurological status, steroid dose, temozolomide schedule, blood counts, liver function, and all concurrent treatments must be reviewed together.

Current Evidence Verdict for Pippali and Piperine

Classical Ayurvedic support is present for Pippali as a Deepana, Rasayana, Vata-Kapha-balancing, light, and unctuous ingredient with a sweet post-digestive effect [43,44].

Direct preclinical glioma evidence is present for purified piperine. It enhanced the effect of temozolomide in temozolomide-resistant U251-MG and T98G glioma cells and was associated with apoptosis and stress-pathway activation [87].

Direct preclinical glioblastoma stem-like cell evidence is also present. Piperine affected survivin-related activity and increased temozolomide responsiveness in an U87-derived stem-like cell model [88].

Human evidence confirms that piperine can substantially alter the pharmacokinetics of curcumin under specific short-term conditions [89].

Human evidence proving that Pippali or piperine shrinks glioblastoma, reverses MGMT resistance, delays recurrence, or improves survival is not established.

Piperine can inhibit P-glycoprotein and CYP3A4 in experimental systems, creating a scientifically important interaction concern [90].

Long-term safety and interaction data for concentrated piperine in glioblastoma patients receiving several medicines remain limited [91].

What Pippali Evidence Means for You

Pippali has a rational place in an individualized glioma or glioblastoma formulation when its purpose is clearly defined.

It may help support Agni and your ability to tolerate a complex Avaleha. Piperine may improve the exposure of selected compounds, and direct laboratory studies suggest that it may make some temozolomide-resistant or stem-like glioblastoma cells more responsive to treatment.

These findings are meaningful, but they do not establish a human glioblastoma cure.

Whole Pippali is not identical to purified piperine. A small amount inside an Avaleha may not reproduce the concentrations used in glioma-cell experiments.

Its bioenhancing effect is also not automatically harmless. The same property that may improve curcumin absorption could alter your exposure to prescription medicines.

Pippali has a credible Ayurvedic role in supporting Agni, Rasayana care, formulation tolerance, and absorption. Its compound piperine has meaningful preclinical evidence in temozolomide-resistant glioma cells and a glioblastoma stem-like model. Human tumour-control evidence is not yet established, and its use requires realistic dose comparison, finished-product piperine testing, careful review of antiseizure and oncology medicines, and close monitoring for digestive or pharmacological interactions.

Guduchi for Glioma and Glioblastoma: Tinospora cordifolia Research, Rasayana Use, and Liver Safety

Guduchi is one of the most respected Rasayana herbs in Ayurveda. It is traditionally used when you have reduced strength, disturbed digestion, recurrent illness, inflammatory symptoms, fever, tissue weakness, or a prolonged recovery period.

Its role in glioma and glioblastoma requires careful explanation. An aqueous-ethanolic extract of Tinospora cordifolia has been studied directly in an experimental glioma model and produced changes associated with slower growth, reduced migration, and greater cellular differentiation [92].

This makes Guduchi scientifically relevant to glioma research. However, the evidence remains preclinical. The study did not involve patients taking Guduchi, did not test Majja-Arbuda Rasayana Avaleha, and did not prove that an oral dose reaches a human brain tumour at a therapeutic concentration.

Guduchi also requires serious safety discussion. Reports of Tinospora cordifolia-associated liver injury have been published, including cases with autoimmune-like features [95–97]. Therefore, it should not be described as a universally safe immune booster for every glioma patient.

Its value depends on the correct species, plant part, preparation, dose, your liver condition, your oncology medicines, and the purpose for which it is being prescribed.

What Is Guduchi?

Guduchi is generally identified as Tinospora cordifolia (Willd.) Hook. f. & Thomson. It belongs to the Menispermaceae family.

It is a climbing shrub with characteristic heart-shaped leaves. The mature stem is the medicinal part most commonly used in classical Ayurvedic preparations, although leaves, roots, extracts, and fresh plant juice may also appear in commercial products.

The plant is also known as Amrita, meaning nectar or that which supports vitality. Other classical names include Amritavalli, Chhinnaruha, Chhinnodbhava, and Vatsadani.

The exact plant part must be stated because Guduchi stem powder, stem decoction, fresh juice, leaf extract, aqueous extract, alcohol extract, and aqueous-ethanolic extract are not identical preparations.

The direct glioma research discussed in this section used a defined aqueous-ethanolic extract. It did not use ordinary Guduchi stem powder inside an Avaleha.

What Ayurveda Says About Guduchi

Bhavaprakasha Nighantu describes Guduchi at the beginning of Guduchyadi Varga. Verse numbering varies across editions because some editions count the synonym verses separately. The following property verses are commonly placed within the opening Guduchi passage, often around texts 6–8.

Book: Bhavaprakasha Nighantu
Section: Guduchyadi Varga
Text numbers: Opening Guduchi verses, commonly around 6–8 depending on the edition

गुडूची कटुका तिक्ता स्वादुपाका रसायनी ।
संग्राहिणी कषायोष्णा लघ्वी बल्याग्निदीपनी ॥

दोषत्रयामतृड्दाहमेहकासांश्च पाण्डुताम् ।
कामलाकुष्ठवातास्रज्वरकृमिवमीन्हरेत् ॥

Transliteration

Guḍūcī kaṭukā tiktā svādupākā rasāyanī |
Saṅgrāhiṇī kaṣāyoṣṇā laghvī balyāgnidīpanī ||

Doṣatrayāma-tṛḍ-dāha-meha-kāsāṁś ca pāṇḍutām |
Kāmalā-kuṣṭha-vātāsra-jvara-kṛmi-vamīn haret ||

English translation

Guduchi is described as bitter and pungent, with a sweet post-digestive effect. It is Rasayana, light, strengthening, supportive of digestive fire, and traditionally used for balancing disturbed Doshas.

It is also traditionally described in conditions involving Ama, excessive thirst, burning, metabolic disturbance, cough, pallor, jaundice, skin disease, Vatarakta, fever, intestinal organisms, and vomiting.

Urdu translation

گڈوچی کو کڑوے اور تیز ذائقے، میٹھے بعد از ہضم اثر، ہلکی خاصیت، طاقت بخش اثر اور اگنی کو بہتر بنانے والی رسایَن دوا کے طور پر بیان کیا گیا ہے۔

روایتی طور پر اسے دوشوں کی بے ترتیبی، آما، زیادہ پیاس، جلن، استحالہ کی خرابی، کھانسی، کمزوری و زردی، یرقان، جلدی امراض، بخار اور قے جیسی حالتوں میں استعمال کیا گیا ہے۔

Arabic translation

تُوصَف الغودوتشي بأنها مُرّة ولاذعة، وذات تأثير حلو بعد الهضم، وخفيفة، ومقوية، وداعمة لقوة الهضم، ومن أدوية الراسايانا.

وقد استُخدمت تقليدياً في اضطرابات الدوشا، وتراكم الآما، والعطش الشديد، والإحساس بالحرارة، واضطرابات الاستقلاب، والسعال، والضعف والشحوب، واليرقان، وبعض أمراض الجلد، والحمى والقيء.

These verses support Guduchi’s classical use as a Rasayana, Balya, Agni-supporting, and Dosha-balancing herb [43,44].

They do not describe glioma, glioblastoma, cellular differentiation, tumour migration, temozolomide resistance, or blood–brain barrier penetration.

The classical evidence supports its role in restoring strength, improving tolerance, addressing selected Ama and Agni patterns, and supporting prolonged recovery. Its possible tumour-directed role must be evaluated separately through modern research.

Why Guduchi May Be Considered in Glioma Care

Guduchi may have several possible roles in an individualized glioma or glioblastoma plan.

Its classical role may relate to Rasayana, strength, digestion, recovery, inflammatory symptoms, and treatment-related depletion.

Its modern investigational role comes from experimental research showing that a Tinospora cordifolia extract may influence the behaviour of glioma cells [92].

A third possible role concerns supportive immune and inflammatory regulation. However, the immune system in glioblastoma is highly complex. Guduchi should not be presented as an herb that simply increases immunity and therefore destroys the tumour.

Its effect may depend on the extract, dose, immune condition, liver condition, concurrent medicines, and tumour-treatment phase.

What Type of Guduchi Was Used in the Glioma Study?

The direct glioma study used an aqueous-ethanolic extract of Tinospora cordifolia [92].

An aqueous-ethanolic extract is prepared using a mixture of water and alcohol. This allows the extraction of a broader range of plant compounds than water alone.

The study material was therefore not equivalent to ordinary Guduchi powder, a classical water decoction, fresh Guduchi juice, or the amount of stem placed in an Avaleha.

Alcohol-containing extraction can concentrate compounds that may be present only in smaller amounts in a traditional preparation.

Before the study can be used to support Majja-Arbuda Rasayana Avaleha, the actual preparation method must be compared. If the Avaleha uses a water decoction of Guduchi stem, the chemical profile may differ significantly from the aqueous-ethanolic research extract.

What Experimental Model Was Used?

The research was performed mainly in C6 glioma cells [92].

C6 is a rat-derived experimental glioma cell line. It has been used for many years to study tumour growth, migration, cellular stress, differentiation, and possible treatment mechanisms.

This model can provide useful mechanistic information. However, it is not the same as a molecularly classified human glioblastoma.

C6 cells do not reproduce the full genetic diversity of IDH-wildtype glioblastoma, IDH-mutant astrocytoma, or other modern glioma groups.

They also do not reproduce your blood–brain barrier, immune system, liver metabolism, tumour blood vessels, steroid exposure, surgery, radiation, or chemotherapy.

The study provides direct experimental glioma evidence, but its disease directness is lower than research using several patient-derived human glioblastoma cultures or human clinical trials.

What Is Differentiation-Based Glioma Treatment?

Cancer cells are often poorly differentiated. This means that they have lost many of the normal features and functions of the mature cells from which they originated.

Poorly differentiated tumour cells may divide rapidly, migrate, and behave more aggressively.

Differentiation-based treatment attempts to encourage malignant cells to become more mature and less aggressive rather than relying only on immediate cell killing.

The Guduchi study was important because the researchers investigated whether the extract could push glioma cells toward a more differentiated state [92].

This is a different approach from simply exposing the cells to a highly toxic concentration and measuring how many die.

A treatment that slows growth and encourages differentiation may theoretically make tumour cells less aggressive or more responsive to other treatment.

However, this remains an experimental concept in glioma. The study did not show that Guduchi differentiates glioblastoma cells inside a patient.

How Guduchi Changed the Appearance of Glioma Cells

The researchers reported changes in the shape and behaviour of the treated glioma cells [92].

Untreated tumour cells commonly show an active proliferating pattern. After exposure to the Guduchi extract, some cells developed features that were interpreted as a shift toward a more mature or differentiated condition.

Changes in cell shape can provide an early clue that the biological state of the cell is changing.

However, appearance alone is not enough to prove differentiation.

Researchers therefore also examine molecular markers, growth behaviour, migration, and other cellular functions.

The reported combination of structural and molecular changes supported the differentiation-based interpretation.

Guduchi and GFAP

GFAP stands for glial fibrillary acidic protein. It is a structural protein found mainly in astrocytes and related glial cells.

In glioma research, increased GFAP expression can sometimes indicate that poorly differentiated tumour cells are moving toward a more mature glial state.

The Guduchi-treated experimental cells showed changes in GFAP consistent with greater differentiation [92].

This is scientifically relevant because a more differentiated tumour cell may divide or migrate less aggressively than an undifferentiated stem-like cell.

However, GFAP is not a universal marker of successful tumour treatment. Gliomas can express GFAP while still remaining malignant.

An increase in GFAP in cultured rat glioma cells does not prove that the tumour has been eliminated or permanently controlled.

Guduchi and Cell Proliferation

The study reported reduced proliferation after exposure to the Guduchi extract [92].

Proliferation means continued cell growth and division.

Reducing proliferation is an important research outcome because rapidly dividing tumour cells contribute to increasing tumour mass.

However, a reduction in proliferation does not always mean that all tumour cells have died. Some cells may become temporarily arrested, enter a senescent state, differentiate, or resume growth later.

The duration of the effect therefore matters.

A short laboratory study cannot show whether the tumour cells will remain controlled for months or whether resistant populations will eventually recover.

What Cellular Senescence Means

The Guduchi study also examined changes associated with cellular ageing or senescence [92].

A senescent cell remains alive but loses much of its ability to divide.

Inducing senescence can reduce tumour growth in the short term. However, senescent tumour cells may still release inflammatory or signalling substances that affect surrounding tissue.

Some senescent cells may also escape the arrested state.

Therefore, senescence is not always equal to permanent tumour elimination.

The study supports Guduchi as a possible regulator of glioma-cell behaviour. It does not prove that the extract permanently destroys every malignant cell.

Guduchi and Tumour-Cell Migration

Migration is especially important in glioma because tumour cells can move away from the central mass and enter surrounding brain tissue [20].

The experimental Guduchi extract reduced glioma-cell migration under the tested conditions [92].

This suggests that the treated cells became less able to move across the experimental surface.

A reduction in migration is relevant because diffuse invasion makes glioma difficult to remove completely through surgery.

However, movement across a laboratory dish is not the same as invasion through the complex structures of the human brain.

In your brain, glioma cells interact with blood vessels, nerve fibres, immune cells, extracellular matrix, oxygen gradients, and treatment-related tissue changes.

The study provides a migration-related mechanism for further research, but not proof that oral Guduchi stops microscopic invasion in a patient.

Guduchi and Invasive Behaviour

The research also examined markers or behaviours connected with tumour invasion [92].

A glioma cell must alter its attachment, surrounding tissue, and movement in order to invade.

The Guduchi extract appeared to reduce some of these aggressive characteristics.

This may help explain why the cells showed a more differentiated and less migratory pattern.

However, the effect was measured in an experimental model. There is no human imaging method that can currently confirm that an oral Guduchi dose has stopped every infiltrating glioma cell.

MRI may show the main tumour and surrounding signal changes, but microscopic invasion can extend beyond visible borders.

Guduchi and Mortalin

Mortalin is a cellular stress protein also known as HSPA9. It participates in mitochondrial function, cellular survival, protein handling, and stress responses.

Abnormal mortalin activity has been studied in several cancers.

The Guduchi research examined mortalin-related changes as part of the shift from an aggressive tumour-cell pattern toward a more differentiated or senescent state [92].

Changes in mortalin may help explain reduced proliferation or altered cellular survival.

However, mortalin is not a simple tumour-only target. It also supports normal cellular functions.

A laboratory change in mortalin should therefore be described as a possible mechanism, not as proof that Guduchi selectively eliminates glioblastoma.

Guduchi Is Not Proven to Kill Glioblastoma Stem Cells

The direct study focused mainly on experimental glioma differentiation and migration [92].

It should not be presented as proof that Guduchi eliminates glioblastoma stem-like cells.

Glioma stem-like cells are a specialized research population associated with self-renewal, treatment resistance, and tumour recurrence [21,22].

To make a direct stem-cell claim, the research would need to use clearly characterized patient-derived glioblastoma stem-like cultures or another suitable stemness model.

Guduchi may affect pathways relevant to stemness, but the available reference should not be stretched beyond what was directly tested.

Guduchi Is Not Proven to Reverse MGMT Resistance

The Guduchi study did not establish that the extract changes MGMT promoter methylation or reverses MGMT-mediated temozolomide resistance.

MGMT status remains an important tumour biomarker affecting the ability of some glioblastoma cells to repair temozolomide-related DNA damage [26].

You should not be told that Guduchi makes an unmethylated tumour behave like a methylated tumour.

Any possible effect on treatment response would require direct testing with temozolomide-resistant, molecularly characterized glioblastoma models and eventual human studies.

Guduchi and Temozolomide

There is no established human evidence showing that Guduchi improves the antitumour effect of temozolomide in glioblastoma patients.

The preclinical differentiation study supports a general tumour-behaviour hypothesis [92]. It was not a clinical temozolomide-combination trial.

Guduchi may still be considered during temozolomide for selected Rasayana, digestive, or recovery purposes, but the safety overlap must be considered.

Temozolomide can affect liver function and blood counts [144]. Guduchi products have also been linked with clinically important liver injury [95–97].

If both are used, baseline liver tests and repeat monitoring become especially important.

A rise in liver enzymes should not be ignored merely because Guduchi is traditionally described as useful in Kamala or jaundice.

A classical indication does not guarantee that every modern extract or commercial product protects the liver.

Guduchi During Radiation

The available Guduchi references do not establish that it increases radiation sensitivity in glioblastoma patients.

It may be used for general recovery, Rasayana support, digestion, or selected inflammatory patterns when your condition permits.

However, its use during radiation should not be described as a clinically proven radiosensitizing treatment.

Radiation may cause fatigue, nausea, appetite loss, skin changes, edema, and temporary worsening on MRI.

If Guduchi is used during this period, the intended outcome should be stated clearly. Support for strength or digestion is different from proof of tumour radiosensitization.

Guduchi and the Immune System

Guduchi is often described as an immune-modulating or immune-supporting herb [93,94].

This is more accurate than simply calling it an immune booster.

The immune system contains several types of cells and signalling proteins. Increasing one immune response may be useful in one condition and harmful in another.

Glioblastoma itself creates an immunosuppressive tumour environment. However, simply stimulating the general immune system does not guarantee that immune cells will recognize or enter the tumour effectively.

Steroids can also suppress immune activity, while temozolomide may reduce lymphocytes.

The effect of Guduchi in this complex situation is not fully established.

You should therefore not be told that Guduchi automatically increases antitumour immunity and destroys glioblastoma.

Why Immune Stimulation May Not Be Suitable for Everyone

An immune-active herb requires greater caution when you have an autoimmune condition.

This may include autoimmune hepatitis, autoimmune thyroid disease, rheumatoid arthritis, lupus, inflammatory bowel disease, or another immune-mediated disorder.

Guduchi-associated liver-injury reports have included autoimmune-like features in some patients [95–97].

This raises the possibility that a susceptible person may respond differently from a healthy individual.

If you are receiving immunotherapy, a cancer vaccine, CAR-T therapy, an immune checkpoint inhibitor, or another investigational immune treatment, Guduchi should not be added without informing the treating team.

It may alter immune activity or make adverse-event interpretation more difficult.

Guduchi Is Not Automatically a Liver-Protective Herb in Every Patient

Classical Ayurveda describes Guduchi in conditions including Kamala, which broadly relates to jaundice and hepatobiliary disturbance [43,44].

Modern laboratory studies have also investigated antioxidant and liver-related effects [93,94].

However, this does not mean that every Guduchi product protects every liver.

Human reports have linked Tinospora cordifolia products with herb-induced liver injury [95–97].

The correct interpretation is that an herb may have beneficial effects in one dose, preparation, condition, or model and still cause harm in another patient.

Traditional use and modern adverse-event evidence must both be considered.

What Guduchi-Associated Liver Injury Reports Show

A published case series during the COVID-19 period described liver injury in people using products containing Tinospora cordifolia as immune support [95].

Some patients showed features resembling autoimmune hepatitis. These included patterns in which the immune system appeared to contribute to liver inflammation.

Later analyses and reviews continued to examine the causality, botanical identity, patient susceptibility, and possible immune mechanisms [96,97].

These reports do not prove that every Guduchi user will develop liver injury.

They do show that serious liver reactions are possible and that the risk should not be dismissed.

Could the Liver Injury Be Due to the Wrong Tinospora Species?

Botanical misidentification is an important concern.

Tinospora cordifolia may be confused with other related species, including Tinospora crispa. Different species may have different chemical and safety profiles.

A poorly controlled commercial product may also contain the wrong plant, a mixture of species, contaminants, or undisclosed ingredients.

However, the reported liver-injury concern cannot be dismissed only by saying that every case must have involved the wrong species.

Some investigated cases were linked to products identified as Tinospora cordifolia [95–97].

The safer response is to require botanical authentication and remain alert to patient-specific liver reactions even when the correct species is used.

Who Requires Greater Caution With Guduchi?

Guduchi requires careful assessment when you already have abnormal liver enzymes, cirrhosis, chronic hepatitis, autoimmune hepatitis, significant jaundice, previous herb-induced liver injury, or active autoimmune disease.

Caution is also needed when you take temozolomide, antiseizure medicines, antibiotics, or other medicines that may affect the liver.

A multi-ingredient Avaleha can make causality difficult to identify. If liver enzymes rise, several ingredients and prescription medicines may need review.

The fact that one herb has a classical Rasayana reputation does not remove the need for modern safety monitoring.

Symptoms That May Suggest Liver Injury

You should report yellowing of the skin or eyes, dark urine, pale stools, severe itching, persistent nausea, loss of appetite, unusual fatigue, or pain in the upper right side of the abdomen.

These symptoms do not prove that Guduchi is responsible.

Temozolomide, antiseizure medicines, infection, another herb, biliary obstruction, or an unrelated liver disease may produce similar symptoms.

Prompt laboratory testing and medical review are more reliable than guessing the cause.

Why Liver Tests Should Be Done Before and During Treatment

A baseline liver test gives your doctors a starting point.

If your liver enzymes are already elevated before Guduchi begins, later changes must be interpreted differently.

During temozolomide or a complex Ayurvedic formulation, repeat liver testing may include bilirubin, ALT, AST, alkaline phosphatase, albumin, and other tests selected according to your condition.

The monitoring schedule should depend on your treatment phase, previous liver history, formula complexity, and symptoms.

A liver test performed only after severe jaundice develops may miss an earlier opportunity to identify a problem.

Whole Guduchi Stem Is Not the Same as a Concentrated Extract

Traditional Guduchi stem powder or decoction may deliver a different chemical exposure from a concentrated aqueous-ethanolic extract.

The research extract may contain a broader or higher concentration of alkaloids, diterpenoid lactones, glycosides, steroids, polysaccharides, and other constituents [93,94].

The safety profile may also change with concentration.

A preparation that is tolerated as a moderate water decoction cannot automatically be assumed safe at a much higher extract-equivalent dose.

The final formulation record should therefore state whether Guduchi is used as stem powder, water decoction, Ghana extract, aqueous-ethanolic extract, fresh juice, or another form.

How the Guduchi Dose in the Avaleha Should Be Calculated

The quantity of Guduchi used in the batch must be recorded together with the final Avaleha weight.

Suppose a 900-gram batch contains 45 grams of Guduchi stem material and you take 30 grams of Avaleha daily.

Guduchi would represent 5% of the finished batch. Your estimated daily whole-stem exposure would be approximately 1.5 grams.

This would not be equivalent to 1.5 grams of a concentrated aqueous-ethanolic extract.

It also would not show how much of any specific active compound reaches your blood or tumour.

If a concentrated extract is used, the extraction ratio should be stated. A 10:1 extract may represent much more starting plant material than the same weight of ordinary powder.

Why Extract Equivalence Matters

A research paper may report its dose in micrograms per millilitre because the extract was placed directly around cultured cells.

Your Avaleha dose is measured in grams.

These units cannot be compared without additional information about extraction yield, absorption, distribution, and tumour exposure.

A direct laboratory concentration cannot be converted simply into grams of Guduchi stem.

The study supports a biological mechanism. It does not provide a clinical oral dose for glioblastoma.

Does Guduchi Cross the Blood–Brain Barrier?

The direct glioma study did not establish brain penetration in patients [92].

The cells were exposed directly to the extract in the laboratory.

The research did not measure Guduchi compounds in human plasma, cerebrospinal fluid, normal brain tissue, or glioblastoma tissue.

Therefore, it would be inaccurate to say that Guduchi is clinically proven to cross the human blood–brain barrier and differentiate glioblastoma cells.

The correct question is not only whether any compound can enter the brain, but whether it reaches the tumour at a biologically relevant concentration without causing harm.

That evidence remains insufficient.

Guduchi and Digestion

Guduchi is bitter and traditionally described as Agnidipana while also being light and Rasayana [43,44].

This makes it potentially useful when you have weakness together with poor digestion or an Ama-related pattern.

However, bitter herbs may reduce appetite or cause digestive discomfort in some weak patients.

A person with nausea, low body weight, dry mouth, and poor food intake may not tolerate a high Guduchi dose in the same way as a person with heaviness, sluggish digestion, and inflammatory symptoms.

Your appetite and weight should be monitored rather than assuming that every bitter Rasayana will improve digestion.

Guduchi and Blood Sugar

Guduchi is often used in Ayurvedic metabolic care and has been studied for glucose-related effects [93,94].

This may be relevant when dexamethasone has raised your blood sugar.

However, if you already take insulin or glucose-lowering medicines, adding a metabolically active herb may alter your glucose pattern.

Your blood sugar should be monitored rather than assuming that any reduction will remain mild and beneficial.

Confusion, sweating, tremor, weakness, or unusual drowsiness may reflect low blood sugar, neurological change, or another medical problem.

Guduchi and Seizure Medicines

Direct Guduchi interactions with every antiseizure medicine have not been fully studied.

The major practical concern is overlapping liver risk when Guduchi is combined with an antiseizure medicine known to affect liver enzymes.

Another concern is that a large multi-herb formulation can make it difficult to identify the cause of sedation, nausea, rash, or liver-test changes.

Your seizure medicines should not be reduced or stopped because Guduchi has been added.

Seizure stability remains a primary neurological goal.

When Guduchi May Need to Be Paused

Guduchi should be reviewed or paused when you develop jaundice, significant liver-enzyme elevation, severe itching, persistent vomiting, a widespread rash, a suspected autoimmune reaction, or another serious adverse effect.

It should also be reconsidered during acute liver disease, severe infection, emergency surgery, inability to swallow safely, or major neurological deterioration.

A formula that was suitable during stable recovery may become unsafe during an acute medical complication.

Where Guduchi Fits in Majja-Arbuda Rasayana Avaleha

Guduchi may fit most clearly within the Rasayana, strength, Agni, and recovery group.

Its classical properties support this role [43,44].

It may also have a secondary position within the tumour-directed research group because a defined extract altered proliferation, migration, differentiation, senescence-related behaviour, and other features in an experimental glioma model [92].

A third possible role concerns immune and inflammatory regulation, but this must be presented cautiously because human immune effects can vary and autoimmune-like liver injury has been reported [95–97].

Guduchi should not be described as a clinically proven glioblastoma-killing herb.

What Must Be Documented in the Finished Formulation

The formulation record should identify Tinospora cordifolia and the exact plant part used.

Botanical authentication is especially important because of the risk of confusion with related species.

The preparation should state whether the ingredient is stem powder, decoction, Ghana extract, aqueous-ethanolic extract, or another form.

The total amount in the batch, extract ratio where applicable, and estimated daily exposure should be recorded.

The raw material and finished product should be checked for identity, microbial contamination, pesticides, aflatoxins, inappropriate elemental contamination, and undeclared substances.

When Guduchi is used during temozolomide or in a patient with liver risk, baseline and follow-up liver monitoring should be included in the treatment plan.

How Your Response Should Be Monitored

If Guduchi is used mainly for Rasayana and recovery, useful outcomes include appetite, body weight, strength, fatigue, digestion, bowel function, treatment completion, and daily activity.

If it is included for an experimental tumour-directed role, supportive improvement cannot prove tumour control.

MRI findings, neurological status, steroid dose, surgery, radiation, temozolomide, and other treatments must be assessed together.

Better digestion is clinically useful. It is not evidence that glioblastoma cells have differentiated inside your brain.

A normal liver test at the beginning does not guarantee that liver injury cannot develop later. Symptoms and repeat testing remain important.

Current Evidence Verdict for Guduchi

Classical Ayurvedic support is strong for Guduchi as a Rasayana, Balya, Agnidipana, and Dosha-balancing herb used in prolonged illness, weakness, Ama-related patterns, and selected inflammatory or metabolic conditions [43,44].

Direct preclinical glioma evidence is present. An aqueous-ethanolic Tinospora cordifolia extract produced changes associated with reduced proliferation, reduced migration, cellular senescence, and greater differentiation in an experimental glioma model [92].

The model was mainly based on rat-derived glioma cells rather than a human clinical trial or a broad panel of molecularly characterized patient-derived glioblastomas.

Direct evidence showing human glioblastoma shrinkage, delayed recurrence, improved progression-free survival, or longer overall survival is not established.

Direct evidence of therapeutically relevant Guduchi-compound concentrations inside human glioblastoma tissue is also not established.

General pharmacological research supports several biological and immune-related actions [93,94], but these should not be presented as direct clinical glioblastoma proof.

Human liver-injury reports require serious attention, particularly in people with autoimmune susceptibility, existing liver disease, or concurrent liver-affecting medicines [95–97].

Guduchi may be a rational ingredient for selected patients when its purpose is clear, the correct species and stem material are verified, the preparation matches the claim being made, and liver safety is actively monitored. Its experimental glioma evidence supports further research, while its present clinical role is more defensibly described as individualized Rasayana and recovery support rather than proven human tumour control.

Brahmi for Glioma and Glioblastoma: Bacoside A Research, Cognitive Support, and Temozolomide Evidence

Brahmi is traditionally used in Ayurveda to support memory, attention, speech, learning, mental calm, and long-term neurological strength. These properties make it relevant when you are recovering from glioma surgery or dealing with cognitive changes caused by the tumour, seizures, radiation, medicines, poor sleep, or emotional stress.

Brahmi also has a second, more experimental role. Its important constituents, especially compounds grouped under the name bacoside A, have been studied directly in established human glioblastoma cell lines. Researchers have examined unusual tumour-cell death, apoptosis, cell-cycle arrest, Notch signalling, and the response of glioblastoma cells to temozolomide [98–101].

This research gives Brahmi a genuine connection with glioblastoma biology. However, the available tumour-directed evidence remains preclinical. It does not prove that whole Brahmi, a Brahmi extract, or the quantity present in Majja-Arbuda Rasayana Avaleha can shrink glioblastoma in a patient.

Its classical neurological role and experimental tumour-directed role must therefore be explained separately.

What Is Brahmi?

Brahmi is generally identified as Bacopa monnieri (L.) Wettst. The whole plant is commonly used medicinally.

It is a small creeping herb that grows in moist or marshy areas. It has soft succulent leaves and small pale flowers. In Ayurveda, Brahmi is especially known as a Medhya Rasayana, meaning that it is traditionally used to support memory, understanding, learning, attention, and mental function.

The name Brahmi can create confusion because it is also used in some regions and commercial products for Centella asiatica, which is more specifically known as Mandukaparni.

Bacopa monnieri and Centella asiatica are different plants. They have different botanical characteristics, chemical constituents, research evidence, and standardized extracts.

When Brahmi is used in a glioma formulation, the prescription and batch record should therefore state the complete botanical name rather than writing only “Brahmi.”

Why Brahmi and Mandukaparni Must Not Be Treated as the Same Herb

The names Brahmi and Mandukaparni are sometimes used interchangeably in regional practice, commercial products, translations, and older publications.

This creates a serious problem when modern research is discussed.

Bacosides are mainly associated with Bacopa monnieri. Asiatic acid, madecassoside, and asiaticoside are mainly associated with Centella asiatica.

A study involving bacoside A cannot be used as evidence for Centella asiatica. In the same way, a study involving asiatic acid cannot be presented as evidence for Bacopa monnieri.

Both herbs may be considered Medhya in Ayurvedic practice, but similar traditional purposes do not make them chemically or pharmacologically identical.

The finished Majja-Arbuda Rasayana Avaleha should clearly identify whether it contains Bacopa monnieri, Centella asiatica, or both. If both are present, their quantities and intended roles should be recorded separately.

What Ayurveda Says About Brahmi

Bhavaprakasha Nighantu discusses Brahmi and Mandukaparni close to each other in Guduchyadi Varga. The passage describes Brahmi as Medhya and Rasayana and then states that Mandukaparni has similar traditional actions.

The wording is valuable because it shows the close classical relationship between the two herbs. It does not mean that they are botanically identical.

Book: Bhavaprakasha Nighantu
Section: Guduchyadi Varga
Text numbers: 236–237

मण्डूकपर्णी माण्डूकी त्वाष्ट्री दिव्या महौषधी ।
ब्राह्मी हिमा सरा तिक्ता लघुर्मेध्या च शीतला ।
कषाया मधुरा स्वादुपाकायुष्या रसायनी ॥२३६॥

स्वर्या स्मृतिप्रदा कुष्ठपाण्डुमेहास्रकासजित् ।
विषशोथज्वरहरी तद्वन्मण्डूकपर्णिनी ॥२३७॥

Transliteration

Maṇḍūkaparṇī māṇḍūkī tvāṣṭrī divyā mahauṣadhī |
Brāhmī himā sarā tiktā laghur medhyā ca śītalā |
Kaṣāyā madhurā svādupākāyuṣyā rasāyanī ||236||

Svaryā smṛtipradā kuṣṭha-pāṇḍu-mehāsra-kāsajit |
Viṣa-śotha-jvaraharī tadvan maṇḍūkaparṇinī ||237||

English translation

Brahmi is described as cooling, light, bitter, mildly astringent and sweet, with a sweet post-digestive effect. It is Medhya, supportive of mental function, and Rasayana, supporting long-term health and vitality.

It is traditionally described as supporting the voice and memory and as being useful in selected conditions involving skin disease, pallor, metabolic disturbance, blood disorders, cough, toxic states, swelling, and fever. Mandukaparni is described as having similar traditional actions.

Urdu translation

براہمی کو ٹھنڈی تاثیر، ہلکی خاصیت، کڑوے اور قدرے کسیلے و میٹھے ذائقے اور میٹھے بعد از ہضم اثر والی دوا کہا گیا ہے۔ اسے میدھیا یعنی حافظہ، فہم اور ذہنی کارکردگی کی معاون اور رسایَن یعنی طویل مدتی قوت و صحت کو سہارا دینے والی دوا سمجھا گیا ہے۔

روایتی طور پر اسے آواز اور یادداشت کی معاون اور بعض جلدی امراض، کمزوری و زردی، استحالہ کی خرابی، خون کی بعض کیفیتوں، کھانسی، سوجن، بخار اور زہریلی حالتوں میں مفید بتایا گیا ہے۔ منڈوک پرنی کو بھی اسی طرح کی بعض روایتی خصوصیات والی دوا بیان کیا گیا ہے۔

Arabic translation

تُوصَف البراهمي بأنها باردة التأثير، وخفيفة، ومُرّة مع شيء من القَبض والحلاوة، وذات تأثير حلو بعد الهضم. كما تُعدّ من أدوية مِدهيا الداعمة للذاكرة والفهم والوظائف الذهنية، ومن أدوية الراسايانا الداعمة للصحة والقوة على المدى الطويل.

وقد استُخدمت تقليدياً لدعم الصوت والذاكرة، وفي بعض حالات الضعف والشحوب، واضطرابات الاستقلاب والدم، والسعال، والتورم، والحمى، وبعض الحالات السمية والجلدية. وتُذكر الماندوكابرني بأنها تحمل بعض الخصائص التقليدية المشابهة.

This classical passage supports Brahmi’s role in memory, cognition, mental function, voice, vitality, and long-term neurological care [43,44].

It does not describe glioblastoma, bacoside A, temozolomide, macropinocytosis, EGFR, Notch signalling, or tumour-cell death.

The classical evidence supports the neurological and Rasayana role of Brahmi. Its possible tumour-directed action must be examined through modern research.

Why Brahmi May Be Relevant After Glioma Surgery

After brain surgery, you may experience difficulty with attention, memory, planning, speech, mental speed, sleep, or emotional stability.

These difficulties may be caused by the tumour location, surgical injury, cerebral edema, seizures, antiseizure medicines, steroids, radiation, fatigue, or prolonged stress.

Brahmi’s classical Medhya and Rasayana roles make it relevant to this recovery phase.

The intended goal may be to support memory, attention, sleep, emotional stability, participation in rehabilitation, and your ability to manage daily activities.

These outcomes are clinically important. However, improved memory or better sleep does not mean that the tumour has reduced.

Cognitive support and tumour control should always be measured separately.

Why Brahmi May Be Relevant to Glioblastoma Research

Brahmi has been studied against glioblastoma because its bacosides can influence cellular stress, calcium signalling, cell division, apoptosis, and other pathways that may be abnormal in tumour cells [98–101].

Several direct laboratory studies used established human glioblastoma cell lines rather than unrelated cancer models.

This increases the disease relevance of the findings.

However, established cell lines remain simplified experimental systems. They do not reproduce your blood–brain barrier, immune system, tumour blood vessels, molecular heterogeneity, surgery, radiation, steroid exposure, liver metabolism, or concurrent medicines.

The research supports further investigation of Brahmi and bacoside A. It does not establish clinical glioblastoma treatment.

Whole Brahmi Is Not the Same as Bacoside A

Whole Bacopa monnieri contains many natural constituents. These include steroidal saponins, alkaloids, flavonoids, plant sterols, and other compounds.

Bacosides are among the best-known constituents.

The term bacoside A is often used as though it describes one pure molecule. In many research and commercial settings, bacoside A actually refers to a mixture of related saponins rather than one single chemical substance.

This mixture may include bacoside A3, bacopaside II, bacopasaponin C, and related compounds.

Different Brahmi extracts may therefore contain different percentages and patterns of bacosides.

A standardized extract containing 50% bacosides is not equivalent to whole dried Brahmi powder. Purified or enriched bacoside A is also different from a traditional water decoction or Avaleha ingredient.

You should know which material is actually present in your formulation.

Why the Plant Part and Extraction Method Matter

The whole Brahmi plant is commonly used in Ayurveda. This may include the stem, leaves, and other aerial portions collected together.

A water extract, alcohol extract, methanol extract, standardized dry extract, and whole-plant powder may contain different concentrations of bacosides and other constituents.

The direct glioblastoma studies did not all use the same Brahmi preparation.

Some used a whole-plant extract. Others used commercially obtained or purified bacoside A.

The results cannot be transferred automatically from one preparation to another.

If Majja-Arbuda Rasayana Avaleha contains whole Brahmi powder or decoction, its bacoside content should be compared with the research material before making a tumour-directed claim.

Bacoside A and Catastrophic Macropinocytosis

A 2017 study examined Bacopa monnieri extract and bacoside A in established human glioblastoma cell lines, including LN229, U87MG, and U251 [98].

The researchers observed an unusual form of tumour-cell death linked with excessive macropinocytosis.

Macropinocytosis is a process through which a cell forms large membrane pockets and takes in fluid and material from its surroundings.

Some cancer cells use controlled macropinocytosis to obtain nutrients.

In this study, bacoside A appeared to push the process beyond a useful level. The tumour cells formed many large fluid-filled structures, became swollen, developed severe internal pressure, and eventually lost membrane integrity.

The researchers described this as catastrophic macropinocytosis because the excessive fluid uptake contributed to cell destruction.

This was different from ordinary apoptosis alone.

Why This Cell-Death Mechanism Is Scientifically Interesting

Many cancer treatments focus on apoptosis. Glioblastoma cells may become resistant to apoptosis by changing survival proteins, DNA-repair mechanisms, or cellular signalling.

A compound that produces a different type of lethal cellular stress may therefore be scientifically useful.

The bacoside A study suggested that excessive macropinocytosis, calcium-related stress, cytoskeletal damage, and cellular swelling contributed to tumour-cell death [98].

This may offer a possible route for affecting cells that do not respond strongly to ordinary apoptosis signals.

However, the study did not prove that this mechanism occurs inside a human glioblastoma after oral Brahmi.

The tumour cells were exposed directly to the extract or bacoside A in a laboratory dish.

What Cell Lines Were Used in the Study

The researchers used LN229, U87MG, and U251 human glioblastoma cell lines [98].

These are established laboratory models. They are widely used because they allow researchers to repeat experiments under controlled conditions.

The study also included non-glioblastoma control cells to examine whether the response was limited to tumour cells.

This provides more information than testing only one tumour line without any comparison.

However, none of these models was a fresh patient-derived glioblastoma culture from an individual with a fully documented IDH, MGMT, EGFR, or other molecular profile.

The findings therefore apply to the tested cell lines and cannot be assumed to represent every glioma subtype.

How Much Bacoside A Was Used

The 2017 study tested Bacopa monnieri extract across a range of concentrations and bacoside A at concentrations reaching approximately 8 micrograms per millilitre [98].

The compound was placed directly into the liquid surrounding the cells.

This is not the same as swallowing eight milligrams or eight grams.

A concentration in a cell-culture dish cannot be converted directly into an oral dose.

After oral administration, bacosides must be released from the formulation, survive digestion, be absorbed, enter the circulation, avoid rapid metabolism, reach the brain, enter tumour tissue, and remain there long enough to act.

The study did not establish that an oral Brahmi dose produces the same concentration inside a human glioblastoma.

Bacoside A, Calcium, and Cellular Stress

The researchers linked the excessive fluid uptake and cellular swelling partly with changes in calcium signalling [98].

Calcium is essential for many normal cell functions. It helps regulate movement, communication, enzyme activity, membrane function, and cell death.

When calcium control becomes severely disturbed, the cell may lose its ability to maintain normal structure and internal balance.

The study reported changes involving calcium-related signalling and CaMK2A, a calcium-dependent enzyme.

These changes appeared to contribute to macropinosome formation, cytoskeletal disturbance, and eventual tumour-cell death.

This provides a possible mechanism. It does not prove that oral Brahmi alters calcium signalling selectively inside your tumour.

What the 2017 Study Does Not Prove

The study does not prove that Brahmi cures glioblastoma.

It does not show that bacoside A reaches a human brain tumour at the same concentration.

It does not show MRI tumour reduction, delayed recurrence, progression-free survival, or overall survival.

It also does not establish the effective oral dose of whole Brahmi.

The finding is still valuable because it demonstrates a direct and unusual effect in several human glioblastoma cell lines.

It should be described as direct preclinical glioblastoma evidence rather than clinical proof.

Bacoside A and Apoptosis in U87MG Cells

A separate study examined bacoside A in U87MG glioblastoma cells [99].

The researchers reported a concentration-dependent reduction in tumour-cell viability.

The approximate IC50 was 83 micrograms per millilitre. This means that around this concentration reduced the measured cell response by approximately half under the tested conditions.

At concentrations around 80 and 100 micrograms per millilitre, the researchers observed an increase in cells within the sub-G0 phase and greater evidence of early apoptosis.

The sub-G0 population often contains cells with fragmented DNA and is commonly used as one indicator of cell death.

This study supports an apoptosis-related mechanism that differs from the catastrophic macropinocytosis emphasized in the earlier research.

Why the Difference Between the Two Bacoside Studies Matters

The 2017 and 2019 studies reported different dominant cell-death patterns [98,99].

One emphasized excessive macropinocytosis and non-apoptotic cellular destruction. The other reported cell-cycle changes and early apoptosis.

This does not necessarily mean that one study was wrong.

The result of bacoside A may change according to the cell line, concentration, exposure period, extract composition, laboratory method, and endpoint measured.

A lower concentration may produce one type of cellular stress, while a higher concentration may produce another.

This is another reason why the statement “bacoside A kills glioblastoma cells” is too simple.

The actual mechanism depends on how and where it is studied.

Bacoside A and the Cell Cycle

The cell cycle is the controlled sequence through which a cell grows, copies its DNA, and divides.

Cancer cells often lose normal control of this cycle.

The 2019 study reported increased accumulation of U87MG cells in a sub-G0 population after bacoside A exposure [99].

This suggested that more cells were undergoing DNA fragmentation and death.

A substance that interferes with tumour-cell division may reduce growth in a laboratory model.

However, a temporary cell-cycle change is not automatically permanent tumour control.

Surviving cells may recover, adapt, or use another signalling pathway.

Bacoside A and Notch Signalling

The 2019 study also examined the Notch pathway [99].

Notch signalling helps regulate cell development, differentiation, survival, and communication.

Abnormal Notch activity has been associated with glioblastoma growth, stem-like behaviour, treatment resistance, and recurrence in some experimental models.

Bacoside A altered Notch-related signalling in the U87MG cells, including reduced Notch1 expression.

This may have contributed to reduced cell survival and greater apoptosis.

However, Notch is not a simple harmful pathway. It also performs important functions in normal tissues.

A laboratory change in Notch1 does not prove that whole Brahmi safely blocks Notch inside a patient’s tumour.

Why One U87MG Study Cannot Represent Every Glioma

The 2019 experiment used one established glioblastoma cell line [99].

U87MG is useful for mechanistic research, but it cannot represent every IDH-wildtype glioblastoma, IDH-mutant astrocytoma, oligodendroglioma, or paediatric high-grade glioma.

Different tumours may have different Notch activity, EGFR changes, MGMT status, metabolism, and treatment resistance.

The authors themselves noted the need to study additional models.

The result should therefore be presented as evidence from U87MG cells, not as evidence that every glioma will respond in the same way.

Bacoside A and Temozolomide

A 2026 laboratory study investigated bacoside A together with temozolomide in U87MG glioblastoma cells [101].

The combination produced greater cytotoxicity than either intervention alone under the tested conditions.

The researchers reported increased intracellular temozolomide accumulation, greater reactive oxygen species, calcium influx, loss of mitochondrial membrane stability, and stronger apoptosis.

They also reported changes involving EGFR-driven MAPK signalling and NF-kappa B activity.

These findings suggest that bacoside A may make selected glioblastoma cells more vulnerable to temozolomide.

This is direct preclinical combination evidence. It is not a human treatment trial.

What Increased Intracellular Temozolomide Means

The study reported greater accumulation of temozolomide within the treated U87MG cells when bacoside A was used in the experimental combination [101].

This may have increased the amount of drug available to damage the tumour cells.

The finding is important because poor intracellular drug exposure can contribute to treatment resistance.

However, a cell-culture result does not prove that oral Brahmi increases temozolomide concentration inside a human brain tumour.

Your body controls temozolomide absorption, chemical conversion, distribution, and elimination differently from a laboratory dish.

The effect also needs to be examined in normal brain cells and other tissues before it can be considered clinically safe.

Bacoside A, Reactive Oxygen Species, and Mitochondrial Damage

The combination study reported increased reactive oxygen species and loss of mitochondrial membrane potential [101].

Mitochondria produce energy and help regulate cell survival and apoptosis.

When mitochondrial membranes become severely damaged, the cell may lose energy control and activate programmed cell death.

In the U87MG model, bacoside A appeared to strengthen temozolomide-related cellular stress and mitochondrial damage.

This provides one possible explanation for the greater tumour-cell death seen in the combination.

It does not prove that the same oxidative stress will occur selectively in your tumour without affecting normal tissue.

Bacoside A and EGFR/MAPK Signalling

EGFR is a growth-related receptor that is frequently altered or amplified in glioblastoma.

When activated, EGFR can send signals through MAPK and other pathways that support cell growth, survival, and treatment resistance.

The 2026 study reported that bacoside A reduced EGFR-driven MAPK signalling in the tested cells [101].

This may have weakened the cells’ ability to survive temozolomide-related stress.

However, EGFR biology varies among glioblastomas. Some tumours have amplification, mutation, or alternative signalling. Others may rely more heavily on different pathways.

The cell result therefore provides a plausible mechanism, not a universal treatment rule.

Bacoside A and NF-Kappa B

NF-kappa B helps regulate inflammation, survival, cellular stress, and immune responses.

Glioblastoma cells may use abnormal NF-kappa B activity to resist treatment.

The combination study reported reduced NF-kappa B nuclear activity after bacoside A exposure [101].

This may have lowered survival signalling and increased the effect of temozolomide.

NF-kappa B also has normal roles in immunity and tissue repair. It should not be described simply as a harmful switch.

Any attempt to influence this pathway in patients requires much more evidence than one cell study.

Why the Temozolomide Dose Must Not Be Reduced From Laboratory Evidence

The researchers suggested that bacoside A might allow stronger effects from lower temozolomide exposure in the experimental model [101].

This is useful for designing future studies.

It does not justify reducing your prescribed temozolomide dose.

A clinical dose can only be changed according to your oncology protocol, blood counts, liver function, age, treatment tolerance, performance status, and tumour response.

No human glioblastoma trial has shown that Brahmi or bacoside A allows temozolomide to be safely reduced while maintaining the same clinical benefit.

Laboratory synergy should never be used as a reason to alter chemotherapy without your oncologist.

Does Bacoside A Reverse MGMT Resistance?

The available Brahmi studies do not prove that bacoside A changes MGMT promoter methylation or reliably overcomes MGMT-mediated resistance.

The 2026 study examined several treatment-related mechanisms, but it was performed in U87MG cells [101].

MGMT remains only one part of temozolomide resistance. Other factors include drug transport, DNA repair, mitochondrial survival, stem-like cells, and cellular signalling.

You should not be told that Brahmi changes an unmethylated MGMT tumour into a methylated one.

A possible increase in temozolomide sensitivity is not the same as altering the tumour’s MGMT promoter status.

Brahmi and Propolis Combination Research

Another laboratory study examined Bacopa monnieri extracts in combination with Polish propolis against T98G, LN-18, and U87MG glioblastoma cell lines [100].

The combination produced greater growth inhibition than either preparation used separately in several experimental conditions.

This suggests that natural products may interact and create effects that are not visible when each is studied alone.

However, the result cannot be attributed only to Brahmi.

Propolis contains many bioactive compounds and may contribute substantially to the combined effect.

The exact Brahmi extract, propolis composition, concentrations, and cell lines are essential parts of the result.

This study does not prove that combining Brahmi with honey, bee products, or an Avaleha base will reproduce the same effect.

Why Combination Studies Cannot Prove the Effect of the Complete Avaleha

Majja-Arbuda Rasayana Avaleha may contain Brahmi together with Shallaki, Ashwagandha, Haridra, Pippali, Guduchi, and other ingredients.

A study of Brahmi plus propolis does not prove how Brahmi will behave with all these other substances.

One ingredient may improve absorption. Another may reduce it. Two compounds may strengthen the same pathway, while another may interfere with the effect.

The complete Avaleha therefore requires its own formulation-level research.

Individual ingredient studies provide the scientific rationale for selecting ingredients. They do not prove the final combined clinical outcome.

Does Brahmi Directly Target Glioma Stem-Like Cells?

The references discussed in this section mainly used established glioblastoma cell lines [98–101].

They did not provide strong direct evidence from a broad panel of well-characterized patient-derived glioblastoma stem-like cultures.

Some of the pathways studied, including Notch, EGFR, NF-kappa B, and cellular survival, may be relevant to stem-like behaviour.

This does not justify stating that Brahmi has been proven to eliminate glioma stem cells.

The evidence is better described as direct activity in established glioblastoma models, with possible relevance to pathways associated with treatment resistance and stemness.

More research is needed in patient-derived stem-like cells, intracranial models, and human tumour samples.

Does Brahmi Cross the Blood–Brain Barrier?

Brahmi has shown effects on memory and cognition in human studies, which suggests that the whole intervention or its absorbed constituents can influence the nervous system [102–104].

This does not prove that unchanged bacoside A reaches a human glioblastoma at a tumour-killing concentration.

Bacosides may be metabolized during digestion and after absorption. Some neurological effects may be produced by metabolites rather than by the original compound.

The clinically important questions are which compounds reach the blood, whether they enter brain tissue, whether they enter tumour tissue, and what concentrations are achieved.

Direct measurements of bacoside A inside human glioblastoma tissue are not established in the evidence reviewed here.

The phrase “Brahmi crosses the blood–brain barrier” should therefore not be used as proof of tumour control.

Human Evidence for Memory and Cognitive Function

Human research on Brahmi is much stronger for selected cognitive outcomes than it is for glioblastoma treatment.

A systematic review of randomized controlled studies found that standardized Bacopa monnieri extracts may improve some aspects of memory, particularly delayed or free recall, after regular use for approximately twelve weeks [102].

A later meta-analysis including nine trials and more than 500 participants also suggested improvement in selected cognitive outcomes, especially speed of attention [103].

These findings support Brahmi’s traditional Medhya role.

However, the participants were generally healthy adults or older adults. They were not patients with active glioblastoma, postoperative cognitive deficits, radiation injury, seizures, or cerebral edema.

The evidence cannot be transferred without qualification.

What the Older-Adult Brahmi Trial Found

One randomized placebo-controlled study included 54 adults aged 65 years or older [104].

The participants received a standardized Bacopa monnieri extract at 300 milligrams daily or placebo for twelve weeks.

The Brahmi group showed improvement in selected measures, including delayed word recall and performance on a Stroop task, which examines attention and the ability to control competing information.

The findings support a possible memory and attention benefit from a standardized extract.

They do not prove that the same dose will improve cognitive deficits caused by a brain tumour.

They also do not prove that whole Brahmi powder inside an Avaleha is equivalent to the standardized extract used in the trial.

Why Cognitive Research Matters to a Glioma Patient

Memory, attention, speech, planning, and mental speed can be affected by the tumour, surgery, radiation, seizures, steroid use, antiseizure medicines, fatigue, poor sleep, anxiety, and depression.

A safe intervention that supports cognition may improve your independence and quality of life.

It may help you follow instructions, remember medicines, communicate with caregivers, participate in rehabilitation, and manage daily activities.

These benefits can be clinically valuable even when the tumour itself remains unchanged.

Brahmi should therefore not be judged only as a possible tumour-directed ingredient. Its Medhya role may be equally important in selected patients.

Cognitive Improvement Does Not Prove Tumour Regression

If your memory improves after taking Brahmi, the improvement may be genuine.

It may result from better sleep, reduced anxiety, improved attention, neurological recovery, rehabilitation, reduced medication burden, or the direct cognitive effect of Brahmi.

It does not prove that the glioblastoma has reduced.

Tumour response requires MRI assessment, neurological examination, steroid review, treatment timing, and consideration of surgery, radiation, and chemotherapy.

Supportive and tumour-directed outcomes should be recorded separately.

Brahmi Should Not Replace Cognitive Rehabilitation

A Medhya herb cannot replace structured rehabilitation when you have a significant neurological deficit.

You may require speech therapy, occupational therapy, neuropsychological assessment, memory strategies, physiotherapy, swallowing support, or caregiver-assisted exercises.

Brahmi may be used alongside these interventions when appropriate.

The aim should be to improve your functional recovery rather than expecting one herb to restore every affected brain function.

Brahmi After Glioma Surgery

Brahmi may be considered after surgery when you are medically stable, able to swallow safely, and tolerating oral medicines.

Its main role during early recovery may be cognitive and neurological support.

However, new confusion, speech difficulty, weakness, severe drowsiness, or memory decline should not be treated automatically with a higher Brahmi dose.

These symptoms may indicate cerebral edema, bleeding, seizure activity, infection, hydrocephalus, medication toxicity, or tumour-related problems.

Urgent neurological causes must be excluded first.

Brahmi During Radiation

There is no human glioblastoma evidence proving that Brahmi makes radiation more effective.

Its possible use during radiation is more defensibly connected with cognitive support, stress, sleep, and recovery.

Radiation may cause fatigue, nausea, appetite changes, edema, and delayed cognitive effects.

If Brahmi is used, its intended supportive purpose should be documented.

Any tumour-directed statement should remain limited to preclinical bacoside research.

Brahmi During Temozolomide

The 2026 cell study provides a reason to investigate bacoside A with temozolomide [101].

It does not establish a human combination protocol.

If Brahmi is prescribed during temozolomide, the actual product should be identified. Whole Brahmi powder, a standardized bacoside extract, and purified bacoside A may produce very different exposures.

Your blood counts, liver function, nausea, appetite, bowel function, seizure control, and complete medicine list should continue to be monitored.

No prescribed temozolomide dose should be changed because of the laboratory findings.

Brahmi and Antiseizure Medicines

Direct interaction evidence between Brahmi and every antiseizure medicine remains limited.

The main practical concern is that both the tumour and neurological medicines may affect alertness, memory, balance, or behaviour.

If you begin Brahmi while taking antiseizure medicine, changes in sleepiness, dizziness, concentration, balance, or seizure frequency should be recorded.

You should not reduce or stop your antiseizure medicine because Brahmi is traditionally described as Medhya.

Seizure prevention remains an essential part of glioma care.

Possible Digestive Side Effects

Human Brahmi studies have generally reported mild adverse effects rather than severe toxicity [102–104].

Digestive symptoms may include nausea, abdominal discomfort, cramping, loose stools, increased stool frequency, or gas.

This matters because you may already have nausea from temozolomide, constipation from antiemetics, or reduced appetite after surgery.

A dose that supports cognition but causes persistent diarrhoea or poor food intake may not be suitable.

The dose, timing, extract concentration, and Avaleha base may need adjustment.

Digestive discomfort should not be described as detoxification.

Brahmi and Liver Safety

The human cognitive trials cited in this section did not identify a strong pattern of serious liver injury [102–104].

However, these were relatively small studies and generally involved healthier participants than a person receiving glioblastoma treatment.

The absence of a major safety signal in those trials does not prove that every Brahmi product or multi-ingredient Avaleha is safe for every liver condition.

Your complete formulation may contain several herbs, concentrated extracts, or bhasmas. Temozolomide and antiseizure medicines may also affect liver function.

Liver monitoring should therefore be based on your complete treatment rather than on Brahmi alone.

Can Brahmi Cause Excessive Sedation?

Brahmi is often used to support mental calm, but it is not necessarily a strong sedative.

Some people may still feel increased relaxation, reduced alertness, or digestive heaviness, particularly when a concentrated extract is combined with sedating medicines.

This is important when you already take antiseizure medicines, sleeping tablets, opioids, or anxiety medicines.

Your caregiver should observe whether you become unusually sleepy, confused, unsteady, or less able to participate in rehabilitation.

A sudden neurological change should never be assumed to be a harmless effect of Brahmi.

How the Brahmi Dose in the Avaleha Should Be Calculated

The quantity of Brahmi placed into the complete batch should be recorded.

Suppose a 900-gram Avaleha contains 45 grams of authenticated Bacopa monnieri whole plant.

Brahmi would represent 5% of the finished formulation.

If you take 30 grams of Avaleha daily, your estimated whole-Brahmi exposure would be approximately 1.5 grams per day.

This does not mean that you receive 1.5 grams of bacoside A.

The actual bacoside content may be only a fraction of the whole-herb weight.

It also does not make the dose equivalent to the 300-milligram standardized extract used in a human cognitive trial [104]. The standardized extract may contain a much higher percentage of bacosides than ordinary plant powder.

Why Bacoside Standardization Matters

A label stating “Brahmi 500 milligrams” does not tell you how much bacoside is present.

One product may contain whole-plant powder. Another may contain a 10:1 extract. Another may be standardized to 20%, 40%, or 50% bacosides.

These products may produce very different biological exposure.

If tumour-directed bacoside research is used to justify Brahmi in the formula, the finished Avaleha should ideally be tested for total bacosides and selected marker compounds.

This would make the research comparison more transparent.

How Avaleha Processing May Change the Final Brahmi Content

Brahmi may be included in the decoction group, added later as a fine powder, or used as a concentrated extract.

Each approach may produce a different chemical profile.

Water extraction may recover some constituents more effectively than others. Later addition as powder may preserve the whole plant but may also affect texture and digestion.

The manufacturing record should state the form of Brahmi, the stage at which it was added, the temperature, the final batch weight, and the storage conditions.

The same ingredient name does not guarantee the same final bacoside exposure.

What Must Be Documented in the Finished Formulation

The batch record should identify Bacopa monnieri by its full botanical name and confirm that the whole plant or stated plant part was used.

It should not rely only on the name Brahmi because of possible confusion with Centella asiatica.

The record should state whether the material is powder, decoction, standardized extract, or bacoside-enriched extract.

The total batch quantity, extract ratio, estimated daily exposure, and bacoside content should be documented wherever possible.

Botanical authentication, chemical fingerprinting, microbial testing, pesticide testing, aflatoxin testing, and inappropriate elemental-contamination testing should also be part of quality control.

Where Brahmi Fits in Majja-Arbuda Rasayana Avaleha

Brahmi fits most clearly within the Majja and neurological-recovery group.

Its classical Medhya and Rasayana properties support its use for memory, attention, speech, mental function, and longer-term recovery [43,44].

It may also have a secondary place within the tumour-directed research group because Brahmi extract and bacoside A have produced direct effects in several established human glioblastoma cell lines [98,99].

A third investigational role relates to temozolomide sensitivity because bacoside A strengthened temozolomide-related cytotoxicity in a U87MG laboratory model [101].

These three roles should remain separate in the patient explanation.

How Your Response Should Be Monitored

If Brahmi is used mainly for cognitive and neurological support, useful outcomes include memory, attention, speech, sleep, orientation, daily activity, rehabilitation participation, and caregiver observations.

Formal cognitive assessment may be valuable when significant impairment is present.

If Brahmi is included partly for tumour-directed research, cognitive improvement cannot prove tumour response.

MRI findings, neurological status, steroid dose, surgery, radiation, temozolomide, seizures, and treatment timing must be evaluated together.

Digestive tolerance, alertness, balance, blood counts, liver function, and seizure stability should also be followed according to your complete treatment.

Current Evidence Verdict for Brahmi and Bacoside A

Classical Ayurvedic support is strong for Brahmi as a Medhya and Rasayana herb used to support memory, attention, mental function, voice, and long-term neurological health [43,44].

Human clinical evidence provides moderate support for selected cognitive outcomes, especially memory recall and attention, after regular use of standardized Bacopa monnieri extracts for approximately twelve weeks [102–104].

These human studies were not performed in glioma or glioblastoma patients.

Direct preclinical glioblastoma evidence is present. Brahmi extract and bacoside A produced catastrophic macropinocytosis, cellular swelling, cytoskeletal damage, apoptosis, and cell-cycle changes in established human glioblastoma cell lines [98,99].

A recent preclinical study also reported that bacoside A increased temozolomide-related cytotoxicity through oxidative stress, mitochondrial damage, calcium changes, and altered EGFR/MAPK and NF-kappa B signalling [101].

Human evidence showing glioblastoma shrinkage, prevention of recurrence, improved progression-free survival, or longer overall survival is not established.

Direct evidence showing a therapeutically effective concentration of bacoside A inside human glioblastoma tissue is also not established.

Brahmi may therefore be valuable as an individualized Medhya and neurological-support ingredient, with a secondary experimental role based on direct glioblastoma-cell research. Its inclusion should use confirmed Bacopa monnieri identity, realistic comparison between whole herb and standardized bacosides, documented daily exposure, digestive monitoring, medicine review, and clear separation between cognitive support and tumour response.

Mandukaparni and Asiatic Acid for Glioma and Glioblastoma: Ayurvedic Neurological Support, Apoptosis, Hypoxia, and Brain-Delivery Research

Mandukaparni is an important Medhya Rasayana herb used in Ayurveda for memory, mental clarity, nervous-system support, wound recovery, and long-term restoration. These traditional actions make it relevant when you are recovering from glioma surgery or experiencing difficulty with memory, speech, attention, sleep, anxiety, or neurological function.

Mandukaparni also has an experimental tumour-directed role. Asiatic acid, one of its important triterpenoid compounds, has been studied directly in human glioblastoma cell lines, animal tumour models, and laboratory conditions that imitate the low-oxygen environment found within aggressive tumours [105–107].

This is meaningful evidence because the studies were not limited to unrelated cancers. Some of the research directly examined glioblastoma cells and included a tumour growing inside the brain of an animal.

However, purified asiatic acid is not the same as whole Mandukaparni. The concentration applied directly to tumour cells in a laboratory is also not the same as the amount that may reach your tumour after you take the whole herb through an Avaleha.

Mandukaparni should therefore be understood through two separate evidence pathways. Its classical Medhya and Rasayana use may support neurological recovery and mental function. Its asiatic acid research provides a direct but still preclinical glioblastoma hypothesis.

What Is Mandukaparni?

Mandukaparni is generally identified as Centella asiatica (L.) Urb. It is commonly known in English as gotu kola or Indian pennywort.

The whole plant is generally used in Ayurvedic medicine. It grows in moist areas and has small rounded leaves that may resemble the shape of a frog’s foot, which is connected with the name Mandukaparni.

The botanical identity must be stated because Mandukaparni is often confused with Brahmi.

Brahmi is generally identified as Bacopa monnieri. Mandukaparni is Centella asiatica. Both may be used as Medhya herbs, but they are different plants with different chemical compounds and different modern research.

Brahmi is mainly associated with bacosides. Mandukaparni is mainly associated with triterpenes such as asiaticoside, madecassoside, asiatic acid, and madecassic acid.

A study involving bacoside A cannot be used as evidence for Mandukaparni. A study involving asiatic acid cannot be presented as evidence for Bacopa monnieri.

If both herbs are included in Majja-Arbuda Rasayana Avaleha, their botanical identities, quantities, and purposes should be recorded separately.

What Ayurveda Says About Mandukaparni

Bhavaprakasha Nighantu discusses Brahmi and Mandukaparni together in Guduchyadi Varga. The passage describes Medhya, cooling, Rasayana, memory-supporting, and long-term restorative actions.

Verse numbering can differ slightly among printed editions. The following passage is commonly numbered 236–237.

Book: Bhavaprakasha Nighantu
Section: Guduchyadi Varga
Text numbers: 236–237 in commonly used editions

मण्डूकपर्णी माण्डूकी त्वाष्ट्री दिव्या महौषधी ।
ब्राह्मी हिमा सरा तिक्ता लघुर्मेध्या च शीतला ।
कषाया मधुरा स्वादुपाकायुष्या रसायनी ॥२३६॥

स्वर्या स्मृतिप्रदा कुष्ठपाण्डुमेहास्रकासजित् ।
विषशोथज्वरहरी तद्वन्मण्डूकपर्णिनी ॥२३७॥

Transliteration

Maṇḍūkaparṇī māṇḍūkī tvāṣṭrī divyā mahauṣadhī |
Brāhmī himā sarā tiktā laghur medhyā ca śītalā |
Kaṣāyā madhurā svādupākāyuṣyā rasāyanī ||236||

Svaryā smṛtipradā kuṣṭha-pāṇḍu-mehāsra-kāsajit |
Viṣa-śotha-jvaraharī tadvan maṇḍūkaparṇinī ||237||

English translation

Mandukaparni is also known as Manduki and is described as an important medicinal herb. The passage describes Medhya, cooling, light, bitter, mildly astringent and sweet properties, together with a sweet post-digestive effect and Rasayana action.

It is traditionally connected with memory, voice, longevity, mental function, swelling, fever, and selected conditions involving disturbed tissues. Mandukaparni is described as having similar important Medhya and restorative actions.

Urdu translation

منڈوک پرنی کو منڈوکی بھی کہا جاتا ہے اور اسے ایک اہم ادویاتی پودا بیان کیا گیا ہے۔ اسے میدھیا یعنی حافظہ، فہم اور ذہنی کارکردگی کی معاون، ٹھنڈی تاثیر، ہلکی خاصیت، کڑوے اور قدرے کسیلے ذائقے اور رسایَن اثر والی دوا سمجھا گیا ہے۔

روایتی طور پر اسے یادداشت، آواز، طویل مدتی قوت، ذہنی کارکردگی، بعض سوزشی کیفیتوں، سوجن اور بخار میں معاون بتایا گیا ہے۔

Arabic translation

تُعرف الماندوكابرني أيضاً باسم ماندوكي، وتُعدّ من النباتات الطبية المهمة. وتُوصَف بأنها من أدوية مِدهيا الداعمة للذاكرة والفهم والوظائف الذهنية، وذات تأثير بارد وخفيف وطعم مر وقابض بدرجة معتدلة، كما تُعدّ من أدوية الراسايانا.

وقد استُخدمت تقليدياً لدعم الذاكرة والصوت والقوة طويلة المدى والوظائف الذهنية، وفي بعض حالات التورم والحمى واضطراب الأنسجة.

This passage supports the traditional neurological and Rasayana role of Mandukaparni. It does not describe glioblastoma, asiatic acid, apoptosis, tumour hypoxia, brain penetration, or chemotherapy sensitivity [43,44].

Its direct tumour-related role must therefore be supported by modern glioblastoma research.

Why Mandukaparni May Be Relevant After Glioma Surgery

Your brain function may be affected by the tumour, surgery, cerebral edema, seizures, radiation, steroids, antiseizure medicines, poor sleep, anxiety, or prolonged physical weakness.

You may notice reduced memory, slow thinking, difficulty finding words, poor concentration, emotional instability, or reduced confidence in daily activities.

Mandukaparni’s classical Medhya and Rasayana actions may make it relevant to this phase of recovery. It may be considered to support mental function, sleep, emotional stability, speech, attention, and participation in rehabilitation.

These outcomes should remain separate from tumour response.

If your memory improves, the change may be valuable. It does not prove that the glioblastoma has reduced. Cognitive improvement may result from healing after surgery, reduced swelling, rehabilitation, better sleep, lower steroid exposure, seizure control, or several treatments working together.

Whole Mandukaparni Is Not the Same as Asiatic Acid

Whole Centella asiatica contains several related triterpenes and many additional natural constituents.

Asiaticoside and madecassoside are triterpenoid glycosides. Asiatic acid and madecassic acid are related aglycone compounds.

Your body may convert some glycosides into related metabolites during digestion and absorption. The chemical profile reaching your blood may therefore differ from the profile present in the original plant.

Purified asiatic acid is one concentrated compound. Whole Mandukaparni contains a much smaller and variable amount of it.

The exact amount may depend on the plant source, plant part, growing conditions, harvesting, drying, extraction, storage, and laboratory method.

A study using purified asiatic acid cannot automatically prove that ordinary Mandukaparni powder or a water decoction will produce the same effect.

Why the Extraction Method Matters

Whole-plant powder, fresh plant juice, water decoction, alcohol extract, water-alcohol extract, standardized triterpene extract, purified asiaticoside, and purified asiatic acid are different interventions.

A water decoction may not extract every triterpenoid in the same concentration as an alcohol-containing extract.

A standardized extract may provide a much higher triterpene exposure than the same weight of whole-plant powder.

A purified asiatic acid experiment removes the other plant compounds and exposes the tumour cells directly to one known concentration.

Therefore, the Mandukaparni preparation used in Majja-Arbuda Rasayana Avaleha should be stated clearly. You should know whether it is included in the decoction group, added later as fine powder, or used as a standardized extract.

The First Direct Glioblastoma Study of Asiatic Acid

One important study examined asiatic acid in U-87 MG human glioblastoma cells [105].

The researchers found that asiatic acid caused cell death in a dose-dependent and time-dependent manner. This means that the effect generally increased when the concentration or exposure period increased.

The tumour cells did not die through only one mechanism. The researchers observed features of both apoptosis and necrosis.

Apoptosis is a controlled form of cell death in which a damaged cell activates an internal process to dismantle itself.

Necrosis is a less controlled form of cell destruction that may involve severe membrane damage, swelling, loss of cellular structure, and leakage of cell contents.

The finding is important because it shows that asiatic acid created several forms of lethal stress in the tested glioblastoma cells.

How Asiatic Acid Affected Mitochondria

Mitochondria help produce cellular energy and regulate whether a cell survives or enters apoptosis.

The U-87 MG study reported that asiatic acid reduced the mitochondrial membrane potential [105].

The mitochondrial membrane potential is an electrical and chemical difference across the mitochondrial membrane. It is essential for normal energy production.

When this potential collapses, the cell may lose its ability to produce energy properly and may activate cell-death pathways.

This provides one possible explanation for the glioblastoma-cell death observed in the experiment.

However, the study does not show that oral Mandukaparni selectively damages glioblastoma mitochondria while leaving every normal brain cell unaffected.

Asiatic Acid and Caspase Activation

The same study reported activation of caspase-9 and caspase-3 [105].

Caspases are enzymes that participate in apoptosis. Caspase-9 is closely associated with the mitochondrial apoptosis pathway, while caspase-3 helps carry out the final stages of cell dismantling.

The activation of these enzymes supports the conclusion that apoptosis contributed to the tumour-cell death.

However, when the researchers used a broad caspase inhibitor, caspase activation was blocked but overall cell death was not fully prevented.

This suggests that asiatic acid was not acting only through caspase-dependent apoptosis.

Other forms of cellular damage, especially calcium-related injury and necrosis, continued to contribute.

Why Calcium Was Important in the Study

Calcium is essential for normal cell communication, energy production, contraction, enzyme activity, and survival.

The amount of calcium inside a cell must be tightly controlled.

The asiatic acid study found an increase in free intracellular calcium in U-87 MG cells [105].

When the researchers used a substance that reduced the available intracellular calcium, much of the asiatic-acid-related cell death was prevented.

This finding suggested that abnormal calcium accumulation played a central role.

The researchers concluded that calcium-mediated necrotic cell death was particularly important in the tested model.

This does not mean that increasing calcium intake will kill glioblastoma. The study concerned abnormal calcium signalling inside tumour cells after direct exposure to purified asiatic acid.

Dietary calcium and intracellular tumour-cell calcium are completely different issues.

Why the 2006 Study Is Important but Limited

The study provides direct evidence that purified asiatic acid can damage U-87 MG human glioblastoma cells [105].

It also provides a detailed mechanism involving mitochondrial disruption, caspase activation, intracellular calcium, apoptosis, and necrosis.

However, only one principal glioblastoma cell line was used.

The study did not involve a person taking Mandukaparni.

It did not measure asiatic acid in human blood, cerebrospinal fluid, or glioblastoma tissue.

It did not examine MRI response, progression-free survival, recurrence, or overall survival.

The correct interpretation is that asiatic acid showed direct cytotoxic activity in a human glioblastoma cell model. The effective oral form and dose in a patient remain unproven.

Research in Several Human Glioblastoma Cell Lines

A later study expanded the research by examining asiatic acid in three human glioblastoma cell lines: LN18, U87MG, and U118MG [106].

The cells were exposed to asiatic acid concentrations ranging from approximately 10 to 100 micromolar.

The researchers reported reduced tumour-cell viability across the tested models.

At equal laboratory concentrations, asiatic acid produced stronger loss of viability than temozolomide in some of the tested conditions [106].

This comparison must be interpreted carefully.

An equimolar comparison in a laboratory does not mean that asiatic acid is clinically stronger than temozolomide. Temozolomide and asiatic acid have different absorption, metabolism, tumour exposure, dosing schedules, and mechanisms.

Temozolomide has human clinical-trial evidence in glioblastoma. Asiatic acid does not yet have comparable human efficacy evidence.

The laboratory comparison is useful for identifying a research signal. It should not be used to advise you to replace temozolomide with Mandukaparni.

Asiatic Acid and Apoptosis-Regulating Proteins

The multi-cell-line study examined several proteins that help decide whether a tumour cell survives or dies [106].

Asiatic acid changed the expression or activation of caspases, Bcl-2 family proteins, and survivin.

Some Bcl-2 family proteins help cells resist apoptosis, while others encourage it. Glioblastoma cells may maintain high survival signalling through this system.

Survivin is another protein that can help tumour cells continue dividing and avoid cell death.

By weakening selected survival signals and strengthening apoptosis-related pathways, asiatic acid made the tested glioblastoma cells more vulnerable to death.

This provides a plausible tumour-directed mechanism. It does not prove that whole Mandukaparni produces the same protein changes inside your tumour.

What Endoplasmic Reticulum Stress Means

The endoplasmic reticulum is a structure inside the cell that helps produce, fold, process, and transport proteins. It also contributes to calcium control.

When too many damaged or incorrectly folded proteins collect, the cell develops endoplasmic reticulum stress.

A moderate stress response may help a tumour cell repair itself and survive.

If the stress becomes too severe or prolonged, the same system may help trigger cell death.

Glioblastoma cells already experience stress because they grow rapidly, compete for nutrients, and survive in low-oxygen areas. They may depend on strong stress-control systems to remain alive.

The 2015 study reported that asiatic acid increased endoplasmic reticulum stress beyond the level that the tested cells could manage [106].

Asiatic Acid, GRP78, Calpain, Calnexin, and IRE1α

The study reported increased GRP78 and calpain together with reduced calnexin and IRE1α expression [106].

GRP78 is an important stress-response protein within the endoplasmic reticulum. Its increase can indicate that the cell is trying to manage an excessive protein-folding burden.

Calpain is a calcium-activated enzyme. Excessive calpain activity can damage structural and functional proteins inside the cell.

Calnexin helps newly formed proteins fold correctly. IRE1α is involved in the unfolded-protein response that helps cells adapt to endoplasmic reticulum stress.

The combined changes suggested that asiatic acid disrupted the tumour cells’ ability to maintain protein quality, calcium balance, and normal internal organization.

When the stress became too severe, the cells entered apoptosis or other forms of death.

This mechanism is scientifically important because treatment-resistant glioblastoma cells may depend on stress-adaptation systems. It remains a preclinical finding.

Animal Research With Tumours Under the Skin

The 2015 study also tested asiatic acid in mice carrying U87MG tumour xenografts [106].

In one part of the experiment, the tumour cells were implanted under the skin. This is called an ectopic or subcutaneous xenograft.

Oral asiatic acid at 30 milligrams per kilogram per day reduced tumour volume by approximately 54% when treatment began immediately after implantation.

When the animals already had established tumours, the reported reduction was approximately 48%.

No obvious toxicity was reported under the studied conditions.

These findings show that orally administered asiatic acid had systemic antitumour activity in the mouse model. However, a tumour grown under the skin does not test brain delivery or the blood–brain barrier in the same way as a tumour growing inside the brain.

Why the Intracranial Model Added More Value

The researchers also used an orthotopic U87MG xenograft model [106].

Orthotopic means that the tumour cells were placed in the organ where the disease naturally occurs. In this case, the human glioblastoma cells were implanted in the brains of immune-deficient mice.

The animals received asiatic acid orally at 30 milligrams per kilogram twice daily.

Tumour growth was assessed through MRI.

The researchers reported reduced intracranial tumour growth in the asiatic-acid-treated group.

This is more relevant than the subcutaneous model because the compound had to be absorbed, enter the circulation, reach the brain, and affect tumour cells growing inside brain tissue.

It remains an animal experiment. It does not establish the safe or effective dose for a person.

Was Asiatic Acid Detected in Brain Tissue?

The researchers used liquid chromatography and mass-spectrometry methods to examine asiatic acid in the animals [106].

Asiatic acid was detected in plasma and brain tissue.

This is important because it provides direct preclinical distribution evidence rather than relying only on molecular size, fat solubility, or computer prediction.

It supports the statement that orally administered asiatic acid reached mouse brain tissue under the tested conditions.

It does not prove that whole Mandukaparni delivers the same amount.

It also does not prove that a therapeutic concentration will be reached inside a human glioblastoma.

How the Blood–Brain Barrier Claim Should Be Written

The phrase “crosses the blood–brain barrier” can easily be overstated.

The evidence supports saying that purified asiatic acid was detected in mouse brain tissue after oral administration and affected an intracranial U87MG xenograft in mice [106].

The evidence does not establish how much asiatic acid reaches human brain tissue after Mandukaparni powder, decoction, or Avaleha use.

It does not establish the concentration within the enhancing tumour core, infiltrating margins, normal brain, cerebrospinal fluid, or individual tumour cells.

It also does not establish whether the amount reached in a patient would be high enough to reproduce the 10–100 micromolar concentrations used in cell studies.

A responsible statement is therefore:

Purified asiatic acid has demonstrated oral brain exposure and intracranial antitumour activity in mouse models. Therapeutically relevant exposure after whole Mandukaparni use in human glioblastoma has not been established.

Why the Mouse Dose Cannot Be Directly Copied for You

A mouse dose expressed as milligrams per kilogram cannot be multiplied directly by your body weight.

Mice and humans differ in metabolism, body-surface area, liver processing, intestinal absorption, tissue distribution, and elimination.

The animal study used purified asiatic acid, not ordinary Mandukaparni.

A whole-herb dose may contain only a small fraction of asiatic acid.

The twice-daily intracranial-model exposure was also different from the once-daily dose used in parts of the subcutaneous experiment.

These differences mean that the study supports a research direction, not a self-treatment dose.

Why the Animal Model Still Has Important Limits

The U87MG xenograft model is useful, but it cannot reproduce the full complexity of your glioblastoma.

The mice were immune-deficient so that human tumour cells could grow in them. Their immune response was therefore different from yours.

U87MG represents one established tumour line. Your tumour may have different IDH, MGMT, EGFR, PTEN, TERT, CDKN2A/B, and other molecular features.

The animal model also does not reproduce your surgery, radiation, steroid exposure, seizure medicines, age, nutrition, or other diseases.

The result is promising preclinical evidence. It is not clinical proof.

Asiatic Acid Under Low-Oxygen Conditions

Glioblastoma often contains areas with very low oxygen. This condition is known as hypoxia.

Hypoxia can develop because the tumour grows rapidly and its abnormal blood vessels cannot deliver enough oxygen to every area.

Low oxygen may make tumour cells more invasive and more resistant to radiation or chemotherapy.

A 2017 study examined asiatic acid in U87-MG glioblastoma cells under normal oxygen and under hypoxia, using approximately 1% oxygen [107].

The researchers also used SVGp12 fetal glial cells as a non-tumour comparison and cisplatin as a chemotherapy comparator.

Asiatic acid reduced U87-MG viability in a concentration-dependent and time-dependent manner. Its cytotoxic effect was greater in the U87-MG cells than in the SVGp12 cells under several tested conditions [107].

Why Hypoxia Research Matters

Many compounds look active when cancer cells are grown under ordinary laboratory oxygen.

The result may change under hypoxia.

Low oxygen can slow cell division and reduce the effectiveness of treatments that work mainly against rapidly dividing cells. It can also activate pathways that help tumour cells survive.

The asiatic acid study found that a greater proportion of U87-MG cells entered apoptosis under hypoxic conditions after asiatic acid exposure than under normal oxygen in some of the tested periods [107].

This suggests that asiatic acid did not lose all activity in a low-oxygen environment.

The result is relevant because hypoxic tumour areas are one of the reasons glioblastoma is difficult to treat.

Asiatic Acid Did Not Simply Stop Cell Division

The hypoxia study found that asiatic acid reduced cell viability but did not significantly reduce cell proliferation or change the cell-cycle distribution at the lower experimental concentration used for those particular tests [107].

This means that the main effect appeared to come from cell death rather than from simply slowing cell division.

Under hypoxia, asiatic acid produced more apoptosis than the cisplatin comparison under the tested conditions.

This does not mean that asiatic acid is clinically more effective than chemotherapy.

The experiment compared one cell line, selected concentrations, and defined laboratory conditions. Cisplatin is also not the standard chemotherapy used for newly diagnosed glioblastoma.

Asiatic Acid and Glioblastoma-Cell Migration

The 2017 study also used a wound-healing or scratch assay to examine cell migration [107].

In this laboratory method, researchers create an empty space across a layer of tumour cells and observe how quickly the cells move into it.

Under ordinary oxygen, asiatic acid produced a greater reduction in U87-MG migration than cisplatin in the tested assay.

Under hypoxia, cell movement was already strongly reduced by the low-oxygen condition itself. Asiatic acid did not produce a clearly greater additional reduction than the hypoxic control in that part of the experiment.

This detail is important because it prevents the result from being oversimplified.

The evidence suggests that asiatic acid affected migration under normal oxygen conditions. It does not prove that it completely blocks invasion in every oxygen environment.

A Scratch Assay Is Not the Same as Brain Invasion

Glioblastoma cells invade through complex brain structures.

They may move along blood vessels, white-matter pathways, nerve fibres, and the extracellular environment.

A scratch assay measures movement across a flat laboratory surface.

It is useful for comparing how treatment changes cellular movement. It cannot reproduce all the barriers, signals, blood vessels, immune cells, and tissue structures present inside your brain.

Reduced scratch closure therefore supports a migration-related mechanism. It does not prove that oral Mandukaparni stops microscopic glioblastoma invasion in a patient.

Does Asiatic Acid Kill Glioma Stem-Like Cells?

The studies discussed in this section mainly used established glioblastoma cell lines [105–107].

They did not provide strong direct evidence from a broad panel of patient-derived glioblastoma stem-like cultures.

Some of the pathways involved, including survivin, stress adaptation, calcium regulation, and hypoxia, may also be relevant to glioma stem-like cells.

This does not justify stating that Mandukaparni has been proven to eliminate glioma stem cells.

A direct stem-cell claim would require properly characterized patient-derived stem-like models and eventual human evidence.

Does Mandukaparni Reverse MGMT Resistance?

The available studies do not prove that Mandukaparni or asiatic acid changes MGMT promoter methylation.

They also do not establish that asiatic acid reliably reverses MGMT-mediated temozolomide resistance.

The research examined general glioblastoma-cell viability, apoptosis, endoplasmic reticulum stress, calcium signalling, animal tumour growth, hypoxia, and migration [105–107].

These mechanisms may remain relevant to treatment resistance, but they are not the same as modifying MGMT.

Your MGMT result should continue to be interpreted through your pathology and oncology plan.

Asiatic Acid Was Not Studied as a Temozolomide Replacement

The 2015 study compared asiatic acid and temozolomide at equal concentrations in laboratory cells [106].

This does not mean that asiatic acid can replace temozolomide in a patient.

Temozolomide has been studied in large human clinical trials and is used according to defined oncology protocols [25,26].

Asiatic acid has promising cell and animal data but lacks comparable human glioblastoma trials.

The correct research question is whether a standardized Mandukaparni or asiatic-acid intervention could safely support or complement existing treatment. Replacement should not be assumed.

Mandukaparni During Temozolomide Treatment

Mandukaparni may be considered during temozolomide for neurological support, mental calm, sleep, recovery, or its experimental tumour-related rationale.

However, there is no established human evidence proving that it increases temozolomide benefit.

Temozolomide can reduce blood counts and affect liver function [144].

A complex Avaleha may contain several active ingredients, making it difficult to identify the cause of nausea, fatigue, sedation, digestive problems, or abnormal liver tests.

Your blood counts, liver function, neurological condition, appetite, bowel function, and complete medicine list should continue to be monitored.

Mandukaparni During Radiation

There is no human glioblastoma trial proving that Mandukaparni improves radiation response.

Its possible role during radiation is more defensibly connected with cognitive support, neurological recovery, mental calm, and an experimental hypothesis involving hypoxic tumour cells.

The hypoxia study examined asiatic acid, not whole Mandukaparni and not radiation [107].

You should therefore not be told that Mandukaparni has been clinically proven to overcome radiation resistance.

If it is used during radiotherapy, the intended role should be stated clearly and safety should be monitored.

Human Evidence for Cognitive Function Is Limited

Mandukaparni is widely promoted as a memory-enhancing herb. Human evidence is less certain than the traditional reputation may suggest.

A systematic review and meta-analysis examined clinical studies of Centella asiatica for cognitive and mood-related outcomes [108].

When the available controlled data were combined, the review did not find a significant overall advantage over placebo across the assessed cognitive domains.

Some individual studies suggested possible benefit in working memory or other selected outcomes. However, the studies used different preparations, doses, treatment periods, populations, and outcome measures.

Several studies also had methodological limitations.

The available human evidence therefore supports further research but does not prove that every Mandukaparni product reliably improves memory.

Why the Cognitive Evidence Should Not Be Ignored Completely

A non-significant overall meta-analysis does not mean that Mandukaparni has no neurological effect.

It means that the available studies were not consistent or strong enough to establish a reliable general cognitive benefit.

The herb may still help selected patients or selected aspects of cognition. Different preparations may also produce different exposures.

The correct conclusion is that the classical Medhya rationale is strong, while modern human cognitive evidence remains mixed and limited.

This is more accurate than saying either that Mandukaparni definitely restores memory or that it has no neurological value.

The Human Acoustic-Startle Study

One small double-blind, placebo-controlled study examined a single oral dose of 12 grams of gotu kola in 40 healthy participants [109].

Twenty participants received gotu kola and twenty received placebo.

The researchers measured the acoustic startle response. This is an automatic physical reaction to a sudden sound and can be used experimentally to study anxiety-related nervous-system reactivity.

Compared with placebo, gotu kola reduced the peak startle response at 30 and 60 minutes.

The study did not find a significant change in self-rated mood, heart rate, or blood pressure.

This provides preliminary evidence that Centella asiatica may influence anxiety-related nervous-system reactivity. It does not prove treatment of clinical anxiety, glioma-related distress, or cognitive impairment.

Why the 12-Gram Study Cannot Be Applied Directly to an Avaleha

The acoustic-startle study used a single 12-gram oral dose of gotu kola [109].

A multi-ingredient Avaleha may deliver a much smaller daily amount of Mandukaparni.

The plant preparation used in the study may also differ from the material in the Avaleha.

A one-time startle-response effect does not establish the correct dose for long-term neurological support.

It also does not show what happens when the herb is combined with antiseizure medicines, steroids, chemotherapy, or other Ayurvedic ingredients.

Mandukaparni and Anxiety During Glioma Treatment

A glioma diagnosis can produce intense fear, sleep disturbance, uncertainty, and repeated worry about recurrence.

Mandukaparni may be considered as part of a wider plan for mental calm and sleep when it is suitable for your constitution and medicines.

However, severe anxiety may also be worsened by dexamethasone, sleep loss, seizures, thyroid disturbance, depression, or changes in the brain caused by the tumour.

A herb should not be used to hide a new behavioural or psychological change that requires medical assessment.

Counselling, family support, sleep management, medication review, and psychiatric or psychological care may also be needed.

Mandukaparni Should Not Replace Neuro-Rehabilitation

Mandukaparni may support a neurological-recovery plan, but it cannot replace rehabilitation.

If you have weakness, speech difficulty, memory loss, impaired planning, poor coordination, or swallowing problems, you may need physiotherapy, speech therapy, occupational therapy, swallowing assessment, and cognitive rehabilitation.

An herb may support sleep, attention, or mental calm. It cannot rebuild every damaged neurological pathway by itself.

Your rehabilitation goals should be measurable and should continue even when Ayurvedic medicine is added.

Can Mandukaparni Help Speech and Voice?

Classical descriptions connect Medhya herbs with Smriti and Svara, meaning memory and voice or speech-related function [43,44].

This can support Mandukaparni’s traditional use in a neurological-recovery formula.

However, speech problems after glioma surgery may result from damage to language areas, weakness of the speech muscles, seizures, swelling, fatigue, or cognitive dysfunction.

Mandukaparni should not replace speech therapy or urgent assessment of a new speech deficit.

Its role is supportive rather than a guaranteed reversal of structural neurological injury.

Does Mandukaparni Reduce Cerebral Edema?

The classical passage includes swelling among its traditional areas of use.

The glioblastoma studies discussed here did not establish that whole Mandukaparni reduces cerebral edema in patients.

Asiatic acid affected tumour cells and tumour growth in experimental models [105–107]. That is different from a human MRI study measuring peritumoral edema.

Shallaki currently has more direct human brain-tumour evidence for an edema-related outcome [57].

Mandukaparni should therefore not be used as a substitute for dexamethasone when dangerous brain swelling is present.

Possible Digestive Effects

Mandukaparni is generally described as light and cooling, but oral products may still cause nausea, abdominal discomfort, reduced appetite, or loose stools in some people.

This becomes important when you already have nausea from temozolomide, constipation from antiemetics, or reduced food intake after surgery.

A dose that appears useful for mental calm may still be unsuitable if it worsens your appetite or causes dehydration.

Digestive symptoms should be recorded and the formulation adjusted when necessary.

They should not be described automatically as detoxification.

Possible Sedation and Reduced Alertness

Mandukaparni may have calming effects in some people.

When it is combined with antiseizure medicines, sleeping tablets, opioid pain medicines, or anti-anxiety medicines, you should be observed for excessive drowsiness, poor balance, slowed thinking, or reduced participation in rehabilitation.

A gradual calming effect is different from new confusion or reduced consciousness.

Sudden drowsiness may also indicate cerebral edema, infection, seizure activity, low sodium, medication toxicity, or tumour progression.

A serious neurological change requires clinical assessment rather than simply reducing or increasing the herb.

Mandukaparni and Antiseizure Medicines

Direct clinical interaction data between Mandukaparni and every antiseizure medicine are limited.

The practical concern is that both may affect alertness, balance, memory, and behaviour.

You should not stop or reduce an antiseizure medicine because Mandukaparni is described as Medhya.

Your seizure frequency, medicine timing, sleepiness, balance, and mental status should be monitored.

Any new seizure or change in consciousness requires prompt medical review.

Why Liver Monitoring May Still Be Appropriate

Human safety data for the exact combination of Mandukaparni, temozolomide, antiseizure medicines, and a complex Ayurvedic Avaleha are limited.

Even when Mandukaparni is tolerated by many people, your liver may already be processing several prescription medicines and other concentrated herbal ingredients.

Baseline and follow-up liver testing may therefore be appropriate according to your oncology treatment, existing liver condition, dose, duration, and complete formulation.

A normal liver test before treatment does not remove the need to investigate jaundice, dark urine, severe itching, persistent nausea, or unexplained fatigue.

When Mandukaparni May Need to Be Reduced or Paused

Mandukaparni should be reviewed when you develop persistent digestive symptoms, excessive sedation, an allergic reaction, a major liver-test abnormality, or another suspected adverse effect.

It should also be reconsidered when you cannot swallow safely, are preparing for surgery, develop a severe infection, or have a sudden neurological decline.

A formula appropriate during stable recovery may not remain suitable during an acute medical event.

How the Mandukaparni Dose in the Avaleha Should Be Calculated

The total amount of Mandukaparni used in the batch should be recorded.

Suppose a 900-gram finished Avaleha contains 45 grams of authenticated Centella asiatica whole plant.

Mandukaparni would represent 5% of the final formulation.

If you take 30 grams of Avaleha daily, your estimated whole-plant exposure would be approximately 1.5 grams per day.

This does not mean that you receive 1.5 grams of asiatic acid.

Asiatic acid would represent only a fraction of the whole-plant material. Its concentration may also change through extraction, heating, filtration, and storage.

The calculated whole-herb dose cannot be directly compared with 10–100 micromolar purified asiatic acid in cell culture or 30 milligrams per kilogram of purified asiatic acid in mice.

Why Triterpene Standardization Matters

A label stating “500 milligrams of Centella asiatica” does not tell you how much asiatic acid, asiaticoside, madecassoside, or madecassic acid is present.

One product may contain whole-plant powder. Another may contain a concentrated extract standardized to total triterpenes. Another may contain purified asiatic acid.

These products may have very different biological and safety profiles.

If the formulation uses the glioblastoma research to support a tumour-directed role, the finished Avaleha should ideally be tested for total triterpenes and selected marker compounds.

This would allow a more honest comparison between the medicine you receive and the material used in research.

How Avaleha Processing May Affect Mandukaparni

Mandukaparni may be used in the decoction group or added later as fine powder.

Water extraction may recover some compounds more effectively than others. Prolonged heating may alter selected constituents.

Adding the herb later may preserve more of the whole-plant material, but it may also change the texture, digestion, and final stability of the Avaleha.

The manufacturing record should state the plant form, extraction method, preparation stage, temperature, final yield, and storage conditions.

Without this information, two formulations containing the same weight of Mandukaparni may not deliver the same triterpene exposure.

What Must Be Documented in the Finished Formulation

The batch record should identify Centella asiatica by its full botanical name and specify the whole plant or other plant part used.

It should clearly distinguish Mandukaparni from Bacopa monnieri.

The record should state whether the ingredient is whole-plant powder, decoction, fresh juice, standardized extract, or a triterpene-enriched preparation.

The quantity placed in the batch, final batch weight, estimated daily whole-herb exposure, and marker-compound content should be documented wherever possible.

Botanical authentication, chemical fingerprinting, microbial testing, pesticide testing, aflatoxin testing, and inappropriate elemental-contamination testing should also form part of quality control.

Where Mandukaparni Fits in Majja-Arbuda Rasayana Avaleha

Mandukaparni fits most clearly within the Majja, Medhya, and neurological-recovery group.

Its classical use supports memory, mental function, voice, calmness, and Rasayana care [43,44].

It may also have a secondary place within the tumour-directed research group because purified asiatic acid caused apoptosis and necrosis in U-87 MG cells, affected multiple human glioblastoma lines, reduced subcutaneous and intracranial tumour growth in mice, and remained active under selected hypoxic conditions [105–107].

A third possible role concerns neurological and emotional support, although human cognitive evidence remains mixed and preliminary [108,109].

These roles should remain clearly separated.

How Your Response Should Be Monitored

If Mandukaparni is used mainly for neurological support, relevant outcomes include memory, attention, speech, sleep, anxiety, orientation, rehabilitation participation, balance, and daily function.

Caregiver observations may be valuable because you may not always notice gradual cognitive or behavioural changes yourself.

If it is included partly for tumour-directed research, improved sleep or memory cannot prove tumour response.

MRI findings, neurological examination, steroid dose, surgery, radiation, temozolomide, seizure control, and treatment dates must be reviewed together.

Digestive tolerance, alertness, liver function, blood counts, and possible medicine interactions should also be monitored according to your complete treatment.

Current Evidence Verdict for Mandukaparni and Asiatic Acid

Classical Ayurvedic support is strong for Mandukaparni as a Medhya and Rasayana herb connected with memory, mental function, voice, cooling support, and long-term restoration [43,44].

Modern human evidence for cognitive improvement is mixed. A systematic review and meta-analysis did not find a consistent significant advantage over placebo across cognitive domains, although selected individual studies suggested possible benefit in areas such as working memory [108].

A small human study found that a single gotu kola dose reduced the acoustic startle response in healthy participants, but it did not establish treatment of clinical anxiety or glioma-related cognitive problems [109].

Direct preclinical glioblastoma evidence is meaningful. Purified asiatic acid caused dose-dependent and time-dependent death in U-87 MG cells through mitochondrial disruption, calcium changes, caspase activation, apoptosis, and necrosis [105].

A later study found activity in LN18, U87MG, and U118MG cells and reported reduced subcutaneous and intracranial U87MG tumour growth in mice. Asiatic acid was also detected in mouse plasma and brain tissue after oral administration [106].

Hypoxia research showed that asiatic acid remained cytotoxic to U87-MG cells and produced substantial apoptosis under low-oxygen conditions, although the migration findings differed between normal oxygen and hypoxia [107].

Human evidence proving glioblastoma shrinkage, delayed recurrence, improved progression-free survival, or longer overall survival is not established.

Direct evidence showing that whole Mandukaparni or a Mandukaparni-containing Avaleha produces a tumour-active asiatic acid concentration inside human glioblastoma tissue is also not established.

What Mandukaparni Evidence Means for You

Mandukaparni has a reasonable place in an individualized glioma or glioblastoma formulation when its purpose is clearly explained.

Its primary clinical role may be Medhya and neurological support during recovery. Its purified compound asiatic acid also has one of the more substantial preclinical evidence chains among the ingredients examined so far, including direct human glioblastoma-cell activity, subcutaneous animal models, an intracranial mouse model, MRI assessment, and detection in mouse brain tissue.

This evidence is stronger than a laboratory claim based only on another cancer.

It remains preclinical evidence.

Whole Mandukaparni is not equivalent to purified asiatic acid. A small amount inside an Avaleha cannot be assumed to reproduce the concentrations used in cell or animal studies.

Its use should therefore depend on verified Centella asiatica identity, clear distinction from Brahmi, documented preparation and dose, triterpene testing where possible, neurological monitoring, medicine review, and honest separation between cognitive support and tumour response.

Jatamansi for Glioma and Glioblastoma: Ayurvedic Neurological Support, U87-MG Research, and Important Evidence Limits

Jatamansi is an important Ayurvedic herb for the brain, memory, mental calm, sleep, neurological recovery, and strength. These traditional uses make it relevant when you are recovering after glioma surgery or experiencing anxiety, disturbed sleep, cognitive changes, seizures, emotional instability, or reduced neurological function.

Jatamansi also has direct experimental relevance to glioblastoma. A methanolic rhizome extract of Nardostachys jatamansi was tested in U87-MG human glioblastoma cells. The extract reduced tumour-cell viability, damaged DNA, affected the cell cycle, produced mitotic catastrophe, and caused changes associated with apoptosis [110].

This is meaningful because the study used a glioblastoma cell line rather than relying only on research from an unrelated cancer.

However, the evidence remains preclinical. The study did not involve people with glioblastoma, did not test the complete Majja-Arbuda Rasayana Avaleha, and did not establish that an oral Jatamansi dose reaches a human brain tumour at the concentration used in the laboratory.

Jatamansi also presents an important scientific difficulty. Another study found that lower concentrations of a Jatamansi extract protected C6 glioma cells from oxidative damage [111]. This means that the biological result may change according to the extract, dose, treatment purpose, cellular condition, and timing.

You should therefore not be told simply that Jatamansi kills glioblastoma cells. The evidence is more complex and must be interpreted carefully.

What Is Jatamansi?

Classical Jatamansi is generally identified as Nardostachys jatamansi (D.Don) DC. It belongs to the Caprifoliaceae family under modern botanical classification, although older publications may place it in the Valerianaceae family.

It is a small aromatic Himalayan plant. Its underground rhizome and attached root-like structures are the medicinal materials most commonly used.

The dried rhizome has a strong characteristic smell and is covered with fibrous structures that resemble matted hair. This appearance is connected with the Sanskrit name Jatamansi.

Jatamansi is also called Mansi, Bhutajata, Jatila and Tapasvini in classical literature.

The exact botanical identity is extremely important. Jatamansi is sometimes confused with Valeriana jatamansi, Indian valerian, Tagara, or other aromatic roots sold under similar regional names.

These plants cannot be treated as interchangeable.

What Ayurveda Says About Jatamansi

Bhavaprakasha Nighantu describes Jatamansi in Karpuradi Varga. Electronic editions commonly display the following passage as text 75, while some printed commentaries number it around text 89. The edition used should therefore be stated whenever the verse is published.

Book: Bhavaprakasha Nighantu

Section: Karpuradi Varga

Text number: 75 in commonly available electronic editions; around 89 in some printed editions

जटामांसी भूतजटा जटिला च तपस्विनी ।
मांसी तिक्ता कषाया च मेध्या कान्तिबलप्रदा ।
स्वाद्वी हिमा त्रिदोषास्रदाहवीसर्पकुष्ठनुत् ॥७५॥

Transliteration

Jaṭāmāṁsī bhūtajaṭā jaṭilā ca tapasvinī |
Māṁsī tiktā kaṣāyā ca medhyā kānti-bala-pradā |
Svādvī himā tridoṣāsra-dāha-vīsarpa-kuṣṭha-nut ||75||

English translation

Jatamansi is also known as Bhutajata, Jatila, Tapasvini and Mansi. It is described as bitter and astringent, Medhya, supportive of mental function, and capable of supporting complexion and strength. It is also described as sweet, cooling, and traditionally useful in conditions involving disturbed Doshas, blood-related disorders, burning, Visarpa and skin disease.

Urdu translation

جٹامانسی کو بھوت جٹا، جٹیلا، تپسونی اور مانسی جیسے ناموں سے بھی بیان کیا گیا ہے۔ اسے کڑوے اور کسیلے ذائقے، ٹھنڈی تاثیر اور میدھیا یعنی حافظہ، فہم اور ذہنی کارکردگی کی معاون دوا کہا گیا ہے۔ روایتی طور پر اسے جسمانی قوت اور رنگت کو سہارا دینے اور دوشوں کی بے ترتیبی، خون کی بعض کیفیتوں، جلن، ورم اور جلدی امراض میں مفید بتایا گیا ہے۔

Arabic translation

تُعرف الجاتامانسي أيضاً بأسماء مثل بهوتاجاتا، وجاتيلا، وتاباسفيني، ومانسي. وتُوصَف بأنها مُرّة وقابضة، وذات تأثير بارد، ومن أدوية مِدهيا الداعمة للذاكرة والفهم والوظائف الذهنية. كما وُصفت تقليدياً بأنها داعمة للقوة وصفاء البشرة، ومفيدة في بعض اضطرابات الدوشا والدم والإحساس بالحرارة والتورم وبعض الأمراض الجلدية.

This verse supports Jatamansi’s classical role as a Medhya, cooling and strength-supporting herb [43,44].

It does not describe glioblastoma, U87-MG cells, EGFR, VEGFR2, apoptosis, mitotic catastrophe, blood–brain barrier penetration, or tumour regression.

Its neurological and recovery role comes from classical Ayurveda. Its possible tumour-directed role must be supported separately through modern research.

Why Jatamansi May Be Relevant After Glioma Surgery

After brain surgery, you may experience disturbed sleep, anxiety, slow thinking, memory difficulty, emotional instability, speech problems, seizures, or reduced mental confidence.

These changes may result from the tumour location, cerebral edema, surgery, antiseizure medicines, steroids, pain, sleep loss, or uncertainty about the future.

Jatamansi’s classical Medhya and Bala-supporting properties may make it relevant to this recovery period.

Its intended supportive role may be to help mental calm, sleep, memory, emotional stability and participation in neurological rehabilitation.

These outcomes are meaningful, but they must remain separate from tumour response.

If you sleep better after taking Jatamansi, this may support your recovery. It does not prove that the tumour has reduced.

If you become calmer, the improvement may be valuable. It does not establish that glioblastoma cells have entered apoptosis inside your brain.

The Medicinal Part Must Be Clearly Identified

The 2017 glioblastoma study used the rhizome of Nardostachys jatamansi [110].

It did not use only the essential oil. It did not use a commercial sleep capsule. It did not use Valeriana jatamansi. It did not use ordinary Jatamansi powder in an Avaleha.

The rhizomes were extracted with methanol for 48 hours. The solvent was then removed, and the dried extract was dissolved for laboratory testing.

A methanolic rhizome extract may contain compounds in a different concentration from a traditional water decoction or whole-rhizome powder.

This distinction must be stated whenever the study is used to support Jatamansi in an Ayurvedic glioma formula.

Whole Jatamansi Is Not the Same as the Research Extract

Whole Jatamansi rhizome contains several groups of natural compounds. These include sesquiterpenes, coumarins, lignans, volatile substances and other plant constituents.

The 2017 researchers identified five marker compounds for computer-based analysis. These were oroselol, jatamansinol, nardostachysin, jatamansinone and nardosinone [110].

A methanolic extract can concentrate some of these compounds more effectively than a traditional water preparation.

Therefore, one gram of whole Jatamansi powder cannot be treated as equivalent to one gram of the research extract.

The difference becomes greater when Jatamansi is only one ingredient within a large multi-herb Avaleha.

What Type of Glioblastoma Model Was Used?

The main study used U87-MG cells [110].

U87-MG is an established human glioblastoma cell line frequently used in laboratory research. It allows researchers to compare cell viability, cell division, DNA damage and treatment mechanisms under controlled conditions.

However, U87-MG cannot represent every glioma or glioblastoma.

Your tumour may have a different IDH status, MGMT promoter methylation status, EGFR alteration, PTEN status, TERT mutation, chromosome pattern, treatment history and cellular composition.

A long-established laboratory cell line also does not reproduce the blood–brain barrier, immune system, tumour blood vessels, surrounding brain tissue, steroid exposure, surgery, radiation or chemotherapy present in your body.

The study is direct glioblastoma-cell evidence, but it remains a simplified model.

What Was the IC50 of the Jatamansi Extract?

The researchers exposed U87-MG cells to different concentrations of the Jatamansi rhizome extract and measured cell viability after 24, 48 and 72 hours [110].

The reported IC50 values were approximately 33.73 micrograms per millilitre after 24 hours, 30.59 micrograms per millilitre after 48 hours and 28.39 micrograms per millilitre after 72 hours.

An IC50 is the concentration that reduces the measured cellular response by approximately half under the tested conditions.

The falling IC50 over time suggests that longer exposure allowed a lower concentration to produce a similar reduction in cell viability.

This is evidence of a dose-related and time-related laboratory effect.

It is not an oral dose recommendation.

Why Micrograms per Millilitre Cannot Be Converted Directly Into Grams of Jatamansi

In the experiment, the extract was placed directly into the liquid surrounding the tumour cells.

When you take Jatamansi orally, the process is very different.

The active substances must be released from the Avaleha, survive digestion, be absorbed through the intestine, enter the bloodstream, avoid rapid liver metabolism, reach the brain, enter the tumour and remain at a useful concentration.

The amount that you swallow is not the amount that reaches the tumour.

You cannot therefore convert an IC50 of approximately 28 to 34 micrograms per millilitre directly into one or two grams of Jatamansi powder.

Pharmacokinetic and human tumour-tissue studies would be required before such a comparison could be made properly.

How Jatamansi Affected Cell Viability

The researchers tested concentrations from approximately 10 to 60 micrograms per millilitre in the main viability experiment [110].

As the concentration increased, the number of viable U87-MG cells decreased.

At around 40 micrograms per millilitre, the number of viable cells was reduced to approximately half in a separate counting method.

Higher concentrations produced extensive changes in cell shape and a greater number of dead cells.

This result supports an antiproliferative and cytotoxic effect under laboratory conditions.

It does not prove that the same concentration can be reached safely inside your brain tumour.

Jatamansi and DNA Fragmentation

The study reported DNA fragmentation at approximately 30 micrograms per millilitre [110].

DNA fragmentation can occur when a cell enters apoptosis or experiences severe internal damage.

Glioblastoma cells must copy their DNA before they divide. Extensive DNA damage can prevent successful division or activate cell-death pathways.

The researchers also used a comet assay, which measures DNA damage by observing how fragmented DNA moves away from the cell nucleus during laboratory processing.

Greater Jatamansi-extract exposure was associated with greater measured DNA damage.

This provides a direct tumour-cell mechanism. It does not show that oral Jatamansi damages glioblastoma DNA inside a patient.

What Early and Late Apoptosis Mean

The study used fluorescent staining to examine different stages of cell death [110].

Early apoptosis was reported at approximately 20 micrograms per millilitre. Higher concentrations produced more features associated with late apoptosis.

During early apoptosis, the cell begins an organized internal death process while the outer membrane may remain relatively intact.

During late apoptosis, the cell loses more of its structure, the nucleus breaks apart and membrane integrity may be lost.

The observed progression supports the conclusion that the extract caused regulated tumour-cell death under the tested conditions.

However, staining in one laboratory model cannot prove tumour regression in a human being.

Jatamansi and the Intrinsic Apoptosis Pathway

The researchers examined caspase-3, caspase-9 and PARP-related changes and interpreted the combined results as evidence of the mitochondrial or intrinsic apoptosis pathway [110].

The intrinsic pathway begins when severe stress develops inside the cell. Mitochondria then participate in activating enzymes that help dismantle the cell.

Caspase-9 is connected with the early mitochondrial pathway. Caspase-3 helps carry out later stages of apoptosis. PARP is involved in DNA repair and is commonly examined during apoptosis research.

The authors reported reduced expression of these proteins in treated cells and interpreted the findings together with DNA fragmentation, fluorescent staining and cell morphology.

A stronger modern analysis would clearly measure the activated or cleaved forms of caspases and PARP. Reduced total protein expression is not by itself the same as direct proof of enzymatic activation.

The available study still provides useful apoptosis evidence, but its interpretation should remain careful.

What Mitotic Catastrophe Means

At approximately 20 and 40 micrograms per millilitre, the researchers observed excessive nucleation, micronuclei and other changes described as mitotic catastrophe [110].

Mitosis is the stage in which a cell separates its duplicated chromosomes and divides into two new cells.

Mitotic catastrophe occurs when this process fails severely.

The tumour cell may form abnormal nuclei, distribute chromosomes incorrectly, stop dividing or eventually die through apoptosis, necrosis or another pathway.

This mechanism is relevant because glioblastoma cells divide abnormally and may depend on defective cell-cycle control.

The study suggests that the Jatamansi extract interfered with successful tumour-cell division.

It does not show whether the same effect occurs at an achievable oral dose.

Jatamansi and Cell-Cycle Arrest

Higher extract concentrations, around 60 and 80 micrograms per millilitre, were associated with G0/G1 cell-cycle arrest [110].

The G0/G1 phase occurs before the cell copies its DNA.

When a cell becomes arrested in this phase, it cannot proceed normally toward DNA replication and division.

Cell-cycle arrest may slow tumour growth. It may also give a damaged cell time to repair itself or later resume division.

Therefore, cell-cycle arrest is not automatically the same as permanent tumour elimination.

In the Jatamansi experiment, the cell-cycle findings appeared together with DNA damage, apoptosis and mitotic abnormalities, supporting a wider antitumour effect in the model.

Jatamansi and Colony Formation

The researchers also examined whether surviving U87-MG cells could continue growing into colonies [110].

Colony formation measures the longer-term reproductive ability of an individual tumour cell.

As the Jatamansi-extract concentration increased, the number of colonies decreased.

This suggests that fewer treated cells retained the ability to survive and reproduce over the test period.

The study authors connected this with reduced tumour-cell growth potential.

It should not be described as proof that Jatamansi stops glioblastoma metastasis. Glioblastoma usually spreads by local brain invasion rather than by the classic distant metastatic pattern seen in many other cancers.

Reduced colony formation is better described as reduced reproductive survival of the tested cells.

Was Jatamansi Tested in More Than One Glioma Cell Line?

The most detailed analysis was performed in U87-MG cells [110].

The researchers also screened the extract in U373-MG cells and several unrelated cancer cell lines. U373-MG showed substantial sensitivity in the additional screening.

This provides some evidence that the result was not limited entirely to one cell line.

However, the secondary analysis was less detailed than the U87-MG work.

The study did not include a broad panel of freshly collected, molecularly classified patient-derived glioblastoma cultures.

It also did not include several IDH-mutant astrocytomas, oligodendrogliomas or paediatric high-grade gliomas.

The result should therefore not be generalized to every glioma subtype.

Was the Extract Safe for Normal Cells?

The researchers compared the extract with HEK cells, described in the study as a normal human embryonic kidney cell line [110].

Across the tested concentrations, HEK-cell viability after 24 hours was reported at approximately 75% to 83%.

The authors concluded that the extract was relatively harmless to the normal cells used in the experiment.

This finding is useful but limited.

HEK cells are not normal neurons, astrocytes, blood–brain barrier cells, liver cells, bone-marrow cells or immune cells.

A viability level near 75% also shows that the cells were not completely unaffected.

The experiment does not establish complete safety for normal human brain tissue or for a patient taking the extract repeatedly.

A proper safety programme would need more relevant normal-cell models, animal toxicology, pharmacokinetics and human monitoring.

Which Jatamansi Compounds Were Studied Through Molecular Docking?

The researchers used computer modelling to examine oroselol, jatamansinol, nardostachysin, jatamansinone and nardosinone [110].

These compounds were tested virtually against four cancer-related targets: VEGFR2, EGFR, CDK2 and BCL2.

The computer program estimated whether each compound could fit within a selected binding area of the target protein.

Several compounds produced favourable predicted interactions.

Oroselol showed the strongest predicted interactions across several targets, followed by some of the other marker compounds.

This supports a multi-target research hypothesis. It does not prove that the compounds physically bind these proteins inside a tumour.

Why VEGFR2 Was Selected

VEGFR2 is involved in blood-vessel formation.

Glioblastoma is often highly vascular and can produce abnormal, leaky blood vessels. These vessels help support tumour growth and contribute to cerebral edema.

A compound that meaningfully affects VEGFR2 might theoretically influence angiogenesis.

The Jatamansi marker compounds showed favourable computer-predicted interactions with VEGFR2 [110].

The study did not demonstrate that Jatamansi reduced blood-vessel formation in a living intracranial glioblastoma.

Molecular docking is the beginning of a research pathway, not proof of an anti-angiogenic clinical effect.

Why EGFR Was Selected

EGFR helps transmit signals that influence growth, survival and cell division.

EGFR amplification or abnormal EGFR activity is common in some IDH-wildtype glioblastomas.

The computer analysis predicted that selected Jatamansi compounds may interact with EGFR [110].

This does not mean that Jatamansi is a clinically proven EGFR inhibitor.

A docking result should be followed by biochemical binding tests, pathway studies in cells, animal research and human trials.

Your EGFR status also cannot be inferred from whether you respond to Jatamansi.

Why CDK2 Was Selected

CDK2 participates in cell-cycle progression.

Cancer cells may use abnormal cyclin-dependent kinase activity to continue dividing.

The Jatamansi marker compounds showed predicted interactions with CDK2 [110].

This prediction appears consistent with the observed cell-cycle arrest in U87-MG cells.

However, the computer prediction does not prove that CDK2 was the direct cause of the laboratory effect.

A crude plant extract contains many compounds. Its cell-cycle activity may result from several pathways acting together.

Why BCL2 Was Selected

BCL2 is part of a protein family that helps regulate apoptosis.

Some BCL2-family proteins protect cells from programmed death, while others promote it.

A compound that reduces tumour-cell survival signalling through this system may make the cell more likely to enter apoptosis.

The Jatamansi compounds showed predicted interactions with BCL2 [110].

This may support the apoptosis findings, but it remains a computational hypothesis.

The study did not prove that an oral Jatamansi dose changes BCL2 activity inside a human glioblastoma.

What Molecular Docking Can and Cannot Prove

Molecular docking can help researchers identify compounds that may fit into a protein-binding site.

It can help prioritize which compounds deserve laboratory testing.

It cannot prove oral absorption, metabolism, blood concentration, brain exposure, tumour entry, binding within the tumour or clinical effectiveness.

A compound may look promising on a computer but fail because it is poorly absorbed, rapidly broken down or unable to reach the target.

A docking diagram should therefore never be used as clinical proof that Jatamansi blocks EGFR, VEGFR2, CDK2 and BCL2 in patients.

Did the Study Prove Blood–Brain Barrier Penetration?

The researchers used computer software to predict absorption, distribution, metabolism and excretion properties of the five marker compounds [110].

The program predicted moderate central nervous system activity and favourable blood–brain barrier crossing for some compounds.

This was a computer prediction.

The study did not administer the compounds to animals or patients and then measure them in plasma, cerebrospinal fluid, brain tissue or glioblastoma tissue.

It would therefore be inaccurate to state that Jatamansi has been clinically proven to cross the human blood–brain barrier.

A responsible statement is that selected marker compounds showed favourable predicted brain-delivery properties and now require direct pharmacokinetic testing.

Why the Extract Used in the Study Matters

The 2017 study used methanol to extract the rhizome [110].

Methanol is a laboratory extraction solvent. It is removed before experimental use and is not the same as giving methanol to a patient.

A methanolic extract can collect compounds that may not be extracted in equal amounts through a traditional water decoction.

The Avaleha may therefore deliver a different chemical profile from the research extract.

If the formulation contains whole Jatamansi powder or a water-based Kwatha, the U87-MG results cannot be transferred without qualification.

A standardized, patient-safe extract would need its own chemical fingerprint, solvent-residue testing and dose assessment.

Why Jatamansi Essential Oil Is a Different Intervention

Jatamansi essential oil mainly contains volatile aromatic compounds.

The methanolic rhizome extract used in the glioblastoma study contained a broader range of non-volatile and semi-volatile constituents.

Therefore, evidence from the methanolic extract cannot be used to claim that smelling, applying or consuming Jatamansi essential oil will reproduce the same antitumour effect.

Topical oil applied to the scalp does not have proven access to the intracranial tumour.

Aromatherapy may help selected people feel calmer, but it should not be presented as direct glioblastoma treatment.

The Cytoprotective C6 Glioma Study Gives an Important Warning

A different study examined methanolic, ethanolic and water extracts of Nardostachys jatamansi in C6 glioma cells exposed to hydrogen peroxide [111].

The purpose of that experiment was not to kill tumour cells. It was to examine protection from oxidative damage.

Hydrogen peroxide reduced C6-cell survival.

Pretreatment with the methanolic Jatamansi extract at approximately 6.2 micrograms per millilitre increased cell viability to around 70.7%.

The ethanolic and water extracts also produced some protection at approximately 12.5 micrograms per millilitre.

The methanolic extract increased antioxidant defences and reduced lipid peroxidation under the tested conditions [111].

This means that at a lower concentration and in a different experimental situation, Jatamansi protected glioma-derived cells rather than killing them.

Why the C6 Study Is Not Antitumour Evidence

C6 is a rat tumour-derived glioma cell line.

The researchers used it as a laboratory model of glial oxidative injury. Their objective was neuroprotection, not cancer treatment.

Protecting C6 cells from hydrogen-peroxide-related death cannot be described as an anticancer effect.

It also cannot automatically be described as protection of normal brain cells because C6 cells are tumour-derived.

The experiment is useful because it shows that the same herb can produce different effects according to concentration and cellular condition.

At lower concentrations, the extract may support antioxidant protection. At higher concentrations, it may become cytotoxic.

This dose-dependent change must be considered before making a simple claim about how Jatamansi acts in glioblastoma.

Could Antioxidant Protection Help Tumour Cells?

The C6 findings create an important research question.

If a Jatamansi extract protects tumour-derived cells from oxidative injury at lower concentrations, could it also protect some glioblastoma cells from treatment-related stress?

The available evidence does not provide a final answer.

The U87-MG study found tumour-cell damage at higher concentrations [110]. The C6 study found protection at lower concentrations under hydrogen-peroxide stress [111].

The studies used different cells, doses and experimental purposes.

The result cannot be reduced to the statement that antioxidants are always helpful or always harmful in cancer.

The timing, dose, extract, tumour biology and concurrent treatment may determine the effect.

Why This Matters During Radiation

Radiation damages tumour cells partly through direct DNA injury and partly through reactive chemical species.

An antioxidant intervention may protect normal tissue, tumour tissue, or both depending on the compound, dose and timing.

The available Jatamansi studies do not establish whether taking the herb during radiotherapy improves tumour response, reduces treatment injury, or weakens radiation-related tumour-cell damage.

Jatamansi should therefore not be described as a proven radiosensitizer.

It should also not be presented as a proven radioprotector for normal brain tissue in glioblastoma patients.

Any use during radiation should have a clearly defined supportive purpose and careful monitoring.

Why This Matters During Temozolomide

The U87-MG study did not test Jatamansi with temozolomide [110].

It does not prove that Jatamansi reverses MGMT resistance, increases temozolomide entry or improves chemotherapy response.

The C6 cytoprotection study also raises a reason to avoid assuming that every antioxidant or neuroprotective effect will strengthen chemotherapy [111].

If Jatamansi is used during temozolomide, its main defensible purpose may be neurological calm, sleep or recovery support unless stronger combination evidence becomes available.

Your blood counts, liver function, seizure control, alertness and complete formulation should continue to be monitored.

The Valeriana jatamansi Glioma Stem-Cell Study Must Not Be Mislabelled

A 2020 study isolated iridoids and bis-iridoids from Valeriana jatamansi and tested them against human glioma stem-cell cultures [112].

Two compounds inhibited the growth of the tested glioma stem-cell models.

This study is scientifically interesting, but it must not be used as direct evidence for Nardostachys jatamansi.

Valeriana jatamansi Jones is commonly associated with Indian valerian or Tagara. It is not the same medicinal raw drug as classical Nardostachys jatamansi.

The confusion becomes greater because older botanical names and incomplete author citations sometimes use similar wording.

The full botanical name and botanical author are therefore essential.

Reference [112] belongs in a separate Valeriana or Tagara evidence section. It should not be counted as proof that classical Jatamansi acts against glioma stem cells.

Why Botanical Author Names Matter

The name written after a plant species helps identify the exact botanical taxon.

Nardostachys jatamansi (D.Don) DC. refers to classical spikenard or Jatamansi.

Valeriana jatamansi Jones ex Roxb. is a different plant commonly connected with Indian valerian.

Older taxonomic literature may also use forms of Valeriana jatamansi as historical synonyms for Nardostachys, which creates further confusion.

A supplier certificate that states only “Jatamansi” is not sufficient.

The source should confirm the accepted botanical name, plant part, macroscopic identity, microscopic identity and chemical fingerprint.

Why Raw-Drug Authentication Is Essential

Jatamansi is an aromatic, high-value Himalayan rhizome. Dried aromatic roots can be difficult to identify after cutting or grinding.

Substitution or mixing may occur with Tagara, other Valeriana species, unrelated roots or exhausted material from which the oil has already been removed.

If the wrong plant is used, the classical reasoning, chemical profile, safety and research evidence may all become invalid.

The raw material should be authenticated before it is powdered or added to the Avaleha.

A finished-product fingerprint is also useful because identification becomes more difficult after many herbs are combined.

Jatamansi for Sleep and Mental Calm

Jatamansi is traditionally used for mental calm, sleep and neurological balance.

These effects may be valuable when dexamethasone causes insomnia or when fear and repeated medical appointments disturb your sleep.

However, the glioblastoma references reviewed here do not provide a strong human clinical trial proving that Jatamansi treats insomnia in glioma patients.

Its sleep-related use is supported mainly by classical practice and broader experimental literature.

Your sleep problem should first be understood correctly.

Insomnia may result from steroids, anxiety, pain, seizures, daytime inactivity, depression, thyroid disturbance or another medicine.

A calming herb may help, but it may not address the underlying cause.

Jatamansi and Excessive Drowsiness

Many glioma patients already take antiseizure medicines that can cause sleepiness, slower thinking or poor balance.

If Jatamansi is added for mental calm, you should be observed for excessive drowsiness, confusion, falls or reduced participation in rehabilitation.

A planned calming effect should not reduce your ability to communicate, eat, walk safely or recognize neurological warning signs.

Sudden sleepiness may also be caused by cerebral edema, infection, seizure activity, low sodium, medication toxicity or tumour progression.

It should not automatically be blamed on Jatamansi or treated by simply changing the herb dose.

Jatamansi Does Not Replace Antiseizure Medicine

Jatamansi has a traditional neurological reputation, but the available evidence does not support replacing prescribed antiseizure medicine.

A glioma-related seizure can cause injury, aspiration, loss of consciousness or a medical emergency.

Your antiseizure medicine should not be reduced because you have started Jatamansi.

Your seizure frequency, seizure duration, medicine timing, sleep pattern and alertness should be documented.

Any new seizure or major change in seizure pattern requires medical review.

Can Jatamansi Improve Memory After Brain Surgery?

The classical Medhya description gives a reasonable basis for considering Jatamansi in a neurological recovery plan [43,44].

However, the glioblastoma studies did not measure memory or cognitive recovery in patients.

A tumour-cell study cannot prove that the same extract improves human cognition.

If you experience memory problems after surgery, the cause may include tumour location, edema, seizure activity, radiation, medicines, sleep loss or depression.

Jatamansi may be used as supportive care, but formal cognitive rehabilitation, speech therapy and occupational therapy may also be required.

Neurological Protection and Tumour Killing Are Different Goals

Jatamansi may be selected to support normal neurological function while another part of the formula is intended for tumour-directed research.

These goals can sometimes create tension.

A dose that protects cells from oxidative stress may be useful for neurological recovery. A higher concentration that damages tumour cells may have a different safety profile.

The physician should therefore state which role is intended.

The formula should not claim that every neurological-support effect is also an antitumour effect.

How the Jatamansi Dose in the Avaleha Should Be Calculated

The total amount of Jatamansi used in the complete batch should be recorded.

Suppose a 900-gram Avaleha contains 18 grams of authenticated Nardostachys jatamansi rhizome.

Jatamansi would represent 2% of the finished formulation.

If you take 30 grams of Avaleha daily, your estimated whole-rhizome exposure would be approximately 600 milligrams per day.

This does not mean that you receive 600 milligrams of methanolic extract.

It also does not reveal how much oroselol, jatamansinol, nardostachysin, jatamansinone or nardosinone is present.

The whole-rhizome dose cannot be compared directly with an extract concentration of 20 to 80 micrograms per millilitre in cell culture.

Why Extract Yield Must Be Known

A dried methanolic extract represents only the compounds removed from a larger quantity of raw rhizome.

If ten grams of rhizome produce one gram of extract, one gram of extract represents much more starting material than one gram of ordinary powder.

The extraction yield from the glioblastoma study should therefore be considered before any dose comparison is attempted.

If Majja-Arbuda Rasayana Avaleha uses a standardized Jatamansi extract, the extraction ratio and solvent must be stated.

If it uses whole rhizome powder, it should not be described as equivalent to the methanolic extract.

Why Marker-Compound Testing Adds Value

If Jatamansi is included partly because of the U87-MG research, the finished formulation should ideally be tested for selected Jatamansi markers.

This may include nardosinone, jatamansone-related compounds or another validated marker selected for raw-material identity and batch comparison.

Testing does not prove clinical effectiveness.

It helps confirm that the intended plant is present and that different batches are reasonably consistent.

Without marker testing, two Avaleha batches containing the same stated weight of Jatamansi may deliver very different chemical profiles.

How Avaleha Processing May Change Jatamansi

Jatamansi contains aromatic and potentially heat-sensitive constituents.

Prolonged boiling may reduce some volatile components. Water extraction may also recover a different group of compounds from methanol extraction.

Adding the rhizome later as a fine powder may preserve more whole-plant material, but it can change texture, taste and digestive tolerance.

A concentrated extract may provide greater consistency but may no longer represent the same exposure as a classical powder.

The manufacturing record should state the form used, preparation stage, temperature, duration of heating and storage conditions.

Jatamansi Essential Oil Should Be Recorded Separately

If Jatamansi oil is used, its quantity and route should be stated separately from the rhizome powder or extract.

The chemical profile of the essential oil may vary greatly according to plant source, distillation and storage.

Evidence for the methanolic rhizome extract should not be applied to the essential oil.

The essential oil should also not be added internally without proper formulation, dose and safety assessment.

Possible Digestive Tolerance

Jatamansi has a strong aroma and bitter-astringent taste.

Some patients may tolerate it well within an Avaleha. Others may develop nausea, dislike of the formulation or reduced appetite.

This matters when you are already experiencing nausea from temozolomide, constipation from antiemetics or poor appetite after surgery.

A medicine intended to support the brain may become unsuitable if its taste repeatedly prevents you from eating or taking other treatment.

Digestive tolerance should be monitored rather than assuming that every unpleasant reaction is a therapeutic cleansing response.

Liver and Kidney Monitoring

Human safety data for repeated use of a standardized Jatamansi extract in glioblastoma patients are limited.

The U87-MG study cannot establish organ safety because it was a cell experiment [110].

Even when Jatamansi alone appears tolerable, you may also be taking temozolomide, steroids, antiseizure medicines, antibiotics and several other Ayurvedic ingredients.

Your liver and kidney monitoring should therefore be based on the complete treatment plan rather than on Jatamansi alone.

New jaundice, dark urine, severe itching, persistent vomiting, marked weakness or a major laboratory change requires medical assessment.

When Jatamansi May Need to Be Reduced or Paused

Jatamansi should be reviewed when you develop excessive drowsiness, new confusion, persistent nausea, an allergic reaction, significant liver abnormalities or another suspected adverse effect.

It should also be reassessed when you cannot swallow safely, are preparing for surgery, develop an acute infection or experience sudden neurological deterioration.

A formula suitable during stable recovery may not remain suitable during an emergency.

Where Jatamansi Fits in Majja-Arbuda Rasayana Avaleha

Jatamansi fits most clearly within the Majja, Medhya, mental-calm and neurological-recovery group.

Its classical description supports memory, mental function, strength and cooling support [43,44].

It may also have a secondary position within the tumour-directed research group because its methanolic rhizome extract reduced viability, caused DNA damage, affected the cell cycle and produced apoptosis-related changes in U87-MG glioblastoma cells [110].

Its antioxidant and cytoprotective research should be treated as a separate supportive evidence pathway [111].

This second pathway cannot automatically be considered beneficial during tumour-directed treatment because lower extract concentrations protected tumour-derived C6 cells from oxidative injury.

The dose, timing and treatment purpose must therefore be stated clearly.

What Must Be Documented in the Finished Formulation

The batch record should identify Nardostachys jatamansi (D.Don) DC. and specify that the authenticated rhizome or stated underground part was used.

It should distinguish this material from Valeriana jatamansi and Tagara.

The record should state whether Jatamansi is used as whole powder, decoction material, methanolic-type standardized extract, hydroalcoholic extract or essential oil.

The total quantity in the batch and your estimated daily exposure should be calculated.

A suitable chemical fingerprint or marker test should be included wherever possible.

The source should also be legally obtained, traceable and properly documented.

How Your Response Should Be Monitored

If Jatamansi is used mainly for sleep, mental calm or neurological support, relevant outcomes include sleep duration, sleep quality, daytime alertness, anxiety, memory, attention, speech, seizure stability and rehabilitation participation.

If it is included partly for tumour-directed research, better sleep cannot prove tumour response.

MRI findings, neurological examination, steroid dose, surgery, radiation, temozolomide and treatment timing must be reviewed together.

A calming effect should not make you excessively drowsy or hide worsening neurological symptoms.

Liver function, kidney function, digestive tolerance and medicine interactions should also be followed according to the complete prescription.

Current Evidence Verdict for Jatamansi

Classical Ayurvedic support is present for Jatamansi as a Medhya, cooling and strength-supporting herb relevant to memory, mental function and neurological care [43,44].

Direct preclinical glioblastoma evidence is present for a methanolic Nardostachys jatamansi rhizome extract. The extract reduced U87-MG viability in a dose-related and time-related manner, with IC50 values of approximately 28 to 34 micrograms per millilitre [110].

The extract also produced DNA fragmentation, apoptosis-related changes, mitotic catastrophe, G0/G1 cell-cycle arrest and reduced colony formation [110].

The study mainly relied on one established human glioblastoma cell line. It did not include an intracranial animal model or a human glioblastoma trial.

The reported normal-cell comparison used HEK cells rather than normal brain cells and cannot establish complete clinical safety.

The predicted interactions with VEGFR2, EGFR, CDK2 and BCL2 came from molecular docking. The predicted blood–brain barrier properties came from computer-based analysis. Neither finding proves direct target binding or brain-tumour exposure in a patient.

A separate study showed that lower concentrations of Jatamansi extract protected C6 glioma cells from hydrogen-peroxide-related oxidative injury [111]. This finding demonstrates that the direction of the effect can change according to the dose, extract, cell model and experimental condition.

Reference [112], involving iridoids from Valeriana jatamansi, should not be used as direct evidence for classical Nardostachys jatamansi. The two raw drugs require separate botanical and scientific evaluation.

Human evidence proving glioblastoma shrinkage, delayed recurrence, improved progression-free survival or longer overall survival is not established.

What Jatamansi Evidence Means for You

Jatamansi has a credible place in an individualized Ayurvedic glioma plan when its purpose is clearly defined.

Its primary role may be neurological and Medhya support for mental calm, sleep, memory and recovery. Its methanolic rhizome extract also has direct laboratory relevance to glioblastoma-cell growth, DNA damage, cell division and apoptosis.

The same evidence also demands caution.

A lower concentration protected tumour-derived C6 cells from oxidative injury, while higher concentrations damaged U87-MG cells. This means that dose and treatment context cannot be ignored.

Whole Jatamansi rhizome is not equivalent to the methanolic research extract. Computer-predicted brain penetration is not proof of human tumour exposure. A Valeriana study cannot be assigned to Nardostachys.

Jatamansi should therefore be used only with verified botanical identity, a documented plant part and preparation, realistic dose comparison, attention to sedation and neurological medicines, finished-product quality testing and clear separation between supportive neurological improvement and actual tumour response.

Yashtimadhu and Glycyrrhizin for Glioma and Glioblastoma: Modern Tumour Research, HMGB1, Edema, and Safety

Yashtimadhu is widely used in Ayurveda for nourishment, strength, voice, throat comfort, wound support, vomiting, thirst, fatigue, and selected Vata-Pitta conditions. These traditional actions may be relevant when you are recovering from glioma surgery or experiencing weakness, poor appetite, nausea, throat irritation after intubation, dryness, disturbed voice, or treatment-related exhaustion.

Yashtimadhu also has an emerging tumour-directed research pathway. Glycyrrhizin, one of the main constituents of licorice root, and its active metabolite 18β-glycyrrhetinic acid have been studied in inflammation, tumour signalling, HMGB1 activity, cell proliferation, migration, apoptosis, and experimental glioblastoma models [113–115].

A recent 2026 study tested purified 18β-glycyrrhetinic acid directly in glioblastoma cells and in mice carrying tumours inside and outside the brain. The compound reduced tumour-cell growth and migration, increased apoptosis, and suppressed tumour growth in the animal models [113].

This is meaningful direct preclinical glioblastoma evidence.

It is not evidence that ordinary Yashtimadhu root powder, Yashtimadhu decoction, or the amount present in Majja-Arbuda Rasayana Avaleha will produce the same effect in a person.

Yashtimadhu also requires unusually careful safety monitoring. Glycyrrhizin can increase sodium retention, lower potassium, raise blood pressure, cause fluid retention, produce muscle weakness, and disturb heart rhythm when the exposure is excessive or prolonged [116,120].

These effects are especially important when you already have cerebral edema, hypertension, heart or kidney disease, low potassium, or prolonged dexamethasone use.

What Is Yashtimadhu?

Yashtimadhu is generally identified as Glycyrrhiza glabra L., a perennial plant belonging to the Fabaceae family.

It is commonly known as Mulethi, licorice root, liquorice root, sweet root, or Jethimadh.

The medicinal material generally consists of the dried root and underground stolon. These underground parts contain the compounds responsible for the characteristic sweet taste.

The exact species must be identified because several licorice species are used internationally. These include Glycyrrhiza glabra, Glycyrrhiza uralensis, and Glycyrrhiza inflata.

The chemical profile may differ between species.

Research performed on purified glycyrrhizin or 18β-glycyrrhetinic acid cannot automatically prove that every licorice species, raw root, commercial powder, or Ayurvedic formulation will behave in the same way.

The finished Avaleha should therefore identify the full botanical name, plant part, preparation method, amount used, and glycyrrhizin content wherever possible.

What Ayurveda Says About Yashtimadhu

Bhavaprakasha Nighantu describes Yashtimadhu in Haritakyadi Varga. Verse numbering differs between editions. The passage is numbered 128–129 in some editions and 145–146 in another commonly available Sanskrit edition.

The word vraṇa, meaning wound, is used in widely circulated editions. Some electronic transcriptions show an OCR or textual variation in this position.

Book: Bhavaprakasha Nighantu
Section: Haritakyadi Varga
Text numbers: 128–129 in some editions; 145–146 in another commonly used edition

यष्टीमधु तथा यष्टीमधुकं क्लीतकं तथा ।
अन्यत्क्लीतनकं तत्तु भवेत्तोये मधूलिका ॥१२८॥

यष्टी हिमा गुरुः स्वाद्वी चक्षुष्या बलवर्णकृत् ।
सुस्निग्धा शुक्रला केश्या स्वर्या पित्तानिलास्रजित् ।
व्रणशोथविषच्छर्दितृष्णाग्लानिक्षयापहा ॥१२९॥

Transliteration

Yaṣṭīmadhū tathā yaṣṭīmadhukaṁ klītakaṁ tathā |
Anyat klītanakaṁ tat tu bhavet toye madhūlikā ||128||

Yaṣṭī himā guruḥ svādvī cakṣuṣyā bala-varṇa-kṛt |
Susnigdhā śukralā keśyā svaryā pittānila-asrajit |
Vraṇa-śotha-viṣa-cchardi-tṛṣṇā-glāni-kṣayāpahā ||129||

English translation

Yashtimadhu is also known by names such as Yashtimadhuka and Klitaka.

It is described as sweet, cooling, nourishing, unctuous, and relatively heavy. It traditionally supports strength, complexion, voice, eyes, hair, and reproductive tissue. It is also described in conditions involving disturbed Vata and Pitta, abnormal bleeding, wounds, swelling, toxic states, vomiting, excessive thirst, fatigue, and depletion.

Urdu translation

یَشٹی مدھو کو یَشٹی مدھُک اور کلیتک جیسے ناموں سے بھی بیان کیا گیا ہے۔

اسے میٹھے ذائقے، ٹھنڈی تاثیر، چکنی اور نسبتاً بھاری خاصیت والی، جسمانی قوت، رنگت، آواز، آنکھوں، بالوں اور تولیدی بافتوں کو سہارا دینے والی دوا کہا گیا ہے۔ روایتی طور پر اسے وات اور پِتّ کی بے ترتیبی، بعض خون کی خرابیوں، زخم، سوجن، قے، زیادہ پیاس، تھکن اور جسمانی کمزوری میں استعمال کیا گیا ہے۔

Arabic translation

تُعرف اليَشْتيمادهو أيضاً بأسماء مثل يَشْتيمادهُكا وكليتاكا.

تُوصَف بأنها حلوة المذاق، باردة التأثير، مغذية، دهنية نسبياً وثقيلة. وقد استُخدمت تقليدياً لدعم القوة واللون والصوت والعينين والشعر والأنسجة التناسلية، وفي بعض حالات اضطراب فاتا وبيتّا، والنزف غير الطبيعي، والجروح والتورم والقيء والعطش الشديد والإجهاد والوهن.

This classical passage supports the nourishing, cooling, voice-supporting, wound-supporting, anti-fatigue, and Vata-Pitta-balancing role of Yashtimadhu. It does not describe glioblastoma, glycyrrhizin, HMGB1, MAPK11, apoptosis, brain penetration, or tumour regression [43,44]. (Sanskrit Documents)

Its possible tumour-directed role must therefore be evaluated through modern research rather than by extending the meaning of the classical verse.

Why Yashtimadhu May Be Relevant During Glioma Recovery

After glioma surgery, you may have weakness, throat discomfort after intubation, nausea, vomiting, dryness, disturbed voice, reduced appetite, poor sleep, fatigue, or difficulty tolerating medicines.

Yashtimadhu’s classical properties may make it useful in selected patients during this recovery period.

Its sweet, cooling, and unctuous nature may be considered when your treatment has produced dryness, burning, irritation, reduced strength, or a strong Vata-Pitta pattern.

Its traditional association with voice and throat comfort may be useful after surgical intubation, repeated coughing, dryness, or irritation.

Its traditional use in vomiting, thirst, fatigue, and depletion may also be relevant when chemotherapy, medicines, or poor intake have reduced your strength.

These are supportive treatment goals.

Improved throat comfort, appetite, voice, or strength does not prove that the glioblastoma has reduced.

Why Yashtimadhu Is Not Suitable for Every Weak Patient

Yashtimadhu is sweet, cooling, nourishing, unctuous, and relatively heavy.

These properties may support a weak, dry, depleted, or Pitta-Vata-dominant patient. The same properties may be unsuitable when you have severe heaviness, uncontrolled fluid retention, poor digestion, marked Kapha accumulation, high blood sugar, uncontrolled hypertension, or increasing body swelling.

A medicine can be nourishing and still be inappropriate during active edema or metabolic complications.

Your Ayurvedic doctor should therefore assess your appetite, digestion, blood pressure, potassium, kidney function, steroid exposure, blood sugar, and fluid status before deciding the dose.

Whole Yashtimadhu Is Not the Same as Glycyrrhizin

Whole Yashtimadhu root contains many natural constituents.

These include glycyrrhizin, glycyrrhetinic-acid precursors, flavonoids, chalcones, coumarins, polysaccharides, sterols, and other compounds.

Glycyrrhizin, also known as glycyrrhizic acid, is one of the best-known compounds in licorice root. It is largely responsible for the intense sweetness.

Purified glycyrrhizin is not the same as whole Yashtimadhu root.

A standardized licorice extract may contain a declared percentage of glycyrrhizin. Ordinary root powder may contain a different and more variable amount.

Deglycyrrhizinated licorice, commonly called DGL, has most of its glycyrrhizin removed. This may reduce some mineralocorticoid-like safety risks, but it also means that DGL cannot automatically be expected to reproduce glycyrrhizin-related HMGB1 or glycyrrhetinic-acid mechanisms.

The exact preparation matters.

Glycyrrhizin and Glycyrrhetinic Acid Are Related but Different

When you swallow glycyrrhizin, intestinal bacteria can convert it into 18β-glycyrrhetinic acid.

Glycyrrhetinic acid is then absorbed and further processed by the liver.

This means that the compound tested in the 2026 glioblastoma study was related to an important licorice constituent, but it was not identical to ordinary whole Yashtimadhu root [113].

The amount of glycyrrhetinic acid formed in your body can vary according to your intestinal bacteria, digestion, dose, liver function, preparation, and other medicines.

Two people taking the same amount of Yashtimadhu may not produce the same blood exposure.

This variability makes it difficult to convert a laboratory glycyrrhetinic-acid concentration directly into a whole-root dose.

The 2026 Glioblastoma Study of 18β-Glycyrrhetinic Acid

A 2026 study examined purified 18β-glycyrrhetinic acid in three glioblastoma-related cell lines and in intracranial and subcutaneous mouse tumour models [113].

The researchers used U87 human glioblastoma cells, GL261 mouse glioma cells, and CT2A mouse glioma cells.

The cells were exposed to concentrations of approximately 30, 50, and 70 micromolar for 24 hours.

The researchers examined cell viability, colony formation, migration, apoptosis, tumour growth, gene expression, and selected signalling pathways.

Glycyrrhetinic acid reduced the viability of all three tested cell lines in a concentration-dependent manner. It also reduced colony formation and migration in GL261 cells and increased the proportion of cells undergoing apoptosis [113].

This is direct preclinical glioblastoma evidence.

The study did not use whole Yashtimadhu root or Majja-Arbuda Rasayana Avaleha.

What Reduced Cell Viability Means

Cell-viability testing estimates how many cells remain metabolically active after treatment.

When glycyrrhetinic-acid concentration increased, the number of viable glioblastoma-related cells decreased [113].

This suggests that the compound either damaged the cells, stopped them from functioning normally, caused cell death, or produced a combination of these effects.

A viability assay alone does not prove permanent tumour elimination.

Some cells may remain alive but temporarily inactive. Others may recover after the compound is removed.

This is why the researchers also examined colony formation, migration, and apoptosis.

Why Colony Formation Was Examined

A colony-formation assay measures whether individual surviving tumour cells can continue dividing and form larger groups over time.

A treatment may reduce short-term viability without preventing the remaining cells from growing again.

In the 2026 study, glycyrrhetinic acid reduced the ability of GL261 cells to form colonies [113].

This suggests that fewer treated cells retained long-term reproductive capacity under the laboratory conditions.

The result is relevant to tumour regrowth.

It does not prove that oral Yashtimadhu prevents glioblastoma recurrence in a patient.

Glycyrrhetinic Acid and Glioblastoma-Cell Migration

Glioblastoma is difficult to control partly because tumour cells move into surrounding brain tissue beyond the visible tumour margin.

The 2026 study used a wound-healing assay to examine migration [113].

Glycyrrhetinic acid reduced GL261-cell movement across the experimental gap.

This suggests that the compound affected cellular functions required for movement.

A wound-healing assay is performed on a flat laboratory surface. It cannot reproduce the white-matter pathways, blood vessels, extracellular matrix, immune cells, and surrounding brain structures through which glioblastoma cells invade.

The finding supports a migration-related mechanism, but it does not prove that Yashtimadhu stops microscopic invasion in your brain.

Glycyrrhetinic Acid and Apoptosis

The researchers used flow cytometry to examine apoptosis in GL261 cells [113].

Higher glycyrrhetinic-acid exposure increased the proportion of apoptotic cells.

Apoptosis is a regulated process through which a severely damaged cell activates an internal programme of death.

Glioblastoma cells may avoid apoptosis by activating strong survival and repair pathways.

A compound that makes these cells enter apoptosis may therefore have tumour-directed value.

The important limitation remains the same. The cells were exposed directly to purified glycyrrhetinic acid. The study did not prove that a traditional Yashtimadhu dose produces the same concentration inside a human glioblastoma.

What Was Tested in the Intracranial Mouse Model

The researchers implanted luciferase-labelled GL261 cells inside the brains of immune-competent C57BL/6 mice [113].

Seven days after tumour implantation, the mice were divided into treatment groups.

They received glycyrrhetinic acid by oral gavage at 12.5, 25, or 50 milligrams per kilogram per day. A comparison group received temozolomide at 35 milligrams per kilogram per day.

The treatment continued for 13 days.

Tumour activity was followed through bioluminescent imaging. The brains were also examined histologically, and Ki-67 staining was used to assess tumour-cell proliferation.

Oral glycyrrhetinic acid reduced intracranial tumour growth, reduced the tumour area seen in brain sections, and reduced Ki-67 staining in the tested model [113].

This is more relevant than a study involving only tumour cells in a dish or only a tumour growing under the skin.

Why the Intracranial Model Adds Important Evidence

In an intracranial model, the compound must be absorbed from the digestive system, enter the blood, reach the brain, and affect tumour cells growing inside brain tissue.

The observed effect therefore suggests that orally administered glycyrrhetinic acid, or a biologically active product formed from it, reached a relevant intracranial site in the mice.

This is a stronger brain-delivery signal than computer prediction alone.

However, the study did not report direct measurement of glycyrrhetinic acid inside the brain tumour.

It also did not establish the concentration reached in the tumour core, infiltrating margin, normal brain, or cerebrospinal fluid.

The intracranial response provides indirect functional evidence of exposure. It is not complete pharmacokinetic proof.

What Was Tested in the Subcutaneous Tumour Model

The researchers also implanted U87 human glioblastoma cells under the skin of immune-deficient mice [113].

The animals received the same oral glycyrrhetinic-acid dose range or temozolomide.

Medium- and high-dose glycyrrhetinic acid reduced tumour volume. The high-dose group also showed lower tumour weight.

A subcutaneous model is useful for measuring tumour size repeatedly and examining general systemic activity.

It does not reproduce the blood–brain barrier.

The intracranial and subcutaneous models should therefore be considered together. The subcutaneous model supports general antitumour activity, while the intracranial model provides greater relevance to brain-tumour delivery.

Did the Study Show Longer Survival?

The 2026 study mainly measured tumour growth, tumour size, cell proliferation, migration, apoptosis, body weight, and tissue findings [113].

It did not establish improved long-term survival in the intracranial model.

A reduction in tumour signal over 13 days is an important preclinical result. It is not the same as proving longer overall survival.

The study also did not examine recurrence after the compound was stopped.

Glioblastoma may initially respond to a treatment and later regrow from resistant cells.

Longer studies would be needed to determine whether the effect remains durable.

What the Safety Findings in Mice Mean

The researchers reported no obvious body-weight loss and no visible histological damage in major organs under the tested conditions [113].

This provides useful preliminary animal tolerability information.

It does not establish complete human safety.

The exposure period was relatively short. The animals did not reproduce all the clinical problems seen in a glioblastoma patient taking dexamethasone, antiseizure medicines, temozolomide, antihypertensives, diuretics, and a multi-ingredient Avaleha.

Licorice-related blood-pressure and potassium effects may also require specific biochemical monitoring that is different from observing body weight and organ appearance.

Glycyrrhetinic Acid and MAPK11

The researchers combined network analysis, tumour gene-expression analysis, RNA sequencing, molecular docking, and laboratory validation to identify possible targets [113].

MAPK11 emerged as an important candidate.

MAPK11 is one member of the p38 MAPK family. This signalling system helps cells respond to stress, inflammation, DNA damage, and environmental changes.

The study found that high MAPK11 expression was associated with poorer outcomes in analysed glioblastoma datasets.

Glycyrrhetinic acid reduced MAPK11 expression in the tested GL261 cells and in tumour tissue from the high-dose intracranial group [113].

This supports MAPK11 as a possible treatment-related target.

It does not prove that MAPK11 is the only or direct clinical target of Yashtimadhu.

What p38 Activation Means

The study reported increased phosphorylation of p38 and its downstream protein MAPKAPK2 after glycyrrhetinic-acid treatment [113].

Phosphorylation is one way of switching signalling proteins into a more active state.

In several experimental settings, strong p38 activation can contribute to cell-cycle arrest, cellular stress, or apoptosis.

In other biological settings, p38 pathways may help cells adapt or survive.

The function of p38 is therefore not universally harmful or beneficial.

In the tested GL261 model, the pattern of p38 activation occurred together with reduced proliferation and increased apoptosis.

This provides a possible mechanism for the observed effect.

Glycyrrhetinic Acid and the MEK/ERK Pathway

The researchers also reported reduced ERK phosphorylation without a major change in total ERK [113].

MEK and ERK form part of an important signalling pathway involved in cell growth, division, survival, and response to growth signals.

Many tumours use persistent MEK/ERK activity to continue growing.

Reducing ERK activation may weaken the ability of selected glioblastoma cells to proliferate or survive.

The study suggested that glycyrrhetinic acid produced coordinated activation of stress-related p38 signalling and suppression of MEK/ERK survival signalling.

This remains a model-specific mechanistic finding.

Molecular Docking Did Not Prove Direct Binding

The researchers used molecular docking to predict whether glycyrrhetinic acid could fit into a binding region of MAPK11 [113].

The predicted binding energy was favourable.

Molecular docking is useful for generating a target hypothesis.

It does not prove that the compound binds MAPK11 inside a living tumour. Direct biochemical binding studies, target-engagement assays, and genetic validation would provide stronger confirmation.

The laboratory protein findings strengthen the overall mechanism, but the docking result should not be described as final proof of direct target binding.

Why the 2026 Study Needs Independent Replication

The study provides one of the more complete preclinical evidence chains among the licorice-related glioblastoma studies.

It included three tumour-cell models, migration, colony formation, apoptosis, intracranial and subcutaneous animal models, oral dosing, tumour imaging, tissue analysis, transcriptomics, and pathway assessment.

It remains one recent study.

Independent researchers need to reproduce the findings. The compound should also be tested in additional patient-derived glioblastoma models, glioma stem-like cells, molecularly different tumours, longer survival studies, and combination studies with standard treatment.

A recent positive study should be treated as promising evidence, not as the final clinical answer.

Can the Mouse Dose Be Converted Directly Into Your Dose?

The mouse doses of 12.5, 25, and 50 milligrams per kilogram per day involved purified glycyrrhetinic acid [113].

They cannot be multiplied directly by your body weight.

Mice and humans differ in metabolism, body-surface area, intestinal absorption, liver processing, blood distribution, and elimination.

Yashtimadhu root also contains glycyrrhizin rather than the same amount of ready-to-absorb purified glycyrrhetinic acid.

Only part of the glycyrrhizin may be converted into glycyrrhetinic acid.

The animal study therefore provides a research exposure, not a clinical Yashtimadhu prescription.

Does Yashtimadhu Cross the Blood–Brain Barrier?

The intracranial mouse response suggests that oral glycyrrhetinic acid produced a biologically relevant effect within the brain [113].

This does not prove that whole Yashtimadhu crosses the human blood–brain barrier at a tumour-controlling concentration.

The root contains many compounds. Each may have different absorption and distribution.

The amount of glycyrrhetinic acid formed after whole-root use may be much lower or more variable than the purified compound used in the mouse study.

Direct human evidence would require measurement in blood, cerebrospinal fluid, resected brain tissue, or glioblastoma tissue.

That evidence is not established.

What Is HMGB1?

HMGB1 stands for high-mobility group box 1.

Inside the cell nucleus, HMGB1 helps organize DNA and regulate gene activity.

When a cell is damaged, stressed, infected, or dying, HMGB1 may be released outside the cell.

Outside the cell, HMGB1 can act as a danger signal. It may activate inflammatory pathways through receptors such as TLR2, TLR4, or RAGE.

In glioblastoma, extracellular HMGB1 may influence inflammation, vascular permeability, cerebral edema, cell migration, stem-like behaviour, immune activity, and treatment response.

Glycyrrhizin is studied partly because it can bind HMGB1 and reduce selected extracellular HMGB1 activities.

HMGB1 and Glioblastoma-Related Edema

One experimental glioblastoma study examined HMGB1 released after oncolytic herpes-virus treatment [114].

The virus caused stressed or dying tumour cells to release HMGB1 into the tumour environment.

The released HMGB1 increased blood-vessel leakiness and cerebral edema in animals carrying intracranial gliomas.

Blocking HMGB1 reduced vascular leakiness and edema and improved survival in animals receiving the experimental viral therapy [114].

The strongest in-vivo edema findings in that study were demonstrated through HMGB1-blocking antibodies rather than through ordinary oral Yashtimadhu.

The study supports HMGB1 as an important edema-related target.

It does not prove that Yashtimadhu reduces cerebral edema in glioblastoma patients.

Why the HMGB1 Edema Study Must Not Be Misrepresented

It would be inaccurate to write that licorice has been clinically proven to reduce glioblastoma edema based on this experiment.

The study involved an intracranial animal model, oncolytic viral therapy, HMGB1 release, and experimental HMGB1 blockade.

It did not involve a human trial of Yashtimadhu.

It did not establish a safe oral licorice dose for cerebral edema.

It also did not show that Yashtimadhu can replace dexamethasone.

This distinction is especially important because glycyrrhizin can cause systemic sodium and water retention in susceptible people.

A compound may reduce one molecular pathway related to local vascular leakiness while still increasing whole-body fluid retention through another mechanism.

HMGB1 Can Also Support Antitumour Immunity

HMGB1 does not always have one harmful role.

Another glioblastoma study found that HMGB1 released from dying tumour cells helped activate TLR2-dependent immune responses and contributed to antitumour immunological memory during an experimental gene-therapy strategy [115].

In this setting, HMGB1 acted as a danger signal that helped immune cells recognize the dying tumour.

Blocking every HMGB1 activity could therefore be undesirable in some treatment situations.

The effect may depend on where HMGB1 is located, how much is released, its chemical state, which receptor is activated, the tumour environment, and the treatment being used.

Why HMGB1 Should Not Be Described as a Simple Bad Protein

HMGB1 may increase inflammation, vascular leakage, edema, invasion, or stem-like behaviour in one setting.

In another setting, HMGB1 released from dying tumour cells may help activate antitumour immunity.

This is a good example of why natural compounds should not be promoted through one simplified pathway.

The correct research question is not whether Yashtimadhu blocks HMGB1.

The better question is whether a defined glycyrrhizin or glycyrrhetinic-acid preparation can influence the harmful form of extracellular HMGB1 at the correct time without weakening a beneficial antitumour immune response.

That question has not yet been answered in human glioblastoma care.

Can Yashtimadhu Be Used During Oncolytic-Virus Treatment?

You should not add high-glycyrrhizin Yashtimadhu independently during oncolytic-virus therapy or another immune-based clinical trial.

HMGB1 may influence both tumour-related edema and the immune response to dying tumour cells [114,115].

Blocking it could theoretically help one part of the treatment while altering another.

The treating research team needs to know every herbal ingredient and extract you are taking.

This is particularly important because clinical trials often depend on carefully controlled immune and inflammatory responses.

Can Yashtimadhu Reduce Cerebral Edema?

Current evidence does not establish that whole Yashtimadhu safely reduces cerebral edema in people with glioblastoma.

The HMGB1 study supports an experimental molecular connection between HMGB1, vascular leakiness, and tumour-related edema [114].

The direct Yashtimadhu-related glioblastoma evidence comes mainly from purified glycyrrhetinic acid in cells and animal tumour models [113].

Neither study is a human Yashtimadhu cerebral-edema trial.

You should not reduce dexamethasone because Yashtimadhu has been added.

A steroid taper must be guided by your neurological symptoms, MRI findings, steroid duration, blood sugar, blood pressure, and medical supervision.

Why Yashtimadhu Could Worsen Fluid Retention

Glycyrrhizin and glycyrrhetinic acid can inhibit an enzyme called 11β-hydroxysteroid dehydrogenase type 2, commonly shortened to 11β-HSD2.

This enzyme normally protects mineralocorticoid receptors from excessive activation by cortisol.

When the enzyme is inhibited, cortisol can activate mineralocorticoid receptors more strongly.

This may cause the kidneys to retain sodium and water while losing potassium.

The resulting condition is often called licorice-induced pseudoaldosteronism.

You may develop high blood pressure, swelling, weight gain, low potassium, metabolic alkalosis, muscle weakness, headache, or abnormal heart rhythm [116,120].

Why This Safety Issue Is Especially Important in Glioblastoma

Glioblastoma patients commonly receive dexamethasone for cerebral edema.

Dexamethasone may already contribute to high blood pressure, high blood sugar, muscle weakness, sleep disturbance, infection risk, and fluid changes.

Adding a high-glycyrrhizin product may make some of these problems more difficult to interpret or control.

A new facial puffiness, ankle swelling, weight increase, weakness, or blood-pressure rise should not automatically be considered part of recovery.

The cause may be steroids, licorice, kidney problems, low albumin, reduced mobility, heart disease, or several factors acting together.

Low Potassium Can Cause Serious Problems

Potassium is important for normal muscle, nerve, and heart function.

Excessive glycyrrhizin exposure can lower blood potassium [116,120].

You may develop muscle weakness, cramps, fatigue, constipation, palpitations, or an abnormal heart rhythm.

A glioma patient may already have weakness because of the tumour, surgery, steroids, reduced movement, or neurological damage.

Licorice-related low potassium can therefore be missed if weakness is assumed to be neurological.

A serum-electrolyte test is more reliable than guessing the cause.

Why Muscle Weakness Can Be Misinterpreted

Dexamethasone can cause steroid-related muscle wasting. Brain tumours can cause one-sided weakness. Low potassium can cause more general muscle weakness.

These conditions may occur together.

If your walking, standing, or ability to rise from a chair worsens after starting a Yashtimadhu-containing formula, your neurological condition, steroid dose, potassium, blood pressure, and other medicines should be reviewed.

Increasing the strength-supporting herbs without finding the cause may delay necessary treatment.

Yashtimadhu and Blood Pressure

Licorice can raise blood pressure, particularly when the glycyrrhizin exposure is high, prolonged, or combined with other risk factors [116,120].

Some people are more sensitive than others.

The risk may be greater when you already have hypertension, kidney disease, heart disease, a high-salt diet, older age, or prolonged steroid use.

Your blood pressure should be recorded before treatment and followed during regular use.

A headache caused by rising blood pressure should not be assumed to come only from the brain tumour.

Yashtimadhu and Heart-Rhythm Risk

Severe potassium loss may disturb the electrical rhythm of the heart.

You may experience palpitations, dizziness, fainting, chest discomfort, or severe weakness.

The risk becomes more important when you take another medicine that affects heart rhythm or when you already have cardiac disease.

Licorice-related serious heart reactions are uncommon when exposure is low and properly supervised, but they are medically important because the consequences can be severe [120].

Possible Interaction With Diuretics

Some patients receive diuretics for blood pressure, swelling, heart disease, or other medical reasons.

Loop and thiazide diuretics can also lower potassium.

Combining them with high-glycyrrhizin licorice may increase the risk of hypokalemia.

Spironolactone and related medicines work through aldosterone-related pathways. Licorice-induced mineralocorticoid effects may complicate the expected response.

Your doctor should know if you take furosemide, hydrochlorothiazide, spironolactone, or another diuretic.

Possible Interaction With Corticosteroids

Interactions between licorice and corticosteroids have been reported [120].

This is highly relevant because dexamethasone is frequently used in glioma care.

Yashtimadhu should not be added simply because both Ayurveda and modern medicine use it in inflammatory or swelling-related conditions.

The combination may affect fluid balance, blood pressure, potassium, blood sugar, and steroid exposure.

The steroid dose, Yashtimadhu dose, treatment duration, blood pressure, glucose, electrolytes, and edema should be monitored together.

Possible Interaction With Digoxin and Heart Medicines

Low potassium can increase sensitivity to digoxin and increase the risk of digoxin-related toxicity.

The concern is not only a direct chemical interaction. It is also the effect of licorice on the electrolyte environment in which the heart medicine acts.

If you take digoxin, antiarrhythmic medicine, or several cardiovascular medicines, glycyrrhizin-containing Yashtimadhu requires specialist review.

Can Deglycyrrhizinated Licorice Avoid These Risks?

Deglycyrrhizinated licorice has most of its glycyrrhizin removed.

This reduces the main compound associated with pseudoaldosteronism, hypertension, potassium loss, and fluid retention.

DGL may therefore be more appropriate when licorice is being used mainly for local digestive or mucosal support.

However, removing glycyrrhizin also changes the research relevance.

The direct 2026 glioblastoma study used glycyrrhetinic acid [113]. HMGB1-related research concerns glycyrrhizin or direct HMGB1 blockade [114,115].

DGL cannot be described as though it provides the same glycyrrhizin-derived tumour-related mechanism.

A safer formulation for blood pressure may no longer match the compound used in the tumour study.

Does Yashtimadhu Improve Temozolomide Response?

The 2026 glycyrrhetinic-acid study used temozolomide as an animal comparison treatment [113].

It did not establish that glycyrrhetinic acid and temozolomide work better together.

It did not show that Yashtimadhu changes MGMT promoter methylation or reverses MGMT-mediated resistance.

The HMGB1 literature provides a possible connection between tumour stress, treatment response, inflammation, and stem-like behaviour, but it does not establish a human Yashtimadhu–temozolomide protocol.

You should therefore not be told that Yashtimadhu has been clinically proven to overcome temozolomide resistance.

Yashtimadhu During Temozolomide Treatment

Yashtimadhu may be considered during temozolomide for selected supportive reasons, such as nausea, dryness, voice, throat comfort, Pitta-Vata balance, or recovery.

Its experimental tumour-directed role remains separate.

Temozolomide can affect blood counts and liver function [144]. Yashtimadhu may affect blood pressure, potassium, sodium, fluid balance, and medicine response.

Your monitoring should therefore include more than liver tests alone.

Blood pressure, body weight, swelling, potassium, sodium, kidney function, blood sugar, muscle strength, and cardiac symptoms may also matter.

Yashtimadhu During Radiation

The references used in this section do not establish that Yashtimadhu increases glioblastoma radiation sensitivity.

Its possible role during radiation may relate to supportive care, irritation, nausea, fatigue, or an experimental inflammation-related rationale.

Radiation and steroids can change edema, appetite, sleep, blood sugar, and neurological symptoms.

A glycyrrhizin-containing formulation may complicate fluid and blood-pressure management in a susceptible person.

Its use should therefore be based on your complete condition rather than on a general anti-inflammatory claim.

Yashtimadhu and Throat Irritation After Surgery

Brain surgery commonly requires endotracheal intubation.

You may develop throat pain, dryness, coughing, hoarseness, or voice difficulty after the breathing tube is removed.

Yashtimadhu has a traditional voice- and throat-supporting role. This may provide a reasonable supportive purpose when you can swallow safely.

However, persistent voice difficulty may also result from nerve injury, aspiration, weakness, infection, or another postoperative complication.

A soothing herb should not delay assessment when the problem is severe or prolonged.

Yashtimadhu for Nausea and Vomiting

The classical passage includes Chardi, or vomiting, among its traditional areas of use [43,44].

This may be relevant during chemotherapy or postoperative recovery.

However, vomiting in a glioma patient may also indicate increased intracranial pressure, cerebral edema, medicine toxicity, infection, bowel obstruction, or electrolyte imbalance.

Repeated vomiting should not be managed only by increasing Yashtimadhu.

The cause must be identified.

Yashtimadhu and Appetite

Yashtimadhu’s sweet, heavy, and unctuous qualities may support nourishment in one patient while reducing appetite or increasing heaviness in another.

A weak patient with dryness and burning may tolerate it differently from a patient with sluggish digestion, nausea, edema, and high blood sugar.

Your food intake, digestion, body weight, glucose, and bowel pattern should be observed.

A nourishing herb is useful only when you can digest and tolerate it.

Yashtimadhu and Blood Sugar

Yashtimadhu tastes intensely sweet because of glycyrrhizin, but this does not mean that glycyrrhizin acts exactly like ordinary sugar.

The complete Avaleha may still contain sugar, jaggery, honey, or another carbohydrate-rich base.

This becomes important when dexamethasone has raised your blood sugar.

The metabolic effect of the complete formulation must be assessed rather than focusing only on whether the root itself tastes sweet.

Yashtimadhu and Kidney Disease

The kidneys control sodium, potassium, water, and blood pressure.

A glycyrrhizin-containing product can disturb this balance.

If you have chronic kidney disease, reduced kidney function, uncontrolled blood pressure, low potassium, or significant swelling, Yashtimadhu requires particular caution.

Kidney impairment may also change how safely you can correct electrolyte disturbances.

The classical reputation of the herb should not be used to ignore a modern renal risk.

Who Should Receive Yashtimadhu Only With Extra Caution?

Greater caution is required when you have uncontrolled hypertension, low potassium, heart disease, kidney disease, significant edema, an abnormal heart rhythm, severe muscle weakness, prolonged dexamethasone use, or treatment with diuretics or digoxin.

A small dose and short duration may produce a very different risk from a concentrated extract used for several months.

Your sensitivity cannot be predicted only from body weight.

When Yashtimadhu May Need to Be Reduced or Paused

Yashtimadhu should be reviewed when your blood pressure rises significantly, potassium falls, swelling increases, body weight rises rapidly, or you develop new muscle weakness, cramps, palpitations, severe headache, or shortness of breath.

It should also be reviewed when you develop severe nausea, inability to swallow, acute kidney injury, a serious cardiac event, or an unexplained neurological decline.

These problems should not be described as detoxification or temporary adjustment.

How the Yashtimadhu Dose in the Avaleha Should Be Calculated

The total Yashtimadhu quantity placed into the complete batch should be recorded.

Suppose a 900-gram Avaleha contains 18 grams of authenticated Glycyrrhiza glabra root.

Yashtimadhu would represent 2% of the final formulation.

If you take 30 grams of Avaleha daily, your estimated whole-root exposure would be approximately 600 milligrams per day.

This does not mean that you receive 600 milligrams of glycyrrhizin.

The glycyrrhizin content may represent only a variable fraction of the root.

It also does not mean that your body produces 600 milligrams of glycyrrhetinic acid.

The whole-root amount cannot be directly compared with 30–70 micromolar glycyrrhetinic acid in cell culture or 12.5–50 milligrams per kilogram of purified glycyrrhetinic acid in mice.

Why Glycyrrhizin Standardization Is Essential

A product label stating “Yashtimadhu 500 milligrams” does not reveal how much glycyrrhizin is present.

One preparation may contain ordinary root powder. Another may contain a concentrated extract. Another may be standardized to a defined glycyrrhizin percentage. Another may be deglycyrrhizinated.

These preparations may produce very different tumour-related hypotheses and very different safety risks.

If reference [113] is used to support a glycyrrhetinic-acid-related role, the finished Avaleha should ideally be tested for glycyrrhizin.

Without this measurement, the research comparison remains weak.

Why Batch Variation Matters

Glycyrrhizin content may vary according to species, plant source, age, root part, cultivation, harvesting, storage, and extraction method.

The amount may also change during Avaleha preparation.

Water extraction, prolonged heating, filtration, and concentration can alter the final exposure.

Two batches containing the same stated weight of Yashtimadhu root may not contain the same amount of glycyrrhizin.

A batch-specific marker test adds real value.

How Avaleha Processing May Affect Yashtimadhu

Yashtimadhu may be used as decoction material, fine powder, or concentrated extract.

A decoction may extract water-soluble glycyrrhizin efficiently but may not recover every flavonoid or less-water-soluble compound in the same proportion.

Adding fine powder later preserves more whole-root material but may change texture and digestion.

A standardized extract may create greater consistency but may also produce higher pharmacological exposure and greater safety concerns.

The formulation record should state the preparation form and stage of addition.

Can Yashtimadhu Be Called a Direct Human Glioblastoma Treatment?

No direct human evidence currently shows that Yashtimadhu shrinks glioblastoma, delays recurrence, improves progression-free survival, or extends overall survival.

The direct evidence chain is preclinical.

Purified glycyrrhetinic acid reduced glioblastoma-related cell growth, migration, and animal tumour growth [113].

HMGB1 research supports possible relevance to vascular leakiness, edema, inflammation, and immune activity [114,115].

These findings justify further research.

They do not establish a clinical tumour-control claim for whole Yashtimadhu.

Where Yashtimadhu Fits in Majja-Arbuda Rasayana Avaleha

Yashtimadhu may fit primarily within the Rasayana, nourishment, voice, throat, mucosal, anti-fatigue, and Vata-Pitta-support group.

Its classical description supports this role [43,44].

It may also have a secondary place within the tumour-directed research group because purified 18β-glycyrrhetinic acid showed activity in glioblastoma cells and oral intracranial mouse models [113].

A third experimental role relates to HMGB1 and the tumour microenvironment [114,115].

This role is complex because HMGB1 may contribute to edema and vascular leakiness in one setting while helping antitumour immune recognition in another.

Yashtimadhu should not be described as a simple HMGB1-blocking glioblastoma cure.

What Must Be Documented in the Finished Formulation

The batch record should identify Glycyrrhiza glabra L. and specify the root or underground stolon used.

It should state whether the material is powder, decoction, extract, standardized extract, or deglycyrrhizinated preparation.

The total quantity placed in the batch and your estimated daily whole-root exposure should be calculated.

The finished product should ideally be tested for glycyrrhizin whenever glycyrrhizin- or glycyrrhetinic-acid-related research is used to support the formulation.

Your baseline blood pressure, potassium, sodium, kidney function, body weight, edema, steroid dose, and cardiovascular medicines should also be documented when clinically relevant.

How Your Response Should Be Monitored

If Yashtimadhu is used mainly for supportive care, relevant outcomes include throat comfort, voice, nausea, vomiting, thirst, fatigue, appetite, digestion, strength, and treatment tolerance.

Its safety outcomes are equally important.

Blood pressure, body weight, facial or ankle swelling, muscle strength, potassium, sodium, kidney function, blood sugar, and cardiac symptoms may need monitoring.

If it is included partly for tumour-directed research, supportive improvement cannot prove tumour response.

MRI findings, neurological status, steroid dose, surgery, radiation, temozolomide, and treatment timing must be assessed together.

Current Evidence Verdict for Yashtimadhu, Glycyrrhizin, and Glycyrrhetinic Acid

Classical Ayurvedic support is strong for Yashtimadhu as a sweet, cooling, nourishing, unctuous, voice-supporting, strength-supporting, and Vata-Pitta-balancing herb [43,44].

Its traditional use may be relevant to weakness, voice or throat irritation, vomiting, thirst, fatigue, wounds, swelling, and depletion.

Direct preclinical glioblastoma evidence is present for purified 18β-glycyrrhetinic acid. A 2026 study reported reduced proliferation, colony formation, migration, and increased apoptosis in U87, GL261, and CT2A tumour-cell models [113].

The same study reported reduced tumour growth after oral glycyrrhetinic acid in intracranial GL261 and subcutaneous U87 mouse models. The doses were 12.5, 25, and 50 milligrams per kilogram daily for 13 days [113].

The study did not establish long-term survival, recurrence prevention, human tumour exposure, or clinical effectiveness.

The proposed MAPK11, p38, and MEK/ERK mechanisms were supported through combined pathway analysis, protein findings, and molecular docking, but direct target binding and human relevance require further confirmation.

HMGB1 research supports an experimental relationship with glioblastoma-related vascular leakiness and edema [114]. Other research shows that HMGB1 may also help activate antitumour immune memory in selected treatment settings [115].

HMGB1 should therefore not be treated as an entirely harmful target that should always be blocked.

Human evidence proving glioblastoma shrinkage, delayed recurrence, improved progression-free survival, or longer overall survival from Yashtimadhu is not established.

The main clinical concern is glycyrrhizin-related pseudoaldosteronism. Excessive or prolonged exposure may cause hypertension, sodium and water retention, low potassium, edema, muscle weakness, and serious cardiac complications [116,120].

Yashtimadhu may be a rational ingredient in selected patients when its exact purpose is stated, its glycyrrhizin exposure is known, and its classical nourishing role is separated from its experimental tumour-directed role.

It should not be used casually in a glioblastoma patient with hypertension, low potassium, heart or kidney disease, marked edema, prolonged dexamethasone use, or interacting medicines. The formula should be adjusted according to your blood pressure, electrolytes, steroid burden, fluid status, digestive condition, and complete treatment plan.

Amalaki for Glioma and Glioblastoma: Ayurvedic Rasayana, U87-MG Research, Antioxidant Effects, and Safety

Amalaki is one of the most important Rasayana fruits in Ayurveda. It is traditionally used to support strength, tissue nourishment, digestion, recovery, healthy ageing, blood and metabolic balance, and the ability of the body to tolerate prolonged illness.

These traditional actions may be relevant when you are recovering from glioma surgery or receiving radiation, temozolomide, steroids, antiseizure medicines, and rehabilitation. You may need support for appetite, physical strength, treatment-related fatigue, bowel function, metabolic health, and long-term recovery.

Amalaki also has a new and emerging tumour-directed evidence pathway. A 2025 laboratory study tested different Emblica officinalis fruit extracts directly against U87-MG human glioblastoma cells. The researchers also used the most active fruit extract to prepare green-synthesized silver nanoparticles and examined their effect on tumour-cell growth and migration [117].

This study gives Amalaki a direct connection with experimental glioblastoma research. However, the evidence remains preliminary and entirely preclinical. It does not prove that eating Amalaki fruit, drinking its juice, taking Amalaki powder, or receiving it through Majja-Arbuda Rasayana Avaleha will shrink glioblastoma in a patient.

The methanolic extract and silver nanoparticles used in the study are not equivalent to traditional Amalaki preparations. Their findings must therefore be explained separately from the classical Rasayana role of the whole fruit.

What Is Amalaki?

The currently accepted botanical name of Amalaki is Phyllanthus emblica L. The older scientific name Emblica officinalis Gaertn. is still widely used in Ayurvedic books, research papers, pharmacopoeial monographs, and commercial products.

Both names generally refer to the same medicinal tree.

Amalaki belongs to the Phyllanthaceae family. Older botanical literature may place it within the Euphorbiaceae family because plant classification has changed over time.

The medicinal part used most commonly in Ayurveda is the fruit. It may be used fresh, dried, powdered, made into juice, decocted, processed into an extract, or included in preparations such as Chyavanaprasha, Triphala, Amalaki Rasayana, and different Avalehas.

The form matters because fresh fruit, dried fruit powder, aqueous extract, methanolic extract, standardized tannin extract, purified vitamin C, and Amalaki-derived silver nanoparticles are different interventions.

You should not assume that research performed on one preparation proves the effect of every other Amalaki product.

Amalaki Is Not the Same as Bhumi Amalaki

Amalaki must not be confused with Bhumi Amalaki.

Amalaki is generally identified as Phyllanthus emblica, a fruit-bearing tree.

Bhumi Amalaki is usually connected with smaller herbaceous species such as Phyllanthus amarus, Phyllanthus niruri, or related plants, depending on the regional and pharmacopoeial source.

These plants have different medicinal parts, chemical compounds, classical uses, and modern research.

A study involving Phyllanthus amarus or Phyllanthus niruri cannot be cited as evidence for Amalaki fruit. In the same way, a study involving Phyllanthus emblica cannot automatically be used to support Bhumi Amalaki.

The complete botanical name must therefore appear in the formulation and evidence record.

What Ayurveda Says About Amalaki

Bhavaprakasha Nighantu describes Amalaki in Haritakyadi Varga. The following verses are commonly numbered 39–40.

Book: Bhavaprakasha Nighantu

Section: Haritakyadi Varga

Text numbers: 39–40

हरीतकीसमं धात्रीफलं किन्तु विशेषतः ।
रक्तपित्तप्रमेहघ्नं परं वृष्यं रसायनम् ॥३९॥

हन्ति वातं तदम्लत्वात्पित्तं माधुर्यशैत्यतः ।
कफं रूक्षकषायत्वात्फलं धात्र्यास्त्रिदोषजित् ॥४०॥

Transliteration

Harītakī-samaṁ dhātrī-phalaṁ kintu viśeṣataḥ |
Rakta-pitta-prameha-ghnaṁ paraṁ vṛṣyaṁ rasāyanam ||39||

Hanti vātaṁ tad-amlatvāt pittaṁ mādhurya-śaityataḥ |
Kaphaṁ rūkṣa-kaṣāyatvāt phalaṁ dhātryās tridoṣajit ||40||

English translation

The fruit of Dhatri, or Amalaki, is considered similar in many respects to Haritaki but has its own special qualities. It is traditionally described as Rasayana, nourishing, and useful in conditions involving disturbed blood, Pitta, and metabolic function.

Its sour taste helps balance Vata, while its sweetness and cooling nature help balance Pitta. Its dryness and astringency help balance Kapha. It is therefore described as a fruit capable of supporting balance among all three Doshas.

Urdu translation

دھاتری یا آملکی کے پھل کو بہت سی خصوصیات میں ہری تکی کے مشابہ لیکن اپنی مخصوص اہمیت رکھنے والا بتایا گیا ہے۔ اسے رسایَن، جسمانی قوت و بافتوں کی پرورش کا معاون اور خون، پِتّ اور استحالہ سے متعلق بعض خرابیوں میں مفید سمجھا گیا ہے۔

اس کا ترش ذائقہ وات کو متوازن کرنے میں مدد دیتا ہے، جبکہ اس کی مٹھاس اور ٹھنڈی تاثیر پِتّ کو متوازن کرتی ہے۔ اس کی خشکی اور کسیلا پن کف کو متوازن کرنے میں معاون ہیں۔ اسی لیے اسے تینوں دوشوں کے توازن میں مدد دینے والا پھل کہا گیا ہے۔

Arabic translation

تُوصَف ثمرة الدهاتري، أو الأمالاكي، بأنها تشبه الهاريتاكي في كثير من الخصائص، مع امتلاكها صفات مميزة. وتُعدّ من أدوية الراسايانا الداعمة للقوة وتغذية الأنسجة، وقد استُخدمت تقليدياً في بعض الحالات المرتبطة باضطرابات الدم وبيتّا والاستقلاب.

يساعد طعمها الحامض في موازنة فاتا، بينما تساعد حلاوتها وتأثيرها البارد في موازنة بيتّا. وتساعد خاصيتها الجافة والقابضة في موازنة كافا. ولهذا توصف بأنها داعمة لتوازن الدوشات الثلاثة.

These verses support Amalaki’s classical role as a Tridosha-balancing, cooling, nourishing, and Rasayana fruit [43,44].

They do not describe glioblastoma, U87-MG cells, silver nanoparticles, tumour migration, the blood–brain barrier, temozolomide resistance, or MRI tumour regression.

The classical evidence supports its role in recovery, nourishment, metabolic balance, and long-term Rasayana care. Its possible tumour-directed role must be evaluated separately through modern research.

Why Amalaki May Be Relevant After Glioma Surgery

Glioma surgery can affect your appetite, digestion, physical strength, bowel function, sleep, mobility, and ability to tolerate medicines.

Steroids may increase blood sugar and appetite while also contributing to muscle weakness. Antiseizure medicines may produce sleepiness, nausea, or reduced coordination. Temozolomide and radiation may cause fatigue, nausea, reduced food intake, and gradual loss of strength.

Amalaki may be considered within a wider Rasayana and recovery plan because it is traditionally used to support tissue nourishment, metabolic balance, digestion, and long-term vitality.

Its cooling nature may also be relevant when treatment has produced excessive heat, mouth irritation, thirst, or Pitta-related digestive discomfort.

These supportive roles should not be confused with tumour control.

If your appetite improves or you feel less fatigued, the change may be useful. It does not prove that the tumour has reduced.

Why Amalaki Is More Than a Source of Vitamin C

Amalaki is widely promoted as a vitamin C-rich fruit. Vitamin C is one important part of its nutritional profile, but it does not explain every reported biological effect.

Amalaki fruit also contains hydrolysable tannins, polyphenols, flavonoids, gallic acid, ellagic acid, emblicanin A, emblicanin B, punigluconin, pedunculagin, and other natural compounds [118].

Some of these compounds can influence oxidation, inflammation, cellular stress, enzymes, and signalling pathways.

The amount of each compound can vary according to the fruit variety, ripeness, geographical source, drying, processing, extraction, and storage.

This means that one Amalaki product cannot be evaluated only by its total fruit weight.

A dried powder and a standardized tannin extract may deliver very different exposures.

Antioxidant Activity Does Not Automatically Mean Anticancer Activity

Amalaki is known for strong antioxidant activity.

Antioxidants can help control excessive oxidative damage in normal tissues. This may be relevant during prolonged illness, inflammation, poor nutrition, and treatment-related stress.

However, a DPPH antioxidant assay does not prove that an extract kills glioblastoma cells.

DPPH is a laboratory test that estimates how effectively a substance can neutralize a stable free radical in a test system. It is useful for comparing antioxidant capacity among extracts.

It does not reproduce your digestive system, bloodstream, brain tissue, tumour microenvironment, radiation exposure, or chemotherapy response.

An extract can perform strongly in a DPPH assay and still have poor absorption or no clinically meaningful tumour effect.

The 2025 Amalaki study examined antioxidant characteristics as part of extract analysis, but the tumour-related conclusion depended on separate U87-MG cell experiments [117].

Why Antioxidants Can Have Different Effects in Cancer

Oxidative stress is involved in both normal tissue damage and tumour-cell death.

A moderate antioxidant effect may help protect normal cells from excessive injury. However, some cancer treatments partly depend on reactive chemical species to damage tumour cells.

Radiation produces direct DNA damage and also creates reactive oxygen species. Some natural compounds may protect normal tissue, tumour tissue, or both depending on the dose, timing, concentration, and biological setting.

This means that the phrase “antioxidants are always beneficial during cancer treatment” is too simple.

The opposite statement that “all antioxidants must always be stopped” is also too broad.

The exact product, dose, route, treatment stage, and available evidence must be considered.

Food-level Amalaki and a highly concentrated polyphenol or antioxidant extract should not be treated as the same exposure.

What the 2025 Amalaki Glioblastoma Study Examined

The 2025 study compared methanolic, ethanolic, and aqueous extracts of Emblica officinalis fruit against U87-MG human glioblastoma cells [117].

The researchers first examined the total phenolic content and antioxidant characteristics of the extracts.

They also used gas chromatography–mass spectrometry to identify compounds present in the most active preparation.

The methanolic extract contained the highest measured phenolic content among the tested extracts.

It also showed the strongest antiproliferative and antimigratory activity against the U87-MG cells.

The researchers then used this methanolic extract to prepare green-synthesized silver nanoparticles and compared the nanoparticle preparation with the original fruit extract [117].

This was an in-vitro study. It did not include animals, human patients, oral dosing, MRI assessment, or survival outcomes.

Why Three Different Extracts Were Tested

Water, ethanol, and methanol do not remove exactly the same compounds from a plant.

Water extracts many polar and water-soluble constituents. Ethanol can extract a broader mixture of polar and moderately non-polar compounds. Methanol is frequently used in laboratory research because it can extract a wide range of phenolic and other compounds efficiently.

The methanolic extract performed more strongly in the U87-MG experiments [117].

This does not mean that methanol itself should be used as a medicine.

Methanol is a toxic laboratory solvent. It must be completely removed from an experimental extract before biological testing.

A methanolic extract may also contain compounds in proportions that differ from a traditional Amalaki juice, powder, water decoction, or Avaleha.

Therefore, the study supports the potential of a laboratory-prepared fruit extract. It does not establish the clinical effect of traditional Amalaki.

What Total Phenolic Content Means

Phenolic compounds are a broad group of plant chemicals that can influence oxidation, inflammation, cellular stress, enzymes, and signalling pathways.

The methanolic Amalaki extract contained the highest total phenolic content among the three preparations studied [117].

This may partly explain its stronger antioxidant and tumour-cell effects.

However, total phenolic content does not identify which specific compound produced the glioblastoma-cell response.

Two extracts can have similar total phenolic values but contain different individual compounds.

The study used GC–MS to improve chemical characterization, but more detailed isolation and mechanistic research would be needed to identify the compounds mainly responsible for the observed U87-MG effects.

What U87-MG Cells Represent

U87-MG is an established human glioblastoma cell line.

It is widely used because it grows reliably and allows researchers to compare cell viability, migration, drug response, and biological pathways under controlled conditions.

However, one U87-MG model cannot represent every glioblastoma patient.

Your tumour may have a different IDH status, MGMT promoter methylation, EGFR pattern, PTEN status, TERT mutation, CDKN2A/B deletion, treatment history, and mixture of tumour-cell populations.

U87-MG cells growing on a laboratory plate also do not reproduce the blood–brain barrier, immune system, surrounding brain tissue, tumour blood vessels, cerebral edema, hypoxia, surgery, steroids, radiation, or antiseizure medicines.

The study provides direct glioblastoma-cell evidence, but it remains an early screening model.

How the Amalaki Extract Affected Cell Growth

The researchers used an MTT assay to estimate the metabolic activity and viability of the U87-MG cells after exposure to different extract concentrations [117].

All three extracts showed dose-dependent antiproliferative activity. This means that the measured tumour-cell viability generally decreased as the extract concentration increased.

The methanolic extract produced the lowest IC50 among the tested fruit extracts.

An IC50 is the concentration required to reduce the measured cellular response by approximately half under the study conditions.

A lower IC50 generally suggests greater potency within that particular experimental comparison.

It does not show the oral dose required in a patient.

Why the IC50 Cannot Be Converted Directly Into Amalaki Grams

In the laboratory, the extract was placed directly in the liquid surrounding the U87-MG cells.

When you take Amalaki orally, the process is very different.

The constituents must be released from the Avaleha, survive digestion, be absorbed through the intestine, enter the blood, avoid rapid metabolism, reach the brain, enter the tumour, and remain there at a useful concentration.

The amount swallowed is not the same as the amount reaching the tumour.

The IC50 of a methanolic extract cannot therefore be converted directly into grams of Amalaki fruit powder.

A pharmacokinetic study would need to identify the active compounds and measure them in blood, cerebrospinal fluid, normal brain tissue, or tumour tissue.

How the Amalaki Extract Affected Cell Migration

The researchers also used a wound-scratch assay to examine U87-MG cell migration [117].

In this method, an empty space is created across a layer of tumour cells. Researchers then observe how quickly the cells move into the gap.

The methanolic Amalaki extract produced the lowest gap closure among the tested extracts. This means that the treated cells moved less effectively across the laboratory surface.

This finding is relevant because glioblastoma cells can migrate into surrounding brain tissue beyond the visible tumour border.

However, a scratch assay is much simpler than invasion through the human brain.

Glioblastoma cells in your brain interact with white-matter pathways, blood vessels, extracellular structures, immune cells, oxygen gradients, and treatment-damaged tissue.

Reduced movement in a scratch assay supports an antimigratory hypothesis. It does not prove that oral Amalaki stops microscopic glioblastoma invasion.

The Study Did Not Establish the Mechanism of Tumour-Cell Death

The 2025 study was mainly a preliminary screening and nanoparticle-development study [117].

It showed reduced U87-MG viability and migration, but the available findings did not establish a complete mechanism involving apoptosis, autophagy, ferroptosis, mitochondrial damage, DNA injury, or a particular signalling pathway.

The authors concluded that more detailed mechanistic research was required.

This is an important limitation.

It would be inaccurate to claim that Amalaki has already been proven to block EGFR, suppress MGMT, eliminate glioma stem cells, or activate a particular apoptosis pathway based only on this study.

Those mechanisms would need to be tested directly.

The Study Did Not Test Glioma Stem-Like Cells

The U87-MG study did not provide strong direct evidence from patient-derived glioblastoma stem-like cultures [117].

Glioma stem-like cells are being studied because they may contribute to self-renewal, treatment resistance, and recurrence.

Activity in ordinary U87-MG cells cannot automatically be described as elimination of glioma stem cells.

The study also did not examine neurosphere formation, stemness markers, or a broad panel of patient-derived stem-like models.

Amalaki should therefore not be promoted as a proven glioma stem-cell treatment.

The Study Did Not Test Temozolomide Resistance

The 2025 Amalaki research did not establish that the fruit extract changes MGMT promoter methylation or reverses temozolomide resistance [117].

It also did not test a combination of Amalaki extract and temozolomide in a resistant glioblastoma model.

A general antioxidant, antiproliferative, or antimigratory effect is not the same as overcoming MGMT-mediated DNA repair.

You should not be told that Amalaki makes an unmethylated glioblastoma respond like a methylated tumour.

That claim is not supported by the current direct evidence.

Why the Researchers Prepared Silver Nanoparticles

The researchers used the methanolic Amalaki fruit extract to synthesize silver nanoparticles [117].

Plant compounds in the extract helped reduce silver ions into metallic silver nanoparticles and also helped stabilize the resulting particles.

This method is called green synthesis because plant-derived compounds are used instead of some conventional chemical reducing and stabilizing agents.

The purpose was to investigate whether converting silver into an Amalaki-assisted nanoparticle preparation could increase the effect against U87-MG cells.

The resulting particles were characterized through particle-size measurement, zeta potential, FTIR, and scanning electron microscopy.

What the Nanoparticle Size Means

The synthesized silver nanoparticles were reported within an approximate size range of 52.56 to 96.18 nanometres [117].

A nanometre is one-billionth of a metre.

This confirms that the laboratory preparation contained particles within the nanoscale range.

It does not prove that the particles can be swallowed safely, absorbed intact, cross the human blood–brain barrier, accumulate in glioblastoma tissue, or produce a clinical benefit.

Particle size is only one part of nanoparticle behaviour.

Surface charge, shape, aggregation, coating, protein binding, stability, dose, route, and clearance also influence what happens inside the body.

What Zeta Potential Means

Zeta potential gives information about the electrical charge surrounding particles in a liquid.

It is often used to estimate how likely nanoparticles are to remain dispersed or to aggregate.

A reasonably stable zeta-potential result may support the physical stability of a laboratory suspension.

It does not prove biological safety.

A stable silver nanoparticle can still damage normal cells, blood cells, liver tissue, kidneys, or the nervous system depending on its dose and route.

Physical stability and medical safety are separate questions.

Why Silver Nanoparticles May Be More Cytotoxic

Silver nanoparticles can produce cellular stress through several mechanisms.

They may release silver ions, increase reactive oxygen species, damage membranes, disturb mitochondria, interact with proteins, and affect DNA.

These effects can reduce tumour-cell viability.

They may also affect normal cells.

The stronger activity of the Amalaki-assisted silver nanoparticles cannot be attributed only to Amalaki. Metallic silver may have contributed substantially to the cytotoxicity.

The study therefore tested a combined Amalaki-extract–silver nanomaterial rather than a more concentrated form of Amalaki alone.

What the Silver Nanoparticles Did to U87-MG Cells

The Amalaki-assisted silver nanoparticles produced stronger cytotoxic and antimigratory effects than the original methanolic extract under the tested conditions [117].

The reported nanoparticle IC50 against U87-MG cells was approximately 183.1 micrograms per millilitre.

This result shows that the nanoparticle preparation reduced U87-MG viability in vitro.

It does not show that 183.1 milligrams taken by mouth would produce the same effect.

The concentration described the combined nanoparticle material present directly around the cultured cells.

There was no digestive system, bloodstream, blood–brain barrier, tumour distribution, or kidney clearance in the cell-culture experiment.

The Silver-Nanoparticle Study Does Not Prove Selective Tumour Killing

A useful anticancer intervention should affect tumour cells more strongly than essential normal cells.

The U87-MG findings alone cannot establish this selectivity.

Further research would need to compare the nanoparticle preparation with normal human astrocytes, neurons, blood–brain barrier cells, liver cells, kidney cells, bone-marrow cells, and immune cells.

The particles would also require animal toxicology, biodistribution, brain-delivery, clearance, and long-term safety assessment.

Without these steps, stronger U87-MG cytotoxicity cannot be interpreted as a safe treatment.

Amalaki-Derived Silver Nanoparticles Are Not Part of a Traditional Avaleha

Majja-Arbuda Rasayana Avaleha does not become a silver-nanoparticle medicine simply because an Amalaki extract was used to synthesize silver nanoparticles in one study.

The laboratory preparation intentionally combined Amalaki phytochemicals with silver.

Traditional Amalaki fruit powder or decoction does not automatically create silver nanoparticles during Avaleha preparation.

The study should therefore not be used to describe ordinary Amalaki as a nanomedicine.

If a silver-nanoparticle intervention were ever considered clinically, it would require separate pharmaceutical development, material characterization, toxicology, dosing, regulatory review, and clinical trials.

It should not be recreated casually by adding silver or a silver-containing material to an Ayurvedic formula.

The Nanoparticle Study Does Not Prove Blood–Brain Barrier Penetration

The Amalaki-assisted silver nanoparticles were tested only against U87-MG cells in vitro [117].

The study did not administer the particles to an animal or a human.

It did not measure them in blood, cerebrospinal fluid, brain tissue, or tumour tissue.

The particle size alone cannot prove blood–brain barrier penetration.

Some nanoparticles can enter the brain under particular conditions, but their behaviour depends on much more than size.

The correct conclusion is that Amalaki-assisted silver nanoparticles showed in-vitro activity against U87-MG cells and require extensive additional investigation before any brain-delivery claim can be made.

Why the 2025 Study Is Valuable Despite Its Limits

The study has important value because it directly examined Amalaki fruit extracts in a glioblastoma cell model [117].

Before this study, much of the Amalaki cancer research came from other tumour types.

The researchers compared three extraction methods, examined phenolic and antioxidant characteristics, measured U87-MG growth and migration, and developed a separate silver-nanoparticle preparation.

This creates a starting point for future glioblastoma research.

The study does not complete the evidence pathway.

The next steps should include repeated testing by independent laboratories, additional molecularly different glioblastoma cell lines, patient-derived cultures, glioma stem-like cells, normal-brain-cell comparisons, mechanism studies, intracranial animal models, pharmacokinetics, and safety assessment.

Why Research From Other Cancers Must Remain Secondary

Amalaki extracts have been studied in laboratory and animal models of lung, cervical, liver, ovarian, breast, and other cancers [118,119].

Some studies report cell-cycle arrest, apoptosis, autophagy, reduced angiogenesis, or reduced tumour growth.

These findings may help identify possible mechanisms.

They are not direct glioblastoma evidence.

A pathway active in ovarian or lung cancer may not have the same importance in glioblastoma.

The brain’s protective barriers, tumour environment, immune condition, and molecular profile make glioblastoma biologically distinct.

The U87-MG study should therefore remain the main direct tumour reference, while research from other cancers should be used only as supporting background.

Does Amalaki Cross the Blood–Brain Barrier?

The current direct Amalaki glioblastoma study does not answer this question [117].

The cells were exposed directly to the extract and nanoparticles in the laboratory.

The study did not measure Amalaki compounds after oral administration.

Some small polyphenol metabolites may enter brain tissue under selected conditions, while others may be poorly absorbed or rapidly metabolized.

The whole fruit contains many compounds with different pharmacokinetic properties.

It would be inaccurate to state that Amalaki is clinically proven to cross the human blood–brain barrier and kill glioblastoma cells.

Direct evidence would require measurement of identified Amalaki compounds or metabolites in blood, cerebrospinal fluid, resected brain tissue, or glioblastoma tissue.

Amalaki During Temozolomide Treatment

There is no human glioblastoma trial showing that Amalaki improves temozolomide effectiveness.

The 2025 U87-MG study did not test the combination [117].

Temozolomide mainly works by adding methyl groups to tumour-cell DNA. The affected cells may die when they cannot repair the damage successfully.

Amalaki’s antioxidant activity does not automatically mean that it will weaken or strengthen temozolomide.

The final effect may depend on the preparation, dose, timing, tumour biology, and other medicines.

Food-level Amalaki and a concentrated polyphenol extract should not be treated as the same exposure.

A highly concentrated Amalaki supplement should be reviewed with the treating team during temozolomide, particularly when you also take several other herbs or medicines.

Amalaki During Radiation

Radiation produces direct DNA damage and reactive chemical stress within cells.

Amalaki has antioxidant and experimental radioprotective properties in non-glioblastoma models [119].

This creates both a supportive possibility and an important question.

A radioprotective compound may help protect normal tissue. It might also protect some tumour cells if the timing and exposure are not appropriate.

The current evidence does not show that Amalaki improves radiation effectiveness in glioblastoma patients.

It also does not show that ordinary dietary Amalaki causes clinically meaningful protection of tumour cells.

The uncertainty is greater with concentrated extracts than with modest food-level use.

The safest evidence-based approach is to disclose the product and dose, avoid claiming proven radiosensitization or radioprotection, and coordinate concentrated supplementation with the radiation team.

Why Amalaki Should Not Automatically Be Stopped During Oncology Treatment

The existence of antioxidant activity does not prove that every Amalaki fruit or food preparation interferes with treatment.

A normal dietary amount may produce a very different exposure from a concentrated extract, purified polyphenol product, or high-dose vitamin C preparation.

Your nutritional condition also matters.

A weak patient with poor food intake may benefit from nutritious foods, while a high-dose experimental extract may create a different pharmacological question.

The decision should be based on the exact formulation rather than on the word antioxidant alone.

Amalaki and Platelet-Related Medicines

Amalaki extracts may increase the antiplatelet effect of medicines such as aspirin and clopidogrel in some human research [119].

This may increase bleeding risk in a susceptible person.

The issue is especially important before brain surgery, biopsy, or another invasive procedure.

It also matters when your platelet count is already low because of temozolomide or another treatment.

Food-level Amalaki may not produce the same effect as a standardized extract. The exact product and dose must be considered.

Your neurosurgeon and treating doctors should know about every concentrated Amalaki product you are taking.

Amalaki Before and After Surgery

A concentrated Amalaki extract should be reviewed before surgery when you are taking aspirin, clopidogrel, anticoagulants, or have a low platelet count.

After surgery, Amalaki may be considered when swallowing is safe, bleeding has been controlled, digestion is stable, and the surgical team has approved oral medicines.

Fresh sour preparations may irritate the stomach or throat in some patients.

A sweetened Amalaki product may also be unsuitable when steroid treatment has raised your blood sugar.

The form of the medicine should match your postoperative condition.

Amalaki and Blood Sugar

Some human and experimental research suggests that Amalaki extracts may influence blood glucose and metabolic markers [118,119].

This may be relevant when dexamethasone has caused high blood sugar.

However, a patient already taking insulin or glucose-lowering medicine may experience a different response.

The complete Avaleha may also contain sugar, jaggery, honey, or another carbohydrate-rich base.

You should not judge the metabolic effect only from Amalaki’s traditional reputation.

Your fasting glucose, post-meal glucose, and symptoms should be monitored when clinically indicated.

Amalaki and Digestive Tolerance

Amalaki has a strongly sour and astringent taste, although Ayurveda describes its overall effect as cooling and Rasayana.

Some people tolerate it well and find that it supports appetite and bowel regularity.

Others may develop acidity, abdominal discomfort, tooth sensitivity, nausea, or loose stools, especially with concentrated juice or a high dose taken on an empty stomach.

Your digestive condition matters.

A patient with Pitta-related heat may still find a very sour preparation irritating. A weak patient with poor appetite may dislike a strongly astringent powder.

The dose, timing, base, and Anupana may need adjustment.

Amalaki and Constipation or Loose Stools

Amalaki can affect bowel function differently according to the dose and preparation.

Whole fruit, dried powder, Triphala, concentrated extract, and sweetened preserve may not produce the same effect.

A small amount may support regularity in one person, while a larger dose may produce loose stools or abdominal discomfort in another.

Temozolomide, antiemetics, reduced movement, low food intake, and opioid medicines can also affect bowel function.

Your bowel response should be recorded rather than assuming that every change comes from detoxification.

Amalaki and Kidney-Stone Risk

Amalaki naturally contains vitamin C and several acids.

High-dose vitamin C supplementation can increase urinary oxalate in some susceptible people. This may be relevant when you have recurrent calcium-oxalate kidney stones, significant kidney disease, or very high supplemental vitamin C exposure.

Ordinary Amalaki fruit is not automatically equivalent to pharmacological vitamin C dosing.

The total exposure from fruit, extract, supplements, and other medicines should be considered.

A patient with kidney disease should not take large concentrated products without medical review.

Amalaki and Iron Absorption

Vitamin C can improve the absorption of non-heme iron from food.

This may be helpful when you have iron deficiency and poor dietary intake.

It may be less appropriate when you have an iron-overload disorder or have been instructed to restrict iron absorption.

The effect of Amalaki on iron status will depend on its vitamin C content, processing, dose, meal timing, and your underlying condition.

It should not replace investigation of anaemia caused by blood loss, bone-marrow suppression, nutritional deficiency, kidney disease, or chronic illness.

Amalaki and Liver Safety

Amalaki is widely consumed as food and is generally tolerated by many people.

However, general food use does not establish the safety of every concentrated extract, nanoparticle preparation, or multi-ingredient Avaleha.

The direct glioblastoma study did not examine human liver safety [117].

Temozolomide, antiseizure medicines, antibiotics, and other Ayurvedic ingredients may also affect the liver.

Your liver monitoring should therefore be based on the complete treatment plan rather than on Amalaki alone.

A claim that Amalaki is hepatoprotective should not be used to ignore rising liver enzymes or jaundice.

Amalaki and the Immune System

Amalaki is frequently promoted as an immunity booster.

This description is too general for glioblastoma.

The immune system includes many different cells and signalling pathways. Glioblastoma creates a complex immune-suppressive environment, while steroids and temozolomide may further alter immunity.

An antioxidant or anti-inflammatory effect does not automatically improve antitumour immune recognition.

Amalaki may support general nutrition and recovery, but it should not be described as a proven way to activate immune cells against glioblastoma.

If you are receiving an immune-based clinical trial, vaccine, checkpoint inhibitor, or cellular therapy, every concentrated herbal product should be disclosed to the research team.

Fresh Amalaki, Dried Powder, Juice, and Extract Are Different

Fresh Amalaki provides water, fibre, acids, vitamins, tannins, and other natural constituents.

Dried powder contains less water and may provide a more concentrated amount of some compounds by weight. Drying and storage may reduce or alter heat-sensitive constituents.

Juice provides soluble compounds but less fibre.

A standardized extract may concentrate selected tannins or polyphenols.

A methanolic laboratory extract may contain a chemical profile that cannot be reproduced through ordinary dietary use.

These preparations should not share one general dose or one evidence statement.

How Avaleha Processing May Change Amalaki

Avaleha preparation commonly involves heating, concentration, and mixing with a sweetening or lipid-containing base.

Heat, oxygen, light, moisture, and pH can affect vitamin C and other Amalaki constituents.

Tannins and polyphenols may behave differently from vitamin C during processing.

If Amalaki is used in the decoction, some compounds may be extracted and others may be reduced during prolonged heating.

If fine fruit powder or extract is added at a later stage, more of some heat-sensitive constituents may remain.

The manufacturing record should state the form used, stage of addition, temperature, final moisture, and storage conditions.

How the Amalaki Dose in the Avaleha Should Be Calculated

The total amount of Amalaki used in the complete batch should be recorded.

Suppose a 900-gram finished Avaleha contains 90 grams of authenticated Amalaki fruit material.

Amalaki would represent 10% of the final formulation.

If you take 30 grams of Avaleha daily, your estimated whole-fruit exposure would be approximately 3 grams per day.

This does not mean that you receive 3 grams of vitamin C, 3 grams of phenolic compounds, or 3 grams of methanolic extract.

It also does not mean that you receive the silver nanoparticles used in the 2025 study.

The actual exposure to marker compounds depends on the raw material, preparation, extraction, processing, and final batch composition.

Why Extract Equivalence Must Be Reported

If a standardized extract is used, the extraction ratio should be stated.

For example, one gram of a 10:1 extract may represent approximately ten grams of starting plant material, although the final chemical equivalence depends on the extraction method and marker compounds.

An extract standardized to total tannins cannot automatically be compared with an extract standardized to vitamin C.

If the direct U87-MG research is cited, the formulation should clearly state whether it contains whole fruit, water extract, hydroalcoholic extract, or another preparation.

A traditional Avaleha containing whole Amalaki should not be described as equivalent to the methanolic research extract.

Which Marker Compounds Should Be Tested?

Quality testing may include vitamin C, gallic acid, ellagic acid, total phenolic content, total tannins, or selected emblicanin-related markers.

The selected markers should reflect the actual preparation and manufacturing purpose.

Vitamin C alone cannot confirm the complete identity or biological activity of Amalaki.

Total phenolic content alone also cannot identify every active constituent.

A chemical fingerprint can help compare one batch with another and reduce the risk of substitution or major variation.

What Must Be Documented in the Finished Formulation

The batch record should identify the accepted botanical name Phyllanthus emblica L. and may also state the recognized synonym Emblica officinalis Gaertn.

It should confirm that the fruit was used and distinguish it from Bhumi Amalaki and other Phyllanthus species.

The record should state whether the ingredient is fresh fruit, dried fruit powder, juice, decoction material, aqueous extract, hydroalcoholic extract, standardized extract, or another preparation.

The amount placed in the batch, final formulation weight, estimated daily exposure, stage of addition, and selected marker content should be documented wherever possible.

Botanical authentication, microbial testing, pesticide testing, aflatoxin testing, and inappropriate elemental-contamination testing should also form part of quality control.

Where Amalaki Fits in Majja-Arbuda Rasayana Avaleha

Amalaki fits most clearly within the Rasayana, nourishment, recovery, metabolic-support, and Pitta-balancing group.

Its classical description supports long-term restoration, Tridosha balance, strength, and selected blood and metabolic functions [43,44].

It may also have a secondary place within the tumour-directed research group because methanolic, ethanolic, and aqueous fruit extracts reduced U87-MG cell viability, while the methanolic extract showed the strongest antiproliferative and antimigratory activity in the 2025 study [117].

The silver-nanoparticle component of that study should remain separate.

It does not support adding silver nanoparticles to an Avaleha or calling traditional Amalaki a nanomedicine.

A third role may relate to antioxidant and nutritional support, but this requires careful timing and dose consideration during radiation and chemotherapy.

How Your Response Should Be Monitored

If Amalaki is used mainly for Rasayana and recovery, relevant outcomes include appetite, digestion, bowel function, fatigue, body weight, treatment tolerance, blood sugar, hydration, and daily activity.

If it is included partly for tumour-directed research, improvement in appetite or energy cannot prove tumour response.

MRI findings, neurological status, steroid dose, surgery, radiation, temozolomide, seizure control, and treatment timing must be reviewed together.

Platelet count, bleeding tendency, blood sugar, kidney function, digestive tolerance, and medicine interactions may also require monitoring according to your condition.

Current Evidence Verdict for Amalaki

Classical Ayurvedic support is strong for Amalaki as a Rasayana, nourishing, cooling, and Tridosha-balancing fruit [43,44].

Its traditional role may be relevant to long-term recovery, strength, Pitta balance, metabolic support, and treatment-related depletion.

Direct preclinical glioblastoma evidence is present but very early. A 2025 study found that methanolic, ethanolic, and aqueous Amalaki fruit extracts reduced U87-MG cell viability in a dose-dependent manner [117].

The methanolic extract had the highest measured phenolic content, produced the lowest IC50 among the tested fruit extracts, and showed the strongest antimigratory effect in the wound-scratch assay [117].

The researchers used this methanolic extract to prepare silver nanoparticles measuring approximately 52.56 to 96.18 nanometres. The nanoparticle preparation produced stronger cytotoxic and antimigratory activity, with a reported IC50 of approximately 183.1 micrograms per millilitre against U87-MG cells [117].

This nanoparticle result reflects a combined Amalaki-extract and silver intervention. It cannot be attributed to Amalaki alone.

The study used one established glioblastoma cell line. It did not include patient-derived glioblastoma cultures, glioma stem-like cells, intracranial animal models, pharmacokinetic testing, human tumour-tissue measurement, or clinical outcomes.

It did not establish the mechanism of cell death, selective safety for normal brain cells, temozolomide sensitization, MGMT modification, radiation response, recurrence prevention, or improved survival.

Human evidence showing that Amalaki shrinks glioblastoma, delays recurrence, improves progression-free survival, or extends overall survival is not established.

Human studies in other conditions support some metabolic, antioxidant, and cardiovascular effects, but these cannot be presented as direct glioblastoma evidence [118,119].

Concentrated Amalaki extracts may increase antiplatelet effects when combined with aspirin or clopidogrel and may require caution before surgery or when platelet counts are low [119].

Its strong antioxidant activity creates an important but unresolved question during radiation and chemotherapy. Food-level use and concentrated pharmacological extracts should not be treated as equivalent.

What Amalaki Evidence Means for You

Amalaki has a credible and important place in an individualized Ayurvedic glioma plan, particularly within Rasayana, recovery, nutrition, metabolic support, and Pitta-balancing care.

It also now has direct preliminary laboratory evidence in U87-MG glioblastoma cells.

That research is valuable because it begins to move Amalaki evidence from general cancer claims toward a brain-tumour-specific model.

The evidence is still at an early stage.

Whole Amalaki fruit is not equivalent to a methanolic extract. The methanolic extract is not equivalent to Amalaki-assisted silver nanoparticles. A small amount in an Avaleha cannot be assumed to reproduce the concentrations used in a cell-culture experiment.

Amalaki should therefore be used with verified botanical identity, clear fruit preparation, realistic dose comparison, marker-compound testing where possible, attention to antiplatelet medicines and surgery, and careful review of concentrated antioxidant use during radiation or chemotherapy.

Its supportive Rasayana benefits and experimental tumour-directed evidence should remain separate until stronger animal and human glioblastoma research becomes available.

Swarna Bhasma, Abhraka Bhasma, and Other Bhasmas for Glioma and Glioblastoma: Nanoparticle Evidence, Safety, and Clinical Limits

Swarna Bhasma and Abhraka Bhasma are among the most discussed Ayurvedic mineral preparations in Rasayana treatment. They are often described as powerful, deep-acting, and capable of reaching tissues that ordinary herbal medicines may not reach easily.

These descriptions require careful interpretation when you have glioma or glioblastoma.

Modern laboratory studies have shown that some properly prepared and tested bhasma samples contain very small mineral or metallic structures, including particles within the nanoscale range [121–125]. This is scientifically important because it helps explain the physical and chemical changes produced through repeated Ayurvedic processing.

However, particle size alone does not prove that a bhasma is absorbed through your intestine, enters your blood unchanged, crosses the human blood–brain barrier, accumulates inside glioblastoma tissue, or destroys tumour cells.

A bhasma should therefore not be called a proven brain-targeting nanomedicine only because one laboratory image shows nanosized particles.

Its raw material, purification, incineration, chemical form, particle distribution, dissolution, absorption, organ distribution, dosage, safety, and actual clinical outcomes must all be examined.

What Is a Bhasma?

A bhasma is a specially processed Ayurvedic preparation made from a metal, mineral, shell, gemstone-related material, or another inorganic substance.

The original raw substance is not simply ground into powder and given to you.

Classical preparation may involve Shodhana, which refers to purification and processing, followed by Bhavana, repeated grinding with specified herbal liquids, Marana, controlled incineration, and repeated heating cycles known as Puta.

The final material is expected to have physical and chemical properties that differ from the original raw metal or mineral.

This difference is important.

Raw metallic gold is not the same as Swarna Bhasma. Raw mica is not the same as Abhraka Bhasma. A raw diamond fragment is not the same as a properly prepared Heeraka Bhasma.

The name of the original material cannot prove the identity, safety, or action of the final medicine. The final processed batch must be tested.

The Classical Rule of Correct Processing and Correct Use

The following classical principle is especially important when discussing bhasma, concentrated extracts, and powerful multi-ingredient formulations.

Book: Charaka Samhita
Section: Sutra Sthana
Chapter: Dirghanjivitiya Adhyaya, Chapter 1
Text number: 1/126

योगादपि विषं तीक्ष्णमुत्तमं भेषजं भवेत् ।
भेषजं चापि दुर्युक्तं तीक्ष्णं सम्पद्यते विषम् ॥१२६॥

Transliteration

Yogād api viṣaṁ tīkṣṇam uttamaṁ bheṣajaṁ bhavet |
Bheṣajaṁ cāpi duryuktaṁ tīkṣṇaṁ sampadyate viṣam ||126||

English translation

Even a highly toxic substance may become a useful medicine when it is correctly prepared and properly used. In contrast, even a medicine may become harmful like poison when it is incorrectly prepared or improperly administered.

Urdu translation

درست تیاری اور صحیح استعمال سے ایک شدید زہریلا مادہ بھی مفید دوا بن سکتا ہے، جبکہ غلط تیاری یا نامناسب استعمال سے اچھی دوا بھی زہر جیسا نقصان پہنچا سکتی ہے۔

Arabic translation

قد تتحول مادة شديدة السمية إلى دواء نافع إذا حُضّرت واستُعملت بطريقة صحيحة، وقد يصبح الدواء نفسه مؤذياً كالسُّم إذا أسيء تحضيره أو استعماله.

This verse does not mean that every toxic material becomes safe merely because it is called Ayurvedic.

Its meaning is that identity, processing, dose, combination, timing, patient selection, and supervision determine whether a strong substance becomes medicine or harm [41].

For bhasma use in glioma, this principle requires modern confirmation through batch testing, toxicology, organ-function monitoring, and transparent documentation.

Why Bhasma Processing Must Be Reproducible

A bhasma may change according to the raw material, purification liquid, grinding duration, herbal media, heating temperature, furnace design, number of Puta, cooling process, particle aggregation, and storage.

Two products carrying the same name may therefore have different physical and chemical characteristics.

One Swarna Bhasma batch may contain mainly metallic gold. Another may contain gold mixed with oxides, sulphides, phosphates, silicates, or residues from the processing materials.

One Abhraka Bhasma may contain highly altered mica structures. Another may remain closer to insufficiently processed raw mica.

This is why classical tests alone are not enough for a modern glioblastoma evidence article.

Traditional tests may help assess colour, fineness, lustre, floatability, and completion of processing. Modern analytical methods are needed to determine what the finished material actually contains.

What Is Swarna Bhasma?

Swarna Bhasma is a processed gold-based Ayurvedic preparation.

It is traditionally used within selected Rasayana, Balya, Medhya, and long-term restorative strategies. It may be considered when a patient has severe depletion, reduced strength, chronic illness, poor recovery, or a need for carefully supervised Rasayana support.

This classical use does not prove that Swarna Bhasma treats glioblastoma.

Its possible role in a glioma formulation must be separated into classical supportive reasoning, material-characterization evidence, safety evidence, and direct tumour evidence.

At present, the strongest modern published evidence relates mainly to the physical and chemical characterization of individual Swarna Bhasma samples [121–123].

Direct human evidence showing glioblastoma shrinkage, recurrence prevention, or longer survival from Swarna Bhasma is not established.

What One Swarna Bhasma Nanostructure Study Found

A modern analytical study examined a specifically prepared Swarna Bhasma sample and found nanoscale gold-containing structures [121].

The researchers used methods such as electron microscopy, X-ray diffraction, elemental analysis, and related material-characterization techniques.

The tested sample contained highly crystalline gold structures, many of which were within a small particle-size range.

This finding is important because it shows that repeated Ayurvedic processing can produce a material containing structures much smaller than ordinary visible gold particles.

It supports the statement that one analysed Swarna Bhasma batch contained nanostructured gold.

It does not prove that every Swarna Bhasma product has the same particle size, chemical composition, purity, or biological behaviour.

Why One Tested Sample Cannot Represent Every Swarna Bhasma

The result of reference [121] applies to the specific material prepared and analysed in that study.

A commercial product prepared through another method may differ.

The number of heating cycles may be different. The raw gold may have different purity. The herbal processing media may differ. The grinding and furnace temperature may not be the same.

Even when two manufacturers follow a broadly similar classical method, small differences may change the final particle shape, aggregation, surface chemistry, and elemental composition.

Therefore, Panaceayur cannot cite one published Swarna Bhasma sample and claim that every batch used in its formulation is physically identical.

The actual clinical batch or a validated representative batch must be tested.

Particle Size Is Not the Same as Oral Absorption

A particle may measure five, ten, or twenty nanometres under an electron microscope and still fail to enter your bloodstream after oral administration.

Inside an Avaleha and inside your digestive tract, particles may form clusters or aggregates.

They may bind with proteins, sugars, fats, salts, plant compounds, or digestive material.

Stomach acid and intestinal fluids may partially dissolve or chemically transform them.

Some material may remain insoluble and leave your body through the stool.

Therefore, the size of an isolated dry particle does not reveal the size or chemical form that reaches your intestinal wall.

Absorption must be measured directly.

What Blood Compatibility Research Can Show

One preliminary study examined the physicochemical properties and blood compatibility of a Swarna Bhasma sample [123].

Blood-compatibility testing may examine whether a material causes obvious red-cell damage, abnormal clotting, or other immediate blood-related reactions under laboratory conditions.

This type of study can provide early safety information.

It does not prove long-term safety after repeated oral use.

It also does not prove that the material enters your blood, reaches the brain, or selectively affects tumour cells.

A material may appear compatible with blood in vitro and still accumulate in an organ, alter immune activity, or produce delayed toxicity.

Does Swarna Bhasma Cross the Blood–Brain Barrier?

The current evidence does not establish that orally administered Swarna Bhasma reaches human glioblastoma tissue at a therapeutic concentration.

To prove this claim, researchers would need to identify the exact gold-containing form in the blood after oral administration and then measure it in cerebrospinal fluid, normal brain tissue, or resected tumour tissue.

The study would also need to distinguish intact particles from dissolved gold ions, protein-bound gold, or other transformed chemical forms.

Material characterization under a microscope cannot answer these questions.

The scientifically correct statement is that selected Swarna Bhasma samples contain nanoscale gold structures. Human absorption, brain distribution, tumour accumulation, and glioblastoma effectiveness remain separate research questions.

Nano-Sized Does Not Automatically Mean Nano-Medicine

A nanomaterial is generally defined partly by its small physical dimensions.

A nanomedicine is a therapeutic product designed and tested for a specific medical use, with known composition, dose, distribution, safety, and clinical effect.

A bhasma may contain nanoscale structures without meeting the complete modern evidence requirements of a clinically validated nanomedicine.

The MIRIBEL reporting recommendations explain that meaningful bio-nano research should report particle identity, size distribution, shape, surface chemistry, charge, aggregation, purity, dose, biological medium, and experimental conditions [54].

A single average particle-size number is not enough.

The material may contain a mixture of nanoscale particles, larger particles, aggregates, dissolved ions, and herbal residues.

Why Particle Distribution Matters More Than One Average Number

A report may state that the average particle size is twenty nanometres.

This does not mean that every particle is twenty nanometres.

Some may be five nanometres. Others may be fifty, one hundred, or several hundred nanometres. Some may be present as large clusters.

A wide particle distribution can change absorption and safety.

Very small particles may interact with cells differently from larger particles. Aggregated particles may behave more like ordinary coarse material.

The full particle-size distribution should therefore be reported rather than only one average value.

Why Surface Chemistry Matters

The surface of a particle is the part that first contacts digestive fluid, proteins, cell membranes, blood, and tissues.

Two particles made mainly of gold may behave differently when their surfaces carry different herbal compounds, salts, oxides, sulphides, or proteins.

Surface chemistry can affect aggregation, absorption, immune recognition, tissue distribution, and clearance.

Repeated Bhavana with herbal liquids may leave plant-derived compounds associated with the particle surface.

This may be scientifically important, but it must be measured rather than assumed.

What Chemical Speciation Means

Elemental analysis may show that a product contains gold, iron, silicon, aluminium, or another element.

This does not tell you the exact chemical form.

Gold may be present as metallic gold, a salt, an oxide-related structure, or another compound.

Iron may be present as iron oxide, sulphide, silicate, or a mixture.

The biological effect and toxicity of an element can change greatly according to its chemical form.

Chemical speciation is therefore more informative than simply reporting the total percentage of an element.

What Is Abhraka Bhasma?

Abhraka Bhasma is prepared from mica, traditionally selected and processed through purification, grinding, herbal treatment, and repeated incineration.

Mica is a layered mineral. It may contain silicon, aluminium, iron, magnesium, potassium, and other elements depending on the source and variety.

Classical Ayurveda describes different types of Abhraka and places importance on selecting the correct variety and completing proper processing.

Abhraka Bhasma is traditionally used in selected Rasayana, respiratory, digestive, neurological, and strength-supporting strategies.

These classical uses do not prove that Abhraka Bhasma treats glioblastoma.

The modern evidence discussed here concerns mainly material characterization rather than tumour control [124,125].

What the Abhraka Nanoparticle Study Found

One study examined a Krishna Vajra Abhraka Bhasma sample prepared from biotite mica [124].

The researchers used modern techniques to examine structural and chemical changes created by Ayurvedic processing.

They reported that the final preparation contained small mineral structures and differed from the original raw mica.

Repeated processing reduced the size, altered the layered mineral structure, and changed the physicochemical characteristics of the material.

This supports the conclusion that Abhraka Bhasma is not simply raw mica powder.

It does not establish oral absorption, human brain penetration, glioblastoma activity, or long-term clinical safety.

Why Mica Nanoparticles Are Not Automatically Bioavailable

Mica-related particles may contain silicon, aluminium, iron, magnesium, and potassium in tightly bound mineral structures.

The presence of small particles does not mean that all these elements are released and absorbed.

Some may remain within poorly soluble silicate structures.

Others may partially dissolve under digestive conditions.

The body may absorb certain ions while leaving much of the particle behind.

A material can therefore be nanosized but still have low systemic absorption.

Dissolution and pharmacokinetic studies are needed to determine what enters the body.

Why Abhraka Processing Must Be Complete

Insufficiently processed mica may retain coarse, sharp, or poorly transformed mineral fragments.

This may affect digestibility, absorption, and safety.

Repeated classical incineration is intended to produce a fine, non-lustrous, altered material.

Modern testing can help confirm whether the final sample still contains large crystalline mica sheets or whether significant structural transformation has occurred.

A product should not be accepted only because the label states that it is Sahasraputi or processed through a large number of Puta.

The claimed process should be supported by manufacturing records and finished-product analysis.

Does Abhraka Bhasma Have Direct Glioblastoma Evidence?

The current core reference bank does not establish direct human or strong preclinical glioblastoma evidence for Abhraka Bhasma.

The material-characterization studies explain what selected Abhraka preparations may contain [124,125].

They do not show that Abhraka Bhasma kills glioblastoma cells, sensitizes tumours to temozolomide, reduces cerebral edema, or improves survival.

If Abhraka is included in Majja-Arbuda Rasayana Avaleha, its main defensible position is within a classical Rasayana, strength, Agni, or recovery framework.

Any tumour-directed claim requires separate experimental evidence using the actual tested preparation.

What About Heeraka Bhasma?

Heeraka Bhasma is a processed diamond-related Ayurvedic preparation.

Its classical reputation may lead some practitioners to include it in difficult, chronic, or severe conditions.

However, the name diamond does not prove that the final preparation behaves as a modern diamond nanoparticle medicine.

The current reference bank does not provide direct human glioblastoma evidence for Heeraka Bhasma.

It also does not establish that oral Heeraka Bhasma crosses the blood–brain barrier, enters glioblastoma tissue, destroys tumour stem-like cells, or improves survival.

If Heeraka Bhasma is used, the actual batch requires separate characterization.

The raw material identity, purification, Marana method, carbon structure, particle size, elemental impurities, surface chemistry, dose, and organ safety must be documented.

A high price or rare raw material is not evidence of clinical effectiveness.

What About Rajata Bhasma?

Rajata Bhasma is a processed silver-based preparation.

Silver nanoparticles have shown antimicrobial and cytotoxic activity in many laboratory models. This does not prove that Rajata Bhasma is identical to a laboratory-designed silver nanoparticle.

The particle composition, surface coating, oxidation state, aggregation, and dose may differ greatly.

The current core references do not establish direct human glioblastoma benefit from Rajata Bhasma.Silver-containing materials also require careful safety assessment because excessive or prolonged silver exposure may accumulate in tissues. A study involving Amalaki-assisted silver nanoparticles cannot be used as evidence for Rajata Bhasma. These are different materials prepared through different methods.

Why One Bhasma Cannot Be Used as Evidence for Another

Swarna Bhasma, Rajata Bhasma, Abhraka Bhasma, Heeraka Bhasma, and other bhasmas contain different elements and chemical structures.

A gold-material study cannot prove the behaviour of mica or diamond-related material.

An Abhraka particle-size study cannot establish Swarna absorption.

A silver-nanoparticle cancer experiment cannot prove the effect of Rajata Bhasma.

Each bhasma requires its own evidence pathway.

The exact product being administered must match the material being cited.

Why Oral Bhasma Research Must Include Digestion

Many nanomaterial experiments place particles directly onto cells.

This route avoids the digestive system.

When you take a bhasma orally, it passes through stomach acid, digestive enzymes, bile, intestinal mucus, food, microbes, and other ingredients in the Avaleha.

These conditions may change the particle.

The material may dissolve partly, aggregate, bind proteins, or form a new surface layer.

A tumour-cell experiment using particles directly in culture cannot reproduce this process.

Oral bioavailability studies are essential before cell-culture concentrations can be connected with a clinical dose.

What a Protein Corona Means

When a particle enters blood or another biological fluid, proteins and other molecules may attach to its surface.

This new coating is called a protein corona.

The body may respond to the coated particle differently from the original material examined in a dry laboratory sample.

The corona can affect which cells recognize the particle, where it travels, how long it remains in the blood, and whether the immune system removes it.

A claim based only on the original particle surface may therefore become inaccurate after the material enters the body.

Why Avaleha Ingredients May Change Bhasma Behaviour

Majja-Arbuda Rasayana Avaleha may contain ghee, honey, sugar, plant powders, extracts, tannins, proteins, acids, salts, and many other compounds.

These can interact with bhasma particles.

They may change aggregation, dissolution, surface coating, intestinal contact, and absorption.

Pippali or piperine may also influence drug transport or metabolism, but this does not prove improved absorption of intact mineral particles.

The complete Avaleha may therefore behave differently from the isolated bhasma.

This is another reason why the finished formulation requires its own research.

Why Nano Claims Require Direct Brain-Delivery Evidence

A convincing brain-delivery study should measure the material after oral administration.

Blood should be tested at defined times. Brain and tumour tissue should be analysed using methods that can distinguish the original particle from dissolved or transformed forms.

The study should compare normal brain tissue, tumour tissue, liver, kidneys, spleen, blood, and excretion.

It should also examine whether the concentration in the tumour is high enough to produce the effect seen in laboratory studies.

Without these measurements, the statement that a bhasma enters glioblastoma tissue remains a hypothesis.

Why Material Presence Does Not Prove Therapeutic Action

Even when a gold-containing or mineral-containing substance is detected in brain tissue, this does not prove that it is helping.

It may be present at a concentration too low to affect tumour cells.

It may remain outside the tumour cells.

It may enter normal brain tissue as well as tumour tissue.

It may accumulate without producing benefit.

The study must connect tissue concentration with a measurable biological and clinical outcome.

Why Contaminant Testing Is Essential

Some Ayurvedic medicines intentionally contain processed metals or minerals. Others are intended to be purely herbal.

Both types require testing.

Studies of Ayurvedic products sold commercially or through the internet have found that some products contained lead, mercury, arsenic, or other metals at concerning levels [127,128].

These studies do not prove that every Ayurvedic bhasma is unsafe.

They show that product quality varies and that the word Ayurvedic cannot replace laboratory testing.

A properly designed product should disclose whether an element is an intentional, processed ingredient or an unintended contaminant.

Intentional Mineral Content Is Not the Same as Contamination

If Swarna Bhasma is intentionally added, the presence of gold is expected.

If a purely herbal product contains unexpected lead, mercury, or arsenic, this may represent contamination, adulteration, environmental exposure, or manufacturing failure.

Even an intentional bhasma must be tested for unwanted elements.

For example, a gold-based preparation may still contain lead or mercury from raw materials, processing equipment, or cross-contamination.

The full elemental profile matters.

Why Total Elemental Content Is Not Enough

An elemental test may show the total amount of lead, mercury, arsenic, cadmium, gold, silver, iron, aluminium, or another element.

The health effect can depend on chemical form, solubility, dose, and duration.

Some forms are more easily absorbed than others.

However, low solubility should not be used as a reason to ignore a high total amount.

Repeated daily use may create gradual exposure.

Both total content and chemical speciation should therefore be evaluated wherever technically possible.

Which Modern Tests Are Needed for a Bhasma Batch?

A serious bhasma quality dossier should identify the raw material and describe the complete preparation process.

X-ray diffraction can help identify crystalline phases. Scanning or transmission electron microscopy can examine particle shape and size. Energy-dispersive X-ray analysis can estimate elemental composition in selected particles.

ICP-MS or ICP-OES can measure total elemental content with high sensitivity. Particle-size analysis can examine distribution in suspension. Zeta potential can provide information about surface charge and aggregation tendency.

Dissolution testing can examine what happens in simulated gastric and intestinal fluids. Surface-chemistry analysis can help identify coatings and processing-related compounds.

Microbial testing, pesticide testing, aflatoxin testing, and stability testing remain necessary because the bhasma is being used inside a multi-ingredient herbal formulation.

Why Elemental Impurity Limits Matter

International pharmaceutical guidance provides principles for evaluating elemental impurities that may create toxicological risk [55].

These limits were not written specifically for classical bhasmas.

They still provide a useful modern safety framework when a formulation may expose you to metals or minerals repeatedly.

The daily dose matters more than the percentage alone.

A small concentration taken in a large daily amount may create meaningful exposure. A higher concentration taken rarely may create another risk pattern.

The calculation should therefore report the amount of each important element delivered per day.

How the Daily Bhasma Dose Should Be Calculated

The batch record should state exactly how much Swarna, Abhraka, Heeraka, Rajata, or another bhasma was added.

Suppose a 900-gram Avaleha contains 900 milligrams of Swarna Bhasma.

Swarna Bhasma would represent 0.1% of the final formulation.

If you take 30 grams of Avaleha daily, your calculated Swarna Bhasma exposure would be approximately 30 milligrams per day.

This example is only mathematical. It is not a recommended dose.

The actual prescription must use its own batch quantity, daily Avaleha dose, patient weight, treatment duration, formulation design, and safety assessment.

The calculation should also state the total elemental gold and any other relevant elements measured in the finished batch.

Why Body Weight Alone Cannot Determine the Dose

A heavier person does not automatically require more bhasma.

Your age, digestive tolerance, liver function, kidney function, blood counts, neurological status, treatment phase, medicines, and duration of use may matter more than body weight alone.

A frail older patient may tolerate less than a younger patient of the same weight.

A patient with reduced kidney function may require greater caution even at a small dose.

The dose should not be increased only because the disease is aggressive.

A stronger disease does not make an unsafe exposure safe.

Can Bhasma Be Used During Temozolomide?

The current evidence does not establish that Swarna, Abhraka, Heeraka, or Rajata Bhasma improves temozolomide effectiveness in glioblastoma patients.

The direct combination evidence available for certain herbs, such as piperine or bacoside A, cannot be transferred to bhasma.

If a bhasma is used during temozolomide, its main role should be stated honestly.

It may be included within a classical Rasayana or strength-support strategy. Any tumour-directed claim remains investigational unless the exact preparation has been tested with temozolomide in suitable models.

Temozolomide can reduce blood counts and affect liver function [144]. The complete Ayurvedic formulation should therefore not add unexplained haematological or organ toxicity.

Why Bhasma Should Not Delay Standard Treatment

Material-characterization studies do not establish that bhasma can replace surgery, radiation, temozolomide, targeted treatment, or another clinically indicated therapy.

If your tumour requires urgent surgery or radiotherapy, those decisions should not be delayed while waiting for a bhasma-based formulation.

Ayurveda may be integrated according to your condition and treatment phase.

The existence of nanoscale structures does not convert a laboratory material study into a clinical glioblastoma treatment trial.

Possible Liver and Kidney Concerns

The liver and kidneys help process and remove many absorbed substances.

Some mineral or metallic materials may accumulate in the liver, kidneys, spleen, or other tissues.

The risk depends on the chemical form, particle size, solubility, dose, frequency, and duration.

A short laboratory safety study cannot prove safety over several months.

If bhasma is used during glioblastoma treatment, baseline liver and kidney function should be available. Repeat testing should be performed according to dose, duration, concurrent medicines, and clinical risk.

Why Blood Counts Should Be Monitored

Temozolomide can reduce platelets, neutrophils, and lymphocytes [144].

A complex Ayurvedic formulation should not make this problem more difficult to detect.

Regular CBC monitoring helps show whether the patient is developing bone-marrow suppression, infection risk, anaemia, or bleeding risk.

A drop in blood counts should not be described as the tumour releasing toxins.

It requires medical assessment.

Possible Neurological Symptoms Must Not Be Ignored

New confusion, worsening weakness, tremor, poor balance, repeated vomiting, severe headache, reduced consciousness, or seizures may result from cerebral edema, tumour progression, infection, electrolyte disturbance, medicine toxicity, or another emergency.

They should not automatically be attributed to bhasma adjustment or detoxification.

A bhasma-containing medicine should be paused and reviewed when a serious unexplained neurological change occurs.

Urgent neurological evaluation may be required.

When a Bhasma-Containing Formula May Need to Be Paused

The formulation should be reviewed when you develop acute kidney injury, marked liver-enzyme elevation, jaundice, severe vomiting, inability to swallow, an allergic reaction, major blood-count decline, unexplained neuropathy, new cardiac symptoms, or another suspected toxicity.

It should also be reconsidered before emergency surgery or during a severe infection.

A product suitable during stable recovery may not remain suitable during an acute medical event.

Why Pregnancy and Children Require Separate Evidence

A bhasma should not be assumed safe in pregnancy or childhood because adults have used it traditionally.

Developing organs may respond differently to metals, minerals, and nanoparticles.

Paediatric gliomas also differ biologically from adult glioblastoma.

A child should not receive an adult bhasma formula simply because both conditions are called glioma.

Separate paediatric dosing, toxicology, tumour biology, and clinical evidence are required.

Why Long-Term Use Needs More Evidence

Glioma care may continue for months or years.

A material that appears tolerable for a few weeks may behave differently after repeated exposure.

Long-term studies should examine accumulation, elimination, neurological safety, immune effects, liver function, kidney function, blood counts, and reproductive safety where relevant.

The absence of an immediate adverse effect does not prove that the product cannot accumulate.

Duration should therefore be defined rather than prescribing indefinitely without reassessment.

Where Swarna Bhasma May Fit in Majja-Arbuda Rasayana Avaleha

Swarna Bhasma may fit primarily within a classical Rasayana, Bala, Ojas, recovery, and long-term restorative framework.

Its material-characterization studies show that specific preparations can contain nanostructured gold [121–123].

This gives a modern scientific basis for studying the finished material more closely.

It does not provide direct evidence of glioblastoma control.

If Swarna Bhasma is included, its purpose should not be described as proven brain-tumour penetration unless the actual formulation has direct distribution evidence.

Where Abhraka Bhasma May Fit in the Avaleha

Abhraka Bhasma may fit within a classical Rasayana, Agni, strength, respiratory, or recovery group depending on the patient and formulation philosophy.

Modern studies show that proper processing can alter mica into a much finer and structurally different material [124,125].

These findings support product characterization.

They do not establish a direct glioblastoma mechanism.

The reason for including Abhraka should therefore remain connected with the exact classical and clinical purpose rather than an unsupported claim that mica nanoparticles kill the tumour.

Where Heeraka or Rajata Bhasma May Fit

Heeraka and Rajata should not be included only because they are considered rare, expensive, or powerful.

Their role should be stated according to classical rationale, patient condition, and available modern evidence.

At present, direct human glioblastoma evidence is not established in the core reference bank.

If Panaceayur wishes to make tumour-directed claims, the exact preparations should first be characterized and tested in suitable glioblastoma models.

Until then, their role should be described as classical and investigational.

Why the Final Avaleha Must Be Tested, Not Only the Separate Bhasma

A safe bhasma certificate does not prove that the finished Avaleha remains chemically unchanged.

The bhasma may be added while the formulation is warm. It may contact acids, tannins, sugars, ghee, honey, piperine, curcumin, and many other compounds.

These conditions may change particle aggregation or chemical form.

The final formulation should therefore be examined for elemental distribution, batch consistency, microbial safety, stability, and appropriate marker compounds.

How Your Response Should Be Monitored

If bhasma is used mainly within a Rasayana and recovery strategy, useful outcomes include strength, appetite, body weight, fatigue, daily activity, neurological recovery, and ability to complete treatment.

These supportive outcomes should not be described as tumour regression.

If a tumour-directed role is proposed, MRI findings, neurological status, steroid dose, surgery, radiation, temozolomide, and treatment timing must all be considered.

Safety monitoring may include CBC, liver function, kidney function, electrolytes, urinalysis where indicated, blood pressure, neurological examination, and adverse-event documentation.

Current Evidence Verdict for Swarna Bhasma and Abhraka Bhasma

Classical Ayurvedic support exists for using properly prepared bhasmas within selected Rasayana and strength-supporting strategies.

Modern material studies show that specific Swarna Bhasma samples may contain nanostructured gold and that specific Abhraka Bhasma samples may contain highly altered and finely divided mica-related structures [121–125].

These findings establish material transformation and justify further pharmaceutical research.

They do not establish oral absorption, blood–brain barrier penetration, glioblastoma accumulation, tumour-cell destruction, recurrence prevention, or survival benefit.

Preliminary blood-compatibility findings for one Swarna Bhasma sample do not establish complete long-term clinical safety [123].

Published contamination studies show why independent elemental testing and manufacturer control are necessary [127,128]. These studies should not be used to declare that every properly prepared Ayurvedic bhasma is unsafe, but they do show that product quality cannot be assumed.

Modern nano-reporting standards require much more than a particle-size image [54]. Elemental impurity principles should also be used to calculate and control daily exposure [55].

Direct human evidence showing that Swarna, Abhraka, Heeraka, or Rajata Bhasma shrinks glioblastoma, delays recurrence, improves progression-free survival, or extends overall survival is not established.

What This Bhasma Evidence Means for You

Bhasma is not as magical powder that enters the brain simply because its particles are small.

A properly prepared bhasma may be physically and chemically different from its raw metal or mineral. Modern studies support this point.

The next questions are more important.

You need to know whether the exact batch is absorbed, what chemical form enters your blood, whether any part reaches the brain or tumour, what concentration is achieved, whether that concentration has a useful biological effect, and whether repeated treatment remains safe.

Until these questions are answered, Swarna Bhasma and Abhraka Bhasma should be described mainly through their classical Rasayana role, verified material quality, and investigational scientific potential.

Their use in Majja-Arbuda Rasayana Avaleha should require batch-specific testing, realistic dosing, organ-function monitoring, complete disclosure of concurrent oncology treatment, and careful separation between improved strength and actual tumour response.

You are right. Featured FAQ snippets should contain only the highest-intent questions, not an entire patient-question library. Keep 6–8 concise FAQs with direct answers of approximately 35–55 words.

Frequently Asked Questions About Ayurveda for Glioma and Glioblastoma

Can Ayurveda cure glioma or glioblastoma?

Current human research does not prove that Ayurveda alone can cure glioblastoma. Individualized Ayurvedic care may support recovery, appetite, strength, neurological function, cerebral-edema management, treatment tolerance, and quality of life. Several Ayurvedic ingredients also have promising laboratory and animal evidence that requires further human research.

Can Ayurveda be taken with radiation and temozolomide?

Selected Ayurvedic medicines may be used alongside radiation and temozolomide under qualified supervision. Your blood counts, liver function, kidney function, seizure medicines, steroid dose, digestion, and possible interactions must be reviewed. Ayurveda should not delay or independently replace prescribed neuro-oncology treatment.

Which Ayurvedic ingredients have evidence in glioblastoma research?

Glioma-related research exists for boswellic acids, withaferin A, curcumin, piperine, Guduchi extract, bacoside A, asiatic acid, Jatamansi extract, glycyrrhetinic acid, and Amalaki extract. Most tumour-directed findings come from cell or animal studies rather than completed human glioblastoma trials.

Can Ayurveda reduce brain swelling in glioblastoma?

Boswellia serrata, known as Shallaki, has limited human evidence for reducing cerebral edema during brain-tumour radiotherapy. It may be considered as supervised supportive care, but it is not a proven replacement for dexamethasone. Severe headache, vomiting, weakness, seizures, or drowsiness require urgent medical assessment.

Why is one Ayurvedic formula not suitable for every glioma patient?

Gliomas differ by tumour type, grade, IDH status, MGMT status, location, surgery, residual disease, recurrence, edema, seizures, and treatment history. Your age, digestion, strength, liver function, kidney function, blood counts, Prakriti, and current medicines also affect ingredient selection, dosage, and safety monitoring.

How should Ayurvedic treatment response be measured?

Response should be assessed through comparable MRI scans, neurological examination, steroid dose, seizure frequency, mobility, speech, cognition, body weight, treatment completion, blood counts, and organ safety. Better appetite, sleep, or strength may be valuable supportive outcomes but do not by themselves prove tumour reduction.

When should Ayurvedic medicine be stopped and urgent care sought?

Seek urgent medical care for a new or prolonged seizure, sudden weakness, speech difficulty, increasing drowsiness, severe headache, repeated vomiting, confusion, loss of consciousness, breathing difficulty, unusual bleeding, jaundice, high fever, or unsafe swallowing. These symptoms should never be described as detoxification or a healing reaction.

Reference

Evidence Search, Appraisal, and Reporting Standards

[1] Page, M. J., McKenzie, J. E., Bossuyt, P. M., et al. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 372, Article n71. https://pubmed.ncbi.nlm.nih.gov/33782057/

Used for: Explaining transparent literature-search methods, study screening, evidence selection, and reporting.

[2] Gagnier, J. J., Boon, H., Rochon, P., Moher, D., Barnes, J., & Bombardier, C. (2006). Reporting randomized, controlled trials of herbal interventions: An elaborated CONSORT statement. Annals of Internal Medicine, 144(5), 364–367. https://pubmed.ncbi.nlm.nih.gov/16520478/

Used for: Establishing how herbal trials should report botanical identity, plant part, preparation, standardization, dosage, and quality control.

[3] Hoffmann, T. C., Glasziou, P. P., Boutron, I., et al. (2014). Better reporting of interventions: Template for intervention description and replication checklist and guide. BMJ, 348, Article g1687. https://pubmed.ncbi.nlm.nih.gov/24609605/

Used for: Describing the complete Majja-Arbuda Rasayana Avaleha, including ingredients, preparation, dosage, administration, and personalization.

[4] Gagnier, J. J., Kienle, G., Altman, D. G., Moher, D., Sox, H., & Riley, D. (2013). The CARE guidelines: Consensus-based clinical case-reporting guideline development. Journal of Medical Case Reports, 7, Article 223. https://pubmed.ncbi.nlm.nih.gov/24078847/

Used for: Structuring properly documented Panaceayur glioma and glioblastoma case reports.

[5] Riley, D. S., Barber, M. S., Kienle, G. S., et al. (2017). CARE guidelines for case reports: Explanation and elaboration document. Journal of Clinical Epidemiology, 89, 218–235. https://pubmed.ncbi.nlm.nih.gov/28529185/

Used for: Reporting patient timelines, diagnostic evidence, concurrent treatments, outcomes, adverse effects, and informed consent.

[6] von Elm, E., Altman, D. G., Egger, M., et al. (2007). The Strengthening the Reporting of Observational Studies in Epidemiology statement: Guidelines for reporting observational studies. Annals of Internal Medicine, 147(8), 573–577. https://pubmed.ncbi.nlm.nih.gov/17938396/

Used for: Designing and reporting prospective or retrospective observational studies involving glioma patients.

[7] Benchimol, E. I., Smeeth, L., Guttmann, A., et al. (2015). The REporting of studies Conducted using Observational Routinely-collected health Data statement. PLOS Medicine, 12(10), Article e1001885. https://pmc.ncbi.nlm.nih.gov/articles/PMC4595218/

Used for: Reporting evidence collected from clinical records, laboratory tests, MRI scans, prescriptions, and routine follow-up data.

[8] Percie du Sert, N., Hurst, V., Ahluwalia, A., et al. (2020). The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLOS Biology, 18(7), Article e3000410. https://pubmed.ncbi.nlm.nih.gov/32663219/

Used for: Evaluating the quality of animal research on herbs, natural compounds, bhasmas, and glioblastoma models.

Why Glioma Is Not One Disease

[9] Louis, D. N., Perry, A., Wesseling, P., et al. (2021). The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro-Oncology, 23(8), 1231–1251. https://pmc.ncbi.nlm.nih.gov/articles/PMC8328013/

Used for: Explaining current glioma classification and distinguishing glioblastoma, IDH-wildtype from astrocytoma, IDH-mutant, CNS WHO grade 4.

[10] International Agency for Research on Cancer. (2021). WHO classification of tumours: Central nervous system tumours (5th ed.). https://whobluebooks.iarc.who.int/structures/central-nervous-system-tumours/

Used for: Official pathological and molecular classification of central nervous system tumours.

[11] Weller, M., van den Bent, M., Preusser, M., et al. (2021). EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nature Reviews Clinical Oncology, 18(3), 170–186. https://pmc.ncbi.nlm.nih.gov/articles/PMC7904519/

Used for: Diagnosis, molecular testing, surgery, radiotherapy, chemotherapy, surveillance, and tumour-specific treatment planning.

[12] Wen, P. Y., Weller, M., Lee, E. Q., et al. (2025). Glioblastoma in adults: A Society for Neuro-Oncology and European Association of Neuro-Oncology consensus review on current management and future directions. Neuro-Oncology, 27(11), 2751–2788. https://pubmed.ncbi.nlm.nih.gov/40827022/

Used for: Current evidence on glioblastoma biology, standard care, treatment resistance, recurrence, targeted treatment, immunotherapy, and emerging research.

[13] Mohile, N. A., Messersmith, H., Gatson, N. T. N., et al. (2022). Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO–SNO guideline. Journal of Clinical Oncology, 40(4), 403–426. https://pmc.ncbi.nlm.nih.gov/articles/PMC8917406/

Used for: Supporting different treatment pathways for astrocytoma, oligodendroglioma, and glioblastoma.

[14] Blakeley, J., Mohile, N. A., Messersmith, H., Lassman, A. B., Schiff, D., & Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults Guideline Expert Panel. (2025). Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO–SNO guideline rapid recommendation update. Journal of Clinical Oncology, 43(18), 2129–2133. https://pubmed.ncbi.nlm.nih.gov/40300117/

Used for: Updated recommendations concerning IDH-mutant gliomas and newer targeted-treatment evidence.

[15] Capper, D., Reifenberger, G., French, P. J., et al. (2023). EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection. Neuro-Oncology, 25(5), 813–826. https://pubmed.ncbi.nlm.nih.gov/36632791/

Used for: Explaining when molecular tests such as IDH, BRAF, NTRK, and FGFR may affect treatment or clinical-trial eligibility.

[16] Brat, D. J., Aldape, K., Colman, H., et al. (2018). cIMPACT-NOW update 3: Recommended diagnostic criteria for diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV. Acta Neuropathologica, 136, 805–810. https://pubmed.ncbi.nlm.nih.gov/30066218/

Used for: Explaining molecularly defined aggressive IDH-wildtype gliomas, even when classic grade 4 microscopic features are not seen.

[17] Louis, D. N., Wesseling, P., Aldape, K., et al. (2020). cIMPACT-NOW update 6: New entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. Brain Pathology, 30(4), 844–856. https://pubmed.ncbi.nlm.nih.gov/32307792/

Used for: Explaining changes in glioma terminology and why older research must be interpreted using the classification applied at that time.

[18] Patel, A. P., Tirosh, I., Trombetta, J. J., et al. (2014). Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science, 344(6190), 1396–1401. https://pmc.ncbi.nlm.nih.gov/articles/PMC4123637/

Used for: Demonstrating that one glioblastoma can contain biologically different tumour-cell populations.

[19] Neftel, C., Laffy, J., Filbin, M. G., et al. (2019). An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell, 178(4), 835–849.e21. https://pubmed.ncbi.nlm.nih.gov/31327527/

Used for: Explaining glioblastoma cellular states, tumour plasticity, and adaptation under treatment pressure.

[20] Giese, A., Bjerkvig, R., Berens, M. E., & Westphal, M. (2003). Cost of migration: Invasion of malignant gliomas and implications for treatment. Journal of Clinical Oncology, 21(8), 1624–1636. https://pubmed.ncbi.nlm.nih.gov/12697889/

Used for: Explaining why microscopic glioma cells can extend beyond the visible MRI or surgical margin.

[21] Lathia, J. D., Mack, S. C., Mulkearns-Hubert, E. E., Valentim, C. L. L., & Rich, J. N. (2015). Cancer stem cells in glioblastoma. Genes & Development, 29(12), 1203–1217. https://pubmed.ncbi.nlm.nih.gov/26109046/

Used for: Explaining glioma stem-like cells, tumour maintenance, heterogeneity, treatment resistance, and recurrence.

[22] Bao, S., Wu, Q., McLendon, R. E., et al. (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 444(7120), 756–760. https://pubmed.ncbi.nlm.nih.gov/17051156/

Used for: Explaining experimental evidence concerning glioma stem cells and resistance to radiation.

[23] Narsinh, K. H., Perez, E., Haddad, A. F., Young, J. S., Savastano, L., Villanueva-Meyer, J. E., Winkler, E., & de Groot, J. (2024). Strategies to improve drug delivery across the blood–brain barrier for glioblastoma. Current Neurology and Neuroscience Reports, 24(5), 123–139. https://pmc.ncbi.nlm.nih.gov/articles/PMC11016125/

Used for: Explaining why laboratory activity does not prove that an orally administered compound reaches a human brain tumour.

[24] Ohmura, K., et al. (2023). Peritumoral edema in gliomas: A review of mechanisms and management. Biomedicines, 11(10), Article 2731. https://pmc.ncbi.nlm.nih.gov/articles/PMC10604286/

Used for: Explaining cerebral edema, neuroinflammation, symptoms, steroid use, and why edema reduction is not equivalent to tumour elimination.

Surgery, Oncology Treatment, and the First 30–90 Days

[25] Stupp, R., Mason, W. P., van den Bent, M. J., et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England Journal of Medicine, 352(10), 987–996. https://pubmed.ncbi.nlm.nih.gov/15758009/

Used for: Foundational clinical evidence for radiotherapy with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma.

[26] Hegi, M. E., Diserens, A. C., Gorlia, T., et al. (2005). MGMT gene silencing and benefit from temozolomide in glioblastoma. The New England Journal of Medicine, 352(10), 997–1003. https://pubmed.ncbi.nlm.nih.gov/15758010/

Used for: Explaining MGMT promoter methylation and its relationship with temozolomide benefit.

[27] Perry, J. R., Laperriere, N., O’Callaghan, C. J., et al. (2017). Short-course radiation plus temozolomide in elderly patients with glioblastoma. The New England Journal of Medicine, 376(11), 1027–1037. https://pubmed.ncbi.nlm.nih.gov/28296618/

Used for: Supporting individualized treatment decisions for older adults and the clinical importance of MGMT status.

[28] Stupp, R., Taillibert, S., Kanner, A. A., et al. (2017). Effect of tumor-treating fields plus maintenance temozolomide versus maintenance temozolomide alone on survival in patients with glioblastoma. JAMA, 318(23), 2306–2316. https://pmc.ncbi.nlm.nih.gov/articles/PMC5820703/

Used for: Clinical evidence for Tumour Treating Fields in newly diagnosed glioblastoma.

[29] Stummer, W., Pichlmeier, U., Meinel, T., et al. (2006). Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: A randomised controlled multicentre phase III trial. The Lancet Oncology, 7(5), 392–401. https://pubmed.ncbi.nlm.nih.gov/16648043/

Used for: Supporting fluorescence-guided maximal safe resection and improved identification of residual enhancing tumour.

[30] Goldbrunner, R., Foroglou, N., Signorelli, F., Schucht, P., Jakola, A. S., Minniti, G., Rola, R., Renovanz, M., Preusser, M., Furtner, J., Grossman, R., Mawrin, C., Demetriades, A., Weller, M., & Simon, M. (2026). EANS–EANO guidelines on the extent of resection in gliomas. Neuro-Oncology, 28(1), 38–54. https://pubmed.ncbi.nlm.nih.gov/40973061/

Used for: Current recommendations on extent of resection, neurological preservation, postoperative imaging, and surgical decision-making.

[31] INTERVAL-GB Collaborative. (2024). Imaging timing after surgery for glioblastoma: An evaluation of practice in Great Britain and Ireland—A multicentre cohort study. Journal of Neuro-Oncology, 169, 517–529. https://pmc.ncbi.nlm.nih.gov/articles/PMC11341661/

Used for: Supporting appropriately timed postoperative MRI and structured surveillance after glioblastoma surgery.

[32] Wen, P. Y., van den Bent, M., Youssef, G., et al. (2023). RANO 2.0: Update to the Response Assessment in Neuro-Oncology criteria for high- and low-grade gliomas in adults. Journal of Clinical Oncology, 41(33), 5187–5199. https://pmc.ncbi.nlm.nih.gov/articles/PMC10860967/

Used for: Interpreting tumour response, progression, steroid exposure, enhancing and non-enhancing disease, and confirmatory imaging.

[33] Young, J. S., Al-Adli, N., Scotford, K., Cha, S., & Berger, M. S. (2023). Pseudoprogression versus true progression in glioblastoma: What neurosurgeons need to know. Journal of Neurosurgery, 139(3), 748–759. https://pmc.ncbi.nlm.nih.gov/articles/PMC10412732/

Used for: Explaining why early post-treatment MRI worsening may represent pseudoprogression rather than true recurrence.

[34] Avila, E. K., Tobochnik, S., Inati, S. K., et al. (2024). Brain tumor-related epilepsy management: A Society for Neuro-Oncology consensus review on current management. Neuro-Oncology, 26(1), 7–24. https://pmc.ncbi.nlm.nih.gov/articles/PMC10768995/

Used for: Seizure assessment, antiseizure medicines, interaction risks, and neurological monitoring during integrative treatment.

[35] Mellinghoff, I. K., van den Bent, M. J., Blumenthal, D. T., et al. (2023). Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. The New England Journal of Medicine, 389(7), 589–601. https://pmc.ncbi.nlm.nih.gov/articles/PMC11445763/

Used for: Demonstrating why IDH-mutant grade 2 glioma is biologically and therapeutically different from glioblastoma.

[36] U.S. Food and Drug Administration. (2024, August 6). FDA approves vorasidenib for grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-vorasidenib-grade-2-astrocytoma-or-oligodendroglioma-susceptible-idh1-or-idh2-mutation

Used for: Confirming the approved indication and eligible patient population for vorasidenib.

[37] Weyer-Jamora, C., Brie, M. S., Luks, T. L., Smith, E. M., Hervey-Jumper, S. L., & Taylor, J. W. (2021). Postacute cognitive rehabilitation for adult brain tumor patients. Neurosurgery, 89(6), 945–953. https://pubmed.ncbi.nlm.nih.gov/33586764/

Used for: Supporting rehabilitation for attention, memory, executive-function, and processing-speed difficulties.

[38] Piil, K., Juhler, M., Jakobsen, J., & Jarden, M. (2016). Controlled rehabilitative and supportive care intervention trials in patients with high-grade gliomas and their caregivers: A systematic review. BMJ Supportive & Palliative Care, 6(1), 27–34. https://pmc.ncbi.nlm.nih.gov/articles/PMC4789693/

Used for: Evaluating rehabilitation and supportive-care interventions for high-grade glioma patients and caregivers.

[39] McBain, C., Lawrie, T. A., Rogozińska, E., et al. (2021). Treatment options for progression or recurrence of glioblastoma: A network meta-analysis. Cochrane Database of Systematic Reviews, Article CD013579. https://pubmed.ncbi.nlm.nih.gov/34559423/

Used for: Explaining uncertainty and limitations surrounding treatment selection after glioblastoma recurrence.

[40] Pace, A., Dirven, L., Koekkoek, J. A. F., et al. (2017). European Association for Neuro-Oncology guidelines for palliative care in adults with glioma. The Lancet Oncology, 18(6), e330–e340. https://pubmed.ncbi.nlm.nih.gov/28593859/

Used for: Symptom control, neurological care, caregiver needs, nutrition, hydration, and advanced-care planning.

Classical Ayurvedic Foundation

[41] Agniveśa. (n.d.). Caraka Saṃhitā: Electronic edition. National Institute of Indian Medical Heritage. https://niimh.nic.in/ebooks/ecaraka/

Used for: Verifying Rasayana, Agni, Ojas, Dhatu, Srotas, and individualized-treatment principles from the original classical text.

[42] Suśruta. (n.d.). Suśruta Saṃhitā: Electronic edition. National Institute of Indian Medical Heritage. https://niimh.nic.in/ebooks/esushruta/

Used for: Verifying classical Granthi and Arbuda descriptions, including relevant verses in Nidāna Sthāna and Cikitsā Sthāna.

[43] National Institute of Indian Medical Heritage. (n.d.). e-Nighantu: Electronic lexicon of Ayurveda. https://niimh.nic.in/ebooks/e-Nighantu/

Used for: Verifying Sanskrit drug names, synonyms, botanical identities, properties, and classical actions.

[44] Bhāvamiśra. (n.d.). Bhāvaprakāśa Nighaṇṭu: Electronic edition. National Institute of Indian Medical Heritage. https://niimh.nic.in/ebooks/e-Nighantu/bhavaprakashanighantu/?mod=read

Used for: Checking Rasa, Guna, Virya, Vipaka, and traditional therapeutic actions of formulation ingredients.

[45] Pharmacopoeia Commission for Indian Medicine & Homoeopathy. (n.d.). Official pharmacopoeial and formulary resources. Ministry of AYUSH, Government of India. https://pcimh.gov.in/

Used for: Official botanical identity, plant part, quality parameters, monographs, and formulation standards.

[46] Jaiswal, Y. S., & Williams, L. L. (2017). A glimpse of Ayurveda: The forgotten history and principles of Indian traditional medicine. Journal of Traditional and Complementary Medicine, 7(1), 50–53. https://pmc.ncbi.nlm.nih.gov/articles/PMC5198827/

Used for: Providing an academic overview of Ayurvedic principles and their historical development.

[47] Narayana, D. B. A. (2021). Ayurveda: Where is the evidence? Journal of Ayurveda and Integrative Medicine, 12(2), 408–411. https://pmc.ncbi.nlm.nih.gov/articles/PMC8185965/

Used for: Discussing how classical knowledge, clinical experience, product quality, and modern research can be evaluated together.

[48] Newton, H. B. (2024). Indian Ayurvedic medicine: Overview and application to brain cancer. Journal of Ayurveda and Integrative Medicine, 15(4), Article 101013. https://pmc.ncbi.nlm.nih.gov/articles/PMC11385779/

Used for: Brain-cancer-focused discussion of Ayurveda, candidate ingredients, biological research, and translational limitations.

Formulation-Level Quality and Evidence

[49] World Health Organization. (2011). Quality control methods for herbal materials. https://iris.who.int/bitstream/handle/10665/44479/9789241500739_eng.pdf

Used for: Botanical authentication, microscopy, moisture, ash values, foreign matter, and contaminant testing.

[50] World Health Organization. (2017). Guidelines for selecting marker substances of herbal origin for quality control of herbal medicines. https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/quality-control/trs1003-annex1-marker-substances-herbal-medicine-quality-control.pdf

Used for: Selecting measurable chemical markers for formulation identity and batch consistency.

[51] World Health Organization. (2018). Good herbal processing practices for herbal medicines. https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/production/trs1010-annex1-herbal-processing.pdf

Used for: Raw-material handling, cleaning, drying, processing, storage, and contamination prevention.

[52] World Health Organization. (2018). Good manufacturing practices for the manufacture of herbal medicines. https://iris.who.int/server/api/core/bitstreams/444528f5-6c78-434e-a39d-0bb6c36e4c30/content

Used for: Manufacturing controls, premises, personnel, batch records, sampling, storage, and finished-product release.

[53] U.S. Food and Drug Administration. (2016). Botanical drug development: Guidance for industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/botanical-drug-development-guidance-industry

Used for: Explaining how complex botanical formulations can be chemically controlled and evaluated as reproducible clinical interventions.

[54] Faria, M., Björnmalm, M., Thurecht, K. J., et al. (2018). Minimum information reporting in bio–nano experimental literature. Nature Nanotechnology, 13(9), 777–785. https://pubmed.ncbi.nlm.nih.gov/30190620/

Used for: Establishing the minimum material characterization required before making nanoparticle or nano-medicine claims.

[55] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2022). ICH Q3D(R2): Guideline for elemental impurities. https://database.ich.org/sites/default/files/Q3D-R2_Guideline_Step4_2022_0308.pdf

Used for: Evaluating potentially toxic elemental impurities in formulations and processed mineral ingredients.

[56] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2021). ICH Q3C(R8): Guideline for residual solvents. https://database.ich.org/sites/default/files/ICH_Q3C-R8_Guideline_Step4_2021_0422_1.pdf

Used for: Controlling residual solvents where botanical extracts or processed ingredients are used.

Shallaki and Boswellic Acids

[57] Kirste, S., Treier, M., Wehrle, S. J., Becker, G., Abdel-Tawab, M., Gerbeth, K., Hug, M. J., Lubrich, B., Grosu, A. L., & Momm, F. (2011). Boswellia serrata acts on cerebral edema in patients irradiated for brain tumors: A prospective, randomized, placebo-controlled, double-blind pilot trial. Cancer, 117(16), 3788–3795. https://pubmed.ncbi.nlm.nih.gov/21287538/

Used for: Direct human evidence concerning radiotherapy-associated cerebral edema; it does not establish glioblastoma eradication or survival benefit.

[58] Winking, M., Sarikaya, S., Rahmanian, A., Jödicke, A., & Böker, D. K. (2000). Boswellic acids inhibit glioma growth: A new treatment option? Journal of Neuro-Oncology, 46(2), 97–103. https://pubmed.ncbi.nlm.nih.gov/10894362/

Used for: Early direct preclinical glioma evidence concerning boswellic-acid-mediated growth inhibition.

[59] Schneider, H., & Weller, M. (2016). Boswellic acid activity against glioblastoma stem-like cells. Oncology Letters, 11(6), 4187–4192. https://pmc.ncbi.nlm.nih.gov/articles/PMC4888275/

Used for: Investigating boswellic acids against glioblastoma stem-like cells.

[60] Li, W., et al. (2018). 3-O-Acetyl-11-keto-β-boswellic acid exerts anti-tumor effects in glioblastoma by arresting the cell cycle at the G2/M phase. Journal of Experimental & Clinical Cancer Research, 37, Article 132. https://pubmed.ncbi.nlm.nih.gov/29970196/

Used for: Preclinical evidence concerning proliferation, migration, invasion, apoptosis, FOXM1, and cell-cycle pathways.

[61] Conti, S., et al. (2018). Combined acetyl-11-keto-β-boswellic acid and radiation treatment inhibited glioblastoma tumor cells. PLOS ONE, 13(7), Article e0198627. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0198627

Used for: Examining AKBA in combination with radiation in experimental glioblastoma models.

[62] Wiese, M., et al. (2024). Boswellic acid formulations are not suitable for treatment of pediatric high-grade glioma due to tumor-promoting potential. Journal of Traditional and Complementary Medicine, 14(1), 101–108. https://pmc.ncbi.nlm.nih.gov/articles/PMC10785237/

Used for: Contradictory evidence showing that Boswellia findings cannot be generalized across ages, tumour types, or formulations.

[63] Dejonckheere, C. S., et al. (2025). Boswellia serrata for the management of radiation-induced cerebral edema and necrosis: A systematic meta-narrative review of clinical evidence. Advances in Radiation Oncology, 10(4), Article 101732. https://pmc.ncbi.nlm.nih.gov/articles/PMC11904484/

Used for: Summarizing available human evidence and identifying major limitations in Boswellia research.

[64] Reising, K., Meins, J., Bastian, B., et al. (2005). Determination of boswellic acids in brain and plasma by high-performance liquid chromatography and mass spectrometry. Analytical Chemistry, 77(20), 6640–6645. https://pubmed.ncbi.nlm.nih.gov/16223251/

Used for: Pharmacokinetic and tissue-distribution evidence relevant to brain-exposure claims.

[65] Frank, A., & Unger, M. (2006). Analysis of frankincense from various Boswellia species with inhibitory activity on human drug-metabolising cytochrome P450 enzymes using liquid chromatography mass spectrometry after automated online extraction. Journal of Chromatography A, 1112(1–2), 255–262. https://pubmed.ncbi.nlm.nih.gov/16364338/

Used for: Assessing potential interactions with medicines metabolized through cytochrome P450 pathways.

[66] National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). Boswellia serrata. In LiverTox: Clinical and research information on drug-induced liver injury. National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK563692/

Used for: Evaluating human hepatic safety and reported liver-injury evidence.

Ashwagandha and Withanolides

[67] Chang, E., Pohling, C., Natarajan, A., et al. (2016). AshwaMAX and withaferin A inhibit gliomas in cellular and murine orthotopic models. Journal of Neuro-Oncology, 126(2), 253–264. https://pmc.ncbi.nlm.nih.gov/articles/PMC5597337/

Used for: Direct preclinical evidence using conventional glioma cells, patient-derived glioblastoma cultures, and an intracranial mouse model.

[68] Chang, E., Pohling, C., Beygui, N., Patel, C. B., Rosenberg, J., Ha, D. H., & Gambhir, S. S. (2017). Synergistic inhibition of glioma cell proliferation by withaferin A and tumor treating fields. Journal of Neuro-Oncology, 134(2), 259–268. https://pmc.ncbi.nlm.nih.gov/articles/PMC5711586/

Used for: Preclinical combination evidence involving withaferin A and Tumour Treating Fields.

[69] Singh, N., Bhalla, M., de Jager, P., & Gilca, M. (2011). An overview on Ashwagandha: A Rasayana of Ayurveda. African Journal of Traditional, Complementary and Alternative Medicines, 8(5 Suppl.), 208–213. https://pmc.ncbi.nlm.nih.gov/articles/PMC3252722/

Used for: Classical Rasayana context, phytochemistry, and general pharmacological background.

[70] Verma, N., Gupta, S. K., Tiwari, S., & Mishra, A. K. (2021). Safety of Ashwagandha root extract: A randomized, placebo-controlled study in healthy volunteers. Complementary Therapies in Medicine, 57, Article 102642. https://pubmed.ncbi.nlm.nih.gov/33338583/

Used for: Human short-term safety evidence for a defined Ashwagandha root extract.

[71] Vaidya, N., et al. (2025). Safety and tolerability of Withania somnifera root extract in healthy adults: A prospective study of 180-day administration. https://pubmed.ncbi.nlm.nih.gov/41458530/

Used for: Longer-duration human tolerability data for a standardized Ashwagandha root extract; not glioma-efficacy evidence.

[72] Björnsson, H. K., Björnsson, E. S., Avula, B., et al. (2020). Ashwagandha-induced liver injury: A case series from Iceland and the U.S. Drug-Induced Liver Injury Network. Liver International, 40(4), 825–829. https://pubmed.ncbi.nlm.nih.gov/31991029/

Used for: Documenting clinically important reports of Ashwagandha-associated liver injury.

[73] Philips, C. A., et al. (2023). Ashwagandha-induced liver injury: A case series from India and literature review. Hepatology Communications, 7(10), Article e0270. https://pubmed.ncbi.nlm.nih.gov/37756041/

Used for: Indian clinical evidence concerning possible Ashwagandha-associated liver injury and product-related uncertainty.

[74] National Institutes of Health, Office of Dietary Supplements. (2025). Ashwagandha: Fact sheet for health professionals. https://ods.od.nih.gov/factsheets/Ashwagandha-HealthProfessional/

Used for: Human safety, pregnancy, thyroid, sedative, autoimmune, and medication-interaction considerations.

[75] Ministry of AYUSH, Government of India. (2021). Advisory to refrain from use of Ashwagandha leaves in ASU drugs. https://ayush.gov.in/assets/pdf/quality_standards/advisory-on-aswagandha.pdf

Used for: Distinguishing classical Ashwagandha root use from research involving leaf preparations.

[76] National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). Ashwagandha. In LiverTox: Clinical and research information on drug-induced liver injury. National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK548536/

Used for: Independent assessment of reported Ashwagandha-associated hepatotoxicity.

Haridra, Turmeric, and Curcumin

[77] Gersey, Z. C., Rodriguez, G. A., Barbarite, E., et al. (2017). Curcumin decreases malignant characteristics of glioblastoma stem cells via induction of reactive oxygen species. BMC Cancer, 17, Article 99. https://pmc.ncbi.nlm.nih.gov/articles/PMC5292151/

Used for: Direct preclinical evidence using patient-derived glioblastoma stem-like cells and examining sphere formation, STAT3, and oxidative mechanisms.

[78] Yin, H., Zhou, Y., Wen, C., et al. (2014). Curcumin sensitizes glioblastoma to temozolomide through reactive oxygen species-dependent inhibition of the AKT/mTOR pathway. https://pubmed.ncbi.nlm.nih.gov/25050915/

Used for: Laboratory evidence concerning possible temozolomide sensitization.

[79] Zoi, V., et al. (2021). Curcumin and radiotherapy exert synergistic anti-glioma effects in preclinical models. Biomedicines, 9(11), Article 1562. https://pmc.ncbi.nlm.nih.gov/articles/PMC8615260/

Used for: Evaluating curcumin with radiation while clarifying that the findings remain preclinical.

[80] Sordillo, L. A., Sordillo, P. P., & Helson, L. (2015). Curcumin for the treatment of glioblastoma. Anticancer Research, 35(12), 6373–6378. https://pubmed.ncbi.nlm.nih.gov/26637846/

Used for: Reviewing proposed glioblastoma mechanisms and barriers to clinical translation.

[81] Shahcheraghi, S. H., Zangui, M., Lotfi, M., et al. (2019). Therapeutic potential of curcumin in the treatment of glioblastoma multiforme. Current Pharmaceutical Design, 25(3), 333–342. https://pubmed.ncbi.nlm.nih.gov/30864499/

Used for: Reviewing curcumin research involving apoptosis, invasion, angiogenesis, stemness, and treatment resistance.

[82] Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007). Bioavailability of curcumin: Problems and promises. Molecular Pharmaceutics, 4(6), 807–818. https://pubmed.ncbi.nlm.nih.gov/17999464/

Used for: Explaining poor absorption, rapid metabolism, and limited systemic exposure after ordinary oral curcumin.

[83] Nelson, K. M., Dahlin, J. L., Bisson, J., et al. (2017). The essential medicinal chemistry of curcumin. Journal of Medicinal Chemistry, 60(5), 1620–1637. https://pubmed.ncbi.nlm.nih.gov/28074653/

Used for: Evaluating curcumin instability, assay interference, chemical behaviour, and overinterpretation of laboratory findings.

[84] Tayyem, R. F., Heath, D. D., Al-Delaimy, W. K., & Rock, C. L. (2006). Curcumin content of turmeric and curry powders. Nutrition and Cancer, 55(2), 126–131. https://pubmed.ncbi.nlm.nih.gov/17044766/

Used for: Showing that turmeric powder is not equivalent to purified curcumin and helping assess actual formulation exposure.

[85] National Cancer Institute. (n.d.). Curcumin: Health professional version. https://www.cancer.gov/about-cancer/treatment/cam/hp/curcumin-pdq

Used for: Independent assessment of curcumin pharmacology, human cancer research, safety, and limitations.

[86] National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). Turmeric. In LiverTox: Clinical and research information on drug-induced liver injury. National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK548561/

Used for: Evaluating turmeric- and curcumin-associated liver-injury reports, particularly with enhanced-bioavailability products.

Pippali, Black Pepper, and Piperine

[87] Jeong, S., et al. (2020). Piperine enhances the effect of temozolomide against temozolomide-resistant human glioma cell lines. Bioengineered, 11(1), 791–800. https://pmc.ncbi.nlm.nih.gov/articles/PMC8291786/

Used for: Direct preclinical evidence concerning temozolomide-resistant glioma models.

[88] Warrier, N. M., et al. (2022). Piperine-mediated survivin inhibition sensitizes glioblastoma stem cells to therapeutic agents. International Journal of Molecular Sciences, 23(14). https://pmc.ncbi.nlm.nih.gov/articles/PMC9323232/

Used for: Supporting the proposed survivin and glioblastoma stem-cell mechanism.

[89] Shoba, G., Joy, D., Joseph, T., Majeed, M., Rajendran, R., & Srinivas, P. S. S. R. (1998). Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Medica, 64(4), 353–356. https://pubmed.ncbi.nlm.nih.gov/9619120/

Used for: Human evidence that piperine can alter curcumin exposure and may therefore also affect medicine interactions.

[90] Bhardwaj, R. K., Glaeser, H., Becquemont, L., Klotz, U., Gupta, S. K., & Fromm, M. F. (2002). Piperine inhibits human P-glycoprotein and CYP3A4. Journal of Pharmacology and Experimental Therapeutics, 302(2), 645–650. https://pubmed.ncbi.nlm.nih.gov/12130727/

Used for: Assessing potential interactions with antiseizure medicines, corticosteroids, anticoagulants, and other drugs.

[91] Srinivasan, K. (2007). Black pepper and its pungent principle piperine: A review of diverse physiological effects. Critical Reviews in Food Science and Nutrition, 47(8), 735–748. https://pubmed.ncbi.nlm.nih.gov/17987447/

Used for: General pharmacology, absorption effects, dosing context, and safety considerations.

Guduchi and Tinospora cordifolia

[92] Mishra, R., & Kaur, G. (2013). Aqueous ethanolic extract of Tinospora cordifolia as a potential candidate for differentiation-based therapy of glioblastomas. PLOS ONE, 8(10), Article e78764. https://pmc.ncbi.nlm.nih.gov/articles/PMC3811968/

Used for: Direct preclinical glioblastoma evidence involving differentiation-related effects.

[93] Saha, S., & Ghosh, S. (2012). Tinospora cordifolia: One plant, many roles. Ancient Science of Life, 31(4), 151–159. https://pmc.ncbi.nlm.nih.gov/articles/PMC3644751/

Used for: Botanical identity, traditional use, phytochemistry, and general pharmacological background.

[94] Sharma, P., Dwivedee, B. P., Bisht, D., Dash, A. K., & Kumar, D. (2019). The chemical constituents and diverse pharmacological importance of Tinospora cordifolia. Heliyon, 5(9), Article e02437. https://pmc.ncbi.nlm.nih.gov/articles/PMC6827274/

Used for: Identifying major chemical constituents and broad pharmacological actions without presenting them as clinical glioblastoma proof.

[95] Nagral, A., Adhyaru, K., Rudra, O. S., et al. (2021). Herbal immune booster-induced liver injury in the COVID-19 pandemic: A case series involving Tinospora cordifolia. https://pubmed.ncbi.nlm.nih.gov/34230786/

Used for: Documenting clinically important liver-injury reports and possible autoimmune-like liver injury.

[96] Nagral, A., et al. (2023). Herb-induced liver injury—A guide to approach: Lessons from the Tinospora cordifolia case-series story. https://pmc.ncbi.nlm.nih.gov/articles/PMC10025683/

Used for: Causality assessment, product identification, and safety lessons from reported Guduchi-associated liver injury.

[97] National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). Tinospora. In LiverTox: Clinical and research information on drug-induced liver injury. National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK608429/

Used for: Independent assessment of Tinospora-associated hepatotoxicity.

Brahmi, Bacopa monnieri, and Bacosides

[98] John, S., et al. (2017). Bacoside A induces tumour cell death in glioblastoma cell lines through catastrophic macropinocytosis. Frontiers in Molecular Neuroscience, 10, Article 171. https://pmc.ncbi.nlm.nih.gov/articles/PMC5471305/

Used for: Direct preclinical glioblastoma evidence involving a non-apoptotic tumour-cell-death mechanism.

[99] Aithal, M. G. S., & Rajeswari, N. (2019). Bacoside A induces sub-G0 arrest and early apoptosis in human glioblastoma cell line U-87 MG through the Notch signaling pathway. Brain Tumor Research and Treatment, 7(1), 25–32. https://pmc.ncbi.nlm.nih.gov/articles/PMC6504756/

Used for: Laboratory evidence involving apoptosis, cell-cycle arrest, and Notch signalling.

[100] Moskwa, J., et al. (2020). Anticancer activity of a combination of propolis and Bacopa monnieri against glioblastoma cell lines. Scientific Reports, 10, Article 21127. https://www.nature.com/articles/s41598-020-78014-w

Used for: Combination laboratory evidence while clarifying that it does not prove the effect of Bacopa alone or of the complete Avaleha.

[101] Mohammed Unais, A. K., Anandan, A., Saju, M. K., & Viswanadha, V. P. (2026). Bacoside-A enhances temozolomide-induced cytotoxicity in U87MG glioblastoma cells via ROS-mediated apoptosis and EGFR/MAPK inhibition. Neuropharmacology, 292, Article 110922. https://pubmed.ncbi.nlm.nih.gov/41839256/

Used for: Recent direct preclinical evidence concerning bacoside-A combined with temozolomide.

[102] Pase, M. P., Kean, J., Sarris, J., Neale, C., Scholey, A. B., & Stough, C. (2012). The cognitive-enhancing effects of Bacopa monnieri: A systematic review of randomized, controlled human clinical trials. Journal of Alternative and Complementary Medicine, 18(7), 647–652. https://pubmed.ncbi.nlm.nih.gov/22747190/

Used for: Human cognition evidence relevant to supportive neurological care, not tumour control.

[103] Kongkeaw, C., Dilokthornsakul, P., Thanarangsarit, P., Limpeanchob, N., & Scholfield, C. N. (2014). Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract. Journal of Ethnopharmacology, 151(1), 528–535. https://pubmed.ncbi.nlm.nih.gov/24252493/

Used for: Higher-level human evidence concerning selected cognitive outcomes.

[104] Calabrese, C., Gregory, W. L., Leo, M., et al. (2008). Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in older adults: A randomized, double-blind, placebo-controlled trial. Journal of Alternative and Complementary Medicine, 14(6), 707–713. https://pubmed.ncbi.nlm.nih.gov/18611150/

Used for: Human supportive evidence and tolerability of a standardized Bacopa extract.

Mandukaparni, Centella asiatica, and Asiatic Acid

[105] Cho, C. W., Choi, D. S., Cardone, M. H., Kim, C. W., Sinskey, A. J., & Rha, C. (2006). Glioblastoma cell death induced by asiatic acid. Cell Biology and Toxicology, 22, 393–408. https://pubmed.ncbi.nlm.nih.gov/16897440/

Used for: Early direct preclinical glioblastoma evidence involving asiatic acid.

[106] Kavitha, C. V., Jain, A. K., Agarwal, C., et al. (2015). Asiatic acid induces endoplasmic reticulum stress and apoptotic death in glioblastoma multiforme cells both in vitro and in vivo. Molecular Carcinogenesis, 54(11), 1417–1429. https://pmc.ncbi.nlm.nih.gov/articles/PMC4369479/

Used for: Direct preclinical evidence involving cellular stress, apoptosis, and an animal tumour model.

[107] Thakor, F. K., et al. (2017). Pharmacological effects of asiatic acid in glioblastoma cells under hypoxic conditions. https://pmc.ncbi.nlm.nih.gov/articles/PMC5437181/

Used for: Investigating asiatic acid under hypoxia, an important feature of aggressive glioblastoma.

[108] Puttarak, P., Dilokthornsakul, P., Saokaew, S., et al. (2017). Effects of Centella asiatica on cognitive function: A systematic review and meta-analysis. https://pubmed.ncbi.nlm.nih.gov/28878245/

Used for: Human supportive evidence concerning cognition and its limitations.

[109] Bradwejn, J., Zhou, Y., Koszycki, D., & Shlik, J. (2000). A double-blind, placebo-controlled study on the effects of Gotu kola on acoustic startle response in healthy subjects. Journal of Clinical Psychopharmacology, 20(6), 680–684. https://pubmed.ncbi.nlm.nih.gov/11106141/

Used for: Human nervous-system and anxiety-related evidence; it does not demonstrate tumour control.

Jatamansi, Yashtimadhu, Amalaki, and Supportive Ingredients

[110] Kapoor, H., et al. (2017). Strong anti-tumorous potential of Nardostachys jatamansi rhizome extract on glioblastoma and in-silico analysis of its molecular drug targets. Current Cancer Drug Targets, 17(1), 74–88. https://pubmed.ncbi.nlm.nih.gov/27774879/

Used for: Direct preclinical evidence involving a Jatamansi rhizome extract and predicted molecular targets.

[111] Dhuna, K., et al. (2013). Cytoprotective and biological evaluation of Nardostachys jatamansi extract. https://pubmed.ncbi.nlm.nih.gov/23513188/

Used for: General pharmacological and safety context rather than direct clinical glioma evidence.

[112] Quan, L. Q., et al. (2020). Iridoids from Valeriana jatamansi with cytotoxicity against glioma stem cells. https://pubmed.ncbi.nlm.nih.gov/32305683/

Used for: Glioma stem-cell evidence while clarifying that Valeriana jatamansi and Nardostachys jatamansi are not botanically interchangeable.

[113] Luo, X., Zeng, Y., Wang, X., et al. (2026). 18β-Glycyrrhetinic acid suppresses glioblastoma by regulating the p38 signaling pathway: An integrative approach combining network analysis, transcriptomics, and experimental assessment. Frontiers in Pharmacology, 17, Article 1727072. https://pmc.ncbi.nlm.nih.gov/articles/PMC12953517/

Used for: Recent preclinical evidence concerning a licorice-derived metabolite, apoptosis, and p38 signalling.

[114] Hong, B., et al. (2019). Suppression of HMGB1 released in the glioblastoma tumour microenvironment using glycyrrhizin. Molecular Therapy: Oncolytics. https://www.cell.com/molecular-therapy-family/oncology/fulltext/S2372-7705%2818%2930035-4

Used for: Examining glycyrrhizin, HMGB1, the tumour microenvironment, and experimental immune mechanisms.

[115] Curtin, J. F., et al. (2009). HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLOS Medicine. https://pubmed.ncbi.nlm.nih.gov/19143470/

Used for: Contradictory mechanistic evidence showing that HMGB1 can also participate in beneficial antitumour immune signalling.

[116] Kwon, Y. J., Son, D. H., Chung, T. H., & Lee, Y. J. (2020). A review of the pharmacological efficacy and safety of licorice root from clinical trials. Journal of Medicinal Food, 23(1), 12–20. https://pubmed.ncbi.nlm.nih.gov/31874059/

Used for: Human safety evidence concerning blood pressure, potassium depletion, fluid retention, and endocrine effects.

[117] Chary, K. J. S., Sharma, A., & Singh, A. (2025). In vitro assessment of anti-glioblastoma potential of Emblica officinalis methanolic fruit extract and green nanoparticles in U87-MG cells. Medical Oncology, 42(11), Article 516. https://pubmed.ncbi.nlm.nih.gov/41085866/

Used for: Direct but preliminary laboratory evidence for Amalaki; it does not establish oral efficacy or human tumour exposure.

[118] Variya, B. C., Bakrania, A. K., & Patel, S. S. (2016). Emblica officinalis (Amla): A review for its phytochemistry, ethnomedicinal uses, and medicinal potentials with respect to molecular mechanisms. Pharmacological Research, 111, 180–200. https://pubmed.ncbi.nlm.nih.gov/27320046/

Used for: Botanical, phytochemical, and general pharmacological background for Amalaki.

[119] Memorial Sloan Kettering Cancer Center. (n.d.). Emblica officinalis. https://www.mskcc.org/cancer-care/integrative-medicine/herbs/emblica-officinalis

Used for: Independent patient-facing information on proposed uses, limited human evidence, and safety considerations.

[120] National Center for Complementary and Integrative Health. (n.d.). Licorice root: Usefulness and safety. https://www.nccih.nih.gov/health/licorice-root

Used for: Hypertension, hypokalaemia, cardiac effects, pregnancy precautions, and medicine interactions associated with licorice.

Swarna Bhasma, Abhraka Bhasma, and Nano-Medicine Claims

[121] Patil-Bhole, T., et al. (2021). Nanostructured gold in an ancient Ayurvedic calcined drug: Swarna Bhasma. Journal of Ayurveda and Integrative Medicine, 12(4), 640–648. https://pmc.ncbi.nlm.nih.gov/articles/PMC8642718/

Used for: Sample-specific evidence that one analysed Swarna Bhasma contained nanoscale gold structures.

[122] Thakur, K., et al. (2017). Preparation and physicochemical characterization of Suvarna Bhasma. https://pmc.ncbi.nlm.nih.gov/articles/PMC5374337/

Used for: Describing classical preparation and laboratory characterization of a specific Swarna Bhasma sample.

[123] Paul, W., & Sharma, C. P. (2011). Blood compatibility and physicochemical characterization of Swarna Bhasma. https://pubmed.ncbi.nlm.nih.gov/21897638/

Used for: Preliminary material and blood-compatibility assessment; it is not evidence of glioblastoma efficacy or brain delivery.

[124] Wele, A., et al. (2021). Nanoparticles of biotite mica as Krishna Vajra Abhraka Bhasma. Journal of Ayurveda and Integrative Medicine, 12(2), 269–282. https://pubmed.ncbi.nlm.nih.gov/33402266/

Used for: Physical and chemical characterization of a particular processed Abhraka sample.

[125] Wijenayake, A., et al. (2020). Characterization of biotite-based drugs used in traditional medicine. Heliyon, 6(7), Article e04483. https://www.cell.com/heliyon/fulltext/S2405-8440%2820%2931327-X

Used for: Comparing mineral composition and processing-related changes in mica-based traditional medicines.

[126] Chaudhary, A. (2011). Ayurvedic Bhasma: Nanomedicine of ancient India—Its global contemporary perspective. Journal of Biomedical Nanotechnology, 7(1), 68–69. https://pubmed.ncbi.nlm.nih.gov/21485807/

Used for: Historical and conceptual discussion of bhasma as nanostructured material; it does not establish pharmacokinetics or clinical benefit.

[127] Saper, R. B., Kales, S. N., Paquin, J., et al. (2004). Heavy metal content of Ayurvedic herbal medicine products. JAMA, 292(23), 2868–2873. https://pubmed.ncbi.nlm.nih.gov/15598918/

Used for: Demonstrating why product-source control and independent batch testing are necessary.

[128] Saper, R. B., Phillips, R. S., Sehgal, A., et al. (2008). Lead, mercury, and arsenic in U.S.- and Indian-manufactured Ayurvedic medicines sold via the internet. JAMA, 300(8), 915–923. https://pmc.ncbi.nlm.nih.gov/articles/PMC2755247/

Used for: Supporting elemental testing, contaminant disclosure, and batch-specific safety documentation.

[129] National Center for Complementary and Integrative Health. (n.d.). Ayurvedic medicine: In depth. https://www.nccih.nih.gov/health/ayurvedic-medicine-in-depth

Used for: Independent overview of Ayurveda, evidence limitations, and safety concerns involving some metal-containing products.

Diet, Exercise, Rehabilitation, Yoga, and Caregiver Support

[130] Muscaritoli, M., Arends, J., Bachmann, P., et al. (2021). ESPEN practical guideline: Clinical nutrition in cancer. Clinical Nutrition, 40(5), 2898–2913. https://pubmed.ncbi.nlm.nih.gov/33946039/

Used for: Calorie and protein requirements, weight loss, sarcopenia, hydration, and nutritional intervention in cancer.

[131] National Cancer Institute. (n.d.). Nutrition in cancer care: Health professional version. https://www.cancer.gov/about-cancer/treatment/side-effects/appetite-loss/nutrition-hp-pdq

Used for: Appetite loss, nausea, swallowing problems, body-weight loss, supplements, and nutrition support.

[132] Rieger, J., Bähr, O., Maurer, G. D., et al. (2014). ERGO: A pilot study of ketogenic diet in recurrent glioblastoma. International Journal of Oncology, 44(6), 1843–1852. https://pmc.ncbi.nlm.nih.gov/articles/PMC4063533/

Used for: Direct human feasibility evidence for ketogenic dietary intervention in recurrent glioblastoma and its limitations.

[133] Amaral, L. J., et al. (2025). Phase 1 study of a ketogenic diet combined with standard care in newly diagnosed glioblastoma. Scientific Reports, 15, Article 21064. https://pmc.ncbi.nlm.nih.gov/articles/PMC12215994/

Used for: Recent human safety and feasibility evidence without presenting ketogenic diet as a proven glioblastoma cure.

[134] Campbell, K. L., Winters-Stone, K. M., Wiskemann, J., et al. (2019). Exercise guidelines for cancer survivors: Consensus statement from an international multidisciplinary roundtable. Medicine & Science in Sports & Exercise, 51(11), 2375–2390. https://pubmed.ncbi.nlm.nih.gov/31626055/

Used for: Individualized aerobic, resistance, flexibility, and functional exercise during cancer recovery.

[135] Rock, C. L., Thomson, C. A., Sullivan, K. R., et al. (2022). American Cancer Society guideline for diet and physical activity for cancer survivors. CA: A Cancer Journal for Clinicians, 72(3), 230–262. https://pubmed.ncbi.nlm.nih.gov/35294043/

Used for: Weight maintenance, muscle preservation, dietary quality, and appropriately modified physical activity.

[136] van der Linden, S. D., et al. (2021). E-health cognitive rehabilitation for brain-tumour patients: A randomized controlled study. https://pubmed.ncbi.nlm.nih.gov/34487313/

Used for: Human evidence concerning structured cognitive rehabilitation after brain-tumour treatment.

[137] O’Keeffe, D. (2021). High-grade glioma and caregiver burden. https://pubmed.ncbi.nlm.nih.gov/33856616/

Used for: Explaining the cognitive, behavioural, emotional, physical, and practical demands placed on high-grade glioma caregivers.

[138] Boele, F. W., Rooney, A. G., Bulbeck, H., & Sherwood, P. (2019). Interventions to help support caregivers of people with a brain or spinal cord tumour. Cochrane Database of Systematic Reviews, Article CD012582. https://pubmed.ncbi.nlm.nih.gov/31264707/

Used for: Evaluating controlled evidence for caregiver-support interventions.

[139] Madsen, K., & Poulsen, H. S. (2011). Needs for everyday-life support for relatives of patients with a brain tumour. https://pubmed.ncbi.nlm.nih.gov/20477857/

Used for: Supporting caregiver education, practical information, and assistance with daily responsibilities.

[140] Wei, H., Zhang, S., Tao, S., Li, J., & Liu, X. (2026). Caregiver burden, quality of life, and psychosocial outcomes among informal caregivers of patients with glioma: A systematic review and meta-analysis. Asia-Pacific Journal of Oncology Nursing. https://pubmed.ncbi.nlm.nih.gov/42253414/

Used for: Current synthesis of caregiver burden, anxiety, depression, distress, and quality-of-life outcomes in glioma caregiving.

[141] Milbury, K., Li, J., Weathers, S. P., et al. (2019). Pilot randomized controlled trial of a dyadic yoga programme for glioma patients undergoing radiotherapy and their family caregivers. Neuro-Oncology Practice, 6(4), 311–320. https://pubmed.ncbi.nlm.nih.gov/31386042/

Used for: Direct human glioma evidence concerning feasibility and supportive outcomes of yoga for patients and caregivers.

[142] Au, T. H., Willis, C., Reblin, M., et al. (2022). Caregiver burden by treatment and clinical characteristics of patients with glioblastoma. Supportive Care in Cancer, 30(2), 1365–1375. https://pubmed.ncbi.nlm.nih.gov/34510238/

Used for: Relating caregiver burden to neurological symptoms, cognition, treatment, and clinical characteristics.

[143] Stout, N. L., et al. (2021). A systematic review of rehabilitation and exercise recommendations in oncology guidelines. https://pubmed.ncbi.nlm.nih.gov/33107982/

Used for: Supporting structured rehabilitation assessment and identifying gaps in oncology exercise guidance.

Temozolomide Safety, Pharmacovigilance, and Clinical Registry

[144] U.S. National Library of Medicine. (n.d.). TEMODAR—Temozolomide prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819571ea-b808-4fd8-93c7-1ea2e33d71cf

Used for: Temozolomide dosage, myelosuppression, lymphopenia, liver injury, infection risk, contraindications, and laboratory monitoring.

[145] World Health Organization. (n.d.). Pharmacovigilance. https://www.who.int/teams/regulation-prequalification/regulation-and-safety/pharmacovigilance

Used for: Detecting, recording, evaluating, understanding, and preventing medicine-related adverse effects.

[146] National Cancer Institute. (2017). Common Terminology Criteria for Adverse Events, version 5.0. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm

Used for: Standardized grading of adverse events in a Panaceayur registry or future clinical study.

[147] National Cancer Institute. (n.d.). Integrative medicine. In NCI dictionary of cancer terms. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/integrative-medicine

Used for: Defining integrative medicine as coordinated use of conventional treatment with complementary approaches.

[148] National Center for Complementary and Integrative Health. (n.d.). Complementary, alternative, or integrative health: What’s in a name? https://www.nccih.nih.gov/health/complementary-alternative-or-integrative-health-whats-in-a-name

Used for: Distinguishing integrative treatment from replacing or delaying necessary oncology care.

[149] U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov. https://clinicaltrials.gov/

Used for: Checking registered, active, completed, withdrawn, and unpublished glioma, botanical, dietary, and integrative clinical trials.

[150] World Health Organization. (n.d.). International Clinical Trials Registry Platform search portal. https://trialsearch.who.int/

Used for: International clinical-trial verification beyond studies registered in the United States.

[151] Indian Council of Medical Research. (n.d.). Clinical Trials Registry–India. https://ctri.nic.in/

Used for: Verifying and prospectively registering Indian interventional and observational studies.